# This Page Is Inserted by IFW Operations and is not a part of the Official Record

# **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

# IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents will not correct images, please do not report the images to the Image Problem Mailbox.

4						
	<b>.</b>					
					•	
*N		ű.				•
						•
			G.			
				•		
						(9)
	•					
	ž.					
						2. *
*						
		*				
					+	·
						9

# **PCT**

# WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



# INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6:

G01N 33/53

(11) International Publication Number: WO 98/45704

(43) International Publication Date: 15 October 1998 (15.10.98)

(21) International Application Number:

PCT/DK98/00145

(22) International Filing Date:

7 April 1998 (07.04.98)

(30) Priority Data:

0392/97

7 April 1997 (07.04.97)

DK

(71) Applicant (for all designated States except US): NOVO NORDISK A/S [DK/DK]; Novo Allé, DK-2880 Bagsvaerd (DK).

(72) Inventors; and

- (75) Inventors/Applicants (for US only): THASTRUP, Ole [DK/DK]; Birkevej 37, DK-3460 Birkerød (DK). PETERSEN BJØRN, Sara [DK/DK]; Klampenborgvej 102, DK-2800 Lyngby (DK). TULLIN, Søren [DK/DK]; Karl Gjellerups Alle 18, DK-2860 Søborg (DK). KASPER, Almholt [DK/DK]; Eigilsgade 32, 4. tv, DK-2300 København S (DK). SCUDDER, Kurt [US/DK]; Lavendelhaven 70, DK-2830 Virum (DK).
- (74) Common Representative: NOVO NORDISK A/S; attn. Lars Kellberg, Novo Allé, DK-2880 Bagsværd (DK).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

#### Published

Without international search report and to be republished upon receipt of that report.

(54) Title: A METHOD FOR EXTRACTING QUANTITATIVE INFORMATION RELATING TO AN INFLUENCE ON A CELLULAR RESPONSE

#### (57) Abstract

Cells are genetically modified to expresss a luminophore, e.g., a modified (F64L, S65T, Y66H) Green Fluorescent Protein (GFP, EGFP) coupled to a component of an intracellular signalling pathway such as a transcription factor, a cGMP- or cAMP-dependent protein kinase, a cyclin-, calmodulin- or phospholipid-dependent or mitogen-activated serine/threonin protein kinase, a tyrosine protein kinase, or a protein phosphatase (e.g. PKA, PKC, Erk, Smad, VASP, actin, p38, Jnk1, PKG, IkappaB, CDK2, Grk5, Zap70, p85, protein-tyrosine phosphatase 1C, Stat5, NFAT, NFkappaB, RhoA, PKB). An influence modulates the intracellular signalling pathway in such a way that the luminophore is being redistributed or translocated with the component in living cells in a manner experimentally determined to be correlated to the degree of the influence. Measurement of redistribution is performed by recording of light intensity, fluorescence lifetime, polarization, wavelength shift, resonance energy transfer, or other properties by an apparatus consisting of e.g. a fluorescence microscope and a CCD camera. Data stored as digital images are processed to numbers representing the degree of redistribution. The method can be used as a screening program for identifying a compound that modulates a component and is capable of treating a disease related to the function of the component.

# FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL Albania AM Armenia AT Austria AU Austria AZ Azerbaijan BA Bosnia and Herzegovina BB Barbados BE Belgium BF Burkina Faso BG Bulgaria BJ Benin BR Brazil BY Belarus CA Canada CF Central African Republic CG Congo CH Switzerland CI Côte d'Ivoire CM Cameroon CN China CU Cuba CZ Czech Republic DE Germany DK Denmark EE Estonia	ES Spain FI Finland FR France GA Gabon GB United Kingdom GE Georgia GH Ghana GN Guinea GR Greece HU Hungary IE Ireland IL Israel IS Iceland IT Italy JP Japan KE Kenya KG Kyrgyzstan KP Democratic People's Republic of Korea KR Republic of Korea KZ Kazakstan LC Saint Lucia LI Liechtenstein LK Sri Lanka LR Liberia	LS Lesotho LT Lithuania LU Luxembourg LV Latvia MC Monaco MD Republic of Moldova MG Madagascar MK The former Yugoslav Republic of Macedonia ML Mali MN Mongolia MR Mauritania MW Malawi MX Mexico NE Niger NL Netherlands NO Norway NZ New Zealand PL Poland PT Portugal RO Romania RU Russian Federation SD Sudan SE Sweden SG Singapore	SI SK SN SZ TD TG TJ TM TR TT UA UG US UZ VN YU ZW	Slovenia Slovakia Senegal Swaziland Chad Togo Tajikistan Turkmenistan Turkey Trinidad and Tobago Ukraine Uganda United States of America Uzbekistam Viet Nam Yugoslavia Zimbabwe
---	---	---	--	--

WO 98/45704 PCT/DK98/00145

1

A METHOD for extracting quantitative information relating to an influence on a cellular response

#### FIELD OF INVENTION

5 The present invention relates to a method and tools for extracting quantitative information relating to an influence, on a cellular response, in particular an influence caused by contacting or incubating the cell with a substance influencing a cellular response, where the cellular response is manifested in redistribution of at least one component in the cell. In particular, the invention relates to a method for extracting quantitative information relating to an influence on an intracellular pathway involving redistribution of at least one component associated 10 with the pathway. The method of the invention may be used as a very efficient procedure for testing or discovering the influence of a substance on a physiological process, for example in connection with screening for new drugs, testing of substances for toxicity, identifying drug targets for known or novel drugs. Other valuable uses of the method and technology of the invention will be apparent to the skilled person on the basis of the following disclosure. In a 15 particular embodiment of the invention, the present invention relates to a method of detecting intracellular translocation or redistribution of biologically active polypeptides, preferably an enzyme, affecting intracellular processes, and a DNA construct and a cell for use in the method.

20

25

30 .

#### BACKGROUND OF THE INVENTION

Intracellular pathways are tightly regulated by a cascade of components that undergo modulation in a temporally and spatially characteristic manner. Several disease states can be attributed to altered activity of individual signalling components (i.e. protein kinases, protein phosphatases, transcription factors). These components therefore render themselves as attractive targets for therapeutic intervention.

Protein kinases and phosphatases are well described components of several intracellular signalling pathways. The catalytic activity of protein kinases and phosphatases are assumed to play a role in virtually all regulatable cellular processes. Although the involvement of protein kinases in cellular signalling and regulation have been subjected to extensive studies, detailed knowledge on e.g. the exact timing and spatial characteristics of signalling events is often difficult to obtain due to lack of a convenient technology.

15

20

25

30

Novel ways of monitoring specific modulation of intracellular pathways in intact, living cells is assumed to provide new opportunities in drug discovery, functional genomics, toxicology, patient monitoring etc.

The spatial orchestration of protein kinase activity is likely to be essential for the high degree of specificity of individual protein kinases. The phosphorylation mediated by protein kinases is balanced by phosphatase activity. Also within the family of phosphatases translocation has been observed, e.g. translocation of PTP2C to membrane ruffles [(Cossette et al.1996)], and likewise is likely to be indicative of phosphatase activity.

Protein kinases often show a specific intracellular distribution before, during and after activation. Monitoring the translocation processes and/or redistribution of individual protein kinases or subunits thereof is thus likely to be indicative of their functional activity. A connection between translocation and catalytic activation has been shown for protein kinases like the diacyl glycerol (DAG)-dependent protein kinase C (PKC), the cAMP-dependent protein kinase (PKA) [(DeBernardi et al.1996)] and the mitogen-activated-protein kinase Erk-1 [(Sano et al.1995)].

Commonly used methods of detection of intracellular localisation/activity of protein kinases and phosphatases are immunoprecipitation, Western blotting and immunocytochemical detection.

Taking the family of diacyl glycerol (DAG)-dependent protein kinase Cs (PKCs) as an example, it has been shown that individual PKC isoforms that are distributed among different tissues and cells have different activator requirements and undergo differential translocation in response to activation. Catalytically inactive DAG-dependent PKCs are generally distributed throughout the cytoplasm, whereas they upon activation translocate to become associated with different cellular components, e.g. plasma membrane [(Farese, 1992),(Fulop Jr. et al. 1995)] nucleus [(Khalil et al. 1992)], cytoskeleton [(Blobe et al. 1996)]. The translocation phenomenon being indicative of PKC activation has been monitored using different approaches: a) immunocytochemistry where the localisation of individual isoforms can be detected after permeabilisation and fixation of the cells [(Khalil et al. 1992)]; and b) tagging all DAG-dependent PKC isoforms with a fluorescently labelled phorbol myristate acetate (PMA) [(Godson et al. 1996)]; and c) chemical tagging PKC b1 with the fluorophore Cy3 [(Bastiaens & Jovin 1996)] and d) genetic tagging of PKC $\alpha$  ([Schmidt et al. 1997]) and of PKC $\alpha$  and PKC  $\alpha$  ([Sakai et al. 1996]). The first method does not provide dynamic information whereas the latter methods will. Tagging PKC with fluorescently labelled phorbol myristate acetate cannot

20

25

30

distinguish between different DAG-dependent isoforms of PKC but will label and show movement of all isoforms. Chemical and genetic labelling of specific DAG-dependent PKCs confirmed that they in an isoform specific manner upon activation move to cell periphery or nucleus.

In an alternative method, protein kinase A activity has been measured in living cells by chemical labelling one of the kinase's subunit (Adams *et al.* 1991). The basis of the methodology is that the regulatory and catalytic subunit of purified protein kinase A is labelled with fluorescein and rhodamine, respectively. At low cAMP levels protein kinase A is assembled in a heterotetrameric form which enables fluorescence resonance energy transfer between the two fluorescent dyes. Activation of protein kinase A leads to dissociation of the complex, thereby eliminating the energy transfer. A disadvantage of this technology is that the labelled protein kinase A has to be microinjected into the cells of interest. This highly invasive technique is cumbersome and not applicable to large scale screening of biologically active substances. A further disadvantage of this technique as compared to the presented invention is that the labelled protein kinase A cannot be inserted into organisms/animals as a transgene.

Recently it was discovered that Green Fluorescent Protein (GFP) expressed in many different cell types, including mammalian cells, became highly fluorescent [(Chalfie et al. 1994)]. WO95/07463 describes a cell capable of expressing GFP and a method for detecting a protein of interest in a cell based on introducing into a cell a DNA molecule having DNA sequence encoding the protein of interest linked to DNA sequence encoding a GFP such that the protein produced by the DNA molecule will have the protein of interest fused to the GFP, then culturing the cells in conditions permitting expression of the fused protein and detecting the location of the fluorescence in the cell, thereby localizing the protein of interest in the cell. However, examples of such fused proteins are not provided, and the use of fusion proteins with GFP for detection or quantitation of translocation or redistribution of biologically active polypeptides affecting intracellular processes upon activation, such as proteins involved in signalling pathways, e.g. protein kinases or phosphatases, has not been suggested. WO 95/07463 further describes cells useful for the detection of molecules, such as hormones or heavy metals, in a biological sample, by operatively linking a regulatory element of the gene which is affected by the molecule of interest to a GFP, the presence of the molecules will affect the regulatory element which in turn will affect the expression of the GFP. In this way the gene encoding GFP is used as a reporter gene in a cell which is constructed for monitoring the presence of a specific molecular identity.

15

20

Green Fluorescent Protein has been used in an assay for the detection of translocation of the glucocorticoid receptor (GR) [Carey, KL et al., The Journal of Cell Biology, Vol. 133, No. 5, p. 985-996 (1996)]. A GR-S65TGFP fusion has been used to study the mechanisms involved in translocation of the glucocorticoid receptor (GR) in response to the agonist dexamethasone from the cytosol, where it is present in the absence of a ligand, through the nuclear pore to the nucleus where it remains after ligand binding. The use of a GR-GFP fusion enables real-time imaging and quantitation of nuclear/cytoplasmic ratios of the fluorescence signal.

Many currently used screening programmes designed to find compounds that affect protein kinase activity are based on measurements of kinase phosphorylation of artificial or natural substrates, receptor binding and/or reporter gene expression.

# DISCLOSURE OF THE INVENTION

The present invention provides an important new dimension in the investigation of cellular systems involving redistribution in that the invention provides quantification of the redistribution responses or events caused by an influence, typically contact with a chemical substance or mixture of chemical substances, but also changes in the physical environment. The quantification makes it possible to set up meaningful relationships, expressed numerically, or as curves or graphs, between the influences (or the degree of influences) on cellular systems and the redistribution response. This is highly advantageous because, as has been found, the quantification can be achieved in both a fast and reproducible manner, and - what is perhaps even more important - the systems which become quantifiable utilizing the method of the invention are systems from which enormous amounts of new information and insight can be derived.

The present screening assays have the distinct advantage over other screening assays, e.g., receptor binding assays, enzymatic assays, and reporter gene assays, in providing a system in which biologically active substances with completely novel modes of action, e.g. inhibition or promotion of redistribution/translocation of a biologically active polypeptide as a way of regulating its action rather than inhibition/activation of enzymatic activity, can be identified in a way that insures very high selectivity to the particular isoform of the biologically active polypeptide and further development of compound selectivity versus other isoforms of

the same biologically active polypeptide or other components of the same signalling pathway.

In its broadest aspect, the invention relates to a method for extracting quantitative information relating to an influence on a cellular response, the method comprising recording variation, 5 caused by the influence on a mechanically intact living cell or mechanically intact living cells, in spatially distributed light emitted from a luminophore, the luminophore being present in the cell or cells and being capable of being redistributed in a manner which is related with the degree of the influence, and/or of being modulated by a component which is capable of being redistributed in a manner which is related to the degree of the influence, the association resulting in a modulation of the luminescence characteristics of the luminophore, detecting and recording the spatially distributed light from the luminophore, and processing the recorded variation in the spatially distributed light to provide quantitative information correlating the spatial distribution or change in the spatial distribution to the degree of the influence. In a preferred embodiment of the invention the luminophore, which is present in the cell or cells, is capable of being redistributed by modulation of an intracellular pathway, in a manner which is related to the redistribution of at least one component of the intracellular pathway. In another preferred embodiment of the invention, the luminophore is a fluorophore.

# The cells

10

15

25

30

In the invention the cell and/or cells are mechanically intact and alive throughout the experiment. In another embodiment of the invention, the cell or cells is/are fixed at a point in time after the application of the influence at which the response has been predetermined to be significant, and the recording is made at an arbitrary later time.

The mechanically intact living cell or cells could be selected from the group consisting of fungal cell or cells, such as a yeast cell or cells; invertebrate cell or cells including insect cell or cells; and vertebrate cell or cells, such as mammalian cell or cells. This cell or these cells is/are incubated at a temperature of 30°C or above, preferably at a temperature of from 32°C to 39°C, more preferably at a temperature of from 35°C to 38°C, and most preferably at a temperature of about 37°C during the time period over which the influence is observed. In one aspect of the invention the mechanically intact living cell is part of a matrix of identical or non-identical cells.

A cell used in the present invention should contain a nucleic acid construct encoding a fusion polypeptide as defined herein and be capable of expressing the sequence encoded by the construct. The cell is a eukaryotic cell selected from the group consisting of fungal cells, such as yeast cells; invertebrate cells including insect cells; vertebrate cells such as mammalian cells. The preferred cells are mammalian cells.

In another aspect of the invention the cells could be from an organism carrying in at least one of its component cells a nucleic acid sequence encoding a fusion polypeptide as defined herein and be capable of expressing said nucleic acid sequence. The organism is selected from the group consisting of unicellular and multicellular organisms, such as a mammal.

10

15

20

# The luminophore

The luminophore is the component which allows the redistribution to be visualised and/or recorded by emitting light in a spatial distribution related to the degree of influence. In one embodiment of the invention, the luminophore is capable of being redistributed in a manner which is physiologically relevant to the degree of the influence. In another embodiment, the luminophore is capable of associating with a component which is capable of being redistributed in a manner which is physiologically relevant to the degree of the influence. In another embodiment, the luminophore correlation between the redistribution of the luminophore and the degree of the influence could be determined experimentally. In a preferred aspect of the invention, the luminophore is capable of being redistributed in substantially the same manner as the at least one component of an intracellular pathway. In yet another embodiment of the invention, the luminophore is capable of being quenched upon spatial association with a component which is redistributed by modulation of the pathway, the quenching being measured as a change in the intensity of the luminescence.

The luminophore could be a fluorophore. In a preferred embodiment of the invention, the lu-25 minophore could be a polypeptide encoded by and expressed from a nucleotide sequence harboured in the cell or cells. The luminophore could be a hybrid polypeptide comprising a fusion of at least a portion of each of two polypeptides one of which comprises a luminescent polypeptide and the other one of which comprises a biologically active polypeptide, as defined herein.

30

The luminescent polypeptide could be a GFP as defined herein or could be selected from the group consisting of green fluorescent proteins having the F64L mutation as defined herein

such as F64L-GFP, F64L-Y66H-GFP, F64L-S65T-GFP, and EGFP. The GFP could be N- or C-terminally tagged, optionally via a peptide linker, to the biologically active polypeptide or a part or a subunit thereof. The fluorescent probe could be a component of a intracellular signalling pathway. The probe is coded for by a nucleic acid construct.

The pathway of investigation in the present invention could be an intracellular signalling pathway.

#### The influence

In a preferred embodiment of the invention, the influence could be contact between the mechanically intact living cell or the group of mechanically intact living cells with a chemical substance and/or incubation of the mechanically intact living cell or the group of mechanically intact living cells with a chemical substance. The influence will modulate the intracellular processes. In one aspect the modulation could be an activation of the intracellular processes. In another aspect the modulation could be an deactivation of the intracellular processes. In yet another aspect, the influence could inhibit or promote the redistribution without directly affecting the metabolic activity of the component of the intracellular processes.

In one embodiment the invention is used as a basis for a screening program, where the effect of unknown influences such as a compound library, can be compared to influence of known reference compounds under standardised conditions.

20

25

30

10

15

# The recording

In addition to the intensity, there are several parameters of fluorescence or luminescence which can be modulated by the effect of the influence on the underlying cellular phenomena, and can therefore be used in the invention. Some examples are resonance energy transfer, fluorescence lifetime, polarisation, wavelength shift. Each of these methods requires a particular kind of filter in the emission light path to select the component of the light desired and reject other components. The recording of property of light could be in the form of an ordered array of values such as a CCD array or a vacuum tube device such as a vidicon tube.

In one embodiment of the invention, the spatially distributed light emitted by a luminophore could be detected by a change in the resonance energy transfer between the luminophore and another luminescent entity capable of delivering energy to the luminophore, each of

15

20

which has been selected or engineered to become part of, bound to or associated with particular components of the intracellular pathway. In this embodiment, either the luminophore or the luminescent entity capable of delivering energy to the luminophore undergoes redistribution in response to an influence. The resonance energy transfer would be measured as a change in the intensity of emission from the luminophore, preferably sensed by a single channel photodetector which responds only to the average intensity of the luminophore in a non-spatially resolved fashion.

In one embodiment of the invention, the recording of the spatially distributed light could be made at a single point in time after the application of the influence. In another embodiment, the recording could be made at two points in time, one point being before, and the other point being after the application of the influence. The result or variation is determined from the change in fluorescence compared to the fluorescence measured prior to the influence or modulation. In another embodiment of the invention, the recording could be performed at a series of points in time, in which the application of the influence occurs at some time after the first time point in the series of recordings, the recording being performed, e.g., with a predetermined time spacing of from 0.1 seconds to 1 hour, preferably from 1 to 60 seconds, more preferably from 1 to 30 seconds, in particular from 1 to 10 seconds, over a time span of from 1 second to 12 hours, such as from 10 seconds to 12 hours, e.g., from 10 seconds to one hour, such as from 60 seconds to 30 minutes or 20 minutes. The result or variation is determined from the change in fluorescence over time. The result or variation could also be determined as a change in the spatial distribution of the fluorescence over time.

## **Apparatus**

The recording of spatially distributed luminescence emitted from the luminophore is performed by an apparatus for measuring the distribution of fluorescence in the cell or cells, and thereby any change in the distribution of fluorescence in the cell or cells, which includes at a minimum the following component parts: (a) a light source, (b) a method for selecting the wavelength(s) of light from the source which will excite the fluorescence of the protein, (c) a device which can rapidly block or pass the excitation light into the rest of the system, (d) a series of optical elements for conveying the excitation light to the specimen, collecting the emitted fluorescence in a spatially resolved fashion, and forming an image from this fluorescence emission, (e) a bench or stand which holds the container of the cells being measured in a predetermined geometry with respect to the series of optical elements, (f) a detector to

20

25

30

record the spatially resolved fluorescence in the form of an image, (g) a computer or electronic system and associated software to acquire and store the recorded images, and to compute the degree of redistribution from the recorded images.

In a preferred embodiment of the invention the apparatus system is automated. In one embodiment the components in d and e mentioned above comprise a fluorescence microscope.

In one embodiment the component in f mentioned above is a CCD camera.

In one embodiment the image is formed and recorded by an optical scanning system.

In one embodiment a liquid addition system is used to add a known or unknown compound to any or all of the cells in the cell holder at a time determined in advance. Preferably, the liquid addition system is under the control of the computer or electronic system. Such an automated system can be used for a screening program due to its ability to generate results from a larger number of test compounds than a human operator could generate using the apparatus in a manual fashion.

## 15 Quantitation of the influence

The recording of the variation or result with respect to light emitted from the luminophore is performed by recording the spatially distributed light as one or more digital images, and the processing of the recorded variation to reduce it to one or more numbers representative of the degree of redistribution comprises a digital image processing procedure or combination of digital image processing procedures. The quantitative information which is indicative of the degree of the cellular response to the influence or the result of the influence on the intracellular pathway is extracted from the recording or recordings according to a predetermined calibration based on responses or results, recorded in the same manner, to known degrees of a relevant specific influence. This calibration procedure is developed according to principles described below (Developing an Image-based Assay Technique). Specific descriptions of the procedures for particular assays are given in the examples.

While the stepwise procedure necessary to reduce the image or images to the value representative of the is particular to each assay, the individual steps are generally well-known methods of image processing. Some examples of the individual steps are point operations such as subtraction, ratioing, and thresholding, digital filtering methods such as smoothing, sharpening, and edge detection, spatial frequency methods such as Fourier filtering, image cross-correlation and image autocorrelation, object finding and classification (blob analysis),

and colour space manipulations for visualisation. In addition to the algorithmic procedures, heuristic methods such as neural networks may also be used.

#### **Nucleic acid constructs**

- The nucleic acid constructs used in the present invention encode in their nucleic acid sequences fusion polypeptides comprising a biologically active polypeptide that is a component of an intracellular signalling pathway, or a part thereof, and a GFP, preferably an F64L mutant of GFP, N- or C-terminally fused, optionally via a peptide linker, to the biologically active polypeptide or part thereof.
- In one embodiment the biologically active polypeptide encoded by the nucleic acid construct is a protein kinase or a phosphatase.
  - In one embodiment the biologically active polypeptide encoded by the nucleic acid construct is a transcription factor or a part thereof which changes cellular localisation upon activation.
- In one embodiment the biologically active polypeptide encoded by the nucleic acid construct is a protein, or a part thereof, which is associated with the cytoskeletal network and which changes cellular localisation upon activation.
  - In one embodiment the biologically active polypeptide encoded by the nucleic acid construct is a protein kinase or a part thereof which changes cellular localisation upon activation.
- In one embodiment the biologically active polypeptide encoded by the nucleic acid construct is a serine/threonine protein kinase or a part thereof capable of changing intracellular localisation upon activation.
  - In one embodiment the biologically active polypeptide encoded by the nucleic acid construct is a tyrosine protein kinase or a part thereof capable of changing intracellular localisation upon activation.
- In one embodiment the biologically active polypeptide encoded by the nucleic acid construct is a phospholipid-dependent serine/threonine protein kinase or a part thereof capable of changing intracellular localisation upon activation.
  - In one embodiment the biologically active polypeptide encoded by the nucleic acid construct is a cAMP-dependent protein kinase or a part thereof capable of changing cellular localisation upon activation. In a preferred embodiment the biologically active polypeptide encoded by the nucleic acid construct is a PKAc-F64L-S65T-GFP fusion.

In one embodiment the biologically active polypeptide encoded by the nucleic acid construct is a cGMP-dependent protein kinase or a part thereof capable of changing cellular localisation upon activation.

In one embodiment the biologically active polypeptide encoded by the nucleic acid construct is a calmodulin-dependent serine/threonine protein kinase or a part thereof capable of changing cellular localisation upon activation.

In one embodiment the biologically active polypeptide encoded by the nucleic acid construct is a mitogen-activated serine/threonine protein kinase or a part thereof capable of changing cellular localisation upon activation. In preferred embodiments the biologically active polypeptide encoded by the nucleic acid constructs are an ERK1-F64L-S65T-GFP fusion or an EGFP-ERK1 fusion.

In one embodiment the biologically active polypeptide encoded by the nucleic acid construct is a cyclin-dependent serine/threonine protein kinase or a part thereof capable of changing cellular localisation upon activation.

In one embodiment the biologically active polypeptide encoded by the nucleic acid construct is a protein phosphatase or a part thereof capable of changing cellular localisation upon activation.

In one preferred embodiment of the invention the nucleic acid constructs may be DNA constructs.

- In one embodiment the biologically active polypeptide encoded by the nucleic acid construct In one embodiment the gene encoding GFP in the nucleic acid construct is derived from Aequorea victoria. In a preferred embodiment the gene encoding GFP in the nucleic acid construct is EGFP or a GFP variant selected from F64L-GFP, F64L-Y66H-GFP and F64L-S65T-GFP.
- In preferred embodiments of the invention the DNA constructs which can be identified by any of the DNA sequences shown in SEQ ID NO: 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 136, 138, 140, 142 or are variants of these sequences capable of encoding the same fusion polypeptide or a fusion polypeptide which is biologically equivalent thereto, e.g. an isoform, or a splice variant or a homologue from another species.

20

25

## Screening program

The present invention describes a method that may be used to establish a screening program for the identification of biologically active substances that directly or indirectly affects intracellular signalling pathways and because of this property are potentially useful as medicaments. Based on measurements in living cells of the redistribution of spatially resolved luminescence from luminophores which undergo a change in distribution upon activation or deactivation of an intracellular signalling pathway the result of the individual measurement of each substance being screened indicates its potential biological activity.

In one embodiment of the invention the screening program is used for the identification of a biologically toxic substance as defined herein that exerts its toxic effect by interfering with an intracellular signalling pathway. Based on measurements in living cells of the redistribution of spatially resolved luminescence from luminophores which undergo a change in distribution upon activation or deactivation of an intracellular signalling pathway the result of the individual measurement of each substance being screened indicates its potential biologically toxic activity. In one embodiment of a screening program a compound that modulates a component of an intracellular pathway as defined herein, can be found and the therapeutic amount of the compound estimated by a method according to the method of the invention. In a preferred embodiment the present invention leads to the discovery of a new way of treating a condition or disease related to the intracellular function of a biologically active polypeptide comprising administration to a patient suffering from said condition or disease of an effective amount of a compound which has been discovered by any method according to the invention. In another preferred embodiment of the invention a method is established for identification of a new drug target or several new drug targets among the group of biologically active polypeptides which are components of intracellular signalling pathways.

In another embodiment of the invention an individual treatment regimen is established for the selective treatment of a selected patient suffering from an ailment where the available medicaments used for treatment of the ailment are tested on a relevant primary cell or cells obtained from said patient from one or several tissues, using a method comprising transfecting the cell or cells with at least one DNA sequence encoding a fluorescent probe according to the invention, transferring the transfected cell or cells back the said patient, or culturing the cell or cells under conditions permitting the expression of said probes and exposing it to an array of the available medicaments, then comparing changes in fluorescence patterns or redistribution patterns of the fluorescent probes in the intact living cell or cells to

detect the cellular response to the specific medicaments (obtaining a cellular action profile), then selecting one or more medicament or medicaments based on the desired activity and acceptable level of side effects and administering an effective amount of these medicaments to the selected patient.

5

10

20

25

30

# Back-tracking of a signal transduction pathway

The present invention describes a method that may be used to establish a screening program for back-tracking signal transduction pathways as defined herein. In one embodiment the screening program is used to establish more precisely at which level one or several compounds affect a specific signal transduction pathway by successively or in parallel testing the influence of the compound or compounds on the redistribution of spatially resolved luminescence from several of the luminophores which undergo a change in distribution upon activation or deactivation of the intracellular signalling pathway under study.

# 15 Construction and testing of probes

In general, a probe, i.e. a "GeneX"-GFP fusion or a GFP-"GeneX" fusion, is constructed using PCR with "GeneX"-specific primers followed by a cloning step to fuse "GeneX" in frame with GFP. The fusion may contain a short vector derived sequence between "GeneX" and GFP (e.g. part of a multiple cloning site region in the plasmid) resulting in a peptide linker between "GeneX" and GFP in the resulting fusion protein.

## Detailed stepwise procedure:

- Identifying the sequence of the gene. This is most readily done by searching a depository of genetic information, e.g. the GenBank Sequence Database, which is widely available and routinely used by molecular biologists. In the specific examples below the GenBank Accession number of the gene in question is provided.
- Design of gene-specific primers. Inspection of the sequence of the gene allows design of gene-specific primers to be used in a PCR reaction. Typically, the top-strand primer encompasses the ATG start codon of the gene and the following ca. 20 nucleotides, while the bottom-strand primer encompasses the stop codon and the ca. 20 preceding nucleotides, if

the gene is to be fused behind GFP, i.e. a GFP-"GeneX" fusion. If the gene is to be fused in front of GFP, i.e. a "GeneX"-GFP fusion, a stop codon must be avoided. Optionally, the full length sequence of GeneX may not be used in the fusion, but merely the part which localizes and redistributes like GeneX in response to a signal.

5

10

In addition to gene-specific sequences, the primers contain at least one recognition sequence for a restriction enzyme, to allow subsequent cloning of the PCR product. The sites are chosen so that they are unique in the PCR product and compatible with sites in the cloning vector. Furthermore, it may be necessary to include an exact number of nucleotides between the restriction enzyme site and the gene-specific sequence in order to establish the correct reading frame of the fusion gene and/or a translation initiation consensus sequence. Lastly, the primers always contain a few nucleotides in front of the restriction enzyme site to allow efficient digestion with the enzyme.

- -Identifying a source of the gene to be amplified. In order for a PCR reaction to produce a product with gene-specific primers, the gene-sequence must initially be present in the reaction, e.g. in the form of cDNA. Information in GenBank or the scientific literature will usually indicate in which tissue(s) the gene is expressed, and cDNA libraries from a great variety of tissues or cell types from various species are commercially available, e.g. from Clontech
   (Palo Alto), Stratagene (La Jolla) and Invitrogen (San Diego). Many genes are also available in cloned form from The American Type Tissue Collection (Virginia).
  - Optimizing the PCR reaction. Several factors are known to influence the efficiency and specificity of a PCR reaction, including the annealing temperature of the primers, the concentration of ions, notably Mg²+ and K+, present in the reaction, as well as pH of the reaction. If the result of a PCR reaction is deemed unsatisfactory, it might be because the parameters mentioned above are not optimal. Various annealing temperatures should be tested, e.g. in a PCR machine with a built-in temperature gradient, available from e.g. Stratagene (La Jolla), and/or various buffer compositions should be tried, e.g. the OptiPrime buffer system from Stratagene (La Jolla).

25

- Cloning the PCR product. The vector into which the amplified gene product will be cloned and fused with GFP will already have been taken into consideration when the primers were designed. When choosing a vector, one should at least consider in which cell types the probe subsequently will be expressed, so that the promoter controlling expression of the probe is compatible with the cells. Most expression vectors also contain one or more selective markers, e.g. conferring resistance to a drug, which is a useful feature when one wants to make stable transfectants. The selective marker should also be compatible with the cells to be used.
- The actual cloning of the PCR product should present no difficulty as it typically will be a one-step cloning of a fragment digested with two different restriction enzymes into a vector digested with the same two enzymes. If the cloning proves to be problematic, it may be because the restriction enzymes did not work well with the PCR fragment. In this case one could add longer extensions to the end of the primers to overcome a possible difficulty of digestion close to a fragment end, or one could introduce an intermediate cloning step not based on restriction enzyme digestion. Several companies offer systems for this approach, e.g. Invitrogen (San Diego) and Clontech (Palo Alto).

Once the gene has been cloned and, in the process, fused with the GFP gene, the resulting product, usually a plasmid, should be carefully checked to make sure it is as expected. The most exact test would be to obtain the nucleotide sequence of the fusion-gene.

## Testing the probe

Once a DNA construct for a probe has been generated, its functionality and usefulness may be tested by subjecting it to the following tests:

- Transfecting it into cells capable of expressing the probe. The fluorescence of the cell is inspected soon after, typically the next day. At this point, two features of cellular fluorescence are noted: the intensity and the sub-cellular localization.

The intensity should usually be at least as strong as that of unfused GFP in the cells. If it is not, the sequence or quality of the probe-DNA might be faulty, and should be carefully checked.

The sub-cellular localization is an indication of whether the probe is likely to perform well. If it localizes as expected for the gene in question, e.g. is excluded from the nucleus, it can immediately go on to a functional test. If the probe is not localized soon after the transfection procedure, it may be because of overexpression at this point in time, as the cell typically will have taken of very many copies of the plasmid, and localization will occur in time, e.g. within a few weeks, as plasmid copy number and expression level decreases. If localization does not occur after prolonged time, it may be because the fusion to GFP has destroyed a localization function, e.g. masked a protein sequence essential for interaction with its normal cellular anchor-protein. In this case the opposite fusion might work, e.g. if GeneX-GFP does not work, GFP-GeneX might, as two different parts of GeneX will be affected by the proximity to GFP. If this does not work, the proximity of GFP at either end might be a problem, and it could be attempted to increase the distance by incorporating a longer linker between GeneX and GFP in the DNA construct.

If there is no prior knowledge of localization, and no localization is observed, it may be because the probe should not be localized at this point, because such is the nature of the protein fused to GFP. It should then be subjected to a functional test.

In a functional test, the cells expressing the probe are treated with at least one compound known to perturb, usually by activating, the signalling pathway on which the probe is expected to report by redistributing itself within the cell. If the redistribution is as expected, e.g. if prior knowledge tell that it should translocate from location X to location Y, it has passed the first critical test. In this case it can go on to further characterization and quantification of the response.

If it does not perform as expected, it may be because the cell lacks at least one component of the signalling pathway, e.g. a cell surface receptor, or there is species incompatibility, e.g. if the probe is modelled on sequence information of a human geneproduct, and the cell is of hamster origin. In both instances one should identify other cell types for the testing process where these potential problems would not apply.

20

25

20

25

30 -

If there is no prior knowledge about the pattern of redistribution, the analysis of the redistribution will have to be done in greater depth to identify what the essential and indicative features are, and when this is clear, it can go on to further characterization and quantification of the response. If no feature of redistribution can be identified, the problem might be as mentioned above, and the probe should be retested under more optimal cellular conditions.

If the probe does not perform under optimal cellular conditions it's back to the drawing board.

## Developing an image-based assay technique

The process of developing an image-based redistribution assay begins with either the unplanned experimental observation that a redistribution phenomenon can be visualised, or the design of a probe specifically to follow a redistribution phenomenon already known to occur. In either event, the first and best exploratory technique is for a trained scientist or technician to observe the phenomenon. Even with the rapid advances in computing technology, the human eye-brain combination is still the most powerful pattern recognition system known, and requires no advance knowledge of the system in order to detect potentially interesting and useful patterns in raw data. This is especially if those data are presented in the form of images, which are the natural "data type" for human visual processing. Because human visual processing operates most effectively in a relatively narrow frequency range, i.e., we cannot see either very fast or very slow changes in our visual field, it may be necessary to record the data and play it back with either time dilation or time compression.

Some luminescence phenomena cannot be seen directly by the human eye. Examples include polarization and fluorescence lifetime. However, with suitable filters or detectors, these signals can be recorded as images or sequences of images and displayed to the human in the fashion just described. In this way, patterns can be detected and the same methods can be applied.

Once the redistribition has been determined to be a reproducible phenomenon, one or more data sets are generated for the purpose of developing a procedure for extracting the quantitative information from the data. In parallel, the biological and optical conditions are determined which will give the best quality raw data for the assay. This can become an iterative process; it may be necessary to develop a quantitative procedure in order to assess the effect on the assay of manipulating the assay conditions.

The data sets are examined by a person or persons with knowledge of the biological phenomenon and skill in the application of image processing techniques. The goal of this exercise is to determine or at least propose a method which will reduce the image or sequence of images constituting the record of a "response" to a value corresponding to the degree of the response. Using either interactive image processing software or an image processing toolbox and a programming language, the method is encoded as a procedure or algorithm which takes the image or images as input and generates the degree of response (in any units) as its output. Some of the criteria for evaluating the validity of a particular procedure are:

- Does the degree of the response vary in a biologically significant fashion, i.e., does it show the known or putative dependence on the concentration of the stimulating agent or condition?
- Is the degree of response reproducible, i.e., does the same concentration or level of stimulating agent or condition give the same response with an acceptable variance?
- Is the dynamic range of the response sufficient for the purpose of the assay? If not,
   can a change in the procedure or one of its parameters improve the dynamic range?
- Does the procedure exhibit any clear "pathologies", i.e., does it give ridiculous values for the response if there are commonly occurring imperfections in the imaging process? Can these pathologies be eliminated, controlled, or accounted for?
- Can the procedure deal with the normal variation in the number and/or size of cells in an image?

In some cases the method may be obvious; in others, a number of possible procedures may suggest themselves. Even if one method appears clearly superior to others, optimisation of parameters may be required. The various procedures are applied to the data set and the criteria suggested above are determined, or the single procedure is applied repeatedly with adjustment of the parameter or parameters until the most satisfactory combination of signal, noise, range, etc. are arrived at. This is equivalent to the calibration of any type of single-channel sensor.

The number of ways of extracting a single value from an image are extremely large, and
thus an intelligent approach must be taken to the initial step of reducing this number to a
small, finite number of possible procedures. This is not to say that the procedure arrived at is

WO 98/45704

5

10

15

20

necessarily the best procedure - but a global search for the best procedure is simply out of the question due to the sheer number of possibilities involved.

Image-based assays are no different than other assay techniques in that their usefulness is characterised by parameters such as the specificity for the desired component of the sample, the dynamic range, the variance, the sensitivity, the concentration range over which the assay will work, and other such parameters. While it is not necessary to characterise each and every one of these before using the assay, they represent the only way to compare one assay with another.

# 10 Example: Developing a Quantitative assay for GLUT4 Translocation

GLUT4 is a member of the class of glucose transporter molecules which are important in cellular glucose uptake. It is known to translocate to the plasma membrane under some conditions of stimulation of glucose uptake. The ability to visualize the glucose uptake response noninvasively, without actually measuring glucose uptake, would be a very useful assay for anyone looking for, for example, treatments for type II diabetes.

A CHO cell line which stably expressed the human insulin receptor was used as the basis for a new cell line which stably expressed a fusion between GLUT4 and GFP. This cell line was expected to show translocation of GLUT4 to the plasma membrane as visualized by the movement of the GFP. The translocation could definitely be seen in the form of the appearance of local increases in the fluorescence in regions of the plasma membrane which had a characteristic shape or pattern. This is shown in Figure 12.

These objects became known as "snircles", and the phenomenon of their appearance as "snircling". In order to quantitate their appearance, a method had to be found to isolate them as objects in the image field, and then enumerate them, measure their area, or determine some parameter about them which correlated in a dose-dependent fashion with the concentration of insulin to which the cells had been exposed. In order to separate the snircles, a binarization procedure was applied in which one copy of the image smoothed with a relatively severe gaussian kernel (sigma = 2.5) was subtracted from another copy to which only a relatively light gaussian smooth had been applied (sigma=0.5). The resultant image was rescaled to its min/max range, and an automatic threshold was applied to divide the image into two levels. The thresholded image contains a background of one value all found object with another value. The found objects were first filtered through a filter to remove objects far too

15

20

25

large and far too small to be snircles. The remaining objects, which represent snircles and other artifacts from the image with approximately the same size and intensity characteristics as snircles, are passed into a classification procedure which has been previously trained with many images of snircles to recognize snircles and exclude the other artifacts. The result of this procedure is a binary image which shows only the found snircles to the degree to which the classification procedure can accurately identify them. The total area of the snircles is then summed and this value is the quantitative measure of the degree of snircling for that image.

#### 10. Definitions:

5

15

20

25

30

In the present specification and claims, the term "an influence" covers any influence to which the cellular response comprises a redistribution. Thus, e.g., heating, cooling, high pressure, low pressure, humidifying, or drying are influences on the cellular response on which the resulting redistribution can be quantified, but as mentioned above, perhaps the most important influences are the influences of contacting or incubating the cell or cells with substances which are known or suspected to exert and influence on the cellular response involving a redistribution contribution. In another embodiment of the invention the influence could be substances from a compound drug library.

In the present context, the term "green fluorescent protein" is intended to indicate a protein which, when expressed by a cell, emits fluorescence upon exposure to light of the correct excitation wavelength (cf. [(Chalfie et al.1994)]). In the following, GFP in which one or more amino acids have been substituted, inserted or deleted is most often termed "modified GFP". "GFP" as used herein includes wild-type GFP derived from the jelly fish *Aequorea victoria* and modifications of GFP, such as the blue fluorescent variant of GFP disclosed by Heim et al. (1994). Proc.Natl.Acad.Sci. 91:12501, and other modifications that change the spectral properties of the GFP fluorescence, or modifications that exhibit increased fluorescence when expressed in cells at a temperature above about 30°C described in PCT/DK96/00051, published as WO 97/11094 on 27 March 1997 and hereby incorporated by reference, and which comprises a fluorescent protein derived from *Aequorea* Green Fluorescent Protein (GFP) or any functional analogue thereof, wherein the amino acid in position 1 upstream from the chromophore has been mutated to provide an increase of fluorescence intensity when the

20

25

fluorescent protein of the invention is expressed in cells. Preferred GFP variants are F64L-GFP, F64L-Y66H-GFP and F64L-S65T-GFP. An especially preferred variant of GFP for use in all the aspects of this invention is EGFP (DNA encoding EGFP which is a F64L-S65T variant with codons optimized for expression in mammalian cells is available from Clontech, Palo Alto, plasmids containing the EGFP DNA sequence, cf. GenBank Acc. Nos. U55762, U55763).

The term "intracellular signalling pathway" and "signal transduction pathway" are intended to indicate the coordinated intracellular processes whereby a living cell transduce an external or internal signal into cellular responses. Said signal transduction will involve an enzymatic reaction said enzymes include but are not limited to protein kinases, GTPases, ATPases, protein phosphatases, phospholipases. The cellular responses include but are not limited to gene transcription, secretion, proliferation, mechanical activity, metabolic activity, cell death.

The term "second messenger" is used to indicate a low molecular weight component involved in the early events of intracellular signal transduction pathways.

The term "luminophore" is used to indicate a chemical substance which has the property of emitting light either inherently or upon stimulation with chemical or physical means. This includes but is not limited to fluorescence, bioluminescence, phosphorescence, chemiluminescence.

The term "mechanically intact living cell" is used to indicate a cell which is considered living according to standard criteria for that particular type of cell such as maintenance of normal membrane potential, energy metabolism, proliferative capability, and has not experienced any physically invasive treatment designed to introduce external substances into the cell such as microinjection.

The term "physiologically relevant" ,when applied to an experimentally determined redistribution of an intracellular component, as measured by a change in the luminescence properties or distribution, is used to indicate that said redistribution can be explained in terms of the underlying biological phenomenon which gives rise to the redistribution.

10

Th terms "image processing" and "image analysis" are used to describe a large family of digital data analysis techniques or combination of such techniques which reduce ordered arrays of numbers (images) to quantitative information describing those ordered arrays of numbers. When said ordered arrays of numbers represent measured values from a physical process, the quantitative information derived is therefore a measure of the physical process.

The term "fluorescent probe" is used to indicate a fluorescent fusion polypeptide comprising a GFP or any functional part thereof which is N- or C-terminally fused to a biologically active polypeptide as defined herein, optionally via a peptide linker consisting of one or more amino acid residues, where the size of the linker peptide in itself is not critical as long as the desired functionality of the fluorescent probe is maintained. A fluorescent probe according to the invention is expressed in a cell and basically mimics the physiological behaviour of the biologically active polypeptide moiety of the fusion polypeptide.

The term "mammalian cell" is intended to indicate any living cell of mammalian origin. The 15 cell may be an established cell line, many of which are available from The American Type Culture Collection (ATCC, Virginia, USA) or a primary cell with a limited life span derived from a mammalian tissue, including tissues derived from a transgenic animal, or a newly established immortal cell line derived froma mammalian tissue including transgenic tissues, or a hybrid cell or cell line derived by fusing different celltypes of mammalian origin e.g. hy-20 bridoma cell lines. The cells may optionally express one or more non-native gene products, e.g. receptors, enzymes, enzyme substrates, prior to or in addition to the fluorescent probe. Preferred cell lines include but are not limited to those of fibroblast origin, e.g. BHK, CHO, BALB, or of endothelial origin, e.g. HUVEC, BAE (bovine artery endothelial), CPAE (cow pulmonary artery endothelial) or of pancreatic origin, e.g. RIN, INS-1, MIN6, bTC3, aTC6, 25 bTC6, HIT, or of hematopoietic origin, e.g. adipocyte origin, e.g. 3T3-L1, neuronal/neuroendocrine origin, e.g. AtT20, PC12, GH3, muscle origin, e.g. SKMC, A10, C2C12, renal origin, e.g. HEK 293, LLC-PK1.

The term "hybrid polypeptide" is intended to indicate a polypeptide which is a fusion of at least a portion of each of two proteins, in this case at least a portion of the green fluorescent protein, and at least a portion of a catalytic and/or regulatory domain of a protein kinase. Furthermore a hybrid polypeptide is intended to indicate a fusion polypeptide comprising a

20

25

30

GFP or at least a portion of the green fluorescent protein that contains a functional fluorophore, and at least a portion of a biologically active polypeptide as defined herein provided that said fusion is not the PKC $\alpha$ -GFP, PKC $\gamma$ -GFP, and PKC $\epsilon$ -GFP disclosed by Schmidt et al.and Sakai et al., respectively. Thus, GFP may be N- or C-terminally tagged to a biologically active polypeptide, optionally via a linker portion or linker peptide consisting of a sequence of one or more amino acids. The hybrid polypeptide or fusion polypeptide may act as a fluorescent probe in intact living cells carrying a DNA sequence encoding the hybrid polypeptide under conditions permitting expression of said hybrid polypeptide.

The term "kinase" is intended to indicate an enzyme that is capable of phosphorylating a cellular component.

The term "protein kinase" is intended to indicate an enzyme that is capable of phosphorylating serine and/or threonine and/or tyrosine in peptides and/or proteins.

The term "phosphatase" is intended to indicate an enzyme that is capable of dephosphorylating phosphoserine and/or phosphothreonine and/or phosphotyrosine in peptides and/or proteins.

In the present context, the term "biologically active polypeptide" is intended to indicate a polypeptide affecting intracellular processes upon activation, such as an enzyme which is active in intracellular processes or a portion thereof comprising a desired amino acid sequence which has a biological function or exerts a biological effect in a cellular system. In the polypeptide one or several aminoacids may have been deleted, inserted or replaced to alter its biological function, e.g. by rendering a catalytic site inactive. Preferably, the biologically active polypeptide is selected from the group consisting of proteins taking part in an intracellular signalling pathway, such as enzymes involved in the intracellular phosphorylation and dephosphorylation processes including kinases, protein kinases and phosphorylases as defined herein, but also proteins making up the cytoskeleton play important roles in intracellular signal transduction and are therefore included in the meaning of "biologically active polypeptide" herein. More preferably, the biologically active polypeptide is a protein which according to its state as activated or non-activated changes localisation within the cell, preferably as an in-

termediary component in a signal transduction pathway. Included in this preferred group of biologically active polypeptides are cAMP dependent protein kinase A.

The term "a substance having biological activity" is intended to indicate any sample which has a biological function or exerts a biological effect in a cellular system. The sample may be a sample of a biological material such as a sample of a body fluid including blood, plasma, saliva, milk, urine, or a microbial or plant extract, an environmental sample containing pollutants including heavy metals or toxins, or it may be a sample containing a compound or mixture of compounds prepared by organic synthesis or genetic techniques.

10

15

20

The phrase "any change in fluorescence" means any change in absorption properties, such as wavelength and intensity, or any change in spectral properties of the emitted light, such as a change of wavelength, fluorescence lifetime, intensity or polarisation, or any change in the intracellular localisation of the fluorophore. It may thus be localised to a specific cellular component (e.g. organelle, membrane, cytoskeleton, molecular structure) or it may be evenly distributed throughout the cell or parts of the cell.

The phrase "back-tracking of a signal transduction pathway" is intended to indicate.

The term "organism" as used herein indicates any unicellular or multicellular organism preferably originating from the animal kingdom including protozoans, but also organisms that are members of the plant kingdoms, such as algae, fungi, bryophytes, and vascular plants are included in this definition.

The term "nucleic acid" is intended to indicate any type of poly- or oligonucleic acid sequence, such as a DNA sequence, a cDNA sequence, or an RNA sequence.

25

30

The term "biologically equivalent" as it relates to proteins is intended to mean that a first protein is equivalent to a second protein if the cellular functions of the two proteins may substitute for each other, e.g. if the two proteins are closely related isoforms encoded by different genes, if they are splicing variants, or allelic variants derived from the same gene, if they perform identical cellular functions in different cell types, or in different species. The term "biologically equivalent" as it relates to DNA is intended to mean that a first DNA sequ-

ence encoding a polypeptide is equivalent to a second DNA sequence encoding a polypeptide if the functional proteins encoded by the two genes are biologically equivalent.

The phrase "back-tracking of a signal transduction pathway" is intended to indicate a process for defining more precisely at what level a signal transduction pathway is affected, either by the influence of chemical compounds or a disease state in an organism. Consider a specific signal transduction pathway represented by the bioactive polypeptides A - B - C - D, with signal transduction from A towards D. When investigating all components of this signal transduction pathway compounds or disease states that influence the activity or redistribution of only D can be considered to act on C or downstream of C whereas compounds or disease states that influence the activity or redistribution of C and D, but not of A and B can be considered to act downstream of B.

The term "fixed cells" is used to mean cells treated with a cytological fixative such as glutaraldehyde or formaldehyde, treatments which serve to chemically cross-link and stabilize soluble and insoluble proteins within the structure of the cell. Once in this state, such proteins cannot be lost from the structure of the now-dead cell.

20

25

15

. 10

## **BRIEF DESCRIPTION OF THE DRAWINGS**

Figure 1. CHO cells expressing the PKAc-F64L-S65T-GFP hybrid protein have been treated in HAM's F12 medium with 50 mM forskolin at 37°C. The images of the GFP fluorescence in these cells have been taken at different time intervals after treatment, which were: a) 40 seconds b) 60 seconds c) 70 seconds d) 80 seconds. The fluorescence changes from a punctate to a more even distribution within the (non-nuclear) cytoplasm.

15

20

25.

30

Figure 2. Time-lapse analysis of forskolin induced PKAc-F64L-S65T-GFP redistribution. CHO cells, expressing the PKAc-F64L-S65T-GFP fusion protein were analysed by time-lapse fluorescence microscopy. Fluorescence micrographs were acquired at regular intervals from 2 min before to 8 min after the addition of agonist. The cells were challenged with 1 mM forskolin immediately after the upper left image was acquired (t=0). Frames were collected at the following times: i) 0, ii) 1, iii) 2, iv) 3, v) 4 and vi) 5 minutes. Scale bar 10 mm.

Figure 3. Time-lapse analyses of PKAc-F64L-S65T-GFP redistribution in response to various agonists. The effects of 1 mM forskolin (A), 50 mM forskolin (B), 1mM dbcAMP (C) and 100 mM IBMX (D) (additions indicated by open arrows) on the localisation of the PKAc-F64L-S65T-GFP fusion protein were analysed by time-lapse fluorescence microscopy of CHO/PKAc-F64L-S65T-GFP cells. The effect of addition of 10 mM forskolin (open arrow), followed shortly by repeated washing with buffer (solid arrow), on the localisation of the PKAc-F64L-S65T-GFP fusion protein was analysed in the same cells (E). In a parallel experiment, the effect of adding 10 mM forskolin and 100 mM IBMX (open arrow) followed by repeated washing with buffer containing 100 mM IBMX (solid arrow) was analysed (F). Removing forskolin caused PKAc-F64L-S65T-GFP fusion protein to return to the cytoplasmic aggregates while this is prevented by the continued presence of IBMX (F). The effect of 100 nM glucagon (Fig 3G, open arrow) on the localisation of the PKAc-F64L-S65T-GFP fusion protein is also shown for BHK/GR, PKAc-F64L-S65T-GFP cells. The effect of 10 mM norepinephrine (H), solid arrow, on the localisation of the PKAc-F64L-S65T-GFP fusion protein was analysed similarly, in transiently transfected CHO, PKAc-F64L-S65T-GFP cells, pretreated with 10 mM forskolin, open arrow, to increase [cAMP], N.B. in Fig 3H the x-axis counts the image numbers, with 12 seconds between images. The raw data of each experiment consisted of 60 fluorescence micrographs acquired at regular intervals including several images acquired before the addition of buffer or agonist. The charts (A-G) each show a quantification of the response seen through all the 60 images, performed as described in analysis method 2. The change in total area of the highly fluorescent aggregates, relative to the initial area of fluorescent aggregates is plotted as the ordinate in all graphs in Figure 3, versus time for each experiment. Scale bar 10 mm.

Figure 4. Dose response curve (two experiments) for forskolin-induced redistribution of the PKAc-F64L-S65T-GFP fusion.

5

10

Figure 5. Time from initiation of a response to half maximal ( $t_{1/2max}$ ) and maximal ( $t_{max}$ ) PKAc-F64L-S65T-GFP redistribution. The data was extracted from curves such as that shown in "Figure 2." All  $t_{1/2max}$  and  $t_{max}$  values are given as mean±SD and are based on a total of 26-30 cells from 2-3 independent experiments for each forskolin concentration. Since the observed redistribution is sustained over time, the  $t_{max}$  values were taken as the earliest time point at which complete redistribution is reached. Note that the values do not relate to the degree of redistribution.

15

Figure 6. Parallel dose response analyses of forskolin induced cAMP elevation and PKAc-F64L-S65T-GFP redistribution. The effects of buffer or 5 increasing concentrations of forskolin on the localisation of the PKAc-F64L-S65T-GFP fusion protein in CHO/PKAc-F64L-S65T-GFP cells, grown in a 96 well plate, were analysed as described above. Computing the ratio of the SD's of fluorescence micrographs taken of the same field of cells, prior to and 30 min after the addition of forskolin, gave a reproducible measure of PKAc-F64L-S65T-GFP redistribution. The graph shows the individual 48 measurements and a trace of their mean±s.e.m at each forskolin concentration. For comparison, the effects of buffer or 8 increasing concentrations of forskolin on [cAMP], was analysed by a scintillation proximity assay of cells grown under the same conditions. The graph shows a trace of the mean ± s.e.m of 4 experiments expressed in arbitrary units.

25

30

20

Figure 7. BHK cells stably transfected with the human muscarinic (hM1) receptor and the PKCa-F64L-S65T-GFP fusion. Carbachol (100 mM added at 1.0 second) induced a transient redistribution of PKCa-F64L-S65T-GFP from the cytoplasm to the plasma membrane. Images were taken at the following times: a) 1 second before carbachol addition, b) 8.8 seconds after addition and c) 52.8 seconds after addition.

Figure 8. BHK cells stably transfected with the hM1 receptor and PKCa-F64L-S65T-GFP fusion were treated with carbachol (1 mM, 10 mM, 100 mM). In single cells intracellular [Ca²+] was monitored simultaneously with the redistribution of PKCa-F64L-S65T-GFP. Dashed line indicates the addition times of carbachol. The top panel shows changes in the intracellular Ca²+ concentration of individual cells with time for each treatment. The middle panel shows changes in the average cytoplasmic GFP fluorescence for individual cells against time for each treatment. The bottom panel shows changes in the fluorescence of the periphery of single cells, within regions that specifically include the circumferential edge of a cell as seen in normal projection, the regions which offers best chance to monitor changes in the fluorescence intensity of the plasma membrane.

Figure 9. a) The hERK1-F64L-S65T-GFP fusion expressed in HEK293 cells treated with 100 mM of the MEK1 inhibitor PD98059 in HAM F-12 (without serum) for 30 minutes at 37 °C. The nuclei empty of fluorescence during this treatment.

- b) The same cells as in (a) following treatment with 10 % foetal calf serum for 15 minutes at 37 °C.
- c) Time profiles for the redistribution of GFP fluorescence in HEK293 cells following treatment with various concentrations of EGF in Hepes buffer (HAM F-12 replaced with Hepes buffer directly before the experiment). Redistribution of fluorescence is expressed as the change in the ratio value between areas in nucleus and cytoplasm of single cells. Each time profile is the mean for the changes seen in six single cells.
- d) Bar chart for the end-point measurements, 600 seconds after start of EGF treatments, of fluorescence change (nucleus:cytoplasm) following various concentrations of EGF.

25

10

15

20

Figure 10.

- a) The SMAD2-EGFP fusion expressed in HEK293 cells starved of serum overnight in HAM F-12. HAM F-12 was then replaced with Hepes buffer pH 7.2 immediately before the experiment. Scale bar is 10 mm.
- b) HEK 293 cells expressing the SMAD2-EGFP fusion were treated with various concentration of TGF-beta as indicated, and the redistribution of fluorescence monitored against time.

WO 98/45704 PCT/DK98/00145

29

The time profile plots represent increases in fluorescence within the nucleus, normalised to starting values in each cell measured. Each trace is the time profile for a single cell nucleus.

c) A bar chart representing the end-point change in fluorescence within nuclei (after 850 seconds of treatment) for different concentrations of TGF-beta. Each bar is the value for a single nucleus in each treatment.

Figure 11. The VASP-F64L-S65T-GFP fusion in CHO cells stably transfected with the human insulin receptor. The cells were starved for two hours in HAM F-12 without serum, then treated with 10% foetal calf serum. The image shows the resulting redistribution of fluorescence after 15 minutes of treatment. GFP fluorescence becomes localised in structures identified as focal adhesions along the length of actin stress fibres.

Figure 12. Time lapse recording GLUT4-GFP redistribution in CHO-HIR cells. Time indicates minutes after the addition of 100 nM insulin.

15

10

## **EXAMPLE 1**

Construction, testing and implementation of an assay for cAMP based on PKA activation in real time within living cells.

Useful for monitoring the activity of signalling pathways which lead to altered concentrations of cAMP, e.g. activation of G-protein coupled receptors which couple to G-proteins of the  $G_s$  or  $G_t$  class.

10

20

The catalytic subunit of the murine cAMP dependent protein kinase (PKAc)was fused C-terminally to a F64L-S65T derivative of GFP. The resulting fusion (PKAc-F64L-S65T-GFP) was used for monitoring *in vivo* the translocation and thereby the activation of PKA.

Construction of the PKAc-F64L-S65T-GFP fusion:

15 Convenient restriction endonuclease sites were introduced into the cDNAs encoding murine PKAc (Gen Bank Accession number: M12303) and F64L-S65T-GFP (sequence disclosed in WO 97/11094) by polymerase chain reaction (PCR). The PCR reactions were performed according to standard protocols with the following primers:

5'PKAc: TTggACACAAgCTTTggACACCCTCAggATATgggCAACgCCgCCgCCGCCAAg (SEQ ID NO:3),

3'PKAc: gTCATCTTCTCgAgTCTTTCAggCgCgCCCAAACTCAgTAAACTCCTTgCCACAC (SEQ ID NO:4),

5'GFP: TTggACACAAgCTTTggACACggCgCCCATgAgTAAAggAgAAGAACTTTTC (SEQ ID NO:1),

25 3'GFP: gTCATCTTCTCgAgTCTTACTCCTgAggTTTgTATAgTTCATCCATgCCATgT (SEQ ID NO:2).

The PKAc amplification product was then digested with HindIII+AscI and the F64L-S65T-GFP product with AscI+XhoI. The two digested PCR products were subsequently ligated with a HindIII+XhoI digested plasmid (pZeoSV® mammalian expression vector, Invitrogen, San Diego, CA, USA). The resulting fusion construct (SEQ ID NO:68 & 69) was under control of the SV40 promoter.

Transfection and cell culture conditions.

Chinese hamster ovary cells (CHO), were transfected with the plasmid containing the PKAc-F64L-S65T-GFP fusion using the calcium phosphate precipitate method in HEPES-buffered saline (Sambrook *et al.*, 1989). Stable transfectants were selected using 1000 mg Zeocin/ml (Invitrogen) in the growth medium (DMEM with 1000 mg glucose/l, 10 % fetal bovine serum (FBS), 100 mg penicillin-streptomycin mixture ml<sup>-1</sup>, 2 mM L-glutamine purchased from Life Technologies Inc., Gaithersburg, MD, USA). Untransfected CHO cells were used as the control. To assess the effect of glucagon on fusion protein translocation, the PKAc-F64L-S65T-GFP fusion was stably expressed in baby hamster kidney cells overexpressing the human glucagon receptor (BHK/GR cells) Untransfected BHK/GR cells were used as the control. Expression of GR was maintained with 500 mg G418/ml (*Neo* marker) andPKAc-F64L-S65T-GFP was maintained with 500 mg Zeocin/ml (*Sh ble* marker). CHO cells were also simultaneously co-transfected with vectors containing the PKAc-F64L-S65T-GFP fusion and the human a2a adrenoceptor (hARa2a).

For fluorescence microscopy, cells were allowed to adhere to Lab-Tek chambered coverglasses (Nalge Nunc Int., Naperville, IL, USA) for at least 24 hours and cultured to about 80% confluence. Prior to experiments, the cells were cultured over night without selection pressure in HAM F-12 medium with glutamax (Life Technologies), 100 mg penicillinstreptomycin mixture ml<sup>-1</sup> and 0.3 % FBS. This medium has low autofluorescence enabling fluorescence microscopy of cells straight from the incubator.

Monitoring activity of PKA activity in real time:

Image aquisition of live cells were gathered using a Zeiss Axiovert 135M fluorescence microscope fitted with a Fluar 40X, NA: 1.3 oil immersion objective and coupled to a Photometrics CH250 charged coupled device (CCD) camera. The cells were illuminated with a 100 W HBO arc lamp. In the light path was a 470±20 nm excitation filter, a 510 nm dichroic mirror

30

10

and a 515±15 nm emission filter for minimal image background. The cells were kept and monitored to be at 37°C with a custom built stage heater.

Images were processed and analyzed in the following manner:.

Method 1: Stepwise procedure for quantitation of translocation of PKA:

- 5 1. The image was corrected for dark current by performing a pixel-by-pixel subtraction of a dark image (an image taken under the same conditions as the actual image, except the camera shutter is not allowed to open).
  - 2. The image was corrected for non-uniformity of the illumination by performing a pixel-by-pixel ratio with a flat field correction image (an image taken under the same conditions as the actual image of a uniformly fluorescent specimen).
  - 3. The image histogram, i.e., the frequency of occurrence of each intensity value in the image, was calculated.
  - 4. A smoothed, second derivative of the histogram was calculated and the second zero is determined. This zero corresponds to the inflection point of the histogram on the high side of the main peak representing the bulk of the image pixel values.
  - 5. The value determined in step 4 was subtracted from the image. All negative values were discarded.
  - 6. The variance (square of the standard deviation) of the remaining pixel values was determined. This value represents the "response" for that image.
- 20 7. Scintillation proximity assay (SPA) for independent quantitation of cAMP:

10

### Method 2: Alternative method for quantitation of PKA redistribution:

- The fluorescent aggregates are segmented from each image using an automatically found threshold based on the maximisation of the information measure between the object and background. The *a priori* entropy of the image histogram is used as the information measure.
  - 2. The area of each image occupied by the aggregates is calculated by counting pixels in the segmented areas.
- 3. The value obtained in step 2 for each image in a series, or treatment pair, is normalised to the value found for the first (unstimulated) image collected. A value of zero (0) indicates no redistribution of fluorescence from the starting condition. A value of one (1) by this method equals full redistribution.
- 15 Cells were cultured in HAM F-12 medium as described above, but in 96-well plates. The medium was exchanged with Ca<sup>2+</sup>-HEPES buffer including 100 mM IBMX and the cells were stimulated with different concentrations of forskolin for 10 min. Reactions were stopped with addition of NaOH to 0.14 M and the amount of cAMP produced was measured with the cAMP-SPA kit, RPA538 (Amersham) as described by the manufacturer.

20

Manipulating intracellular levels of cAMP to test the PKAc-F64L-S65T-GFP fusion.

The following compounds were used to vary cAMP levels: Forskolin, an activator of adenylate cyclase; dbcAMP, a membrane permeable cAMP analog which is not degraded by phosphodiesterase; IBMX, an inhibitor of phosphodiesterase.

- 25 CHO cells stably expressing the PKAc-F64L-S65T-GFP, showed a dramatic translocation of the fusion protein from a punctate distribution to an even distribution throughout the cytoplasm following stimulation with 1 mM forskolin (n=3), 10 mM forskolin (n=4) and 50 mM forskolin (n=4) (Fig 1), or dbcAMP at 1mM (n=6).
  - Fig. 2 shows the progression of response in time following treatment with 1 mM forskolin.

Fig. 3 gives a comparison of the average temporal profiles of fusion protein redistribution and a measure of the extent of each response to the three forskolin concentrations (Fig. 3A, E, B), and to 1 mM dbcAMP (fig 3C) which caused a similar but slower response, and to addition of 100 mM IBMX (n=4, Fig. 3D) which also caused a slow response, even in the absence of adenylate cyclase stimulation. Addition of buffer (n=2) had no effect (data not shown).

As a control for the behavior of the fusion protein, F64L-S65T-GFP alone was expressed in CHO cells and these were also given 50 mM forskolin (n=5); the uniform diffuse distribution characteristic of GFP in these cells was unaffected by such treatment (data not shown).

The forskolin induced translocation of PKAc-F64L-S65T-GFP showed a dose-response relationship (Fig 4 and 6), see quantitative procedures above.

Reversibility of PKAc-F64L-S65T-GFP translocation.

The release of the PKAc probe from its cytoplasmic anchoring hotspots was reversible. Washing the cells repeatedly (5-8 times) with buffer after 10µM forskolin treatment completely restored the punctate pattern within 2-5 min (n=2, Fig. 3E). In fact the fusion protein returned to a pattern of fluorescent cytoplasmic aggregates virtually indistinguishable from that observed before forskolin stimulation.

To test whether the return of fusion protein to the cytoplasmic aggregates reflected a decreased [cAMP], cells were treated with a combination of 10 mM forskolin and 100 mM IBMX (n=2) then washed repeatedly (5-8 times) with buffer containing 100 mM IBMX (Fig. 3F). In these experiments, the fusion protein did not return to its prestimulatory localization after removal of forskolin.

Testing the PKA-F64L-S65T-GFP probe with physiologically relevant agents.

To test the probe's response to receptor activation of adenylate cyclase, BHK cells stably transfected with the glucagon receptor and the PKA-F64L-S65T-GFP probe were exposed to glucagon stimulation. The glucagon receptor is coupled to a G<sub>s</sub> protein which activates adenylate cyclase, thereby increasing the cAMP level. In these cells, addition of 100 nM glucagon (n=2) caused the release of the PKA-F64L-S65T-GFP probe from the cytoplasmic aggregates and a resulting translocation of the fusion protein to a more even cytoplasmic

30

15

distribution within 2-3 min (Fig. 3G). Similar but less pronounced effects were seen at lower glucagon concentrations (n=2, data not shown). Addition of buffer (n=2) had no effect over time (data not shown).

Transiently transfected CHO cells expressing hARa2a and the PKA-F64L-S65T-GFP probe were treated with 10 mM forskolin for 7.5 minutes, then, in the continued presence of forskolin, exposed to 10 mM norepinephrine to stimulate the exogenous adrenoreceptors, which couple to a G<sub>1</sub> protein, which inhibit adenylate cyclase. This treatment led to reappearance of fluorescence in the cytoplasmic aggregates indicative of a decrease in [cAMP]<sub>i</sub> (Fig. 3H).

10

15

Fusion protein translocation correlated with [cAMP],

As described above, the time it took for a response to come to completion was dependent on the forskolin dose (Fig. 5) In addition the degree of responses was also dose dependent. To test the PKA-F64L-S65T-GFP fusion protein translocation in a semi high through-put system, CHO cells stably transfected with the PKA-F64L-S65T-GFP fusion was stimulated with buffer and 5 increasing doses of forskolin (n=8). Using the image analysis algorithm described above (Method 1), a dose response relationship was observed in the range from 0.01-50 mM forskolin (Fig. 6). A half maximal stimulation was observed at about 2 mM forskolin. In parallel, cells were stimulated with buffer and 8 increasing concentrations of forskolin (n=4) in the range 0.01-50 mM. The amount of cAMP produced was measured in an SPA assay. A steep increase was observed between 1 and 5 mM forskolin coincident with the steepest part of the curve for fusion protein translocation (also Fig. 6)

#### 25 EXAMPLE 2

Quantitation of redistribution in real-time within living cells.

Probe for detection of PKC activity in real time within living cells:

Construction of PKC-GFP fusion:

The probe was constructed by ligating two restriction enzyme treated polymerase chain reaction (PCR) amplification products of the cDNA for murine PKCα (GenBank Accession number: M25811) and F64L-S65T-GFP (sequence disclosed in WO 97/11094) respectively. Taq® polymerase and the following oligonucleotide primers were used for PCR;

5 5'mPKCa: TTggACACAAgCTTTggACACCCTCAggATATggCTgACgTTTACCCggCCAACg (SEQ ID NO:5),

3'mPKCa: gTCATCTTCTCgAgTCTTTCAggCgCgCCCTACTgCACTTTgCAAgATTgggTgC (SEQ ID NO:6),

5'F64L-S65T-GFP: TTggACACAAgCTTTggACACggCgCgCCATgAgTAAAggAgAAACTT-10 TTC (SEQ ID NO:1),

3'F64L-S65T-GFP: gTCATCTTCTCgAgTCTTACTCCTgAggTTTgTATAgTTCATCCATgC-CATgT (SEQ ID NO:2).

The hybrid DNA strand was inserted into the pZeoSV® mammalian expression vector as a HindIII-XhoI casette as described in example 1.

#### 15 Cell Culture:

BHK cells expressing the human M1 receptor under the control of the inducible metal-lothionine promoter and maintained with the dihydrofolate reductase marker were transfected with the PKCα-F64L-S65T-GFP probe using the calcium phosphate precipitate method in HEPES buffered saline (HBS [pH 7.10]). Stable transfectants were selected using 1000 μg Zeocin®/ml in the growth medium (DMEM with 1000 mg glucose/l, 10 % foetal bovine serum (FBS), 100 mg penicillin-streptomycin mixture ml-1, 2 mM l-glutamine). The hM1 receptor and PKCα-F64L-S65T-GFP fusion protein were maintained with 500 nM methotrexate and 500 μg Zeocin®/ml respectively. 24 hours prior to any experiment, the cells were transferred to HAM F-12 medium with glutamax, 100 μg penicillin-streptomycin mixture ml-1 and 0.3 % FBS. This medium relieves selection pressure, gives a low induction of signal transduction pathways and has a low autofluorescence at the relevant wavelength enabling fluorescence microscopy of cells straight from the incubator.

Monitoring the PKC activity in real time:

Digital images of live cells were gathered using a Zeiss Axiovert 135M fluorescence microscope fitted with a 40X, NA: 1.3 oil immersion objective and coupled to a Photometrics

20

20

25

CH250 charged coupled device (CCD) camera. The cells were illuminated with a 100 W arc lamp. In the light path was a 470±20 nm excitation filter, a 510 nm dichroic mirror and a 515±15 nm emission filter for minimal image background. The cells were kept and monitored to be at 37°C with a custom built stage heater.

5 Images were analyzed using the IPLab software package for Macintosh.

Upon stimulation of the M1-BHK cells, stably expressing the PKCα-F64L-S65T-GFP fusion, with carbachol we observed a dose-dependent transient translocation from the cytoplasm to the plasma membrane (Fig. 7a,b,c). Simultaneous measurement of the cytosolic free calcium concentration shows that the carbachol-induced calcium mobilisation precedes the translocation (Fig. 8).

Stepwise procedure for quantitation of translocation of PKC:

- 1. The image was corrected for dark current by performing a pixel-by-pixel subtraction of a dark image (an image taken under the same conditions as the actual image, except the camera shutter is not allowed to open).
- 2. The image was corrected for non-uniformity of the illumination by performing a pixel-bypixel ratio with a flat field correction image (an image taken under the same conditions as the actual image of a uniformly fluorescent specimen).
  - 3. A copy of the image was made in which the edges are identified. The edges in the image are found by a standard edge-detection procedure convolving the image with a kernel which removes any large-scale unchanging components (i.e., background) and accentuates any small-scale changes (i.e., sharp edges). This image was then converted to a binary image by threshholding. Objects in the binary image which are too small to represent the edges of cells were discarded. A dilation of the binary image was performed to close any gaps in the image edges. Any edge objects in the image which were in contact with the borders of the image are discarded. This binary image represents the edge mask.
  - 4. Another copy of image was made via the procedure in step 3. This copy was further processed to detect objects which enclose "holes" and setting all pixels inside the holes to the binary value of the edge, i.e., one. This image represents the whole cell mask.
- 5. The original image was masked with the edge mask from step 3 and the sum total of all pixel values is determined.

- 6. The original image was masked with the whole cell mask from step 4 and the sum total of all pixel values was determined.
- 7. The value from step 5 was divided by the value from step 6 to give the final result, the fraction of fluorescence intensity in the cells which was localized in the edges.

### **EXAMPLE 3**

Probes for detection of mitogen activated protein kinase Erk1 redistribution.

Useful for monitoring signalling pathways involving MAPK, e.g. to identify compounds which modulate the activity of the pathway in living cells.

Erk1, a serine/threonine protein kinase, is a component of a signalling pathway which is activated by e.g. many growth factors.

Probes for detection of ERK-1 activity in real time within living cells:

- The extracellular signal regulated kinase (ERK-1, a mitogen activated protein kinase, MAPK) is fused N- or C-terminally to a derivative of GFP. The resulting fusions expressed in different mammalian cells are used for monitoring *in vivo* the nuclear translocation, and thereby the activation, of ERK1 in response to stimuli that activate the MAPK pathway.
  - a) Construction of murine ERK1 F64L-S65T-GFP fusion:
- Convenient restriction endonuclease sites are introduced into the cDNAs encoding murine ERK1 (GenBank Accession number: Z14249) and F64L-S65T-GFP (sequence disclosed in WO 97/11094) by polymerase chain reaction (PCR). The PCR reactions are performed according to standard protocols with the following primers:
- 5'ERK1: TTggACACAAgCTTTggACACCCTCAggATATggCggCggCggCggCggCggCTCCgggggggCgggg (SEQ ID NO:7),

5'F64L-S65T-GFP: TTggACACAAgCTTTggACACggCgCgCCATgAgTAAAggAgAAGAACTT-TTC (SEQ ID NO:1)

5 3'F64L-S65T-GFP: gTCATCTTCTCgAgTCTTACTCCTgAggTTTgTATAgTTCATCCATgC-CATgT (SEQ ID NO:2)

To generate the mERK1-F64L-S65T-GFP (SEQ ID NO:56 & 57) fusion the ERK1 amplification product is digested with HindIII+AscI and the F64L-S65T-GFP product with AscI+XhoI. To generate the F64L-S65T-GFP-mERK1 fusion the ERK1 amplification product is then digested with HindIII+Bsu36I and the F64L-S65T-GFP product with Bsu36I+XhoI. The two pairs of digested PCR products are subsequently ligated with a HindIII+XhoI digested plasmid (pZeoSV® mammalian expression vector, Invitrogen, San Diego, CA, USA). The resulting fusion constructs are under control of the SV40 promoter.

b) The human Erk1 gene (GenBank Accession number: X60188) was amplified using PCR according to standard protocols with primers Erk1-top (SEQ ID NO:9) and Erk1-bottom/+stop (SEQ ID NO:10). The PCR product was digested with restriction enzymes E-coR1 and BamH1, and ligated into pEGFP-C1 (Clontech, Palo Alto; GenBank Accession number U55763) digested with EcoR1 and BamH1. This produces an EGFP-Erk1 fusion
 (SEQ ID NO:38 &39) under the control of a CMV promoter.

The plasmid containing the EGFP-Erk1 fusion was transfected into HEK293 cells employing the FUGENE transfection reagent (Boehringer Mannheim). Prior to experiments the cells were grown to 80%-90% confluency 8 well chambers in DMEM with 10% FCS. The cells were washed in plain HAM F-12 medium (without FCS), and then incubated for 30-60 minutes in plain HAM F-12 (without FCS) with 100 micromolar PD98059, an inhibitor of MEK1, a kinase which activates Erk1; this step effectively empties the nucleus of EGFP-Erk1. Just before starting the experiment, the HAM F-12 was replaced with Hepes buffer following a wash with Hepes buffer. This removes the PD98059 inhibitor; if blocking of MEK1 is still wanted (e.g. in control experiments), the inhibitor is included in the Hepes buffer.

The experimental setup of the microscope was as described in example 1.

25

10

60 images were collected with 10 seconds between each, and with the test compound added after image number 10.

Addition of EGF (1-100 nM) caused within minutes a redistribution of EGFP-Erk1 from the cytoplasm into the nucleus (Fig. 9a,b).

The response was quantitated as described below and a dose-dependent relationship between EGF concentration and nuclear translocation of EGFP-Erk1 was found (Fig. 9c,d). Reditribution of GFP fluorescence is expressed in this example as the change in the ratio value between areas in nuclear versus cytoplasmic compartments of the cell. Each time profile is the average of nuclear to cytoplasmic ratios from six cells in each treatment.

## EXAMPLE 4: .....

Probes for detection of Erk2 redistribution.

Useful for monitoring signalling pathways involving MAPK, e.g. to identify compounds which modulate the activity of the pathway in living cells.

Erk2, a serine/threonine protein kinase, is closely related to Erk1 but not identical; it is a component of a signalling pathway which is activated by e.g. many growth factors.

- a) The rat Erk2 gene (GenBank Accession number: M64300) was amplified using PCR according to standard protocols with primers Erk2-top (SEQ ID NO:11) and Erk2-bottom/+stop (SEQ ID NO:13) The PCR product was digested with restriction enzymes Xho1 and BamH1, and ligated into pEGFP-C1 (Clontech, Palo Alto; GenBank Accession number U55763) digested with Xho1 and BamH1. This produces an EGFP-Erk2 fusion (SEQ ID NO:40 &41) under the control of a CMV promoter.
- b) The rat Erk2 gene (GenBank Accession number: M64300) was amplified using PCR according to standard protocols with primers (SEQ ID NO:11) Erk2-top and Erk2-bottom/-stop (SEQ ID NO:12). The PCR product was digested with restriction enzymes Xho1 and BamH1, and ligated into pEGFP-N1 (Clontech, Palo Alto; GenBank Accession number U55762) digested with Xho1 and BamH1. This produces an Erk2-EGFP fusion (SEQ ID NO:58 &59) under the control of a CMV promoter.

The resulting plasmids were transfected into CHO cells and BHK cells. The cells were grown under standard conditions. Prior to experiments, the cells were starved in medium without serum for 48-72 hours. This led to a predominantly cytoplasmic localization of both probes, especially in BHK cells. 10% fetal calf serum was added to the cells and the fluorescence of the cells was recorded as explained in example 3. Addition of serum caused the probes to redistribute into the nucleus within minutes of addition of serum.

#### **EXAMPLE 5:**

15

20

25

10 Probes for detection of Smad2 redistribution.

Useful for monitoring signalling pathways activated by some members of the transforming growth factor-beta family, e.g. to identify compounds which modulate the activity of the pathway in living cells.

Smad 2, a signal transducer, is a component of a signalling pathway which is induced by some members of the TGFbeta family of cytokines.

- a) The human Smad2 gene (GenBank Accession number: AF027964) was amplified using PCR according to standard protocols with primers Smad2-top (SEQ ID NO:24) and Smad2-bottom/+stop (SEQ ID NO:26). The PCR product was digested with restriction enzymes E-coR1 and Acc65I, and ligated into pEGFP-C1 (Clontech; Palo Alto; GenBank Accession number U55763) digested with EcoR1 and Acc65I. This produces an EGFP-Smad2 fusion (SEQ ID NO:50&51) under the control of a CMV promoter.
- b) The human Smad2 gene (GenBank Accession number: AF027964) was amplified using PCR according to standard protocols with primers Smad2-top (SEQ ID NO:24) and Smad2-bottom/-stop (SEQ ID NO:25). The PCR product was digested with restriction enzymes E-coR1 and Acc65I, and ligated into pEGFP-N1 (Clontech, Palo Alto; GenBank Accession number U55762) digested with EcoR1 and Acc65I. This produces a Smad2-EGFP fusion (SEQ ID NO:74 &75) under the control of a CMV promoter.
- The plasmid containing the EGFP-Smad2 fusion was transfected into HEK293 cells, where it showed a cytoplasmic distribution. Prior to experiments the cells were grown in 8 well Nunc

chambers in DMEM with 10% FCS to 80% confluency and starved overnight in HAM F-12 medium without FCS.

For experiments, the HAM F-12 medium was replaced with Hepes buffer pH 7.2.

The experimental setup of the microscope was as described in example 1.

90 images were collected with 10 seconds between each, and with the test compound added after image number 5.

After serum starvation of cells, each nucleus contains less GFP fluorescence than the surrounding cytoplasm (Fig. 10a). Addition of TGFbeta caused within minutes a redistribution of EGFP-Smad2 from the cytoplasma into the nucleus (Fig. 10b).

The redistribution of fluorescence within the treated cells was quantified simply as the fractional increase in nuclear fluorescence normalised to the starting value of GFP fluorescence in the nucleus of each unstimulated cell.

#### 15 EXAMPLE 6:

10

. 20

25

Probe for detection of VASP redistribution.

Useful for monitoring signalling pathways involving rearrangement of cytoskeletal elements, e.g. to identify compounds which modulate the activity of the pathway in living cells.

VASP, a phosphoprotein, is a component of cytoskeletal structures, which redistributes in response to signals which affect focal adhesions.

a) The human VASP gene (GenBank Accession number: Z46389) was amplified using PCR according to standard protocols with primers VASP-top (SEQ ID NO:94) and VASP-bottom/+stop (SEQ ID NO:95). The PCR product was digested with restriction enzymes Hind3 and BamH1, and ligated into pEGFP-C1 (Clontech, Palo Alto; GenBank Accession number U55763) digested with Hind3and BamH1. This produces an EGFP-VASP fusion (SEQ ID NO:124 &125) under the control of a CMV promoter.

The resulting plasmid was transfected into CHO cells expressing the human insulin receptor using the calcium-phosphate transfection method. Prior to experiments, cells were grown in 8 well Nunc chambers and starved overnight in medium without FCS.

Experiments are performed in a microscope setup as described in example 1.

10% FCS was added to the cells and images were collected. The EGFP-VASP fusion was redistributed from a somewhat even distribution near the periphery into more localized structures, identified as focal adhesion points (Fig. 11).

. 5

A large number of further GFP fusions have been made or are in the process of being made, as apparent from the following Examples 7-22 which also suggest suitable host cells and substances for activation of the cellular signalling pathways to be monitored and analyzed.

10

#### **EXAMPLE 7:**

Probe for detection of actin redistribution.

Useful for monitoring signalling pathways involving rearrangement or formation of actin filaments, e.g. to identify compounds which modulate the activity of pathways leading to cytoskeletal rearrangements in living cells.

Actin is a component of cytoskeletal structures, which redistributes in response to very many cellular signals.

20

25

30

The actin binding domain of the human alpha-actinin gene (GenBank Accession number: X15804) was amplified using PCR according to standard protocols with primers ABD-top (SEQ ID NO:90) and ABD-bottom/-stop (SEQ ID NO:91). The PCR product was digested with restriction enzymes Hind3 and BamH1, and ligated into pEGFP-N1 (Clontech, Palo Alto; GenBank Accession number U55762) digested with Hind3 and BamH1. This produced an actin-binding-domain-EGFP fusion (SEQ ID NO:128 &129) under the control of a CMV promoter.

The resulting plasmid was transfected into CHO cells expressing the human insulin receptor. Cells were stimulated with insulin which caused the actin binding domain-EGFP probe to become redistributed into morphologically distinct membrane-associated structures.

### Example 8:

10

Probes for detection of p38 redistribution.

5 Useful for monitoring signalling pathways responding to various cellular stress situations, e.g. to identify compounds which modulate the activity of the pathway in living cells, or as a counterscreen.

p38, a serine/thronine protein kinase, is a component of a stress-induced signalling pathway which is activated by many types of cellular stress, e.g. TNFalpha, anisomycin, UV and mitomycin C.

- a) The human p38 gene (GenBank Accession number: L35253) was amplified using PCR according to standard protocols with primers p38-top (SEQ ID NO:14) and p38-bottom/+stop (SEQ ID NO: 16). The PCR product was digested with restriction enzymes
   Xho1 and BamH1, and ligated into pEGFP-C1 (Clontech, Palo Alto; GenBank Accession number U55763) digested with Xho1 and BamH1. This produced an EGFP-p38 fusion (SEQ ID NO:46 &47) under the control of a CMV promoter.
- b) The human p38 gene (GenBank Accession number: L35253) was amplified using PCR according to standard protocols with primers p38-top (SEQ ID NO:13) and p38-bottom/-stop
  (SEQ ID NO:15). The PCR product was digested with restriction enzymes Xho1 and BamH1, and ligated into pEGFP-N1 (Clontech, Palo Alto; GenBank Accession number U55762) digested with Xho1 and BamH1. This produced a p38-EGFP fusion (SEQ ID NO:64 &65) under the control of a CMV promoter.

The resulting plasmids are transfected into a suitable cell line, e.g. HEK293, in which the EGFP-p38 probe and/or the p38-EGFP probe should change its cellular distribution from predominantly cytoplasmic to nuclear within minutes in response to activation of the signal-ling pathway with e.g. anisomycin.

### Example 9:

30 Probes for detection of Jnk1 redistribution.

10

Useful for monitoring signalling pathways responding to various cellular stress situations, e.g. to identify compounds which modulate the activity of the pathway in living cells, or as a counterscreen.

Jnk1, a serine/threonine protein kinase, is a component of a stress-induced signalling pathway different from the p38 described above, though it also is activated by many types of cellular stress, e.g. TNFalpha, anisomycin and UV.

- a) The human Jnk1 gene (GenBank Accession number: L26318) was amplified using PCR according to standard protocols with primers Jnk-top (SEQ ID NO:17) and Jnk-bottom/+stop (SEQ ID NO:19). The PCR product was digested with restriction enzymes Xho1 and BamH1, and ligated into pEGFP-C1 (Clontech, Palo Alto; GenBank Accession number U55763) digested with Xho1 and BamH1. This produced an EGFP-Jnk1 fusion (SEQ ID NO:44 &45) under the control of a CMV promoter.
- b) The human Jnk1 gene (GenBank Accession number: L26318) was amplified using PCR according to standard protocols with primers Jnk-top (SEQ ID NO:17) and Jnk-bottom/-stop (SEQ ID NO:18). The PCR product was digested with restriction enzymes Xho1 and BamH1, and ligated into pEGFP-N1 (Clontech, Palo Alto; GenBank Accession number U55762) digested with Xho1 and BamH1. This produced a Jnk1-EGFP fusion (SEQ ID NO:62 &63) under the control of a CMV promoter.
- The resulting plasmids are transfected into a suitable cell line, e.g. HEK293, in which the EGFP-Jnk1 probe and/or the Jnk1-EGFP probe should change its cellular distribution from predominantly cytoplasmic to nuclear in response to activation of the signalling pathway with e.g. anisomycin.

25

# Example 10:

Probes for detection of PKG redistribution.

Useful for monitoring signalling pathways involving changes in cyclic GMP levels, e.g. to identify compounds which modulate the activity of the pathway in living cells.

30 PGK, a cGMP-dependent serine/threonine protein kinase, mediates the guanylylcyclase/cGMP signal.

- a) The human PKG gene (GenBank Accession number: Y07512) is amplified using PCR according to standard protocols with primers PKG-top (SEQ ID NO:81) and PKG-bottom/+stop (SEQ ID NO:83). The PCR product is digested with restriction enzymes Xho1 and BamH1, and ligated into pEGFP-C1 (Clontech, Palo Alto; GenBank Accession number U55763) digested with Xho1 and BamH1. This produces an EGFP-PKG fusion (SEQ ID NO:134 &135) under the control of a CMV promoter.
- b) The human PKG gene (GenBank Accession number: Y07512) is amplified using PCR according to standard protocols with primers PKG-top (SEQ ID NO:81) and PKG-bottom/-stop (SEQ ID NO: 82). The PCR product is digested with restriction enzymes Xho1 and BamH1, and ligated into pEGFP-N1 (Clontech, Palo Alto; GenBank Accession number U55762) digested with Xho1 and BamH1. This produces a PKG-EGFP fusion (SEQ ID NO:136 &137) under the control of a CMV promoter.

The resulting plasmids are transfected into a suitable cell line, e.g. A10, in which the EGFP-PKG probe and/or the PKG-EGFP probe should change its cellular distribution from cyto-plasmic to one associated with cytoskeletal elements within minutes in response to treatment with agents which raise nitric oxide (NO) levels.

#### Example 11:

10

- 20 Probes for detection of IkappaB kinase redistribution.
  - Useful for monitoring signalling pathways leading to NFkappaB activation, e.g. to identify compounds which modulate the activity of the pathway in living cells.
  - IkappaB kinase, a serine/threonine kinase, is a component of a signalling pathway which is activated by a variety of inducers including cytokines, lymphokines, growth factors and stress.
  - a) The alpha subunit of the human IkappaB kinase gene (GenBank Accession number: AF009225) is amplified using PCR according to standard protocols with primers IKK-top (SEQ ID NO:96) and IKK-bottom/+stop (SEQ ID NO:98). The PCR product is digested with restriction enzymes EcoR1 and Acc65I, and ligated into pEGFP-C1 (Clontech, Palo Alto;

25

GenBank Accession number U55763) digested with EcoR1and Acc65I. This produces an EGFP-lkappaB-kinase fusion (SEQ ID NO:120 &121) under the control of a CMV promoter.

b) The alpha subunit of the human IkappaB kinase gene (GenBank Accession number: AF009225) is amplified using PCR according to standard protocols with primers IKK-top (SEQ ID NO:96) and IKK-bottom/-stop (SEQ ID NO:97). The PCR product is digested with restriction enzymes EcoR1 and Acc65I, and ligated into pEGFP-N1 (Clontech, Palo Alto; GenBank Accession number U55762) digested with EcoR1 and Acc65I. This produces an IkappaB-kinase-EGFP fusion (SEQ ID NO:122 &123) under the control of a CMV promoter.

The resulting plasmids are transfected into a suitable cell line, e.g. Jurkat, in which the

EGFP-lkappaB-kinase probe and/or the lkappaB-kinase-EGFP probe should achieve a more
cytoplasmic distribution within seconds following stimulation with e.g. TNFalpha.

#### Example 12:

Probes for detection of CDK2 redistribution.

- Useful for monitoring signalling pathways of the cell cycle, e.g. to identify compounds which modulate the activity of the pathway in living cells.
  - CDK2, a cyclin-dependent serine/threonine kinase, is a component of the signalling system which regulates the cell cycle.
- a) The human CDK2 gene (GenBank Accession number: X61622) is amplified using PCR according to standard protocols with primers CDK2-top (SEQ ID NO:102) and CDK2-bottom/+stop (SEQ ID NO: 104). The PCR product is digested with restriction enzymes Xho1 and BamH1, and ligated into pEGFP-C1 (Clontech, Palo Alto; GenBank Accession number U55763) digested with Xho1 and BamH1. This produces an EGFP-CDK2 fusion (SEQ ID NO:114 &115) under the control of a CMV promoter.
  - b) The human CDK2 gene (GenBank Accession number: X61622) is amplified using PCR according to standard protocols with primers CDK2-top (SEQ ID NO:102) and CDK2-bottom/-stop (SEQ ID NO:103). The PCR product is digested with restriction enzymes Xho1 and BamH1, and ligated into pEGFP-N1 (Clontech, Palo Alto; GenBank Accession number U55762) digested with Xho1 and BamH1. This produces a CDK2-EGFP fusion (SEQ ID NO:112 &113) under the control of a CMV promoter.

The resulting plasmids are transfected into a suitable cell line, e.g. HEK293 in which the EGFP-CDK2 probe and/or the CDK2-EGFP probe should change its cellular distribution from cytoplasmic in contact-inhibited cells, to nuclear location in response to activation with a number of growth factors, e.g. IGF.

5

### Example 13:

Probes for detection of Grk5 redistribution.

Useful for monitoring signalling pathways involving desensitization of G-protein coupled receptors, e.g. to identify compounds which modulate the activity of the pathway in living cells.

Grk5, a G-protein coupled receptor kinase, is a component of signalling pathways involving membrane bound G-protein coupled receptors.

- a) The human Grk5 gene (GenBank Accession number: L15388) is amplified using PCR according to standard protocols with primers Grk5-top (SEQ ID NO:27) and Grk5-
- bottom/+stop (SEQ ID NO:29). The PCR product is digested with restriction enzymes EcoR1 and BamH1, and ligated into pEGFP-C1 (Clontech, Palo Alto; GenBank Accession number U55763) digested with EcoR1 and BamH1. This produces an EGFP-Grk5 fusion (SEQ ID NO:42 &43) under the control of a CMV promoter.
- b) The human Grk5 gene (GenBank Accession number: L15388) is amplified using PCR according to standard protocols with primers Grk5-top (SEQ ID NO:27) and Grk5-bottom/-stop (SEQ ID NO:28). The PCR product is digested with restriction enzymes EcoR1 and BamH1, and ligated into pEGFP-N1 (Clontech, Palo Alto; GenBank Accession number U55762) digested with EcoR1 and BamH1. This produces a Grk5-EGFP fusion (SEQ ID NO:60 &61) under the control of a CMV promoter.
- The resulting plasmids are transfected into a suitable cell line, e.g. HEK293 expressing a rat dopamine D1A receptor, in which the EGFP-Grk5 probe and/or the Grk5-EGFP probe should change its cellular distribution from predominantly cytoplasmic to peripheral in response to activation of the signalling pathway with e.g. dopamine.
- 30 Example 14:

Probes for detection of Zap70 redistribution.

Useful for monitoring signalling pathways involving the T cell receptor, e.g. to identify compounds which modulate the activity of the pathway in living cells.

Zap70, a tyrosine kinase, is a component of a signalling pathway which is active in e.g. T-cell differentiation.

- a) The human Zap70 gene (GenBank Accession number: L05148) is amplified using PCR according to standard protocols with primers Zap70-top (SEQ ID NO:105) and Zap70-bottom/+stop (SEQ ID NO:107). The PCR product is digested with restriction enzymes E-coR1 and BamH1, and ligated into pEGFP-C1 (GenBank Accession number U55763) digested with EcoR1 and BamH1. This produces an EGFP-Zap70 fusion (SEQ ID NO:108 &109) under the control of a CMV promoter.
- b) The human Zap70 gene (GenBank Accession number: L05148) is amplified using PCR according to standard protocols with primers Zap70-top (SEQ ID NO:105) and Zap70-bottom/-stop (SEQ ID NO:106). The PCR product is digested with restriction enzymes E-coR1 and BamH1, and ligated into pEGFP-N1 (Clontech, Palo Alto; GenBank Accession number U55762) digested with EcoR1 and BamH1. This produces a Zap70-EGFP fusion (SEQ ID NO:110 &111) under the control of a CMV promoter.
- The resulting plasmids are transfected into a suitable cell line, e.g. Jurkat, in which the EGFP-Zap70 probe and/or the Zap70-EGFP probe should change its cellular distribution from cytoplasmic to membrane-associated within seconds in response to activation of the T cell receptor signalling pathway with e.g. antibodies to CD3epsilon.

#### Example 15:

25 Probes for detection of p85 redistribution.

Useful for monitoring signalling pathways involving PI-3 kinase, e.g. to identify compounds which modulate the activity of the pathway in living cells.

p85alpha is the regulatory subunit of PI3-kinase which is a component of many pathways involving membrane-bound tyrosine kinase receptors and G-protein-coupled receptors.

10

15

- a) The human p85alpha gene (GenBank Accession number: M61906) was amplified using PCR according to standard protocols with primers p85-top-C (SEQ ID NO:22) and p85bottom/+stop (SEQ ID NO:23) . The PCR product was digested with restriction enzymes Bgl2 and BamH1, and ligated into pEGFP-C1 (Clontech, Palo Alto; GenBank Accession number U55763) digested with Bgl2 and BamH1. This produced an EGFP-p85alpha fusion (SEQ ID NO:48 &49) under the control of a CMV promoter.
- b) The human p85alpha gene (GenBank Accession number: M61906) was amplified using PCR according to standard protocols with primers p85-top-N (SEQ ID NO:20) and p85bottom/-stop (SEQ ID NO:21) . The PCR product was digested with restriction enzymes EcoR1 and BamH1, and ligated into pEGFP-N1 (Clontech, Palo Alto; GenBank Accession number U55762) digested with EcoR1 and BamH1. This produced a p85alpha-EGFP fusion (SEQ ID NO:66 &67) under the control of a CMV promoter.

The resulting plasmids are transfected into a suitable cell line, e.g. CHO expressing the human insulin receptor, in which the EGFP-p85 probe and/or the p85-EGFP probe may change its cellular distribution from cytoplasmic to membrane-associated within minutes in response 15 to activation of the receptor with insulin.

## Example 16:

10

Probes for detection of protein-tyrosine phosphatase redistribution.

- Useful for monitoring signalling pathways involving tyrosine kinases, e.g. to identify com-20 pounds which modulate the activity of the pathway in living cells.
  - Protein-tyrosine phosphatase1C, a tyrosine-specific phosphatase, is an inhibitory component in signalling pathways involving e.g. some growth factors.
- a) The human protein-tyrosine phosphatase 1C gene (GenBank Accession number: X62055) 25 is amplified using PCR according to standard protocols with primers PTP-top (SEQ ID NO:99) and PTP-bottom/+stop (SEQ ID NO:101). The PCR product is digested with restriction enzymes Xho1 and EcoR1, and ligated into pEGFP-C1 (Clontech, Palo Alto; GenBank Accession number U55763) digested with Xho1 and EcoR1. This produces an EGFP-PTP 30
- fusion (SEQ ID NO:116 &117) under the control of a CMV promoter.

b) The human protein-tyrosine phosphatase 1C gene (GenBank Accession number: X62055) is amplified using PCR according to standard protocols with primers PTP-top (SEQ ID NO:99) and PTP-bottom/-stop (SEQ ID NO:100). The PCR product is digested with restriction enzymes Xho1 and EcoR1, and ligated into pEGFP-N1 (Clontech, Palo Alto; GenBank Accession number U55762) digested with Xho1 and EcoR1. This produces a PTP-EGFP fusion (SEQ ID NO:118 &119) under the control of a CMV promoter.

The resulting plasmids are transfected into a suitable cell line, e.g. MCF-7 in which the EGFP-PTP probe and/or the PTP-EGFP probe should change its cellular distribution from cytoplasm to the plasma membrane within minutes in response to activation of the growth inhibitory signalling pathway with e.g. somatostatin.

#### Example 17:

10

Probes for detection of Smad4 redistribution.

Useful for monitoring signalling pathways involving most members of the transforming growth factor-beta family, e.g. to identify compounds which modulate the activity of the pathway in living cells.

Smad4, a signal transducer, is a common component of signalling pathways induced by various members of the TGFbeta family of cytokines.

- a) The human Smad4 gene (GenBank Accession number: U44378) was amplified using PCR according to standard protocols with primers Smad4-top and Smad4-bottom/+stop (SEQ ID NO:35). The PCR product was digested with restriction enzymes EcoR1 and BamH1, and ligated into pEGFP-C1 (Clontech, Palo Alto; GenBank Accession number U55763) digested with EcoR1 and BamH1. This produce an EGFP-Smad4 fusion (SEQ ID NO:52 &53) under the control of a CMV promoter.
  - b) The human Smad4 gene (GenBank Accession number: U44378) was amplified using PCR according to standard protocols with primers Smad4-top (SEQ ID NO:33) and Smad4-bottom/-stop (SEQ ID NO:34). The PCR product was digested with restriction enzymes E-coR1 and BamH1, and ligated into pEGFP-N1 (Clontech, Palo Alto; GenBank Accession number U55762) digested with EcoR1 and BamH1. This produced a Smad4-EGFP fusion (SEQ ID NO:76 &77) under the control of a CMV promoter.

The resulting plasmids are transfected into a cell line, e.g. HEK293 in which the EGFP-Smad4 probe and/or the Smad4-EGFP probe should change its cellular distribution within minutes from cytoplasmic to nuclear in response to activation of the signalling pathway with e.g. TGFbeta.

5

10

#### Example 18:

Probes for detection of Stat5 redistribution.

Useful for monitoring signalling pathways involving the activation of tyrosine kinases of the Jak family, e.g. to identify compounds which modulate the activity of the pathway in living cells.

Stat5, signal transducer and activator of transcription, is a component of signalling pathways which are induced by e.g. many cytokines and growth factors.

- a) The human Stat5 gene (GenBank Accession number: L41142) was amplified using PCR
   according to standard protocols with primers Stat5-top (SEQ ID NO:30) and Stat5-bottom/+stop (SEQ ID NO:32). The PCR product was digested with restriction enzymes Bgl2 and Acc65I, and ligated into pEGFP-C1 (Clontech; Palo Alto; GenBank Accession number U55763) digested with Bgl2 and Acc65I. This produced an EGFP-Stat5 fusion (SEQ ID NO:54 &55) under the control of a CMV promoter.
- b) The human Stat5 gene (GenBank Accession number: L41142) was amplified using PCR according to standard protocols with primers Stat5-top (SEQ ID NO:30) and Stat5-bottom/stop (SEQ ID NO:331). The PCR product was digested with restriction enzymes Bgl2 and Acc65I, and ligated into pEGFP-N1 (Clontech, Palo Alto; GenBank Accession number U55762) digested with Bgl2 and Acc65I. This produced a Stat5-EGFP fusion (SEQ ID NO:78
   &79) under the control of a CMV promoter.

The resulting plasmids are transfected into a suitable cell line, e.g. MIN6 in which the EGFP-Stat5 probe and/or the Stat5-EGFP probe should change its cellular distribution from cyto-plasmic to nuclear within minutes in response to activation signalling pathway with e.g. prolactin.

#### Example 19:

Probes for detection of NFAT redistribution.

Useful for monitoring signalling pathways involving activation of NFAT, e.g. to identify compounds which modulate the activity of the pathway in living cells.

- 5 NFAT, an activator of transcription, is a component of signalling pathways which is involved in e.g. immune responses.
- a) The human NFAT1 gene (GenBank Accession number: U43342) is amplified using PCR according to standard protocols with primers NFAT-top (SEQ ID NO:84) and NFAT bottom/+stop (SEQ ID NO:86). The PCR product is digested with restriction enzymes Xho1 and EcoR1, and ligated into pEGFP-C1 (Clontech, Palo Alto; GenBank Accession number U55763) digested with Xho1 and EcoR1. This produces an EGFP-NFAT fusion (SEQ ID NO:130 &131) under the control of a CMV promoter.
- b) The human NFAT gene (GenBank Accession number: U43342) is amplified using PCR according to standard protocols with primers NFAT-top (SEQ ID NO:84) and NFAT-bottom/stop (SEQ ID NO:85). The PCR product is digested with restriction enzymes Xho1 and E-coR1, and ligated into pEGFP-N1 (Clontech, Palo Alto; GenBank Accession number U55762) digested with Xho1 and EcoR1. This produces an NFAT-EGFP fusion (SEQ ID NO:132 &133) under the control of a CMV promoter.
- The resulting plasmids are transfected into a suitable cell line, e.g. Jurkat, in which the EGFP-NFAT probe and/or the NFAT-EGFP probe should change its cellular distribution from cytoplasmic to nuclear within minutes in response to activation of the signalling pathway with e.g. antibodies to CD3epsilon.

## 25 Example 20:

Probes for detection of NFkappaB redistribution.

Useful for monitoring signalling pathways leading to activation of NFkappaB, e.g. to identify compounds which modulate the activity of the pathway in living cells.

NFkappaB, an activator of transcription, is a component of signalling pathways which are responsive to a varity of inducers including cytokines, lymphokines, some immunosuppressive agents.

- a) The human NFkappaB p65 subunit gene (GenBank Accession number: M62399) is amplified using PCR according to standard protocols with primers NFkappaB-top (SEQ ID NO:87) and NFkappaB-bottom/+stop (SEQ ID NO:89). The PCR product is digested with restriction enzymes Xho1 and BamH1, and ligated into pEGFP-C1 (Clontech, Palo Alto; GenBank Accession number U55763) digested with Xho1 and BamH1. This produces an EGFP-NFkappaB fusion (SEQ ID NO:142 & 143) under the control of a CMV promoter.
  - b) The human NFkappaB p65 subunit gene (GenBank Accession number: M62399) is amplified using PCR according to standard protocols with primers NFkappaB-top (SEQ ID NO:87) and NFkappaB-bottom/-stop (SEQ ID NO:88). The PCR product is digested with restriction enzymes Xho1 and BamH1, and ligated into pEGFP-N1 (Clontech, Palo Alto; Gen-
- Bank Accession number U55762) digested with Xho1 and BamH1. This produces an NFkappaB-EGFP fusion (SEQ ID NO:140 & 141) under the control of a CMV promoter.

The resulting plasmids are transfected into a suitable cell line, e.g. Jurkat, in which the EGFP-NFkappaB probe and/or the NFkappaB-EGFP probe should change its cellular distribution from cytoplasmic to nuclear in response to activation of the signalling pathway with e.g. TNFalpha.

#### Example 21:

20

25

Probe for detection of RhoA redistribution.

Useful for monitoring signalling pathways involving RhoA, e.g. to identify compounds which modulate the activity of the pathway in living cells.

RhoA, a small GTPase, is a component of many signalling pathways, e.g. LPA induced cytoskeletal rearrangements.

The human RhoA gene (GenBank Accession number: L25080) was amplified using PCR according to standard protocols with primers RhoA-top (SEQ ID NO:92) and RhoA-bottom/+stop (SEQ ID NO:93). The PCR product was digested with restriction enzymes

Hind3 and BamH1, and ligated into pEGFP-C1 (Clontech, Palo Alto; GenBank Accession number U55763) digested with Hind3and BamH1. This produced an EGFP-RhoA fusion (SEQ ID NO:126 &127) under the control of a CMV promoter.

The resulting plasmid is transfected into a suitable cell line, e.g. Swiss3T3, in which the EGFP-RhoA probe should change its cellular distribution from a reasonably homogenous to a peripheral distribution within minutes of activation of the signalling pathway with e.g. LPA.

Probes for detection of PKB redistribution.

Example 22:

10

Useful for monitoring signalling pathways involving PKB e.g. to identify compounds which modulate the activity of the pathway in living cells.

PKB, a serine/threonine kinase, is a component in various signalling pathways, many of which are activated by growth factors.

- a) The human PKB gene (GenBank Accession number: M63167) is amplified using PCR according to standard protocols with primers PKB-top (SEQ ID NO:36) and PKB-bottom/+stop (SEQ ID NO:80). The PCR product is digested with restriction enzymes Xho1 and BamH1, and ligated into pEGFP-C1 (Clontech, Palo Alto; GenBank Accession number U55763) digested with Xho1 and BamH1. This produces an EGFP-PKB fusion (SEQ ID NO:138 & 139) under the control of a CMV promoter.
- b) The human PKB gene (GenBank Accession number: M63167) was amplified using PCR according to standard protocols with primers PKB-top (SEQ ID NO:36) and PKB-bottom/stop (SEQ ID NO:37). The PCR product was digested with restriction enzymes Xho1 and BamH1, and ligated into pEGFP-N1 (Clontech, Palo Alto; GenBank Accession number U55762) digested with Xho1 and BamH1. This produced a PKB-EGFP fusion (SEQ ID NO:70 &71) under the control of a CMV promoter.

The resulting plasmids are transfected into a suitable cell line, e.g. CHO expressing the human insulin receptor, in which the EGFP-PKB probe and/or the PKB-EGFP probe cycles between cytoplasmic and membrane locations during the activation-deactivation process following addition of insulin. The transition should be apparent within minutes.

# **REFERENCES:**

- Adams, S.R., Harootunian, A.T., Buechler, Y.J., Taylor, S.S. & Tsien, R.Y. (1991) Nature 349, 694-697
- Blobe, G.C., Stribling, D.S., Fabbro, D., Stabel, S & Hannun, Y.A. (1996) J. Biol. Chem. 271, 15823-15830
  - Chalfie, M., Tu, Y., Euskirchen, G., Ward, W.W. & Prasher, D.C. (1994) Science 263, 802-805
  - Cossette, L.J., Hoglinger, O., Mou, L.J. & Shen, S.H. (1997) Exp. Cell Res. 223, 459-466
- DeBernardi, M.A. & Brooker, G. (1996) Proc. Natl. Acad. Sci. USA **93**, 4577-4582 Farese, R.V.. (1992) Biochem. J. **288**, 319-323
  - Fulop Jr., T., Leblanc, C., Lacombe, G. & Dupuis, G. (1995) FEBS Lett. 375, 69-74 Godson, C., Masliah, E., Balboa, M.A., Ellisman, M.H. & Insel, P.A. (1996) Biochem. Biophys. Acta 1313, 63-71
- Khalil, R.A., Lajoie, C., Resnick, M.S. & Morgan, K.G. (1992) American Physiol. Society c, 714-719
  - Sano, M., Kohno, M. & Iwanaga, M. (1995) Brain Res. **688**, 213-218

    Bastiaens, P.I.H. & Jovin, T.M. (1996) Proc. Natl. Acad. Sci. USA **93**, 8407-8412

    Schmidt, D.J., Ikebe, M., Kitamura, K., & Fay, F.S. (1997) FASEB J. **11**, 2924 (Abstract)
- Sakai, N., Sasaki, K., Hasegawa, C., Ohkura, M., Suminka, K., Shirai, Y. & Saito, N. (1996) Soc. Neuroscience 22, 69P (Abstract)
  - Sakai, N., Sakai, K. Hasegawa, C., Ohkura, M., Sumioka, ., Shirai, Y., & Naoaki, S. (1997) Japanese Journal of Pharmacology 73, 69P (Abstract of a meeting held 22-23 March)

## SEQUENCE LISTING

. 5	(1) GENERAL INFORMATION
	(i) APPLICANT: NovoNordisk, BioImage
10	(ii) TITLE OF THE INVENTION: A Method of Detecting Cellular Translocation of Biologically Active Polypeptides Using Fluorescense Imaging
	(iii) NUMBER OF SEQUENCES: 143
15	<ul><li>(iv) CORRESPONDENCE ADDRESS:</li><li>(A) ADDRESSEE: NovoNordisk, BioImage</li><li>(B) STREET: Mørkhøjbygade 28</li><li>(C) CITY: Søborg</li></ul>
	(D) STATE: DK
20	(E) COUNTRY: DENMARK (F) ZIP: 2860
	(F) ZIP: 2860
	(v) COMPUTER READABLE FORM:
	(A) MEDIUM TYPE: Diskette
25	(B) COMPUTER: IBM Compatible
	(C) OPERATING SYSTEM: DOS
	(D) SOFTWARE: FastSEQ for Windows Version 2.0
30	(viii) ATTORNEY/AGENT INFORMATION:
••	(A) NAME: , PV&P R
	(B) REGISTRATION NUMBER:
	(C) REFERENCE/DOCKET NUMBER:
35	(2) INFORMATION FOR ORD ID NO.1.
	(2) INFORMATION FOR SEQ ID NO:1:
	(i) SEQUENCE CHARACTERISTICS:
	(A) LENGTH: 53 base pairs
40	(B) TYPE: nucleic acid
	(C) STRANDEDNESS: single
	(D) TOPOLOGY: linear
	•
45	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:
	TTGGACACAA GCTTTGGACA CGGCGCGCCA TGAGTAAAGG AGAAGAACTT TTC 53
50	(2) INFORMATION FOR SEQ ID NO:2:
JU	(i) SEQUENCE CHARACTERISTICS:
	(A) LENGTH: 53 base pairs (B) TYPE: nucleic acid
	(C) STRANDEDNESS: single
55	(C) STRANDEDNESS: Single (D) TOPOLOGY: linear
JJ	(b) Toronogi: Timeat

	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:	
5	GTCATCTTCT CGAGTCTTAC TCCTGAGGTT TGTATAGTTC ATCCATGCCA TGT	53
	(2) INFORMATION FOR SEQ ID NO:3:	33
10	<ul> <li>(i) SEQUENCE CHARACTERISTICS:</li> <li>(A) LENGTH: 54 base pairs</li> <li>(B) TYPE: nucleic acid</li> <li>(C) STRANDEDNESS: single</li> <li>(D) TOPOLOGY: linear</li> </ul>	
15	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:	
	TTGGACACAA GCTTTGGACA CCCTCAGGAT ATGGGCAACG CCGCCGCCGC CAAG	54
20	(2) INFORMATION FOR SEQ ID NO:4:	
	<ul><li>(i) SEQUENCE CHARACTERISTICS:</li><li>(A) LENGTH: 55 base pairs</li><li>(B) TYPE: nucleic acid</li></ul>	
25	(C) STRANDEDNESS: single (D) TOPOLOGY: linear	
	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:	
30	GTCATCTTCT CGAGTCTTTC AGGCGCGCCC AAACTCAGTA AACTCCTTGC CACAC	55
	(2) INFORMATION FOR SEQ ID NO:5:	
35	<ul> <li>(i) SEQUENCE CHARACTERISTICS:</li> <li>(A) LENGTH: 55 base pairs</li> <li>(B) TYPE: nucleic acid</li> <li>(C) STRANDEDNESS: single</li> <li>(D) TOPOLOGY: linear</li> </ul>	
40	(e) Islandi. Ilmear	
	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:	
	TTGGACACAA GCTTTGGACA CCCTCAGGAT ATGGCTGACG TTTACCCGGC CAACG	55
45	(2) INFORMATION FOR SEQ ID NO:6:	
50	<ul> <li>(i) SEQUENCE CHARACTERISTICS:</li> <li>(A) LENGTH: 55 base pairs</li> <li>(B) TYPE: nucleic acid</li> <li>(C) STRANDEDNESS: single</li> <li>(D) TOPOLOGY: linear</li> </ul>	
55	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:	
	GTCATCTTCT CGAGTCTTTC AGGCGCGCCC TACTGCACTT TGCAAGATTG GGTGC	55
		58

	(2) INFORMATION FOR SEQ ID NO:7:	
5	<ul><li>(i) SEQUENCE CHARACTERISTICS:</li><li>(A) LENGTH: 64 base pairs</li><li>(B) TYPE: nucleic acid</li><li>(C) STRANDEDNESS: single</li><li>(D) TOPOLOGY: linear</li></ul>	
10	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:	
	TTGGACACAA GCTTTGGACA CCCTCAGGAT ATGGCGGCGG CGGCGGCGGC TCCGGGGGGC	60 64
15	(2) INFORMATION FOR SEQ ID NO:8:	
20	<ul><li>(i) SEQUENCE CHARACTERISTICS:</li><li>(A) LENGTH: 55 base pairs</li><li>(B) TYPE: nucleic acid</li><li>(C) STRANDEDNESS: single</li><li>(D) TOPOLOGY: linear</li></ul>	
25	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:	
	GTCATCTTCT CGAGTCTTTC AGGCGCGCCC GGGGCCCTCT GGCGCCCCTG GCTGG	55
30 35	<ul> <li>(2) INFORMATION FOR SEQ ID NO:9:</li> <li>(i) SEQUENCE CHARACTERISTICS: <ul> <li>(A) LENGTH: 30 base pairs</li> <li>(B) TYPE: nucleic acid</li> <li>(C) STRANDEDNESS: single</li> <li>(D) TOPOLOGY: linear</li> </ul> </li> </ul>	
	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:	•
40	TAGAATTCAA CCATGGCGGC GGCGGCGCG	30
	(2) INFORMATION FOR SEQ ID NO:10:	
45	<ul><li>(i) SEQUENCE CHARACTERISTICS:</li><li>(A) LENGTH: 29 base pairs</li><li>(B) TYPE: nucleic acid</li><li>(C) STRANDEDNESS: single</li><li>(D) TOPOLOGY: linear</li></ul>	
50	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:	
	TAGGATCCCT AGGGGGCCTC CAGCACTCC	29
55	(2) INFORMATION FOR SEQ ID NO:11:	

5	<ul><li>(i) SEQUENCE CHARACTERISTICS:</li><li>(A) LENGTH: 31 base pairs</li><li>(B) TYPE: nucleic acid</li><li>(C) STRANDEDNESS: single</li><li>(D) TOPOLOGY: linear</li></ul>		
	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:		•
10	TACTCGAGTA ACCATGGCGG CGGCGGCGGC G		31
	(2) INFORMATION FOR SEQ ID NO:12:		
15	<ul><li>(i) SEQUENCE CHARACTERISTICS:</li><li>(A) LENGTH: 25 base pairs</li><li>(B) TYPE: nucleic acid</li></ul>	·	
	<ul><li>(C) STRANDEDNESS: single</li><li>(D) TOPOLOGY: linear</li></ul>		•
20	•		
	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:		
	TAGGATCCAT AGATCTGTAT CCTGG	;	25
25	(2) INFORMATION FOR SEQ ID NO:13:		•
	(i) SEQUENCE CHARACTERISTICS:		
	<ul><li>(A) LENGTH: 26 base pairs</li><li>(B) TYPE: nucleic acid</li></ul>		
30	(C) STRANDEDNESS: single	•	
	(D) TOPOLOGY: linear		
35	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:		
	TAGGATCCTT AAGATCTGTA TCCTGG	:	26
	(2) INFORMATION FOR SEQ ID NO:14:		
40	(i) SEQUENCE CHARACTERISTICS:	•	
	(A) LENGTH: 28 base pairs		
	(B) TYPE: nucleic acid (C) STRANDEDNESS: single	•	
	(D) TOPOLOGY: linear		
45			
	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:		
50	ATCTCGAGGG AAAATGTCTC AGGAGAGG	2	28
3 <del>-</del>	(2) INFORMATION FOR SEQ ID NO:15:		
	(i) SEQUENCE CHARACTERISTICS:		
ce	(A) LENGTH: 28 base pairs	• •	
55	(B) TYPE: nucleic acid		
	(C) STRANDEDNESS: single		

	(D) TOPOLOGY: linear	•
5	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:	
J	ATGGATCCTC GGACTCCATC TCTTCTTG	28
	(2) INFORMATION FOR SEQ ID NO:16:	
10	<ul><li>(i) SEQUENCE CHARACTERISTICS:</li><li>(A) LENGTH: 29 base pairs</li><li>(B) TYPE: nucleic acid</li><li>(C) STRANDEDNESS: single</li></ul>	,
15	(D) TOPOLOGY: linear	
	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:	
20	ATGGATCCTC AGGACTCCAT CTCTTCTTG	29
<u>ڊ</u> ن	(2) INFORMATION FOR SEQ ID NO:17:	
25	<ul><li>(i) SEQUENCE CHARACTERISTICS:</li><li>(A) LENGTH: 28 base pairs</li><li>(B) TYPE: nucleic acid</li><li>(C) STRANDEDNESS: single</li><li>(D) TOPOLOGY: linear</li></ul>	
30	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:	
	GTCTCGAGCC ATCATGAGCA GAAGCAAG	28
35	(2) INFORMATION FOR SEQ ID NO:18:  (i) SEQUENCE CHARACTERISTICS:	
	(A) LENGTH: 27 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single	q %
40	(D) TOPOLOGY: linear	
	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:	
45	GTGGATCCCA CTGCTGCACC TGTGCTA	27
	(2) INFORMATION FOR SEQ ID NO:19:	
50	<ul><li>(i) SEQUENCE CHARACTERISTICS:</li><li>(A) LENGTH: 28 base pairs</li><li>(B) TYPE: nucleic acid</li><li>(C) STRANDEDNESS: single</li><li>(D) TOPOLOGY: linear</li></ul>	
55		
	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:	

	GTGGATCCTC ACTGCTGCAC CTGTGCTA	28
5	(2) INFORMATION FOR SEQ ID NO:20:	
3	(i) SEQUENCE CHARACTERISTICS:	
	(A) LENGTH: 40 base pairs	
	(B) TYPE: nucleic acid	
10	(C) STRANDEDNESS: single	
10	(D) TOPOLOGY: linear	
	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:	
15	CGCGAATTCC GCCACCATGA GTGCTGAGGG GTACCAGTAC	40
	(2) INFORMATION FOR SEQ ID NO:21:	
	(i) SEQUENCE CHARACTERISTICS:	
20	(A) LENGTH: 32 base pairs	
	(B) TYPE: nucleic acid	
	(C) STRANDEDNESS: single (D) TOPOLOGY: linear	
	(b) TOPOLOGI: Timear	
25		
	(x1) SEQUENCE DESCRIPTION: SEQ ID NO:21:	
	CGCGGATCCT GTCGCCTCTG CTGTGCATAT AC	32.
30	(2) INFORMATION FOR SEQ ID NO:22:	
	(i) SEQUENCE CHARACTERISTICS:	
	(A) LENGTH: 30 base pairs	
35	(B) TYPE: nucleic acid	
JJ	(C) STRANDEDNESS: single	
	(D) TOPOLOGY: linear	*
	(vi) ORIGINAL SOURCE:	
40	(A) ORGANISM: p85-top-C	
	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:	
	GGGAGATCTA TGAGTGCTGA GGGGTACCAG	_
15		30
15	(2) INFORMATION FOR SEQ ID NO:23:	
	(i) SEQUENCE CHARACTERISTICS:	
	(A) LENGTH: 34 base pairs	
50	(B) TYPE: nucleic acid	
,,	(C) STRANDEDNESS: single (D) TOPOLOGY: linear	
	(2) TOPOLOGI: IInear	
	(vi) SPOJENCE DESCRIPTION	
55	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:	
	GGGCGGATCC TCATCGCCTC TGCTGTGCAT ATAC	34
		62

	(2) INFORMATION FOR SEQ ID NO:24:	
5	<ul><li>(i) SEQUENCE CHARACTERISTICS:</li><li>(A) LENGTH: 33 base pairs</li><li>(B) TYPE: nucleic acid</li><li>(C) STRANDEDNESS: single</li><li>(D) TOPOLOGY: linear</li></ul>	
10	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:	
	GTGAATTCGA CCATGTCGTC CATCTTGCCA TTC	33
15	(2) INFORMATION FOR SEQ ID NO:25:	
20	<ul><li>(i) SEQUENCE CHARACTERISTICS:</li><li>(A) LENGTH: 31 base pairs</li><li>(B) TYPE: nucleic acid</li><li>(C) STRANDEDNESS: single</li><li>(D) TOPOLOGY: linear</li></ul>	
25	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:	
	GTGGTACCCA TGACATGCTT GAGCAACGCA C	31
	(2) INFORMATION FOR SEQ ID NO:26:	
30	<ul><li>(i) SEQUENCE CHARACTERISTICS:</li><li>(A) LENGTH: 32 base pairs</li><li>(B) TYPE: nucleic acid</li><li>(C) STRANDEDNESS: single</li></ul>	
35	(D) TOPOLOGY: linear	
	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:	
	GTGGTACCTT ATGACATGCT TGAGCAACGC AC	32
40	(2) INFORMATION FOR SEQ ID NO:27:	
45	<ul><li>(i) SEQUENCE CHARACTERISTICS:</li><li>(A) LENGTH: 31 base pairs</li><li>(B) TYPE: nucleic acid</li><li>(C) STRANDEDNESS: single</li><li>(D) TOPOLOGY: linear</li></ul>	
50	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:	
	GTGAATTCGT CAATGGAGCT GGAAAACATC G	31
	(2) INFORMATION FOR SEQ ID NO:28:	•
55	(i) SEQUENCE CHARACTERISTICS:	
	•	63

	<b>3</b> 7	
5	<ul><li>(A) LENGTH: 30 base pairs</li><li>(B) TYPE: nucleic acid</li><li>(C) STRANDEDNESS: single</li><li>(D) TOPOLOGY: linear</li></ul>	
	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:28:	
10	GTGGATCCCT GCTGCTTCCG GTGGAGTTCG	30
4-	(2) INFORMATION FOR SEQ ID NO:29:	
15	<ul><li>(i) SEQUENCE CHARACTERISTICS:</li><li>(A) LENGTH: 31 base pairs</li><li>(B) TYPE: nucleic acid</li><li>(C) STRANDEDNESS: single</li><li>(D) TOPOLOGY: linear</li></ul>	
20	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:	
	GTGGATCCCT AGCTGCTTCC GGTGGAGTTC G	31
25	(2) INFORMATION FOR SEQ ID NO:30:	
	(i) SEQUENCE CHARACTERISTICS:  (A) LENGTH: 32 base pairs  (B) TYPE: nucleic acid	
30	(C) STRANDEDNESS: single (D) TOPOLOGY: linear	
	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:30:	
35	GTAGATCTAC CATGGCGGGC TGGATCCAGG CC	32
	(2) INFORMATION FOR SEQ ID NO:31:	
40	<ul> <li>(i) SEQUENCE CHARACTERISTICS:</li> <li>(A) LENGTH: 31 base pairs</li> <li>(B) TYPE: nucleic acid</li> <li>(C) STRANDEDNESS: single</li> <li>(D) TOPOLOGY: linear</li> </ul>	
45		
	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:31:	
	GTGGTACCCA TGAGAGGGAG CCTCTGGCAG A	31
50	(2) INFORMATION FOR SEQ ID NO:32:	
55	<ul> <li>(i) SEQUENCE CHARACTERISTICS:</li> <li>(A) LENGTH: 31 base pairs</li> <li>(B) TYPE: nucleic acid</li> <li>(C) STRANDEDNESS: single</li> <li>(D) TOPOLOGY: linear</li> </ul>	

•	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:32:		
5	GTGGTACCTC ATGAGAGGGA GCCTCTGGCA G		31
	(2) INFORMATION FOR SEQ ID NO:33:		
10	<ul><li>(i) SEQUENCE CHARACTERISTICS:</li><li>(A) LENGTH: 33 base pairs</li><li>(B) TYPE: nucleic acid</li><li>(C) STRANDEDNESS: single</li><li>(D) TOPOLOGY: linear</li></ul>		
15	(b.d) another prominers, and in No. 22.		
	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:33:		
	GTGAATTCAA CCATGGACAA TATGTCTATT ACG		33
20	(2) INFORMATION FOR SEQ ID NO:34:	•	
25	<ul><li>(i) SEQUENCE CHARACTERISTICS:</li><li>(A) LENGTH: 31 base pairs</li><li>(B) TYPE: nucleic acid</li><li>(C) STRANDEDNESS: single</li></ul>		
	(D) TOPOLOGY: linear		
30	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:34:		
	GTGGATCCCA GTCTAAAGGT TGTGGGTCTG C		31
	(2) INFORMATION FOR SEQ ID NO:35:		
35	<ul><li>(i) SEQUENCE CHARACTERISTICS:</li><li>(A) LENGTH: 32 base pairs</li><li>(B) TYPE: nucleic acid</li><li>(C) STRANDEDNESS: single</li></ul>		
40	(D) TOPOLOGY: linear	•	
	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:35:		
45	GTGGATCCTC AGTCTAAAGG TTGTGGGTCT GC		32
	(2) INFORMATION FOR SEQ ID NO:36:		
50	<ul><li>(i) SEQUENCE CHARACTERISTICS:</li><li>(A) LENGTH: 27 base pairs</li><li>(B) TYPE: nucleic acid</li><li>(C) STRANDEDNESS: single</li></ul>		
	(D) TOPOLOGY: linear		
55	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:36:		

	GTCTCGAGGC A	ACCATGAGCG ACG	rggc			2.						
	(2)	INFORMATION I	FOR SEQ ID	NO:37:								
5	(A) (B)	EQUENCE CHARACT LENGTH: 27 bas TYPE: nucleic STRANDEDNESS:	se pairs acid									
10	(D)	TOPOLOGY: line	ear	·	-							
	(xi) S	EQUENCE DESCRI	PTION: SEC	Q ID NO:37:								
15	TGGGATCCGA G	GCCGTGCTG CTGG	CCG			27						
	(2) INFORMATION FOR SEQ ID NO:38:											
20	(A) .I (B) 7 (C) 5	QUENCE CHARACT LENGTH: 1896 b TYPE: nucleic STRANDEDNESS: TOPOLOGY: line	ase pairs acid single									
25	(ii) MC (ix) FE	OLECULE TYPE: EATURE:	CDNA		4 <sup>-2</sup>							
30	(D)	NAME/KEY: Cod. LOCATION: 1 OTHER INFORMATE	.1891 TION:									
35	ATG GTG AGC A	AAG GGC GAG GAG	G CTG TTC :	ACC GGG GTG	GTG CCC ATC CTC Val Pro Ile Let 15	G 4:8						
40	var Giu beu A	GAC GGC GAC GTA Asp Gly Asp Val	A AAC GGC ( Asn Gly ) 25	CAC AAG TTC His Lys Phe	AGC GTG TCC GGG Ser Val Ser Gly 30	96 7						
	GAG GGC GAG GGU Glu Gly Glu G	GGC GAT GCC ACC	TAC GGC ATYR Gly I	AAG CTG ACC Lys Leu Thr	CTG AAG TTC ATC Leu Lys Phe Ile 45	144						
45	TGC ACC ACC GG Cys Thr Thr G	GC AAG CTG CCC ly Lys Leu Pro 55	GTG CCC 1	TGG CCC ACC Frp Pro Thr 60	CTC GTG ACC ACC Leu Val Thr Thr	192						
50	CTG ACC TAC GO Leu Thr Tyr G	GC GTG CAG TGC ly Val Gln Cys 70	TTC AGC (	CGC TAC CCC Arg Tyr Pro 75	GAC CAC ATG AAG Asp His Met Lys 80	3 240						
55	CAG CAC GAC TO	TC TTC AAG TCC he Phe Lys Ser 85	Ala Met I	CCC GAA GGC Pro Glu Gly	TAC GTC CAG GAG Tyr Val Gln Glu 95	288						

						GGC Gly 105					_	336
5						GTG Val					_	384
10						ATC Ile						432
15						ATC Ile						480
20						CGC Arg						528
						CAG Gln 185						576
25						TAC Tyr						624
30						GAT Asp						672
35						GGC Gly						720
40	GGA Gly					TCG Ser						768
				 	 	 GAG Glu 265	 					816
45						GAG Glu						864
50			Gly			TTG Leu			Gly			912
55		Gly			Ala	GAC Asp		Arg				960

٠	68	
5	GCC ATC AAG AAG ATC AGC CCC TTC GAA CAT CAG ACC TAC TGC CAG CGC Ala ile Lys Lys ile Ser Pro Phe Glu His Gln Thr Tyr Cys Gln Arg 325 330 335	1008
·	Thr Leu Arg Glu Ile Gln Ile Leu Leu Arg Phe Arg His Glu Asn Val  340  345  350	1056
10	355 360 365	1104
15	GAT GTC TAC ATT GTG CAG GAC CTG ATG GAG ACT GAC CTG TAC AAG TTG Asp Val Tyr Ile Val Gln Asp Leu Met Glu Thr Asp Leu Tyr Lys Leu 370 375 380	1152
20	CTG AAA AGC CAG CAG CTG AGC AAT GAC CAT ATC TGC TAC TTC CTC TAC  Leu Lys Ser Gln Gln Leu Ser Asn Asp His Ile Cys Tyr Phe Leu Tyr  395  CAG ATC CTC CGG CAG	1200
25	CAG ATC CTG CGG GGC CTC AAG TAC ATC CAC TCC GCC AAC GTG CTC CAC Gln Ile Leu Arg Gly Leu Lys Tyr Ile His Ser Ala Asn Val Leu His 405 410 415	1248
25	420 425 430 Thr Thr Cys Asp Leu	1296
30	AAG ATT TGT GAT TTC GGC CTG GCC CGG ATT GCC GAT CCT GAG CAT GAC Lys Ile Cys Asp Phe Gly Leu Ala Arg Ile Ala Asp Pro Glu His Asp 435 440 445	1344
35	CAC ACC GGC TTC CTG ACG GAG TAT GTG GCT ACG CGC TGG TAC CGG GCC  His Thr Gly Phe Leu Thr Glu Tyr Val Ala Thr Arg Trp Tyr Arg Ala  450  450	392
40	465 470 475 Lys Ser Ile Asp Ile	 440
	485 490 495	188
45	TTC CCT GGC AAG CAC TAC CTG GAT CAG CTC AAC CAC ATT CTG GGC ATC  Phe Pro Gly Lys His Tyr Leu Asp Gln Leu Asn His Ile Leu Gly Ile  500  500  500	536
50	CTG GGC TCC CCA TCC CAG GAG GAC CTG AAT TGT ATC ATC AAC ATG AAG Leu Gly Ser Pro Ser Gln Glu Asp Leu Asn Cys Ile Ile Asn Met Lys 515 520 525	84
55	GCC CGA AAC TAC CTA CAG TCT CTG CCC TCC AAG ACC AAG GTG GCT TGG Ala Arg Asn Tyr Leu Gln Ser Leu Pro Ser Lys Thr Lys Val Ala Trp 530 535 540	32

PCT/DK98/00145

69

										69							
					CCC Pro												1680
5					TTT Phe 565											_	1728
10					TAC Tyr												1776
15					CCC Pro												1824
20					AAG Lys												1872
20		Gly			GAG Glu			CTAG									1896
25			(2)	INI	FORM	OITA	1 FOI	R SE(	QI Q	NO:3	39:						
30		( i	(A) (B) (C)	LENG TYPI STR	NCE (GTH: E: ar ANDEI OLOGY	631 mino ONESS	amin acio S: s:	no ao i ingle	cids		•						
35		(1	/) F	RAGMI	CULE ENT : ENCE	TYPE	: int	cerna	al	Q ID	NO::	39:					
40	Met	Val	Ser	Lys	Gly 5	Glu	Glu	Leu	Phe	Thr		Val	Val	Pro	Ile 15	Leu	
	Val			20	Gly Asp	_			25	His	Lys			30			
45		Thr	35		Lys		Pro	40				Thr	45				
	65			•	Val	70				•	75					80	
50					Phe 85 Phe					90					95	Glu Glu	
				100	Gly				105 Val					110			
55	Ile	Asp 130		Lys	Glu	Asp	Gly 135	Asn		Leu	Gly	His 140	Lys	Leu	Glu	Tyr	

WO 98/45704

																			ys Asn
							n P	he L					s As	sn I					160 y Ser
5												n As	n Th						p Gly
											Туз	. Le			_	^-		r Al	a Leu
10									13					~ ~ ~	l L	eu			u Phe
		-					~ ~ ~	יטו					2 2	p Gl	u L				s Ser
4.5													n Se	r Th					240 a Ala
15												Pro	o Ar					ı Gl	y Val
										נוא					~ ~ ~		Glr	n Pro	o Phe
20		_						- 25	<i>'</i>					20	e Gl	·y			y Ala
														l Ar	д Гу				y Val 320
25							,					220	1						Arg.
25					- 10						445							Asr	val
									• • •							u i	Ala	Met	Arg
30																			Leu
							220	,					205						Tyr 400
35						4 U J						11 n							400 His
										- 4	., .					_			Leu
																			Asp
40			-					** -	)					4 - 0					Ala
																			Ile 480
45												4 Q N		Ser					
				_						_	115			His		_			
	Leu Ala								- J Z L	,									
50								222						Thr 540					
	Ala 545 Arg																		
55	Arg Leu																		
	Leu			5	80				GIL	. 13 58	yr 1 85	ıyr	ASP	Pro	Thr	As	ge oe	Glu	Pro

•	Val .	Ala	Glu 595	Glu	Pro	Phe	Thr	Phe 600	Ala	Met	Glu	Leu	Asp 605	Asp	Leu	Pro	
	Lys	Glu 610		Leu	Lys		Leu 615	Ile	Phe	Gln		Thr 620	Ala	Arg	Phe	Gln	
5	Pro 625	Gly	Val	Leu	Glu	Ala 630	Pro										
			(2)	INF	'ORMA	TION	FOR	SEC	) ID	NO : 4	0:						
10		(i	(A) (B) (C)	QUEN LENG TYPE STRA	TH: : nu NDED	1818 clei NESS	bas c ac	e pa id ngle	irs							•	
15			i) M	OLEC	ULE												•
20			(B)	MAN OOL TO	ATIC	N: 1	3	815	equer	ice							
		(х	i) S	EQUE	NCE	DESC	RIPT	: NOI	SEÇ	) ID	NO:4	10:					
25	ATG Met 1																48
30	GTC Val															Gly GGC	96
35	GAG Glu			GGC Gly													144
				GGC Gly													192
40				GGC Gly													240
45				TTC Phe													288
50				TTC Phe 100													336
55				GAG Glu													384

	GAC Asp 130											432
5	TAC Tyr											480
10	ATC Ile											528
15	 CAG Gln										_	576
20	GTG Val									_		624
20	 AAA Lys 210									_		672
25	ACC Thr	_	_	_				_		_	_	720.
30	CTC Leu				,							768
35	ATG Met											816
40	TCG Ser											864
40	AAT Asn 290											912
45	CAC His											960
50	CGC Arg			Glu			Ile			_		1008
55	CCA Pro		Glu			Val				Asp		1056

						13						
	GAG Glu											1104
5	CAT His 370											1152
10	 CAT His											1200
15	CTG Leu											1248
	GTT Val											1296
20	GCC Ala											1344
25	TAT Tyr 450											1392
30	ATG Met											1440
35	CTG Leu											1488
40	AAT Asn											1536
40	CAC His											1584
45	AAA Lys 530				Asp				Phe			1632
50	AGG Arg			Gln				Pro				1680
55	TAT		Asp				Glu				Phe	1728

74

GAC ATG GAG CTG GAC GAC TTA CCT AAG GAG AAG CTC AAA GAA CTC ATT
ASP Met Glu Leu Asp Asp Leu Pro Lys Glu Lys Leu Lys Glu Leu Ile
580

TTT GAA GAG ACT GCT CGA TTC CAG CCA GGA TAC AGA TCT TAA
Phe Glu Glu Thr Ala Arg Phe Gln Pro Gly Tyr Arg Ser

10 (2) INFORMATION FOR SEQ ID NO:41:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 605 amino acids
  - (B) TYPE: amino acid
- (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear
  - (ii) MOLECULE TYPE: protein
  - (v) FRAGMENT TYPE: internal

20

15

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:41:

Met Val Ser Lys Gly Glu Glu Leu Phe Thr Gly Val Val Pro Ile Leu 1 10 Val Glu Leu Asp Gly Asp Val Asn Gly His Lys Phe Ser Val Ser Gly 25 Glu Gly Glu Gly Asp Ala Thr Tyr Gly Lys Leu Thr Leu Lys Phe Ile Cys Thr Thr Gly Lys Leu Pro Val Pro Trp Pro Thr Leu Val Thr Thr 30 55 Leu Thr Tyr Gly Val Gln Cys Phe Ser Arg Tyr Pro Asp His Met Lys 70 75 Gln His Asp Phe Phe Lys Ser Ala Met Pro Glu Gly Tyr Val Gln Glu 85 90 Arg Thr Ile Phe Phe Lys Asp Asp Gly Asn Tyr Lys Thr Arg Ala Glu 35 100 105 Val Lys Phe Glu Gly Asp Thr Leu Val Asn Arg Ile Glu Leu Lys Gly 120 Ile Asp Phe Lys Glu Asp Gly Asn Ile Leu Gly His Lys Leu Glu Tyr 40 135 Asn Tyr Asn Ser His Asn Val Tyr Ile Met Ala Asp Lys Gln Lys Asn 150 155 Gly Ile Lys Val Asn Phe Lys Ile Arg His Asn Ile Glu Asp Gly Ser 165 170 Val Gln Leu Ala Asp His Tyr Gln Gln Asn Thr Pro Ile Gly Asp Gly 45 185 Pro Val Leu Pro Asp Asn His Tyr Leu Ser Thr Gln Ser Ala Leu 200 Ser Lys Asp Pro Asn Glu Lys Arg Asp His Met Val Leu Leu Glu Phe 50 215 Val Thr Ala Ala Gly Ile Thr Leu Gly Met Asp Glu Leu Tyr Lys Ser 230 235 Gly Leu Arg Ser Arg Val Thr Met Ala Ala Ala Ala Ala Gly Pro 245 250 Glu Met Val Arg Gly Gln Val Phe Asp Val Gly Pro Arg Tyr Thr Asn 55

```
Leu Ser Tyr Ile Gly Glu Gly Ala Tyr Gly Met Val Cys Ser Ala Tyr
                                 280
     Asp Asn Leu Asn Lys Val Arg Val Ala Ile Lys Lys Ile Ser Pro Phe
                             295
                                                300
5
     Glu His Gln Thr Tyr Cys Gln Arg Thr Leu Arg Glu Ile Lys Ile Leu
                        310
                                            315
     Leu Arg Phe Arg His Glu Asn Ile Ile Gly Ile Asn Asp Ile Ile Arg
                 . 325
                                        330
     Ala Pro Thr Ile Glu Gln Met Lys Asp Val Tyr Ile Val Gln Asp Leu
10
                                     345
     Met Glu Thr Asp Leu Tyr Lys Leu Leu Lys Thr Gln His Leu Ser Asn
                                 360
     Asp His Ile Cys Tyr Phe Leu Tyr Gln Ile Leu Arg Gly Leu Lys Tyr
                             375
15
     Ile His Ser Ala Asn Val Leu His Arg Asp Leu Lys Pro Ser Asn Leu
                         390
                                             395
     Leu Leu Asn Thr Thr Cys Asp Leu Lys Ile Cys Asp Phe Gly Leu Ala
                                         410
     Arg Val Ala Asp Pro Asp His Asp His Thr Gly Phe Leu Thr Glu Tyr
20
                                     425
     Val Ala Thr Arg Trp Tyr Arg Ala Pro Glu Ile Met Leu Asn Ser Lys
                                 440
     Gly Tyr Thr Lys Ser Ile Asp Ile Trp Ser Val Gly Cys Ile Leu Ala
                         455
                                                 460
     Glu Met Leu Ser Asn Arg Pro Ile Phe Pro Gly Lys His Tyr Leu Asp
25
                      470
                                            475
      Gln Leu Asn His Ile Leu Gly Ile Leu Gly Ser Pro Ser Gln Glu Asp
                     485
                                         490
     Leu Asn Cys Ile Ile Asn Leu Lys Ala Arg Asn Tyr Leu Leu Ser Leu
30
                                     505
                 500
      Pro His Lys Asn Lys Val Pro Trp Asn Arg Leu Phe Pro Asn Ala Asp
                                 520
      Ser Lys Ala Leu Asp Leu Leu Asp Lys Met Leu Thr Phe Asn Pro His
                             535
                                                 540
35
     Lys Arg Ile Glu Val Glu Gln Ala Leu Ala His Pro Tyr Leu Glu Gln
                         550
                                             555
      Tyr Tyr Asp Pro Ser Asp Glu Pro Ile Ala Glu Ala Pro Phe Lys Phe
                     565
                                         570
      Asp Met Glu Leu Asp Asp Leu Pro Lys Glu Lys Leu Lys Glu Leu Ile
40
                                     585
      Phe Glu Glu Thr Ala Arg Phe Gln Pro Gly Tyr Arg Ser
               (2) INFORMATION FOR SEQ ID NO:42:
45
            (i) SEQUENCE CHARACTERISTICS:
              (A) LENGTH: 2529 base pairs
              (B) TYPE: nucleic acid
              (C) STRANDEDNESS: single
              (D) TOPOLOGY: linear
50
```

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

(A) NAME/KEY: Coding Sequence (B) LOCATION: 1...2526

## (D) OTHER INFORMATION:

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:42:

5	ATG Met 1	GTG Val	AGC Ser	AAG Lys	GGC Gly 5	GAG Glu	GAG Glu	CTG Leu	TTC Phe	ACC Thr 10	GGG Gly	GTG Val	GTG Val	CCC Pro	ATC Ile 15	CTG Leu	48
10	GTC Val	GAG Glu	CTG Leu	GAC Asp 20	GGC Gly	GAC Asp	GTA Val	AAC Asn	GGC Gly 25	CAC His	AAG Lys	TTC Phe	AGC Ser	GTG Val 30	TCC Ser	GGC Gly	96
15	GAG Glu	GGC Gly	GAG Glu 35	GGC Gly	GAT Asp	GCC Ala	ACC Thr	TAC Tyr 40	GGC Gly	AAG Lys	CTG Leu	ACC Thr	CTG Leu 45	AAG Lys	TTC Phe	ATC Ile	144
20	TGC Cys	ACC Thr 50	ACC Thr	GGC Gly	AAG Lys	CTG Leu	CCC Pro 55	GTG Val	CCC Pro	TGG Trp	CCC Pro	ACC Thr 60	CTC Leu	GTG Val	ACC Thr	ACC Thr	192
20	CTG Leu 65	ACC Thr	TAC Tyr	GGC Gly	GTG Val	CAG Gln 70	TGC Cys	TTC Phe	AGC Ser	CGC Arg	TAC Tyr 75	CCC Pro	GAC Asp	CAC His	ATG Met	AAG Lys 80	240
25		CAC His															288
30	CGC Arg	ACC Thr	ATC Ile	TTC Phe 100	TTC Phe	AAG Lys	GAC Asp	GAC Asp	GGC Gly 105	AAC Asn	TAC Tyr	AAG Lys	ACC Thr	CGC Arg 110	GCC Ala	GAG Glu	336
35	GTG Val	AAG Lys	TTC Phe 115	GAG Glu	GGC Gly	GAC Asp	ACC Thr	CTG Leu 120	GTG Val	AAC Asn	CGC Arg	ATC Ile	GAG Glu 125	CTG Leu	AAG Lys	GGC Gly	384
40		GAC Asp 130															432
		TAC Tyr															480
45	GGC Gly	ATC Ile	AAG Lys	GTG Val	AAC Asn 165	TTC Phe	AAG Lys	ATC Ile	CGC Arg	CAC His 170	AAC Asn	ATC Ile	GAG Glu	GAC Asp	GGC Gly 175	AGC Ser	528
50		CAG Gln															576
55	CCC Pro	GTG Val	CTG Leu 195	CTG Leu	CCC Pro	GAC Asp	AAC Asn	CAC His 200	TAC Tyr	CTG Leu	AGC Ser	ACC Thr	CAG Gln 205	TCC Ser	GCC Ala	CTG Leu	624

		•					//						
			CCC Pro									•	672
5	 		GCC Ala										720 ·
10	 		TCT Ser										768
15			GCC Ala 260										816
20			AAA Lys	_				_	_		_		864
20			AGC Ser										912
25			TTA Leu										960
30	 		GAA Glu									;	1008
35			GCA Ala 340								_	:	1056
40			GAA Glu		•							;	1104
40			CAA Gln									:	1152
45			AAG Lys									:	1200
50			TAC Tyr										1248
55			GAC Asp 420									:	1296

										10							
	GTG Val	ACC Thr	Lys 435	Asn	ACT Thr	TTC Phe	AGG Arg	Gln 440	Tyr	CGA Arg	GTG Val	Leu	GGA Gly 445	Lys	GGG	GGC Gly	1344
5	TTC	GGG Gly 450	Glu	GTC Val	TGT Cys	GCC Ala	TGC Cys 455	Gln	GTT Val	CGG	GCC Ala	ACG Thr 460	Gly	AAA Lys	ATG Met	TAT	1392
10	GCC Ala 465	Cys	AAG Lys	CGC	TTG Leu	GAG Glu 470	AAG Lys	AAG Lys	AGG Arg	ATC	AAA Lys 475	AAG Lys	AGG Arg	AAA Lys	GGG Gly	GAG Glu 480	1440
15	Ser	Met	Ala	Leu	Asn 485	GAG Glu	Lys	Glņ	Ile	Leu 490	Glu	Lys	Val	Asn	Ser 495	Gln	1488
20	Phe	Val	Val	Asn 500	Leu	GCC Ala	Tyr	Ala	Tyr 505	Glu	Thr	Lys	Asp	Ala 510	Leu	Cys	1536
	TTG Leu	GTC Val	CTG Leu 515	ACC Thr	ATC Ile	ATG Met	AAT Asn	GGG Gly 520	GGT Gly	GAC Asp	CTG Leu	AAG Lys	TTC Phe 525	CAC His	ATC Ile	TAC Tyr	1584
25	AAC Asn	ATG Met 530	GGC Gly	AAC Asn	CCT Pro	GGC Gly	TTC Phe 535	GAG Glu	GAG Glu	GAG Glu	CGG Arg	GCC Ala 540	TTG Leu	TTT Phe	TAT Tyr	GCG Ala	1632
30	GCA Ala 545	GAG Glu	ATC Ile	CTC Leu	TGC Cys	GGC Gly 550	TTA Leu	GAA Glu	GAC Asp	CTC Leu	CAC His 555	CGT Arg	GAG Glu	AAC Asn	ACC Thr	GTC Val 560	1680
35	TAC	CGA Arg	GAT Asp	CTG Leu	AAA Lys 565	CCT Pro	GAA Glu	AAC Asn	ATC Ile	CTG Leu 570	TTA Leu	GAT Asp	GAT Asp	TAT Tyr	GGC Gly 575	CAC His	1728
40	ATT Ile	AGG Arg	ATC Ile	TCA Ser 580	GAC Asp	CTG Leu	GGC Gly	TTG Leu	GCT Ala 585	GTG Val	AAG Lys	ATC Ile	CCC Pro	GAG Glu 590	GGA Gly	GAC Asp	1776
	CTG Leu	ATC Ile	CGC Arg 595	GGC Gly	CGG Arg	GTG Val	GGC Gly	ACT Thr 600	GTT Val	GGC Gly	TAC Tyr	ATG Met	GCC Ala 605	CCC Pro	GAA Glu	GTC Val	1824
45	CTG Leu	AAC Asn 610	AAC Asn	CAG Gln	AGG Arg	TAC Tyr	GGC Gly 615	CTG Leu	AGC Ser	CCC Pro	GAC Asp	TAC Tyr 620	TGG Trp	GGC Gly	CTT Leu	GGC Gly	1872
50	TGC Cys 625	CTC Leu	ATC Ile	TAT Tyr	GAG Glu	ATG Met 630	ATC Ile	GAG Glu	GGC Gly	CAG Gln	TCG Ser 635	CCG Pro	TTC Phe	CGC Arg	Gly	CGT Arg 640	1920
55	AAG Lys	GAG Glu	AAG Lys	GTG Val	AAG Lys 645	CGG Arg	GAG Glu	GAG Glu	Val	GAC Asp 650	CGC Arg	CGG Arg	GTC Val	CTG Leu	GAG Glu 655	ACG Thr	1968

79

							19					
				TCC Ser								2016
5				ACG Thr								2064
10				GAG Glu								2112
15				GAA Glu								2160
20				TAC Tyr 725								2208
20				GTC Val								2256
25				GGC Gly								2304
30	_		_	TTT Phe	_							2352
35				CTG Leu								2400
10				AGA Arg 805								2448
40				TCC Ser							AAC Asn	2496
45				AAC Asn				TAG				2529
50		(:		FORM			NO:4	<b>1</b> 3:				

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 842 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

```
(ii) MOLECULE TYPE: protein (v) FRAGMENT TYPE: internal
```

5			(xi)	SEQ	UENC	E DE	SCRI	PTIO	N: SI	EQ I	D NO	:43:				
	_									חד						e Leu
10				2.0					25	/ Hi	s Lys			2.0	l Se	r Gly
			23					40					4 5	1 Lys		e Ile
45							55					60	Let			r Thr
15						, ,					75					t Lys
					0.5					90					^-	ı Glu
20				100	,				105					3 3 0		a Glu
								120					325			Gly
25		100	,				115					7 4 0				Tyr
						720					155					Asn 160
					100					170					3	Ser
30				100					785					700		Gly Leu
			200					200			Ser Met		205			
35		210					215				Asp	220				
						230					235 Ser					0.4.0
					440					250	Ala				255	
40				200					265		Lys			270		
÷.		His	2,7					280			Arg		205			
45	Tyr						233				Gly	3 0 0				
	_				Thr	210					315 Cys					200
50				Ala	323					330	Asp		-		225	
			Lys	740			Thr	Lys	345					250		Val.
						Gly	Gln	360			Ser		265			
55	Leu 385				Pro		3/5			Phe		3 B U			•	Ser
																400

	Val	His	Glu	Tyr	Leu 405	_	Gly	Glu	Pro	Phe 410	His	Glu	Tyr	Leu	Asp 415	Sei
	Met	Phe	Phe	Asp 420	Arg	Phe	Leu	Gln	Trp 425	Lys	Trp	Leu	Glu	Arg 430	Gln	Pro
5			435					440	-	_			445	<u>.</u>	Gly	
		450					455					460			Met	
10	465	-	_			470			_		475	_		-	Gly	480
					485		•			490					Ser 495	
				500			_		505			-	_	510	Leu	
15			515					520	_			_	525		Ile	
		530	_				535				_	540			Tyr	
20	545		•		-	550			_		555				Thr	560
					565					570					Gly 575	
		_		580	_		_		585		-			590	Gly	_
25			595					600					605		Glu	
		610					615					620			Leu	
30	625					630					635				Gly	640
	-		_		645					650	_	_			Glu 655	
o.r				660					665				_	670	Ile	
35			675					680					685		Gln	
		690					695	_				700			Met	
40	705					710					715				Pro	720
					725					730					Phe 735	
45	•			740					745					750	Tyr	
45	_	•	755		_			760			_		765		Met	
		770					775					780			Gly	
50	785					790					795				Lys	800
					805					810					Ser 815	
55				820	•				825		HIS	HIS	rie	Asn 830	Ser	ASI
55	nis	vaı	ser 835		Asn	ser	inr	61y 840		ser						

(2) INFORMATION	FOR	SEQ	ID	NO:44:
-----------------	-----	-----	----	--------

10		(	(A) (B) (C) (D) ii) ix) (A	EQUE LEN TYP STR TOP MOLE FEAT ) NA ) LO ) OT	GTH: E: n ANDE OLOG CULE URE: ME/K CATI	190 ucle DNES Y: 1 TYP EY: ON:	2 ba ic a S: s inea E: c Codi	se p cid ingl r DNA ng S 1899	airs e			٠						
		ι	xi)	SEQU:	ENCE	DES	ים ד קי	<b>ጥፐ</b> በእፕ	. ce	0 TD	NO.	44.						
20	ATG Met 1	GTG Val	Ser	AAG Lys	GGC Gly 5	GAG Glu	GAG Glu	CTG Leu	TTC Phe	ACC Thr 10	GGG	GTG Val	GTG Val	CCC Pro	ATC Ile 15	CTG Leu		48
25	GTC Val	GAG Glu	CTG Leu	GAC Asp 20	GGC Gly	GAC Asp	GTA Val	AAC Asn	GGC Gly 25	CAC His	AAG Lys	TTC Phe	AGC Ser	GTG Val 30	TCC Ser	GGC Gly		96
30	GAG Glu	GGC Gly	GAG Glu 35	GGC Gly	GAT Asp	GCC Ala	ACC Thr	TAC Tyr 40	GGC Gly	AAG Lys	CTG Leu	ACC Thr	CTG Leu 45	AAG Lys	TTC Phe	ATC Ile	1	.44
	TGC Cys	ACC Thr 50	ACC Thr	GGC Gly	AAG Lys	CTG Leu	CCC Pro 55	GTG Val	CCC Pro	TGG Trp	CCC Pro	ACC Thr 60	CTC Leu	GTG Val	ACC Thr	ACC Thr	1	92
35	CTG Leu 65	ACC Thr	TÁC Tyr	GGC Gly	GTG Val	CAG Gln 70	TGC Cys	TTC Phe	AGC Ser	CGC Arg	TAC Tyr 75	CCC Pro	GAC Asp	CAC His	ATG Met	AAG Lys 80	2	40
40	CAG Gln	CAC His	GAC Asp	TTC Phe	TTC Phe 85	AAG Lys	TCC Ser	GCC Ala	ATG Met	CCC Pro 90	GAA Glu	GGC Gly	TAC Tyr	GTC Val	CAG Gln 95	GAG Glu	2	88
45	CGC Arg	ACC Thr	ATC Ile	TTC Phe 100	TTC Phe	AAG Lys	GAC Asp	GAC Asp	GGC Gly 105	AAC Asn	TAC Tyr	AAG Lys	ACC Thr	CGC Arg 110	GCC Ala	GAG Glu	3	36
50	GTG Val	AAG Lys	TTC Phe 115	GAG Glu	GGC Gly	GAC Asp	ACC Thr	CTG Leu 120	GTG Val	AAC Asn	CGC Arg	ATC Ile	GAG Glu 125	CTG Leu	AAG Lys	GGC Gly	3	84
50	ATC Ile	GAC Asp 130	TTC Phe	AAG Lys	GAG Glu	GAC Asp	GGC Gly 135	AAC Asn	ATC Ile	CTG Leu	GGG Gly	CAC His 140	AAG Lys	CTG Leu	GAG Glu	TAC Tyr	4	32
55	AAC Asn	TAC Tyr	AAC Asn	AGC Ser	CAC His	AAC Asn	GTC Val	TAT Tyr	ATC Ile	ATG Met	GCC Ala	GAC Asp	AAG Lys	CAG Gln	AAG Lys	 AAC Asn	4	80

PCT/DK98/00145

							00						
	145			150				155			160		
5			GTG Val									Ę	528 ·
10			GCC Ala 180									5	576
			CTG Leu			Tyr						. (	524
15			CCC Pro							_		•	572
20			GCC Ala									•	720
25			TCT Ser										7 <b>68</b>
30 <sup>-</sup>			TAT Tyr 260									1	816
30			CAG Gln	•						_	_	į	864
35			GCT Ala							-		:	912
40			CGA Arg								TAC Tyr 320	!	960
<b>4</b> 5		 	GTT Val								_	1	800
50			GTT Val 340									1	056
			GTC Val									1	104
55			CTA Leu									1	152

•				•						84			•				
		37	0				37	5				38	0				•
5	CTO Let 385	ч су	T GO	SA AT .y Il	C AA e Ly	G CA s Hi 39	s re	T CA u Hi	T TC s Se	T GC r Al	T GG a Gl 39	y Il	T AT	T CA e Hi	T CG s Ar	G GAC g Asp 400	1200
. 10	TT <i>I</i> Lei	A AA 1 Ly	G CC	C AG	T AA r As: 40	n 11	A GT e Va	A GT. l Va	A AA 1 Ly:	A TC' s Se: 410	r As	T TG	C AC	r Tr	G AA u Ly 41	G ATT s Ile 5	1248
	CTT Lev	GA As	C TT p Ph	C GG e Gl 42	y. Lei	G GC	C AG	G AC	r GC r Ala 425	a Gly	A ACC	G AG	r TTT	T ATO	t Me	G ACG t Thr	1296
15	CCT Pro	TA'	T GT r Va 43	ı va.	G ACT	CGC Arg	TAC	TAC TY1	Arg	A GCA J Ala	A CCC	GAC Glu	G GTC 1 Val 445	. Ile	CT'	r GGC ı Gly	1344
20	ATG Met	GG( Gl <sub>y</sub> 45(	, -y.	C AAC	G GAZ G Glu	A AAC 1 Asn	GT( Va) 455	L Asp	TTA Leu	TGG Trp	TCT Ser	GTC Val	Gly	TGC Cys	C ATT	T ATG	1392
25	GGA Gly 465	GAZ Glı	A ATO	GTT Val	TGC . Cys	CAC His	Lys	A ATC	CTC	TTT Phe	CCA Pro 475	Gly	AGG Arg	GAC Asp	TAT	ATT Ile 480	1440
30	nop.	O.L.		ASI	485	vai	TIE	Giu	Gln	Leu 490	Gly	Thr	Pro	Сув	Pro 495	GAA Glu	1488
	TTC Phe	ATG Met	Lys	AAA Lys 500	ren	CAA Gln	CCA Pro	ACA	GTA Val 505	AGG Arg	ACT	TAC Tyr	GTT Val	GAA Glu 510	AAC Asn	AGA Arg	1536
35		υγs	515	WIG	GIY	Tyr	Ser	Phe 520	Glu	Lys	Leu	Phe	CCT Pro 525	Asp	Val	Leu	1584
40	TTC Phe	CCA Pro 530	GCT Ala	GAC Asp	TCA Ser	GAA Glu	CAC His 535	AAC Asn	AAA Lys	CTT Leu	AAA Lys	GCC Ala 540	AGT Ser	CAG Gln	GCA Ala	AGG Arg	1632
45	GAT Asp 545	TTG Leu	TTA Leu	TCC Ser	AAA Lys	ATG Met 550	CTG Leu	GTA Val	ATA Ile	GAT Asp	GCA Ala 555	TCT Ser	AAA Lys	AGG Arg	ATC Ile	TCT Ser 560	1680
50	GTA Val	GAT Asp	GAA Glu	GCT Ala	CTC Leu 565	CAA Gln	CAC His	CCG Pro	TAC. Tyr	ATC Ile 570	AAT Asn	GTC Val	TGG Trp	TAT Tyr	GAT Asp 575	CCT Pro	1728
	TCT Ser	GAA Glu	GCA Ala	GAA Glu 580	GCT Ala	CCA Pro	CCA Pro	CCA Pro	AAG Lys 585	ATC Ile	CCT Pro	GAC Asp	AAG Lys	CAG Gln 590	TTA Leu	GAT Asp	1776
55	GAA :	AGG Arg	GAA Glu	CAC His	ACA Thr	ATA Ile	GAA Glu	GAG Glu	TGG Trp	AAA Lys	GAA Glu	TTG Leu	ATA Ile	TAT Tyr	AAG Lys	GAA Glu	1824

PCT/DK98/00145 WO 98/45704

85 595 600 605 GTT ATG GAC TTG GAG GAG AGA ACC AAG AAT GGA GTT ATA CGG GGG CAG 1872 Val Met Asp Leu Glu Glu Arg Thr Lys Asn Gly Val Ile Arg Gly Gln CCC TCT CCT TTA GCA CAG GTG CAG CAG TGA 1902 Pro Ser Pro Leu Ala Gln Val Gln Gln 10 (2) INFORMATION FOR SEQ ID NO:45: (i) SEQUENCE CHARACTERISTICS: 15 (A) LENGTH: 633 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear 20 . (ii) MOLECULE TYPE: protein (v) FRAGMENT TYPE: internal (xi) SEQUENCE DESCRIPTION: SEQ ID NO:45: Met Val Ser Lys Gly Glu Glu Leu Phe Thr Gly Val Val Pro Ile Leu 25 Val Glu Leu Asp Gly Asp Val Asn Gly His Lys Phe Ser Val Ser Gly Glu Gly Glu Gly Asp Ala Thr Tyr Gly Lys Leu Thr Leu Lys Phe Ile 30 Cys Thr Thr Gly Lys Leu Pro Val Pro Trp Pro Thr Leu Val Thr Thr 55 Leu Thr Tyr Gly Val Gln Cys Phe Ser Arg Tyr Pro Asp His Met Lys 70 75 35 Gln His Asp Phe Phe Lys Ser Ala Met Pro Glu Gly Tyr Val Gln Glu 85 90 Arg Thr Ile Phe Phe Lys Asp Asp Gly Asn Tyr Lys Thr Arg Ala Glu 105 Val Lys Phe Glu Gly Asp Thr Leu Val Asn Arg Ile Glu Leu Lys Gly 40 120 Ile Asp Phe Lys Glu Asp Gly Asn Ile Leu Gly His Lys Leu Glu Tyr 135 Asn Tyr Asn Ser His Asn Val Tyr Ile Met Ala Asp Lys Gln Lys Asn 150 155 45 Gly Ile Lys Val Asn Phe Lys Ile Arg His Asn Ile Glu Asp Gly Ser 170 Val Gln Leu Ala Asp His Tyr Gln Gln Asn Thr Pro Ile Gly Asp Gly 185 Pro Val Leu Leu Pro Asp Asn His Tyr Leu Ser Thr Gln Ser Ala Leu 50 200 Ser Lys Asp Pro Asn Glu Lys Arg Asp His Met Val Leu Leu Glu Phe 215 Val Thr Ala Ala Gly Ile Thr Leu Gly Met Asp Glu Leu Tyr Lys Ser 230 235 55 Gly Leu Arg Ser Arg Ala Arg Ala Ile Met Ser Arg Ser Lys Arg Asp

250

```
Asn Asn Phe Tyr Ser Val Glu Ile Gly Asp Ser Thr Phe Thr Val Leu
                   260
                                       265
       Lys Arg Tyr Gln Asn Leu Lys Pro Ile Gly Ser Gly Ala Gln Gly Ile
               275
                                 280
                                                      285
       Val Cys Ala Ala Tyr Asp Ala Ile Leu Glu Arg Asn Val Ala Ile Lys
                                       300
                             295
       Lys Leu Ser Arg Pro Phe Gln Asn Gln Thr His Ala Lys Arg Ala Tyr
                          310
                                              315
       Arg Glu Leu Val Leu Met Lys Cys Val Asn His Lys Asn Ile Ile Gly
 10
                      325
                                          330 ,
       Leu Leu Asn Val Phe Thr Pro Gln Lys Ser Leu Glu Glu Phe Gln Asp
                  340
                                      345
       Val Tyr Ile Val Met Glu Leu Met Asp Ala Asn Leu Cys Gln Val Ile
                                  360
                                                      365
       Gln Met Glu Leu Asp His Glu Arg Met Ser Tyr Leu Leu Tyr Gln Met
 15
                              375
       Leu Cys Gly Ile Lys His Leu His Ser Ala Gly Ile Ile His Arg Asp
                          390
                                              395
      Leu Lys Pro Ser Asn Ile Val Val Lys Ser Asp Cys Thr Leu Lys Ile
 20
                      405
                                          410
      Leu Asp Phe Gly Leu Ala Arg Thr Ala Gly Thr Ser Phe Met Met Thr
                                      425
      Pro Tyr Val Val Thr Arg Tyr Tyr Arg Ala Pro Glu Val Ile Leu Gly
                                  440
      Met Gly Tyr Lys Glu Asn Val Asp Leu Trp Ser Val Gly Cys Ile Met
25
                           455
      Gly Glu Met Val Cys His Lys Ile Leu Phe Pro Gly Arg Asp Tyr Ile
                         470
                                             475
      Asp Gln Trp Asn Lys Val Ile Glu Gln Leu Gly Thr Pro Cys Pro Glu
30 -
                     485
                                        490
      Phe Met Lys Lys Leu Gln Pro Thr Val Arg Thr Tyr Val Glu Asn Arg
                                     505
      Pro Lys Tyr Ala Gly Tyr Ser Phe Glu Lys Leu Phe Pro Asp Val Leu
                                 520
      Phe Pro Ala Asp Ser Glu His Asn Lys Leu Lys Ala Ser Gln Ala Arg
35
                             535
      Asp Leu Leu Ser Lys Met Leu Val Ile Asp Ala Ser Lys Arg Ile Ser
                        550
                                             555
      Val Asp Glu Ala Leu Gln His Pro Tyr Ile Asn Val Trp Tyr Asp Pro
40
                     565
                                        570
     Ser Glu Ala Glu Ala Pro Pro Pro Lys Ile Pro Asp Lys Gln Leu Asp
                 580
                                     585
     Glu Arg Glu His Thr Ile Glu Glu Trp Lys Glu Leu Ile Tyr Lys Glu
                                600
                                                    605
     Val Met Asp Leu Glu Glu Arg Thr Lys Asn Gly Val Ile Arg Gly Gln
45
                             615
     Pro Ser Pro Leu Ala Gln Val Gln Gln
                         630
```

50 (2) INFORMATION FOR SEQ ID NO:46:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 1824 base pairs
  - (B) TYPE: nucleic acid
- 55 (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

87

(11)	MODECODE	TIPE:	CDM
(ix)	FEATURE:		

(A) NAME/KEY: Coding Sequence (B) LOCATION: 1...1821

(D) OTHER INFORMATION:

10	(	xi) S	EQUI	ENCE	DESC	RIP	CION:	SEÇ	) ID	NO:4	6:					
10 Ar	rg gro	AGC	DAG	GGC	GAG	GAG	CTG	ттс	ACC	GGG	GTG	GTG	CCC	ATC	CTG	48
	et Val															10
	1	•	-	5					10	•				15		
	C GAC															96
Va	al Glu	Leu		GIY	Asp	Val	Asn	_	His	Lys	Phe	Ser		Ser	Gly	
•			20			•		25					30			
G)	AG GGO	GAG	GGC	GAT	GCC	ACC	TAC	GGC	AAG	CTG	ACC	CTG	AAG	TTC	ATC	144
	lu Gly															
	-	35					40	_	-			45	-			
											•					
	GC ACC															192
25	ys Thi 50	Thr	GIY	ràs	Leu	Pro 55	vai	Pro	Trp	Pro	Thr	Leu	vaı	Thr	Thr	
23	50					22										
C.	rg acc	TAC	GGC	GTG	CAG	TGC	TTC	AGC	CGC	TAC	CCC	GAC	CAC	ATG	AAG	240
Le	eu Thi	Tyr	Gly	Val	Gln	Cys	Phe	Ser	Arg	Tyr	Pro	Asp	His	Met	Lys	
69	5				70					75					80	
30															~~~	
	AG CAC												_	_	_	288
G.	ln His	Asp	Pne	85	гуу	ser	Ala	met	90	GIU	GIY	TYL.	·vai	95	GIU	•
				0.5					,,					,,		
35 C	GC ACC	ATC	TTC	TTC	AAG	GAC	GAC	GGC	AAC	TAC	AAG	ACC	CGC	GCC	GAG	336
A	rg Thi	Ile	Phe	Phe	Lys	Asp	Asp	Gly	Asn	Tyr	Lys	Thr	Arg	Ala	Glu	
			100					105					110			
C.	rg aac	י יייירי	GNG	ccc	CAC	N.C.C	CTC	CTC	א א כי	ccc	איזיכי	CNC	CTC	מממ	GGC .	384
	al Lys															204
	,.	115			p		120	• • • •		*** 9		125	200	_,_	/	
									•							
	TC GA															432
	le Asp		Lys	Glu	Asp	•	Așn	Ile	Leu	Gly		Lys	Leu	Glu	Tyr	
45	. 130	)				135					140					
A	AC TAC	· AAC	AGC	CAC	AAC	GTC	тат	АТС	DTG.	GCC	GAC	DAG	CAG	AAG	AAC	480
	sn Ty															
	45				150		•	•		155	•	•		-	160	
50																
	GC AT															528
G.	ly Ile	Lys	val		Phe	ŗλs	Ile	Arg		Asn	Ile	GIu	Asp		ser	
				165					170					175		
55 G'															_	
-	TG CA	CTC	GCC	GAC	CAC	TAC	CAG	CAG	AAC	ACC	CCC	ATC	GGC	GAC	GGC	576

										88			•					
				18	0				18	5				19	0			
5	CC Pr	C GT o Va	G CT l Le 19	u ne	G CC	C GA	C AA p As	C CA n Hi 20	s Ту	C CT	'G AG	C AC	C CA r Gl 20	n Se	C GC r Al	C CTG a Leu	62	4
10	50.	21	0 AS	Ď PI		1 G11	и Бу: 21:	s Ar	g As	p Hi	s Me	t Va 22	l Le O	u Le	u Gl	G TTC u Phe	67	2
	GT( Va] 225		C GC	C GCG a Ala	C GGC a Gly	3 ATC / Ile 230	: In	r Lei	C GGG	C AT	G GA t As	p Gl	G CT	G TAG	C AA r Ly	G TCC s Ser 240	<b>72</b>	0
15	GGA Gly	CTO	Z AGA	A TCT	CGA Arg 245	GTA	AA/ Lys	A ATO	G TC: Sei	CA( Gl: 25(	a Gl	G AG	g CCO	C ACC	TTO Pho	C TAC e Tyr	761	3
<b>20</b>	CGG Arg	Glr	G GAC	G CTG 1 Leu 260	ASI	AAG Lys	ACA Thr	A ATO	TGC Trp 265	Gli	GT(	CCC Pro	C GAC	G CG7	Туз	CAG Gln	816	5
25	AAC Asn	CTC Leu	TCT Ser 275	PIO	GTG Val	GGC	TCT Ser	GGC Gly 280	Ala	TAT	GGC Gly	TC1	GTG Val 285	Cys	GC1	GCT Ala	864	ļ
.30		290		пу	1111	GIY	295	Arg	Val	Ala	Val	. Lys 300	Lys	Leu	Ser	AGA Arg	912	
	CCA Pro 305	TTT	CAG Gln	TCC Ser	ATC Ile	ATT Ile 310	CAT His	GCG Ala	AAA Lys	AGA Arg	ACC Thr 315	Tyr	AGA Arg	GAA Glu	CTG Leu	CGG Arg 320	960	
35	TTA Leu	CTT Leu	AAA Lys	CAT His	ATG Met 325	AAA Lys	CAT His	GAA Glu	AAT Asn	GTG Val 330	ATT	GGT Gly	CTG Leu	TTG Leu	GAC Asp 335	GTT Val	1008	
40	TTT Phe	ACA Thr	CCT Pro	GCA Ala 340	AGG Arg	TCT Ser	CTG Leu	GAG Glu	GAA Glu 345	TTC Phe	AAT Asn	GAT Asp	GTG Val	TAT Tyr 350	CTG Leu	GTG Val	1056	
45	ACC Thr	CAT His	CTC Leu 355	ATG Met	GGG Gly	GCA Ala	GAT Asp	CTG Leu 360	AAC Asn	AAC Asn	ATT Ile	GTG Val	AAA Lys 365	TGT Cys	CAG Gln	AAG Lys	1104	
50	CTT Leu	ACA Thr 370	GAT Asp	GAC Asp	CAT His	vaı	CAG Gln 375	TTC Phe	CTT Leu	ATC Ile	TAC Tyr	CAA Gln 380	ATT Ile	CTC Leu	CGA Arg	GGT Gly	1152	
	CTA Leu 385	AAG Lys	TAT Tyr	ATA- Ile	HIS	TCA Ser 390	GCT Ala	GAC Asp	ATA Ile	ATT Ile	CAC His 395	AGG Arg	GAC Asp	CTA Leu	AAA Lys	CCT Pro 400	1200	
55	AGT :	AAT Asn	CTA Leu	GCT Ala	GTG . Val .	AAT (	GAA Glu	GAC Asp	TGT Cys	GAG Glu	CTG Leu	AAG Lys	ATT Ile	CTG Leu	GAT Asp	TTT Phe	1248	88

89

				405			410			415		
5			CGG Arg 420	4						Ala		1296
10			AGG Arg									1344
10			GAT Asp									1392
15			ACA Thr									1440
20			AGA Arg					Ala				1488
25 ·			GAG Glu 500									1536
30			AAC Asn									1584
•			CTG Leu									1632
35			CAA Gln									1680
40			GAA Glu			 		Asp	 			1728
45			CTT Leu 580									1776
	ATC Ile		GTG Val								TGA	1824
50			•			-						

(2) INFORMATION FOR SEQ ID NO:47:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 607 amino acids

(B) TYPE: amino acid

90

- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (v) FRAGMENT TYPE: internal

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:47:

.10								lu Gļ											
								p Va											
15								a Th								u Ly	s Pl		
15								u Pr 55							r Le	u Va			
								n Cy											
20								s Se											
								s As											
25								p Th:											
								9 Gly											
								val											
30								Lys											
								туг											
35								Asn											
								Lys 215											
								Thr											
40								Lys				3ln (	Glu						
****								Thr			G	lu '							
45								Ser								Cys			
40								Leu 295							Lys				
								His											
50								His											
								Leu									Leu		
55								Asp							Lys	Cys			
3.0	-cu	37	0	. qer	Asp .	HIS	vaı	Gln 375	Phe	Leu	I	le T	yr (	Gln 380	Ile	Leu	Arg	G1	У

	-	Lys	Tyr	Ile	His		Ala	Asp	Ile	Ile		Arg	Asp	Leu	Lys		•
	385	Λcn	Len	בות	V=1	390	CI.	λεν	Cuc	C111	395	T	710	T 011	7	400	
_					405					410		-		Leu	415		
5				420					425			•		Val 430			
	Arg	Trp	Tyr 435	Arg	Ala	Pro	Glu	Ile 440	Met	Leu	Asn	Trp	Met 445	His	Tyr	Asn	
10	Gln	Thr 450	Val	Asp	Ile	Trp	Ser 455	Val	Gly	Cys	Ile	Met 460	Ala	Glu	Leu	Leu	
	Thr 465	Gly	Arg	Thr	Leu	Phe 470	Pro	Gly	Thr	Asp	His 475	Ile	Asp	Gln	Leu	Ļys 480	
	Leu	Ile	Leu	Arg	Leu 485	Val	Gly	Thr	Pro	Gly 490		Glu	Leu	Leu	Lys 495	Lys	
15	Ile	Ser	Ser	Glu 500		Ala	Arg	Asn	Tyr 505			Ser	Leu	Thr 510		Met	
	Pro	Lys	Met 515		Phe	Ala	Asn	Val 520		Ile	Gly	Ala	Asn 525	Pro	Leu	Ala	
20	Val	Asp 530		Leu	Glu	Lys	Met 535		Val	Leu	Asp	Ser 540		Ŀys	Arg	Ile	
20	Thr 545		Ala	Gln	Ala	Leu 550		His	Ala	Tyr	Phe 555		Gln	Tyr	His	_	
		Asp	Asp	Glu	Pro 565		Ala	Asp	Pro			Gln	Ser	Phe		560 Ser	
25	Arg	Asp	Leu			Asp	Glu	Trp		570 Ser	Leu	Thr	Tyr	Asp	575 Glu	Vaļ	
	Ile	Ser		580 Val	Pro	Pro	Pro		585 Asp	Gln	Glu	Glu		590 Glu	Ser		
			595					600					605				
30	-		-	INI						NO:4	18:						
		( :	(A)	EQUEI LENC	STH:	2907	7 bas	se pa						ě			
35			(C)	TYPI STRA	NDEI	ONES	S: s:	ingle	<b>=</b>								
				TOPO													
				OLEC		TYPI	E: cI	ANC									
40				IAN					quer	ıce							
				LOC													
45		()	ci) S	EQUE	ENCE	DESC	CRIPT	CION:	SEC	Q ID	NO:4	18:					
														CCC Pro			48
50	1	Vu2	502	2,5	5	Oru	014	Deu	riic	10	Gly	VAI	VAI	FIU	15	Deu	
														GTG			96
	Val	Glu	Leu	Asp 20	Gly	Asp	Val	Asn.	Gly 25	His	Lys	Phe	Ser	Val 30	Ser	Gly	
55	GAG																144
	GIU	CTA	JIU	GIA	vəħ	274	TITE	TAL	GTA	пÀг	neu	TILE	ne u	Lys	FIIE	TTG	

•										92								
			35					40					45					
5	TGC Cys	ACC Thr	C ACC	GGC Gly	AAC Lys	CTG Leu	CCC Pro 55	C GTO	CCC Pro	TGC Trp	CCC Pro	ACC Thr	CTC	GTC Val	ACC Thr	ACC Thr		192
10	CTG Leu 65	ACC Thr	TAC Tyr	GGC Gly	GTG Val	Gln 70	TGC Cys	TTC Phe	AGC Ser	CGC Arg	TAC Tyr 75	CCC Pro	GAC Asp	CAC	ATG Met	AAG Lys 80		240
	CAG Gln	CAC His	GAC Asp	TTC Phe	TTC Phe 85	AAG Lys	TCC Ser	GCC Ala	ATG Met	Pro 90	GAA Glu	GGC	TAC Tyr	GTC Val	CAG Gln 95	GAG Glu		288
15	CGC Arg	ACC	ATC Ile	Phe 100	Phe	AAG Lys	GAC Asp	GAC Asp	GGC Gly 105	Asn	TAC Tyr	AAG Lys	ACC Thr	CGC Arg 110	GCC Ala	GAG Glu		336
20	GTG Val	AAG Lys	TTC Phe 115	GAG Glu	GGC Gly	GAC Asp	ACC Thr	CTG Leu 120	Val	AAC Asn	CGC	ATC	GAG Glu 125	CTG Leu	AAG Lys	GGC Gly		384
25	ATC Ile	GAC Asp 130	TTC Phe	AAG Lys	GAG Glu	GAC Asp	GGC Gly 135	AAC Asn	ATC Ile	CTG Leu	GGG Gly	CAC His 140	AAG Lys	Leu	GAG Glu	Tyr		432
30	AAC Asn 145	TAC Tyr	AAC Asn	AGC Ser	CAC His	AAC Asn 150	GTC Val	TAT Tyr	ATC Ile	ATG Met	GCC Ala 155	GAC Asp	AAG	CAG	AAG Lys	AAC		480
	GGC Gly	ATC Ile	AAG Lys	GTG Val	AAC Asn 165	TTC Phe	AAG Lys	ATC Ile	CGC Arg	CAC His 170	AAC Asn	ATC Ile	GAG Glu	GAC Asp	GGC Gly 175	AGC Ser		528
.35	GTG Val	CAG Gln	CTC Leu	GCC Ala 180	GAC Asp	CAC His	TAC Tyr	CAG Gln	CAG Gln 185	AAC Asn	ACC Thr	CCC Pro	ATC Ile	GGC Gly 190	GAC Asp	GGC Gly	٠	576
40	CCC Pro	GTG Val	CTG Leu 195	CTG Leu	CCC Pro	GAC Asp	AAC Asn	CAC His 200	TAC Tyr	CTG Leu	AGC Ser	ACC Thr	CAG Gln 205	TCC Ser	GCC Ala	CTG <sup>.</sup> Leu		624
45	AGC Ser	AAA Lys 210	GAC Asp	CCC Pro	AAC Asn	GAG Glu	AAG Lys 215	CGC Arg	GAT Asp	CAC His	ATG Met	GTC Val 220	CTG Leu	CTG Leu	GAG Glu	TTC Phe		672
50	GTG Val 225	ACC Thr	GCC Ala	GCC Ala	GGG Gly	ATC Ile 230	ACT Thr	CTC Leu	GGC Gly	ATG Met	GAC Asp 235	GAG Glu	CTG Leu	TAC Tyr	AAG Lys	TCC Ser 240		720
	GGA Gly	CTC Leu	AGA Arg	TCT Ser	ATG Met 245	AGT Ser	GCT Ala	GAG Glu	GGG Gly	TAC Tyr 250	CAG- Gln	TAC Tyr	AGA Arg	GCG Ala	CTG Leu 255	TAT Tyr		768
55	GAT Asp	TAT Tyr	AAA Lys	AAG Lys	GAA Glu	AGA Arg	GAA Glu	GAA Glu	GAT Asp	ATT Ile	GAC Asp	TTG Leu	CAC His	TTG Leu	GGT Gly	GAC Asp		816

PCT/DK98/00145

										93		•					
				260					265					270			
	א חווא	TTC.	አ ርጥ	GTG	አአጥ	מממ	GGG	TCC	ጥጥአ	CTN	CCT	СТТ	CCA	<b>ጥጥ</b> ር	ΔCT	GAT	864
				Val													004
5			275		•			280					285				
		-		GCC													912
	Gly	Gln 290	Glu	Ala	Arg	Pro	Glu 295	Glu	Ile	Gly	Trp	Leu 300	Asn	Gly	Tyr	Asn	
10		290					2,5					500					
				GGG Gly													960
	305	Int	1111	GT.Y	GIU	310	Gly	waħ	FIIC	FIU	315	1111	1 y 1	Val	014	320	
15	ΑΤΤ	GGA	AGG	AAA	AAA	ATC	TCG	CCT	CCC	ACA	CCA	AAG	CCC	CGG	CCA	CCT	1008
				Lys	Lys	Ile				Thr					Pro		
					325	•				330					335	•	•
				CCT													1056
20	Arg	Pro	Leu	Pro 340	Val	Ala	Pro	Gly	Ser	Ser	Lys	Thr	GIu	350	Asp	vai	
															daa	aam	1104
				GCT Ala													1104
25			355					360	•	•			365				•
	CCT	GAC	ATT	GCC	CCG	CCT	CTT	CTT	ATC	AAG	CTC	GTG	GAA	GCC	ATT	GAA	1152
	Pro	_	Ile	Ala	Pro	Pro		Leu	Ile	Lys	Leu		Glu	Ala	Ile	Glu	
30		370					375					380					
				CTG													1200
	Lys 385	Lys	Gly	Leu	Glu	Cys 390	Ser	Thr	Leu	Tyr	Arg	Thr	GIn	Ser	Ser	ser 400	
.=												0 h m			maa	ama	1249
35				GAA Glu													1248
					405	_				410	Ī	_			415		
	GAC	TTG	GAA	ATG	ATC	GAT	GTG	CAC	GTT	ŢTG	GCT	GAC	GCT	TTC	AAA	ĊGC	1296
40				Met													
				420					425					430			
				GAC Asp													1344
45	Tyr	Leu	435	_	Leu	PIO	ASII	440	vai	116	PIO	Ala	.445	vai	ıyı	561	
	(1) N	א ייי	א תיימי	TCT	ጥጥአ	CCT	CCA	CAA	Стр	C 7 7	አርር	ጥሮሮ	GAA	CDD	ጥልጥ	Δጥጥ	1392
				Ser												_	2372
E0.		450					455					460					
50	CAG	CTA	TTG	AAG	AAG	CTT	ATT	AGG	TCG	CCT	AGC	ATA	CCT	CAT	CAG	TAT	1440
	Gln	Leu		Lys		Leu	Ile				Ser	Ile					
	465					470					475						
55																CAA	1488
	Trp	Leu	Thr	ьeu	GIN.	ıyr	ьeи	ьeu	туѕ	HIS	Pne	rne	ьys	Leu	ser	Gln	

										94			•				
					485					490	)				499	5	
5	ACC Thr	TC(	C AGO	C AAA Lys 500	Asn	CTG Leu	TTC Let	G AAC	GCA Ala 505	Arc	GTA Val	CTC Lev	TCT Ser	GAA Glu 510	Ile	TTC Phe	1536
. 10	AGC	Pro	ATO Met	Leu	TTC Phe	AGA Arg	TTC Phe	Ser 520	Ala	GCC Ala	AGC Ser	TCI Ser	GAT Asp 525	Asn	ACT Thr	GAA Glu	1584
	AAC Asn	Leu 530	ıııe	AAA : Lys	GTT Val	ATA Ile	GAA Glu 535	Ile	TTA Leu	ATC Ile	TCA Ser	ACT Thr 540	Glu	TGG	AAT Asn	GAA Glu	1632
15	CGA Arg 545	GIN	CCT Pro	GCA Ala	CCA Pro	GCA Ala 550	CTG Leu	CCT Pro	CCT Pro	AAA Lys	CCA Pro 555	CCA Pro	AAA Lys	CCT	ACT Thr	ACT Thr 560	1680
20	GTA Val	GCC	AAC Asn	AAC Asn	GGT Gly 565	ATG Met	AAT Asn	AAC Asn	AAT Asn	ATG Met 570	TCC Ser	TTA Leu	CAA Gln	AAT Asn	GCT Ala 575	GAA Glu	1728
25	TGG Trp	TAC	TGG Trp	GGA Gly 580	GAT Asp	ATC Ile	TCG Ser	AGG Arg	GAA Glu 585	GAA Glu	GTG Val	AAT Asn	GAA Glu	AAA Lys 590	CTT Leu	CGA Arg	1776
30	GAT Asp	ACA Thr	GCA Ala 595	GAC Asp	GGG Gly	ACC Thr	TTT Phe	TTG Leu 600	GTA Val	CGA Arg	GAT Asp	GCG Ala	TCT Ser 605	ACT Thr	AAA Lys	ATG Met	1824
	CAT His	GGT Gly 610	GAT Asp	TAT Tyr	ACT Thr	CTT Leu	ACA Thr 615	CTA Leu	AGG Arg	AAA Lys	GGG Gly	GGA Gly 620	AAT Asn	AAC Asn	AAA Lys	TTA Leu	1872
35	ATC Ile 625	AAA Lys	ATA Ile	TTT Phe	CAT His	CGA Arg 630	GAT Asp	GGG Gly	AAA Lys	TAT Tyr	GGC Gly 635	TTC Phe	TCT Ser	GAC Asp	CCA Pro	TTA Leu 640	1920
40	ACC Thr	TTC Phe	AGT Ser	TCT Ser	GTG Val 645	GTT Val	GAA Glu	TTA Leu	ATA Ile	AAC Asn 650	CAC His	TAC Tyr	CGG Arg	AAT Asn	GAA Glu 655	TCT Ser	1968
45	CTA Leu	GCT Ala	CAG Gln	TAT Tyr 660	AAT Asn	CCC Pro	AAA Lys	TTG Leu	GAT Asp 665	GTG Val	AAA Lys	TTA Leu	CTT Leu	TAT Tyr 670	CCA Pro	GTA Val	2016
50	TCC Ser	AAA Lys	TAC Tyr 675	CAA Gln	CAG Gln	GAT Asp	CAA Gln	GTT Val 680	GTC Val	AAA Lys	GAA Glu	GAT Asp	AAT Asn 685	ATT Ile	GAA Glu	GCT Ala	2064
	GTA Val	GGG Gly 690	AAA Lys	AAA Lys	TTA Leu	His	GAA Glu 695	TAT Tyr	AAC Asn	ACT Thr	CAG Gln	TTT Phe 700	CAA Gln	GAA Glu	AAA Lys	AGT Ser	2112
55	CGA Arg	GAA Glu	TAT Tyr	GAT Asp	AGA Arg	TTA Leu	TAT Tyr	GAA Glu	GAA Glu	TAT Tyr	ACC Thr	CGC Arg	ACA Thr	TCC Ser	CAG Gln	GAA Glu	2160

		•					95		•				
	705			•	710			715	•			720	
5				AGG Arg 725									2208
				CAG Gln									2256
10				AAA Lys									2304
15				GAT Asp									2352
20				TTG Leu									2400
25				AAA Lys 805									2448
20				AGA Arg									2496
30				AAG Lys								_	2544
35				CTG Leu									2592
40				AAT Asn									2640
45				AAG Lys 885									2688
50				TAT Tyr							_		2736
50				AAC Asn									2784
55				AGC Ser									2832

96 930 935 940 ACC TCC CTT GTG CAG CAC AAC GAC TCC CTC AAT GTC ACA CTA GCC TAC Thr Ser Leu Val Gln His Asn Asp Ser Leu Asn Val Thr Leu Ala Tyr 5 CCA GTA TAT GCA CAG CAG AGG CGA TGA 2907 Pro Val Tyr Ala Gln Gln Arg Arg 10 (2) INFORMATION FOR SEQ ID NO:49: (i) SEQUENCE CHARACTERISTICS: 15 (A) LENGTH: 968 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear 20 (ii) MOLECULE TYPE: protein (v) FRAGMENT TYPE: internal (xi) SEQUENCE DESCRIPTION: SEQ ID NO:49: Met Val Ser Lys Gly Glu Glu Leu Phe Thr Gly Val Val Pro Ile Leu 25 Val Glu Leu Asp Gly Asp Val Asn Gly His Lys Phe Ser Val Ser Gly Glu Gly Glu Gly Asp Ala Thr Tyr Gly Lys Leu Thr Leu Lys Phe Ile 30 Cys Thr Thr Gly Lys Leu Pro Val Pro Trp Pro Thr Leu Val Thr Thr Leu Thr Tyr Gly Val Gln Cys Phe Ser Arg Tyr Pro Asp His Met Lys 70 Gln His Asp Phe Phe Lys Ser Ala Met Pro Glu Gly Tyr Val Gln Glu 35 90 Arg Thr Ile Phe Phe Lys Asp Asp Gly Asn Tyr Lys Thr Arg Ala Glu 105 . Val Lys Phe Glu Gly Asp Thr Leu Val Asn Arg Ile Glu Leu Lys Gly 40 120 Ile Asp Phe Lys Glu Asp Gly Asn Ile Leu Gly His Lys Leu Glu Tyr 135 140 Asn Tyr Asn Ser His Asn Val Tyr Ile Met Ala Asp Lys Gln Lys Asn

Val Gln Leu Ala Asp His Tyr Gln Gln Asn Thr Pro Ile Gly Asp Gly 185 Pro Val Leu Leu Pro Asp Asn His Tyr Leu Ser Thr Gln Ser Ala Leu 200 Ser Lys Asp Pro Asn Glu Lys Arg Asp His Met Val Leu Leu Glu Phe 215 220 Val Thr Ala Ala Gly Ile Thr Leu Gly Met Asp Glu Leu Tỳr Lys Ser

155

170

230 235 Gly Leu Arg Ser Met Ser Ala Glu Gly Tyr Gln Tyr Arg Ala Leu Tyr 55 245

Gly Ile Lys Val Asn Phe Lys Ile Arg His Asn Ile Glu Asp Gly Ser

150

165

180

45

	Asn	Tvr	Lvs	Lys	Glu	Ara	Glu	Glu	Asn	Tle	Asn	Len	His	Len	Glv	Ast
	nsp	-7-	נעם	260	0.10	- A- 9	Olu	GIU	265	110	vəħ	Deu	1113	270	GIY	NO.
			275	Val			_	280					285			
5	Gly	Gln 290	Glu	Ala	Arg	Pro	Glu 295	Glu	Ile	Gly	Trp	Leu 300	Asn	Gly.	Tyr	Ası
	Glu 305	Thr	Thr	Gly	Glu	Arg 310	Gly	Asp	Phe	Pro	Gly 315	Thr	Tyr	Val	Glu	Ty:
10	Ile	Gly	Arg	Lys	Lys 325	Ile	Ser	Pro	Pro	Thr 330	Pro	Lys	Pro	Arg	Pro 335	Pro
	Arg	Pro	Leu	Pro 340	Val	Ala	Pro	Gly	Ser 345	Ser	Lys	Thr	Glu	Ala 350	Asp	Val
	Glu	Gln	Gln 355	Ala	Leu	Thr	Leu	Pro 360	Asp	Leu	Ala	Glu ·	Gln 365	Phe	Ala	Pro
15	Pro	Asp 370	Ile	Ala	Pro	Pro	Leu 375	Leu	Ile	Lys	Leu	Val 380	Glu	Ala	Ile	Gli
	Lys 385	Lys	Gly	Leu	Glu	Cys 390	Ser	Thr	Leu	Tyr	Arg 395	Thr	Gln	Ser	Ser	Se1
20	Asn	Leu	Ala	Glu	Leu 405	Arg	Gln	Leu	Leu	Asp 410	Cys	Asp	Thr	Pro	Ser 415	Va]
	Asp	Leu	Glu	Met 420	Ile	Asp	Val	His	Val 425	Leu	Ala	Asp	Ala	Phe 430	Lys	Arg
	Tyr	Leu	Leu 435	Asp	Leu	Pro	Asn	Pro 440	Val	Ile	Pro	Ala	Ala 445	Val	Tyr	Sei
25	Glu	Met 450		Ser	Leu	Ala	Pro 455	Glu	Val	Gln	Ser	Ser 460	Glu	Glu	Tyr	Ile
	Gln 465	Leu	Leu	Lys	Lys	Leu 470	Ile	Arg	Ser	Pro	Ser 475	Ile	Pro	His	Gln	Ту: 480
30	Trp	Leu	Thr	Leu ·	Gln 485	Tyr	Leu	Leu	Lys	His 490	Phe	Phe	ГÄг	Leu	Ser 495	Glı
	Thr	Ser	Ser	Lys 500	Asn	Leu	Leu	Asn	Ala 505	Arg	Val	Leu	Ser	Glu 510	Ile	Phe
	Ser	Pro	Met 515	Leu	Phe	Arg	Phe	Ser 520	Ala	Ala	Ser	Ser	Asp 525	Asn	Thr	Glı
35	Asn	Leu 530	Ile	Lys	Val	Ile	Glu 535	Ile	Leu	Ile	Ser	Thr 540	Glu	Trp	Asn	Glı
	Arg 545	Gln	Pro	Ala	Pro	Ala 550	Leu	Pro	Pro	Lys	Pro 555	Pro	Lys	Pro	Thr	Th:
40	Val	Ala	Asn	Asn	Gly 565		Asn	Asn	Asn	Met 570	Ser	Leu	Gln	Asn	Ala 575	Glu
	Trp	Tyr	Trp	Gly 580	Asp	Ile	Ser	Arg	Glu 585	Glu	Val	Asn	Glu	Lys 590	Leu	Arg
	Asp	Thr	Ala 595	Asp	Gly	Thr	Phe	Leu 600	Val	Arg	Asp	Ala	Ser 605	Thr	Lys	Met
45	His	Gly 610	Asp	Tyr	Thr	Leu	Thr 615	Leu	Arg	Lys	Gly	Gly 620	Asn	Asn	Lys	Let
	Ile 625	Lys	Ile	Phe	His	Arg 630	Asp	Gly	Lys	Tyr	Gly 635	Phe	Ser	Asp	Pro	Let 640
50	Thr	Phe	Ser	Ser	Val 645	Val	Glu	Leu	Ile	Asn 650	His	Tyr	Arg	Asn	Glu 655	Se
•	Leu	Ala	.Gln	Tyr 660	Asn	Pro	Lys	Leu	Asp 665	Val	Lys	Leu	Leu	Tyr 670	Pro	Va:
	Ser	Lys	Tyr 675	Gln	Gln	Asp	Gln	Val 680	Val	Lys	Glu	Asp	Asn 685	Ile	Glu	Ala
55	Val	Gly		Lys	Leu	His	Glu		Asn	Thr	Gln	Phe		Glu	Lys	Se

						110					715					Glu	
	Ile	Glr	Met	Lys	Arg 725	Thr	Ala	Ile	Glu	Ala	Phe	Asn	Glu	Thr			
5	Ile	Phe	Glu	Glu 740	Gln		Gln	Thr	Gln 745	730 Glu	Arg	Tyr	Ser			Tyr	
	Ile	Glu	Lys 755	Phe	Lys	Arg	Glu	Gly 760	Asn	Glu	Lys	Glu		750 Gln	Arg	Ile	
10					Asp		//2	Lys	Ser			700					
	Ser 785	Arg	Arg	Arg	Leu	Glu 790	Glu	Asp	Leu	Lys	Lys 795	780 Gln	Ala	Ala	Glu		
	Arg	Glu	Ile	Asp	Lys 805		Met	Asn	Ser	Ile 810	Lys	Pro	Asp	Leu		800 Gln	
15	Leu	Arg	Lys	Thr 820	Arg	Asp	Gln	Tyr	Leu 825	Met	Trp	Leu	Thr		815 Lys	Gly	
	Val	Arg	Gln 835	Lys	Lys	Leu	Asn	Glu 840	Trp	Leu	Gly	Asn		830 Asn	Thr	Glu	
20	Asp	Gln 850	Tyr	Ser	Leu	Val	Glu 855	Asp	Asp	Glu	Asp		845 Pro	His	His	Asp	
	Glu 865	Lys	Thr	Trp	Asn	Val 870	Gly	Ser	Ser	Asn	Arg 875	860 Asn	Lys	Ala	Glu		
	Leu	Leu	Arg	Gly	Lys 885	Arg	Asp	Gly	Thr	Phe 890	Leu	Val	Arg	Glu		880 Ser	
25				900	Tyr				Val	Val				~ ~ ~			
	His	Ċ Ув	Val 915	Ile	Asn	Lys	Thr	Ala 920	Thr	Gly	Tyr	Gly		910 Ala	Glu	Pro	
30					Ser		<b>335</b>	Lys				040					
	Thr 945	Ser	Leu	Val	Gln	His 950	Asn	Asp	Ser	Leu	Asn 955	Val	Thr	Leu			
	Pro	Val	Tyr	Ala	Gln 965	Gln .	Arg	Arg			,,,					960	
35		•	(2)	INF	'ORMA'	TION	FOR	SEO	י מד	NO · S	ο.						
		(i			CE C						٠.			•	-		
40		•	(A)	LENG	TH: :	2160	base	e pa	irs								
			(C)	STRA	NDEDI LOGY:	NESS	: si	ngle									
		(i:	i) Mo	OLEC	ULE 7			NA.									•
45		(i:	x) Fl														
			(B)	LOC	E/KEY ATION	I: 1.	21	L57	quenc	e							
50					ER IN												
					NCE I												
	ATG G	TG A	AGC A Ser I	AAG (	GGC G	AG G	AG C	TG T	TC A	CC G	GG G	TG G	TG C	CC F	ATC C	TG	48
55	1				5				1	.0		•			5 .	-u	

		GAC Asp 20							96
5		GGC Gly							144
10		GGC Gly							192
15		GGC Gly							240
20		TTC Phe							288
		TTC Phe 100							336
25		GAG Glu							384
30		AAG Lys							432
35		AGC Ser							480
40		GTG Val							528
		GCC Ala 180			 				576
45		CTG Leu							624
50		CCC Pro							672
55		GCC Ala							720

										100								
	GG. Gl	A CT y Le	C AG u Ar	A TC	r CGA r Arg 245	3 ATS	r cai	A GC:	r TCC	AA Ası 250	ı Se	G AC	C ATO	G TC	G TC r Se 25	C ATO r Ile 5	2	768
<b>.</b>	TT	G CC u Pr	A TT	C ACC e Th: 260	LPIC	CCA Pro	A GTT	r Gro	AAC Lys 265	Arc	A CTO	G CTO	G GGI	A TG	р Гу	G AA( s Lys	3 i	816
10	TC! Sei	A GC	T GG' a Gly 27!	y GI	G TCT	GGA	GG#	A GCA Ala 280	Gly	GGA Gly	GGA Gly	A GAC	G CAC I Glr 285	Ası	r GGG	G CAG	; {	364
15	GAA Glu	A GA 1 Gl1 29	л пуз	G TGC	TGT Cys	GAG Glu	AAA Lys 295	Ala	GTG Val	AAA Lys	AG1 Ser	CTC Leu	ı Val	AA0	AAC Lys	G CTA	. 9	912
20	AAG Lys 305	цys	A ACA	A GGA Gly	CGA Arg	TTA Leu 310	Asp	GAG Glu	CTT Leu	GAG Glu	AAA Lys 315	Ala	ATC	ACC Thr	ACT	CAA Gln 320		60
	AAC Asn	TG1	TAAT Asn	ACT Thr	AAA Lys 325	TGT Cys	GTT Val	ACC Thr	ATA Ile	CCA Pro 330	AGC Ser	ACT	TGC Cys	TCT Ser	GAA Glu 335	ATT	10	80
25	TGG Trp	GGA Gly	CTG Leu	AGT Ser 340	ACA Thr	CCA Pro	AAT Asn	ACG Thr	ATA Ile 345	GAT Asp	CAG Gln	TGG Trp	GAT Asp	ACA Thr	Thr	GGC Gly	10	56
30	CTT Leu	TAC	Ser 355	Pne	TCT Ser	GAA Glu	CAA Gln	ACC Thr 360	AGG Arg	TCT Ser	CTT Leu	GAT Asp	GGT Gly 365	CGT Arg	CTC Leu	CĄG Gln	11	04
35	GTA Val	TCC Ser 370	nis	CGA Arg	AAA Lys	GGA Gly	TTG Leu 375	CCA Pro	CAT His	GTT Val	ATA Ile	TAT Tyr 380	TGC Cys	CGA Arg	TTA Leu	TGG Trp	11:	52
40	CGC Arg 385	TGG	CCT Pro	GAT Asp	CTT Leu	CAC His 390	AGT Ser	CAT His	CAT His	GAA Glu	CTC Leu 395	AAG Lys	GCA Ala	ATT Ile	GAA Glu	AAC Asn 400	120	00
			TAT Tyr		TTT Phe 405	AAT Asn	CTT	AAA Lys	AAG Lys	GAT Asp 410	GAA Glu	GTA Val	TGT Cys	GTA Val	AAC Asn 415	CCT Pro	124	18
45	TAC Tyr	CAC His	TAT Tyr	CAG Gln 420	AGA Arg	GTT Val	GAG Glu	ACA Thr	CCA Pro 425	GTT Val	TTG Leu	CCT Pro	CCA Pro	GTA Val 430	TTA Leu	GTG Val	129	96
50	CCC Pro	CGA Arg	CAC His 435	ACC Thr	GAG . Glu	ATC Ile	Leu	ACA Thr 440	GAA Glu	CTT Leu	CCG Pro	CCT Pro	CTG Leu 445	GAT Asp	GAC Asp	TAT Tyr	134	4
55		CAC His 450	TCC Ser	ATT Ile	CCA (	JIU ,	AAC Asn 455	ACT Thr	AAC Asn	TTC Phe	Pro	GCA Ala 460	GGA Gly	ATT Ile	GAG Glu	CCA Pro	139	2

								101					
			TAT Tyr										1440
5			ACA Thr										1488
10			GAA Glu 500										1536
15			CAG Gln										1584
20			TAT Tyr										1632
20		_	TCA Ser	_	_								1680
25			TGC Cys										1728
30	_	_	ACA Thr 580			_	_		_	_			1776
35			GAA Glu										1824
40			CCC Pro										1872
· 40			ATT Ile										1920
45			GCT Ala										1968
50			CTA Leu 660										2016
55			GCA Ala										2064

102

TGG ATT GAA CTT CAT CTG AAT GGA CCT CTA CAG TGG TTG GAC AAA GTA Trp Ile Glu Leu His Leu Asn Gly Pro Leu Gln Trp Leu Asp Lys Val 2112 TTA ACT CAG ATG GGA TCC CCT TCA GTG CGT TGC TCA AGC ATG TCA TAA 5 Leu Thr Gln Met Gly Ser Pro Ser Val Arg Cys Ser Ser Met Ser 2160 710 715 10 (2) INFORMATION FOR SEQ ID NO:51: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 719 amino acids (B) TYPE: amino acid 15 (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (v) FRAGMENT TYPE: internal 20 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:51: Met Val Ser Lys Gly Glu Glu Leu Phe Thr Gly Val Val Pro Ile Leu 10 Val Glu Leu Asp Gly Asp Val Asn Gly His Lys Phe Ser Val Ser Gly 25 Glu Gly Glu Gly Asp Ala Thr Tyr Gly Lys Leu Thr Leu Lys Phe Ile 40 Cys Thr Thr Gly Lys Leu Pro Val Pro Trp Pro Thr Leu Val Thr Thr 30 ... 55 Leu Thr Tyr Gly Val Gln Cys Phe Ser Arg Tyr Pro Asp His Met Lys Gln His Asp Phe Phe Lys Ser Ala Met Pro Glu Gly Tyr Val Gln Glu 90 35 Arg Thr Ile Phe Phe Lys Asp Asp Gly Asn Tyr Lys Thr Arg Ala Glu 105 Val Lys Phe Glu Gly Asp Thr Leu Val Asn Arg Ile Glu Leu Lys Gly 120 Ile Asp Phe Lys Glu Asp Gly Asn Ile Leu Gly His Lys Leu Glu Tyr 40 135 Asn Tyr Asn Ser His Asn Val Tyr Ile Met Ala Asp Lys Gln Lys Asn Gly Ile Lys Val Asn Phe Lys Ile Arg His Asn Ile Glu Asp Gly Ser 170 Val Gln Leu Ala Asp His Tyr Gln Gln Asn Thr Pro Ile Gly Asp Gly 45 185 Pro Val Leu Leu Pro Asp Asn His Tyr Leu Ser Thr Gln Ser Ala Leu 200 Ser Lys Asp Pro Asn Glu Lys Arg Asp His Met Val Leu Leu Glu Phe 50 215 Val Thr Ala Ala Gly Ile Thr Leu Gly Met Asp Glu Leu Tyr Lys Ser Gly Leu Arg Ser Arg Ala Gln Ala Ser Asn Ser Thr Met Ser Ser Ile 235 250 Leu Pro Phe Thr Pro Pro Val Val Lys Arg Leu Leu Gly Trp Lys Lys 55 265

	Ser	Ala	Gly 275	Gly	Ser	Gly	Gly	Ala 280	Gly	Gly	Gly	Glu	Gln 285	Asn	Gly	Gln
	Glu	Glu 290	Lys	Trp	Cys	Glu	Lys 295	Ala	Val	Lys	Ser	Leu 300	Val	Lys	Lys	Leu
5	Lys 305	Lys	Thr	Gly	Arg	Leu 310	Asp	Glu	Leu	Glu	Lys 315	Ala	Ile	Thr	Thr	Gln 320
	Asn	Cys	Asn	Thr	Lys 325	Cys	Val	Thr	Ile	Pro 330	Ser	Thr	Cys	Ser	Glu 335	Ile
10	Trp	Gly	Leu	Ser 340	Thr	Pro	Asn	Thr	Ile 345	Asp	Gln	Trp	Asp	Thr 350	Thr	Gly
	Leu	Tyr	Ser 355	Phe	Ser	Glu	Gln	Thr 360	Arg	Ser	Leu	Asp	Gly 365	Arg	Leu	Gln
		370		_	-	_	375					380	_	_	Leu	
15	385	_				390					395				Glu	400
	_		_		405			_	_	410			_		Asn 415	
20	_			420					425					430	Leu	
	· Pro		435					440					445			
		450					455					460			Glu	
25	465					470					475				Ser	480
	_	_			485	_				490					Thr 495	
30				500					505					510	His	
		_	515					520					525		Cys	
		530					535				_	540			His	
35	545					550					555				Asn	560
					565					570					Ala 575	
40	·Val			580					585		_			590		
			595					600					605		Ile	
4E		610					615					620			Ala	
45	625					630					635				Asn	640
					645					650					Glu 655	
50				660					665					670		
			675					680					685		Pro	
	_	690					695	_				700			Lys	
55	Leu 705	Thr	Gln	Met	Gly	Ser 710	Pro	Ser	val	Arg	Cys 715		ser	Met	Ser	

(2) INFORMATION FOR SEQ ID NO:52:

## (i) SEQUENCE CHARACTERISTICS: 5 (A) LENGTH: 2421 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear 10 (ii) MOLECULE TYPE: cDNA (ix) FEATURE: (A) NAME/KEY: Coding Sequence (B) LOCATION: 1...2418 15 (D) OTHER INFORMATION: (xi) SEQUENCE DESCRIPTION: SEQ ID NO:52: ATG GTG AGC AAG GGC GAG GAG CTG TTC ACC GGG GTG GTG CCC ATC CTG Met Val Ser Lys Gly Glu Glu Leu Phe Thr Gly Val Val Pro Ile Leu 20 48 10 . GTC GAG CTG GAC GGC GAC GTA AAC GGC CAC AAG TTC AGC GTG TCC GGC Val Glu Leu Asp Gly Asp Val Asn Gly His Lys Phe Ser Val Ser Gly 96 25 GAG GGC GAG GGC ACC TAC GGC AAG CTG ACC CTG AAG TTC ATC Glu Gly Glu Gly Asp Ala Thr Tyr Gly Lys Leu Thr Leu Lys Phe Ile 40 30 TGC ACC ACC GGC AAG CTG CCC GTG CCC TGG CCC ACC CTC GTG ACC ACC Cys Thr Thr Gly Lys Leu Pro Val Pro Trp Pro Thr Leu Val Thr Thr 192 55 CTG ACC TAC GGC GTG CAG TGC TTC AGC CGC TAC CCC GAC CAC ATG AAG 35 Leu Thr Tyr Gly Val Gln Cys Phe Ser Arg Tyr Pro Asp His Met Lys 240 70 CAG CAC GAC TTC TTC AAG TCC GCC ATG CCC GAA GGC TAC GTC CAG GAG Gln His Asp Phe Phe Lys Ser Ala Met Pro Glu Gly Tyr Val Gln Glu 40 288

104

336

432

480

CGC ACC ATC TTC TAG GAC GAC GGC AAC TAC AAG ACC CGC GCC GAG Arg Thr Ile Phe Phe Lys Asp Asp Gly Asn Tyr Lys Thr Arg Ala Glu

GTG AAG TTC GAG GGC GAC ACC CTG GTG AAC CGC ATC GAG CTG AAG GGC Val Lys Phe Glu Gly Asp Thr Leu Val Asn Arg Ile Glu Leu Lys Gly

ATC GAC TTC AAG GAG GAC GGC AAC ATC CTG GGG CAC AAG CTG GAG TAC Ile Asp Phe Lys Glu Asp Gly Asn Ile Leu Gly His Lys Leu Glu Tyr

AAC TAC AAC AGC CAC AAC GTC TAT ATC ATG GCC GAC AAG CAG AAG AAC

Asn Tyr Asn Ser His Asn Val Tyr Ile Met Ala Asp Lys Gln Lys Asn

45

50

55

100

115

105

						100					
	145			150			155			160	
5			AAC Asn 165								528
10			GAC Asp								576
			CCC Pro								624
15			AAC Asn								672
20		•	GGG Gly								720
25			CGA Arg 245								768
30			ACG Thr								816
30			TTG Leu								864
35			GCA Ala								912
40			GAT Asp								960
45			TGT Cys 325								1008
50			CGG Arg								1056
00			GAT Asp								1104
55			TTT Phe								1152

			106	•
	370	375	380	
5	385 3	90	GGA ATT GAT CTC TCA GGA TTA Gly Ile Asp Leu Ser Gly Leu 395 400	1200
10	405	-u 110 Ser Ser	ATG ATG GTG AAG GAT GAA TAT Met Met Val Lys Asp Glu Tyr 410 415	1248
	420	425	TTG TCC ACT GAA GGA CAT TCA Leu Ser Thr Glu Gly His Ser 430	1296
15	435	440	AAT CGT GCA TCG ACA GAG ACA Asn Arg Ala Ser Thr Glu Thr 445	1344
20	450	455	TCT GAG TCT AAT GCT ACC AGC Ser Glu Ser Asn Ala Thr Ser 460	1392
25	465 47	O THE PIO VAL	GCT TCC ACA AGT CAG CCT GCC Ala Ser Thr Ser Gln Pro Ala 475 480	1440
30	485	mis ser Giu (	GGA CTG TTG CAG ATA GCA TCA Gly Leu Leu Gln Ile Ala Ser 190 495	1488
	500	505	GGA TTT ACT GGT CAG CCA GCT Bly Phe Thr Gly Gln Pro Ala 510	1536
35	ACT TAC CAT CAT AAC AGC Thr Tyr His His Asn Ser 515	ACT ACC ACC T Thr Thr Thr T 520	GG ACT GGA AGT AGG ACT GCA rp Thr Gly Ser Arg Thr Ala 525	1584
40	E20	CCT CAC CAC C Pro His His G 535	AA AAC GGC CAT CTT CAG CAC ln Asn Gly His Leu Gln His 540	1632
45	CAC CCG CCT ATG CCG CCC His Pro Pro Met Pro Pro 545 550	CAT CCC GGA C	AT TAC TGG CCT GTT CAC AAT is Tyr Trp Pro Val His Asn 555 560	1680
50	GAG CTT GCA TTC CAG CCT Glu Leu Ala Phe Gln Pro 565	CCC ATT TCC APPro Ile Ser As	on His Pro Ala Pro Glu Tyr	.728
	TGG TGT TCC ATT GCT TAC Trp Cys Ser Ile Ala Tyr 580	TTT GAA ATG GA Phe Glu Met As 585	T GTT CAG GTA GGA GAG ACA 1 p Val Gln Val Gly Glu Thr 590	776
55	TTT AAG GTT CCT TCA AGC Phe Lys Val Pro Ser Ser	TGC CCT ATT GT Cys Pro Ile Va	T ACT GTT GAT GGA TAC GTG 1 1 Thr Val Asp Gly Tyr Val	824
			• • • • • • • • • • • • • • • • • • • •	400

107

		595			600			605		•	
5			GGA Gly								1872
10			GCC Ala								1920
			TGT Cys 645								1968
15			GTC Val								2016
20			GGA Gly								2064
25			GAT Asp								2112
30			CAA Gln								2160
			GGC Gly 725								2208
35			GCT Ala								2256
40			ATG Met								2304
45			AAA Lys								2352
50			CTC Leu								2400
		•	 TTA Leu 805	TGA		•					2421

55 (2) INFORMATION FOR SEQ ID NO:53:

```
(i) SEQUENCE CHARACTERISTICS:
                (A) LENGTH: 806 amino acids
                (B) TYPE: amino acid
  5
                (C) STRANDEDNESS: single
                (D) TOPOLOGY: linear
             (ii) MOLECULE TYPE: protein
             (v) FRAGMENT TYPE: internal
 10
             (xi) SEQUENCE DESCRIPTION: SEQ ID NO:53:
       Met Val Ser Lys Gly Glu Glu Leu Phe Thr Gly Val Val Pro Ile Leu
       Val Glu Leu Asp Gly Asp Val Asn Gly His Lys Phe Ser Val Ser Gly
 15
       Glu Gly Glu Gly Asp Ala Thr Tyr Gly Lys Leu Thr Leu Lys Phe Ile
       Cys Thr Thr Gly Lys Leu Pro Val Pro Trp Pro Thr Leu Val Thr Thr
 20
      Leu Thr Tyr Gly Val Gln Cys Phe Ser Arg Tyr Pro Asp His Met Lys
                          70
      Gln His Asp Phe Phe Lys Ser Ala Met Pro Glu Gly Tyr Val Gln Glu
                                           90
25
      Arg Thr Ile Phe Phe Lys Asp Asp Gly Asn Tyr Lys Thr Arg Ala Glu
                                      105
      Val Lys Phe Glu Gly Asp Thr Leu Val Asn Arg Ile Glu Leu Lys Gly
                                  120
      Ile Asp Phe Lys Glu Asp Gly Asn Ile Leu Gly His Lys Leu Glu Tyr
30
                              135
                                                  140
      Asn Tyr Asn Ser His Asn Val Tyr Ile Met Ala Asp Lys Gln Lys Asn
                          150
                                              155
      Gly Ile Lys Val Asn Phe Lys Ile Arg His Asn Ile Glu Asp Gly Ser
                      165
                                          170
      Val Gln Leu Ala Asp His Tyr Gln Gln Asn Thr Pro Ile Gly Asp Gly
35
                                      185
      Pro Val Leu Leu Pro Asp Asn His Tyr Leu Ser Thr Gln Ser Ala Leu
                                  200
                                                      205
      Ser Lys Asp Pro Asn Glu Lys Arg Asp His Met Val Leu Leu Glu Phe
40
                              215
                                                  220
      Val Thr Ala Ala Gly Ile Thr Leu Gly Met Asp Glu Leu Tyr Lys Ser
                          230
                                              235
      Gly Leu Arg Ser Arg Ala Gln Ala Ser Asn Ser Asn Ser Thr Met Asp
                     245
                                          250
      Asn Met Ser Ile Thr Asn Thr Pro Thr Ser Asn Asp Ala Cys Leu Ser
45
                                      265
      Ile Val His Ser Leu Met Cys His Arg Gln Gly Glu Ser Glu Thr
                                  280
      Phe Ala Lys Arg Ala Ile Glu Ser Leu Val Lys Lys Leu Lys Glu Lys
50
                              295
                                                  300
     Lys Asp Glu Leu Asp Ser Leu Ile Thr Ala Ile Thr Thr Asn Gly Ala
                         310
                                              315
     His Pro Ser Lys Cys Val Thr Ile Gln Arg Thr Leu Asp Gly Arg Leu
                     325
                                         330
     Gln Val Ala Gly Arg Lys Gly Phe Pro His Val Ile Tyr Ala Arg Leu
55
```

. 109

										•						
	Trp	Arg	Trp 355	Pro	Asp	Leu	His	Lys 360	Asn	Glu	Leu	Lys	His 365	Val	Lys	Tyr
		370					375					380		Val		
5	Tyr 385	His	Tyr	Glu	Arg	Val 390	Val	Ser	Pro	Gly	Ile 395	Asp	Leu	Ser	Gly	Leu 400
	Thr	Leu	Gln	Ser	Asn 405	Ala	Pro	Ser	Ser	Met 410	Met	Val	Lys	Asp	Glu 415	Tyr
10	Val	His	Asp	Phe 420	Glu	Gly	Gln	Pro	Ser 425	Leu	Ser	Thr	Glu	Gly 430	His	Ser
	Ile	Gln	Thr 435	Ile	Gln	His	Pro	Pro 440	Ser	Asn	Arg	Ala	Ser 445	Thr	Glu	Thr
	Tyr	Ser 450	Thr	Pro	Ala	Leu	Léu 455	Ala	Pro	Ser	Glu	Ser 460	Asn	Ala	Thr	Ser
15	Thr 465	Ala	Asn	Phe	Pro	Asn 470	Ile	Pro	Val	Ala	Ser 475	Thr	Ser	Gln	Pro	Ala 480
		•			485					490				Ile	495	
20				500					505					Gln 510		
		_	515					520		-		-	525	Arg		
		530					535					540		Leu		
25	545	•				550					555			Val		560
					565					570				Pro	575	
30				580					585	_				Gly 590		
			595					600					605	Gly	_	
35		610					615				_	620		Ser		
33	625					630				_	635			Gly		640
					645				_	650		Ī		Arg	655	
40				660	_		_		665	-				670 Ser		
			675		_	_		680		_		_	685	Gln		_
45		690					695					700		Ala		
	705					710					715			Pro		720
					725					730				Arg	735	
50				740					745					750 Asp		
			755					760					765	His		
55		770					775					780		Pro		
	785					790	p			~~4	795					800

Asp Pro Gln Pro Leu Asp 805

5			(2	e) IN	FORM	ATIC	N FC	R SE	Q II	NO:	54:							
J		(	(A)	LEN	NCE GTH: E: n	312	0 ba	se p										
10			(C)	STR	ANDE OLOG	DNES	S: s	ingl	e									
					CULE URE :	TYP	E: c	DNA										
15			(B	) LO	ME/K CATI HER	ON:	1	3117	eque	nce								
20		(:	xi)	SEQU	ENCE	DES	CRIP	TION	: SE	Q ID	NO:	54:						
	ATG Met 1	GTG Val	AGC Ser	AAG Lys	GGC Gly 5	GAG Glu	GAG Glu	CTG Leu	TTC Phe	ACC Thr 10	GGG Gly	GTG Val	GTG Val	CCC Pro	ATC Ile 15	CTG Leu	-	48
25	GTC Val	GAG Glu	CTG Leu	GAC Asp 20	GGC Gly	GAC Asp	GTA Val	AAC Asn	GGC Gly 25	CAC His	AAG Lys	TTC Phe	AGC Ser	GTG Val 30	TCC Ser	GGC Gly		96
30	GAG Glu	GGC Gly	GAG Glu 35	GGC Gly	GAT Asp	GCC Ala	ACC Thr	TAC Tyr 40	GGC Gly	AAG Lys	CTG Leu	ACC Thr	CTG Leu 45	AAG Lys	TTC Phe	ATC Ile		144
35	TGC Cys	ACC Thr 50	ACC Thr	GGC Gly	AAG Lys	CTG Leu	CCC Pro 55	GTG Val	CCC Pro	TGG Trp	CCC Pro	ACC Thr 60	CTC Leu	GTG Val	ACC Thr	ACC Thr		192
40	CTG Leu 65	ACC Thr	TAC Tyr	GGC Gly	GTG Val	CAG Gln 70	TGC Cys	TTC Phe	AGC Ser	CGC Arg	TAC Tyr 75	CCC Pro	GAC Asp	CAC His	ATG Met	AAG Lys 80	:	240
.•	CAG Gln	CAC His	GAC Asp	TTC Phe	TTC Phe 85	AAG Lys	TCC Ser	GCC Ala	ATG Met	CCC Pro 90	GAA Glu	GGC	TAC Tyr	GTC Val	CAG Gln 95	GAG Glu	:	288
45	CGC Arg	ACC Thr	ATC Ile	TTC Phe 100	TTC Phe	AAG Lys	GAC Asp	GAC Asp	GGC Gly 105	AAC Asn	TAC Tyr	AAG Lys	ACC Thr	CGC Arg 110	GCC Ala	GAG Glu	:	336
50	GTG Val	AAG Lys	TTC Phe 115	GAG Glu	GGC Gly	GAC Asp	ACC Thr	CTG Leu 120	GTG Val	AAC Asn	CGC Arg	ATC Ile	GAG Glu 125	CTG Leu	AAG Lys	GGC	3	384
55	He	GAC Asp 130	TTC Phe	AAG Lys	GAG Glu	GAC Asp	GGC Gly 135	AAC Asn	ATC Ile	CTG Leu	GGG Gly	CAC His 140	AAG Lys	CTG Leu	GÁG Glu	TAC Tyr	4	132

		AGC Ser							480
5		GTG Val							528
10		GCC Ala 180							576
15		CTG Leu							624
20		CCC Pro							672
		GCC Ala							720
25		TCT Ser							768
30		CTG Leu 260							816
35		CGG Arg	_						864
40		GAC Asp							912
		GGC Gly							960
45		GAT Asp							1008
50		CAG Gln 340							1056
55		CAC His							1104

	112	
5	AAC AAT TGC AGC TCT CCG GCT GGG ATC CTG GTT GAC GCC ATG TCC CAG Asn Asn Cys Ser Ser Pro Ala Gly Ile Leu Val Asp Ala Met Ser Gln 370 375 380	2
5	AAG CAC CTT CAG ATC AAC CAG ACA TTT GAG GAG CTG CGA CTG GTC ACG Lys His Leu Gln Ile Asn Gln Thr Phe Glu Glu Leu Arg Leu Val Thr 395 400	)
10	CAG GAC ACA GAG AAT GAG CTG AAG AAA CTG CAG CAG ACT CAG GAG TAC 1248 Gln Asp Thr Glu Asn Glu Leu Lys Lys Leu Gln Gln Thr Gln Glu Tyr 405 410 415	1
15	TTC ATC ATC CAG TAC CAG GAG AGC CTG AGG ATC CAA GCT CAG TTT GCC 1296 Phe Ile Ile Gln Tyr Gln Glu Ser Leu Arg Ile Gln Ala Gln Phe Ala 420 425 430	
20	CAG CTG GCC CAG CTG AGC CCC CAG GAG CGT CTG AGC CGG GAG ACG GCC  Gln Leu Ala Gln Leu Ser Pro Gln Glu Arg Leu Ser Arg Glu Thr Ala  435  440  445	
25	CTC CAG CAG AAG CAG GTG TCT CTG GAG GCC TGG TTG CAG CGT GAG GCA  Leu Gln Gln Lys Gln Val Ser Leu Glu Ala Trp Leu Gln Arg Glu Ala  450  450  460	
25	CAG ACA CTG CAG CAG TAC CGC GTG GAG CTG GCC GAG AAG CAC CAG AAG Gln Thr Leu Gln Gln Tyr Arg Val Glu Leu Ala Glu Lys His Gln Lys 470 475 480	
30	ACC CTG CAG CTG CGG AAG CAG CAG ACC ATC ATC CTG GAT GAC GAG  Thr Leu Gln Leu Arg Lys Gln Gln Thr Ile Ile Leu Asp Asp Glu  485  490  495	
35	CTG ATC CAG TGG AAG CGG CGG CAG CAG CTG GCC GGG AAC GGC GGG CCC Leu Ile Gln Trp Lys Arg Arg Gln Gln Leu Ala Gly Asn Gly Gly Pro 500 505 510	
40	CCC GAG GGC AGC CTG GAC GTG CTA CAG TCC TGG TGT GAG AAG TTG GCC Pro Glu Gly Ser Leu Asp Val Leu Gln Ser Trp Cys Glu Lys Leu Ala 515 520 525	
<b>1</b>	GAG ATC ATC TGG CAG AAC CGG CAG CAG ATC CGC AGG GCT GAG CAC CTC Glu Ile Ile Trp Gln Asn Arg Gln Gln Ile Arg Arg Ala Glu His Leu 530 535 540	
45	TGC CAG CAG CTG CCC ATC CCC GGC CCA GTG GAG GAG ATG CTG GCC GAG  Cys Gln Gln Leu Pro Ile Pro Gly Pro Val Glu Glu Met Leu Ala Glu  545 550 560	
	GTC AAC GCC ACC ATC ACG GAC ATT ATC TCA GCC CTG GTG ACC AGC ACA Val Asn Ala Thr Ile Thr Asp Ile Ile Ser Ala Leu Val Thr Ser Thr 565 570 575	
55	TTC ATC ATT GAG AAG CAG CCT CCT CAG GTC CTG AAG ACC CAG ACC AAG  Phe Ile Ile Glu Lys Gln Pro Pro Gln Val Leu Lys Thr Gln Thr Lys  580  585  590	

					113						
	 	ACC Thr								٠	1824
5 ·		CCC Pro									1872
10	Ser	CTT Leu									1920
15		AAC Asn									1968
20		CAC His 660									2016
		GGT Gly									2064
25	 	CAG Gln									2112
30		TCC Ser									2160
35		ACG Thr									2208
40		CCA Pro 740									2256
40		CTC Leu									2304
45		AAG Lys									2352
50	Ser	AGC Ser					Leu				2400
55		AAC Asn	Glu			Trp			Trp		2448

										114							
			<b></b>	82	0	y va	ı MG	C GI	u va 82	1 Le	u Ly:	s Lys	His	830	S Ly	G CCC S Pro	2496
5		<b>-</b> ,	83!	5	P G1,	y Ale	a 11	84:	0 0	y Phe	e Val	l Asn	Lys 845	Glr	ı Glı	G GCC	2544
10		850	)		~ II(	s ASI	855	s Pro	o Asp	o Gly	/ Thr	9he 860	Leu	Leu	Arg		2592
15	865	;		. 010		870	GI	/ 116	• Thr	: Ile	875		Lys	Phe	Asp	Ser 880	2640
20				ADI	885	i	ASI	. ьеч	і Гув	890	Phe	ACC Thr	Thr	Arg	Asp 895	Phe	2688
0.5			••••	900	Deu	MIG	Asp	Arg	905	Gly	Asp	CTG Leu	Ser	Tyr 910	Leu	Ile	2736
25	-2-		915	110	vaħ	Arg	PIO	ьув 920	Asp	Glu	Val	TTC Phe	Ser 925	Lys	Tyr	Tyr	2784
30		930	vuı	дец	MIG	тув	935	val	Asp	Gly	Tyr	GTG Val 940	Lys	Pro	Gln	Ile	2832
35	945				FIO	950	Pne	vaı	Asn	Ala	Ser 955	GCA Ala	Asp .	Ala	Gly	Gly 960	2880
40		501	ALG	1111	965	Met	Asp	GIN	Ala	Pro 970	Ser	CCA (	Ala '	Val	Сув 975	Pro	2928
	CAG Gln	GCT Ala	CCC Pro	TAT Tyr 980	AAC Asn	ATG Met	TAC Tyr	CCA Pro	CAG Gln 985	AAC Asn	CCT Pro	GAC ( Asp 1	lis V	GTA Val 990	CTC Leu	GAT Asp	2976
45	CAG Gln		GGA Gly 995	GAA Glu	TTC Phe	GAC Asp	Leu	GAT Asp 000	GAG Glu	ACC Thr	ATG Met	GAT C Asp V	STG ( /al #	SCC A	AGG Arg	CAC His	3024
50		GAG Glu 010	GAA Glu	CTC Leu	TTA Leu .	Arg .	CGA Arg 015	CCA Pro	ATG Met	GAC . Asp :	Ser :	CTT G Leu A 020	SAC I	CC (	CGC ( Arg )	CTC Leu	3072
55	TCG ( Ser 1 1025	CCC ( Pro 1	CCT ( Pro 1	GCC ( Ala (	GLY.	CTT ( Leu )	TTC :	ACC f	TCT (	Ala	AGA ( Arg (	GGC T	CC C	TC T	CA ' Ser 1	rga	3120

115

## (2) INFORMATION FOR SEQ ID NO:55:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 1039 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear
- 10 (ii) MOLECULE TYPE: protein

5

(v) FRAGMENT TYPE: internal

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:55:

15 Met Val Ser Lys Gly Glu Glu Leu Phe Thr Gly Val Val Pro Ile Leu Val Glu Leu Asp Gly Asp Val Asn Gly His Lys Phe Ser Val Ser Gly 25 Glu Gly Glu Gly Asp Ala Thr Tyr Gly Lys Leu Thr Leu Lys Phe Ile 20 Cys Thr Thr Gly Lys Leu Pro Val Pro Trp Pro Thr Leu Val Thr Thr Leu Thr Tyr Gly Val Gln Cys Phe Ser Arg Tyr Pro Asp His Met Lys 70 25 Gln His Asp Phe Phe Lys Ser Ala Met Pro Glu Gly Tyr Val Gln Glu Arg Thr Ile Phe Phe Lys Asp Asp Gly Asn Tyr Lys Thr Arg Ala Glu 105 Val Lys Phe Glu Gly Asp Thr Leu Val Asn Arg Ile Glu Leu Lys Gly 30 120 Ile Asp Phe Lys Glu Asp Gly Asn Ile Leu Gly His Lys Leu Glu Tyr 135 Asn Tyr Asn Ser His Asn Val Tyr Ile Met Ala Asp Lys Gln Lys Asn 150 155 35 Gly Ile Lys Val Asn Phe Lys Ile Arg His Asn Ile Glu Asp Gly Ser 165 170 Val Gln Leu Ala Asp His Tyr Gln Gln Asn Thr Pro Ile Gly Asp Gly 185 Pro Val Leu Pro Asp Asn His Tyr Leu Ser Thr Gln Ser Ala Leu 40 200 Ser Lys Asp Pro Asn Glu Lys Arg Asp His Met Val Leu Leu Glu Phe 215 220 Val Thr Ala Ala Gly Ile Thr Leu Gly Met Asp Glu Leu Tyr Lys Ser 230 235 45 Gly Leu Arg Ser Thr Met Ala Gly Trp Ile Gln Ala Gln Gln Leu Gln 245 250 Gly Asp Ala Leu Arg Gln Met Gln Val Leu Tyr Gly Gln His Phe Pro Ile Glu Val Arg His Tyr Leu Ala Gln Trp Ile Glu Ser Gln Pro Trp 50 280

115

Asp Ala Ile Asp Leu Asp Asn Pro Gln Asp Arg Ala Gln Ala Thr Gln

Leu Leu Glu Gly Leu Val Gln Glu Leu Gln Lys Lys Ala Glu His Gln

Val Gly Glu Asp Gly Phe Leu Leu Lys Ile Lys Leu Gly His Tyr Ala

315

295

310

				340					345					350		
			355		Ile			360					365	Arg	Glu	
5		370			Ser		375					380	- Ala	Met		
	385				Ile	390					395					400
10					Asn 405					410					415	Tyr
				420					425					430	Phe	Ala
			435		Leu			440					445			
15		450			Gln		455					460				
	465				Gln	470					475					480
20					Leu 485					490					495	
				500	Lys				505					510		
05			515		Leu			520					525			
25		530			Gln		535					540				
	545				Pro	550					555					560
30					Ile 565					570					575	
				580	Lys				585					590		
35			595		Val			600					605			
33		610			Gln		615					620				
	625				Lys	630					635					640
40					Cys 645					650					655	
				000	Phe				665					670		
45			675		Ala			680					685			
40		690			Phe		695					700				
	705				Leu	710					715					720
50					Ala 725					730					735	
				740	Phe				745					750		
55			755		Asn			760					765		•	
55	GIÀ	170	Inr	гуѕ	Glu	Asn	Leu 775	Val	Phe	Leu	Ala	Gln	Lys	Leu	Phe	Asn

117

	Asn 785	Ser	Ser	Ser		190	Glu	Asp	Tyr	Ser	Gly 795	Leu	Ser	Val	Ser	Trp 800	
		Gln	Phe	Asn			Asn	Leu	Pro	Gly		Asn	Tyr	Thr	Phe		
_					805					810					815		
5		Trp		820					825					830			
	His	Trp	Asn 835	Asp	Gly	Ala	Ile	Leu 840	Gly	Phe	Val	Asn	Lys 845	Gln	Gln	Ala	
10	His	Asp 850	Leu	Leu	Ile	Asn	Lys 855	Pro	Asp	Gly	Thr	Phe 860	Leu	Leu	Arg	Phe	
	Ser 865	Asp	Ser	Glu	Ile	Gly 870	Gly	Ile	Thr	Ile	Ala 875	Trp	Lys	Phe	Asp	Ser 880	
	Pro	Glu	Arg	Asn	Leu 885	Trp	Asn	Leu	Lys	Pro 890	Phe	Thr	Thr	Arg	Asp 895	Phe	
15	Ser	Ile	Arg	Ser 900	Leu	Ala	Asp	Arg	Leu 905	Gly	Asp	Leu	Ser	Tyr 910	Leu	Ile	
	Tyr	Val	Phe 915	Pro	Asp	Arg	Pro	Lys 920	Asp	Glu	Val	Phe	Ser 925	ГÀЗ	Tyr	Tyr	
20	Thr	Pro 930	Val	Leu	Ala	Lys	Ala 935	Val	Asp	Gly	Tyr	Val 940	Lys	Pro	Gln	Ile .	
	Lys 945	Gln	Val	Val	Pro	Glu 950	Phe	Val	Asn	Ala	Ser 955	Ala	qaA	Ala	Gly	Gly 960	
	Ser	Ser	Ala	Thr	Tyr 965	Met	Asp	Gln	Ala	Pro 970	Ser	Pro	Ala	Val	Cys 975	Pro	
25	Gln	Ala	Pro	Tyr 980	Asn	Met	Tyr	Pro	Gln 985	Asn	Pro	qaA	His	Val 990	Leu	Asp	
	Gln	Asp	Gly 995	Glu	Phe	Asp		Asp 000	Glu	Thr	Met	-	Val	Ala	Arg	His	
30		Glu 1010	Glu	Leu	Leu		Arg 1015	Pro	Met	Asp		Leu 1020	Asp	Ser	Arg	Leu	
	Ser 025	Pro	Pro	Ala		Leu 1030	Phe	Thr	Ser		Arg L035	Gly	Ser	Leu		1	
			(2)	INI	FORM	OITA	v FOI	R SEC	) ID	NO:5	56:						
35		( :	i) SI	EQUE	NCE (	CHARA	ACTE	RIST	cs:								
				LENG				-	airs								
40				STRA				_	=								
		( <u>:</u>	ii) N	OLE	CULE	TYPI	E: cI	ONA									
				FEAT													
45			(B)	NAI LOC OTI	CATIO	ON:	1:	1872	equer	nce							
50		()	ci) s	EQUI	ENCE	DES	CRIP:	CION	: SE(	Q ID	NO : !	56:					
		GCG Ala														AGG Arg	48
55		ACT Thr															96

				20		-			25					30				
5 .	AAG Lys	GGG	CAG Gln 35	CCA Pro	TTC Phe	GAT Asp	GTG Val	GGC Gly 40	CCA Pro	CGC Arg	TAC	ACG Thr	CAG Gln 45	CTG Leu	CAG Gln	TAC Tyr	14	4
10	ATC Ile	GGC Gly 50	GAG Glu	GGC	GCG Ala	TAC	GGC Gly 55	ATG Met	GTC Val	AGC Ser	TCA Ser	GCT Ala 60	TAT Tyr	GAC Asp	CAC	GTG Val	19	2
	CGC Arg 65	AAG Lys	ACC Thr	AGA Arg	GTG Val	GCC Ala 70	ATC Ile	AAG Lys	AAG Lys	ATC Ile	AGC Ser 75	CCC Pro	TTT Phe	GAG Glu	CAT	CAA Gln 80	24	0
15	ACC Thr	TAC Tyr	TGT Cys	CAG Gln	CGC Arg 85	ACG Thr	CTG Leu	AGG Arg	GAG Glu	ATC Ile 90	CAG Gln	ATC Ile	TTG Leu	CTG Leu	CGA Arg 95	TTC Phe	288	8
20	CGC Arg	CAT His	GAG Glu	AAT Asn 100	Val	ATA Ile	GGC Gly	ATC Ile	CGA Arg 105	GAC Asp	ATC Ile	CTC Leu	AGA Arg	GCG Ala 110	CCC Pro	ACC Thr	336	6
25	CTG Leu	GAA Glu	GCC Ala 115	ATG Met	AGA Arg	GAT Asp	GTT Val	TAC Tyr 120	ATT Ile	GTT Val	CAG Gln	GAC Asp	CTC Leu 125	ATG Met	GAG Glu	ACA Thr	384	1
30	GAC Asp	CTG Leu 130	TAC Tyr	AAG Lys	CTG Leu	CTT	AAA Lys 135	AGC Ser	CAG Gln	CAG Gln	CTG Leu	AGC Ser 140	AAT Asn	GAC Asp	CAC His	ATC Ile	432	2
	TGC Cys 145	TAC Tyr	TTC Phe	CTC Leu	TAC Tyr	CAG Gln 150	ATC Ile	CTC Leu	CGG Arg	GGC Gly	CTC Leu 155	AAG Lys	TAT Tyr	ATA Ile	CAC His	TCA Ser 160	480	)
35	GCC Ala	AAT Asn	GTG Val	CTG Leu	CAC His 165	CGG Arg	GAC Asp	CTG Leu	AAG Lys	CCT Pro 170	TCC Ser	AAT Asn	CTG Leu	CTT Leu	ATC Ile 175	AAC Asn	528	}
40	ACC Thr	ACC Thr	TGC Cys	GAC Asp 180	CTT Leu	AAG Lys	ATC Ile	TGT Cys	GAT Asp 185	TTT Phe	GGC Gly	CTG Leu	GCC Ala	CGG Arg 190	ATT Ile	GCT Ala	576	í
45	GAC Asp	CCT Pro	GAG Glu 195	CAC His	GAC Asp	CAC His	ACT Thr	GGC Gly 200	TTT Phe	CTG Leu	ACG Thr	GAG Glu	TAT Tyr 205	GTG Val	GCC Ala	ACA Thr	624	ı
50	CGC Arg	TGG Trp 210	TAC Tyr	CGA Arg	GCC Ala	CCA Pro	GAG Glu 215	ATC Ile	ATG Met	CTT Leu	AAT Asn	TCC Ser 220	AAG Lys	GGC Gly	TAC Tyr	ACC Thr	672	
	AAA Lys 225	TCC Ser	ATC Ile	GAC Asp	ATC Ile	TGG Trp 230	TCT Ser	GTG Val	GGC	TGC Cys	ATT Ile 235	CTG Leu	GCT Ala	GAG Glu	ATG Met	CTC Leu 240	720	1
55	TCC Ser	AAC Asn	CGG Arg	CCC Pro	ATC Ile	TTC Phe	CCC Pro	GGC Gly	AAG Lys	CAC His	TAC Tyr	CTG Leu	GAC Asp	CAG Gln	CTC Leu	AAC Asn	768	

			•							119							
					245					250					255		
5														CTT Leu 270			816
10	ATC Ile	ATT Ile	AAC Asn 275	ATG Met	AAG Lys	GCC Ala	CGA Arg	AAC Asn 280	TAC Tyr	CTG Leu	CAG Gln	TCT Ser	CTG Leu 285	CCC Pro	TCG Ser	AAA Lys	864
	ACC Thr	AAG Lys 290	GTG Val	GCT Ala	TGG Trp	GCC Ala	AAG Lys 295	CTC Leu	TTT Phe	CCT Pro	AAA Lys	TCT Ser 300	GAC Asp	TCC Ser	AAA Lys	GCT Ala	912
15														AAG Lys			960
20	ACA Thr	GTA Val	GAG Glu	GAA Glu	GCG Ala 325	CTG Leu	GCT Ala	CAC His	CCT Pro	TAC Tyr 330	CTG Leu	GAA Glu	CAG Gln	TAC Tyr	TAC Tyr 335	GAT Asp	1008
25	CCG Pro	ACA Thr	GAT Asp	GAG Glu 340	CCA Pro	GTG Val	GCC Ala	GAG Glu	GAG Glu 345	CCA Pro	TTC Phe	ACC Thr	TTC Phe	GAC Asp 350	ATG Met	GAG Glu	1056
30														TTC Phe			1104
														CGC Arg			1152
35														CTT Leu			1200
40														GGA Gly			1248
45														ATT Ile 430			1296
50														ACT Thr			1344
	TAT Tyr	GGT Gly 450	GTT Val	CAA Gln	TGC Cys	TTT Phe	TCT Ser 455	AGA Arg	TAC Tyr	CCA Pro	GAT Asp	CAT His 460	ATG Met	AAA Lys	CAG Gln	CAT His	1392
55														GAA Glu			1440

										120							
	46	5				470	)				475	5				480	
5	AT.	A TTT e Phe	TAC Tyr	C AAA	A GAT S Asp 485	nsp	GGG Gly	AA( Asi	C TAC	AAG Lys 490	Thr	CGT Arg	GCT Ala	GAA Glu	GT( Val 495	C AAG L Lys	1488
10	TT: Phe	r GAA ≥ Glu	GGT Gly	GAT Asp 500	1111	CTT	GTT Val	' AAT Asn	AGA Arg 505	Ile	GAG Glu	TTA Leu	AAA Lys	GGT Gly 510	ATT	GAT Asp	1536
	TTT Phe	AAA Lys	GAA Glu 515	بر ت	GGA Gly	AAC Asn	ATT Ile	CTT Leu 520	GIY	CAC His	AAA Lys	ATG Met	GAA Glu 525	TAC Tyr	AAT Asn	TAT	1584
15	AAC Asn	TCA Ser 530	CAT His	AAT Asn	GTA Val	TAC Tyr	ATC Ile 535	ATG Met	GCA Ala	GAC Asp	AAA Lys	CCA Pro 540	AAG Lys	AAT Asn	GGC Gly	ATC Ile	1632
20	AAA Lys 545	GTT Val	AAC Asn	TTC Phe	AAA Lys	ATT Ile 550	AGA Arg	CAC His	AAC Asn	ATT Ile	AAA Lys 555	GAT Asp	GGA Gly	AGC Ser	GTT Val	CAA Gln 560	1680
25	TTA Leu	GCA Ala	GAC Asp	CAT His	TAT Tyr 565	CAA Gln	CAA Gln	AAT Asn	ACT Thr	CCA Pro 570	ATT Ile	GGC Gly	GAT Asp	GGC Gly	CCT Pro 575	GTC Val	1728
30		TTA Leu		580 580	veii	nis	ıyr	Leu	Ser 585	Thr	Gln	Ser	Ala	Leu 590	Ser	Lys	1776
	GAT Asp	CCC Pro	AAC Asn 595	GAA Glu	AAG . Lys .	AGA (	Asp .	CAC His 600	ATG Met	ATC (	CTT Leu	Leu (	GAG ' Glu : 605	TTT (	GTA Val	ACA Thr	1824
35	GCT Ala	GCT ( Ala ( 610	GGG . Gly	ATT Ile	ACA (	115 (	GGC . Gly 1	ATG Met	GAT (	GAA ( Glu 1	Leu '	TAC 1 Tyr 1 620	AAA (	CCT (	CAG Gln	GAG T Glu	1873
40	AA		(2)	INF	ORMAI	LION	FOR	SEQ	ID 1	NO:57	7:						1875
45		(	(A) I (B) 7 (C) S	LENGT TYPE: STRAI	CE CH: 6: ami NDEDN	24 a .no a ÆSS:	mind cid sir	ac	CS: ids	·						. "	
50		(v)	FRA	GMEN	LE T	PE:	inte	rnal	l								
									SEQ								
55	Met A 1 Gly T				_				7	n				_	_		

				20					25					30		
	Lys	Gly	Gln 35	Pro	Phe.	Asp	Val	Gly 40	Pro	Arg	Tyr	Thr	Gln 45	Leu	Gln	Tyr
5	Ile	Gly 50	Glu	Gly	Ala	Tyr	Gly 55	Met	Val	Ser	Ser	Ala 60	Tyr	Asp	His	Val
	Arg 65	Lys	Thr	Arg	Val	Ala 70	Ile	Lys	Lys	Ile	Ser 75	Pro	Phe	Glu	His	Gln 80
					Arg 85					90					95	
10	Arg	His	Glu	Asn 100	Val	Ile	Gly	Ile	Arg 105	Asp	Ile	Leu	Arg	Ala 110	Pro	Thr
			115		Arg			120					125			
15	_	130			Leu		135					140				
	145				Tyr	150				_	155	_	_			160
					His 165					170					175	
20				180	Leu				185		_			190		
	-		195		Asp			200					205			
25		210			Ala		215					220				
	225			-	Ile	230			-	-	235					240
					1le 245				-	250	_				255	
30				260	Ile		_		265				_	270		
			275		Lys -			280	-				285			
35		290			Trp		295				-	300	_		_	
	305	_			Asp	310					315			-		320
					Ala 325					330	•				335	
40				340	Pro				345					350		
			355		Pro			360					365			
45		370			Gln		375				_	380				
	385				Glu	390			_		395					400
					Val 405				_	410					415	
50				420	Thr				425					430		
			435		Pro			440					445			
55		450			Cys		455				_	460		_		••
	Asp	Phe	Phe	Lys	Ser	Ala	Met	Pro	Glu	Gly	Tyr	Val	Gln	Glu	Arg	Thr

. 122

		_										_								
	46						470						475						480	
												ys '	Thr	Arg						
5	Phe	e Gl	u G	Ly A:	sp T	hr 1	Leu	Val	Ası	1 Ar 50	g I	le (	Glu	Leu	Lys	Gl	4 y I	95 le	Asp	
•	Phe	е Ly	's G] 51	lu A:	sp G	ly A	Asn	Ile	Let	ı Gl	у Н:	is 1	Гуs	Met	Glu	51 Ty:	O r A	sn	Tyr	
			r Hi		sn V			Ile												
10					e Ly	ys I	le													
					s Ty	r G														
15				o As	p As							n								
.0			aA c	n Gl	u Ly					- N H I	-									-
		Ala	a Gl		e Th															
20		610					•	013						620				•	olu	
			(:	2) I	NFOR	MAT:	ION	FOR	SE	Q II	ои о	:58	:							
		(	(i) S (A)	EEQU!	ENCE NGTH	CH2: 18	ARA0 815	CTER bas	IST:	ICS:										
25			(B)	TY	PE:	nuc.	leic	ac	id							•			÷	
			(D)	TO	POLO	GY:	lir	near	910	•										
30		(	ii) ix)	MOLE FEAT	CULI	E T)	PE:	CD:	NA											
35			(B	) LC	ME/I CATI HER	ON:	1.	18	811	que:	nce									
00		(:	xi)	SEQU	ENCE	DE	SCR	IPT]	ON:	SE	Q ID	) ио	:58	:						
	ATG Met	GCG	GCG	GCG	GCG	GC	G G	CG 6	GC .	CCG	GNG	n m		mo e	GC (	GGG	CAG	: G	TG	48
40	Met 1	АТА	Ala	Ala	Ala 5	Al	a A	la c	Sly	Pro	Glu 10	Me	t V	al A	rg (	ily	Gln 15	V	al	<b>3</b> 0
	TTC Phe	GAC	GTG	GGG	CCG	CG	C T	AC A	CT	TAA	CTC	TC	G T	AC A	TC C	GA	GAA	. G(	3C	96
45	Phe .	w	Val	20	PIO	Ar	g Ty	yr I	nr I	Asn 25	Leu	Se	r T	yr I	le G	Sly O	Glu	G.	ly	
	GCC :	TAC	GGC	ATG	GTT	TG:	г то	CT G	CT T	TAT	GAT	AA'	r c'	TC A	AC A	AA.	GTT	CC	3A	144
	Ala 1	ıyr	35 35	Met	Val	Суя	s Se	er A	la 7 0	ſуr	Asp	Ası	n L	eu A 4	sn L	ys	Val	Aı	g	
50	GTT (	3CT	ATC	AAG	ААА	ATO	C AG	T C	CT 1	TT	GAG	CAC	- C			יארי י	TOT	C 2		
		Ala 50	Ile	Lys	Lys	Ile	5 Se	E P	ro F	he	Glu	His	G G G	ln T	hr T	yr (	Cys	G1	.n	192
55	AGA A	ACC	CTG	AGA	GAG	ATA	AA A	A A	TC C	TA	CTG	CGC	T	C A	GA C	AT (	GAG	AA	C	240
J.	Arg T	IIIE .	neu	мrg	GIU	11e 70	: Ly	s I	le L	eu	Leu	Ar <u>c</u> 75	Ph	ne Ar	rg H	is (	3lu	As 80	n	

					Asn									GAG Glu			288
5					85					90					95		
3	AAA	GAT	GTA	TAT	ATA	GTA	CAG	GAC	CTC	ATG	GAG	ACA	GAT	CTT	TAC	AAG	336
														Leu			550
				100					105					110			
10	רידירי	ጥጥር	אממ	۵۵۵	CAG	CAC	СТС	AGC	ידית מ	CAT	CNT	א ידיכי	TOO	TĄT	thirties.	Cirron	384
														Tyr			204
•			115					120		•			125	•			
	m v m	an a	3 m.c	CTTC	202	CCZ	mm a										
15														AAT Asn			432
	-1-	130			3	1	135	-,,	-,-			140				Dou	
														ACT Thr			480
20	145	ALG	ASP	neu	Буъ	150	Jer.	ASII	пеп	neu	155	ASII	1111	Int	Cys	160	
														CCA			528
	Leu	гàг	IIE	Cys	165	Pne	GIY	Leu	Ala	Arg	Val	Ala	Asp	Pro	175	His	
25							•			1,0					1,3		
														TGG			576
	Asp	His	Thr	Gly 180	Phe	Leu	Thr	Glu		Val	Ala	Thr	Arg	Trp	Tyr	Arg	
				100					185					190			
30														TCC			624
	Ala	Pro		Ile	Met	Leu	Asn		Lys	Gly	Tyr	Thr		Ser	Ile	Asp	
			195					200					205				
	ATT	TGG	TCT	GTG	GGC	TGC	ATC	CTG	GCA	GAG	ATG	CTA	TCC	AAC	AGG	CCT	672
35	Ile		Ser	Val	Gly	Cys		Leu	Ala	Glu	Met	Leu	Ser	Asn	Arg	Pro	
		210					215					220					
	ATC	TTC	CCA	GGA	AAG	CAT	TAC	CTT	GAC	CAG	CTG	TAA	CAC	ATC	CTG	GGT	720
														Ile			
40	225					230					235					240	
	ATT	CTT	GGA	тст	CCA	TCA	CAG	GAA	GAT	СТС	דממ	тст	ΔΤΔ	ATA	ΔΔΤ	ጥጥል	768
														Ile			,00
					245					250		_			255		
45	מממ	CCT	אכא	እ አ C	ጥስጥ	TTC	CTT	TOT	CTC	ccc	CA C	***	מיתת	AAG	ara		916
														Lys			816
	-		_	260	•				265			-1-		270			
50	mc-c	220	200	mm-	mma	963			ar -	m.e			-				
50														GAT Asp			864
	1		275	u				280	raħ	PET	-y s	A10	285	rah	Ten	<b></b>	
55														GTT			912
JJ	Ash	பழ்த் 290	Mec	ьeu	IUL	rne	Asn 295	PTO	HIS	гÀг	arg	300	GIU	Val	GIU	GID	

		•															
5	GC' Ala 30!		G GC u Al	C CA	C CCC	G TAC D Tyr 310	те:	G GAG	G CAC	TA:	T TAT T Ty:	r Asp	CC#	A AGT	GAT Asp	GAG Glu 320	960
	Pro	C AT	T GC	T GAZ a Glu	A GC/ 1 Ala 325	Pro	TTC Phe	AA(	3 TTT s Phe	GAC Asp 330	Met	GAG Glu	CTC Leu	GAC Asp	GAC Asp 335	TTA Leu	1008
10	CCT	C AAG	G GAO	3 AAC 1 Lys 340	, rec	AAA Lys	GAA Glu	CTC Leu	ATT lle	Phe	GAA Glu	GAG	ACT Thr	GCT Ala 350	Arg	TTC Phe	1056
15	CAG Gln	CCI Pro	A GGA O Gly 355	TAT	AGA Arg	TCT Ser	ATG Met	GAT Asp 360	Pro	CCG	GTC Val	GCC Ala	ACC Thr 365	ATG Met	GTG Val	AGC Ser	1104
20	AAG Lys	GG( Gly 370	GIU	GAG Glu	CTG Leu	TTC Phe	ACC Thr 375	GGG	GTG Val	GTG Val	CCC Pro	ATC Ile 380	CTG Leu	GTC Val	GAG Glu	CTG Leu	1152
25	GAC Asp 385	GGC	GAC Asp	GTA Val	AAC Asn	GGC Gly 390	CAC His	AAG Lys	TTC Phe	AGC Ser	GTG Val 395	TCC Ser	GGC Gly	GAG Glu	GGC Gly	GAG Glu 400	1200
	GGC Gly	GAT Asp	GCC Ala	ACC Thr	TAC Tyr 405	GGC Gly	AAG Lys	CTG Leu	ACC Thr	CTG Leu 410	AAG Lys	TTC Phe	ATC Ile	TGC Cys	ACC Thr 415	ACC Thr	1248
30	GGC Gly	AAG Lys	CTG Leu	CCC Pro 420	GTG Val	CCC Pro	TGG Trp	CCC Pro	ACC Thr 425	CTC Leu	GTG Val	ACC Thr	ACC Thr	CTG Leu 430	ACC Thr	TAC Tyr	1296
35	GGC Gly	GTG Val	CAG Gln 435	TGC Cys	TTC Phe	AGC Ser	CGC Arg	TAC Tyr 440	CCC Pro	GAC Asp	CAC His	ATG Met	AAG Lys 445	CAG Gln	CAC His	GAC Asp	1344
40	TTC Phe	TTC Phe 450	AAG Lys	TCC Ser	GCC Ala	ATG Met	CCC Pro 455	GAA Glu	GGC Gly	TAC Tyr	GTC Val	CAG Gln 460	GAG Glu	CGC Arg	ACC Thr	ATC Ile	1392
45	TTC Phe 465	TTC Phe	AAG Lys	GAC Asp	GAC Asp	GGC Gly 470	AAC Asn	TAC Tyr	AAG Lys	Thr	CGC Arg 475	GCC Ala	GAG Glu	GTG Val	Lys	TTC Phe 480	1440
	GAG Glu	GGC Gly	GAC Asp	ACC Thr	CTG Leu 485	GTG . Val .	AAC Asn	CGC Arg	Ile	GAG Glu 490	CTG Leu	AAG (	GGC . Gly	Ile .	GAC Asp 495	TTC Phe	1488
50	AAG Lys	GAG Glu	GAC Asp	GGC Gly 500	AAC Asn	ATC (	CTG ( Leu (	GIY	CAC His 505	AAG Lys	CTG (	GAG ' Glu '	Tyr .	AAC ' Asn '	rac . ryr .	AAC Asn	1536
55	AGC Ser	1112	AAC Asn 515	GTC Val	TAT . Tyr	ATC I	wet i	GCC Ala 520	GAC A	AAG Lys (	CAG :	Lys 1	AAC ( Asn (	GGC A	ATC :	AAG Lys	1584

125

5												GGC Gly 540					1632
												GAC Asp					1680
10												GCC Ala					1728
15												GAG Glu					1776
20					CTC Leu							AA (	STAA				1815
			(2)	INI	FORM	ATIO	N FOI	R SE(	Q ID	NO:	59:						
25		<b>( )</b>	(A) (B) (C)	LENG TYPI STR	NCE (GTH: E: an ANDEI	604 mino ONESS	amin acio S: s:	no ao i ingle	cids								
30		(7	Li) P	MOLE(	CULE ENT :	TYPI TYPE	E: pi	rote: cerna	al	חז ה	NO ·	: a ·					
35	Met									_		Val	Arg	Gly	Gln	Val	
	1 Phe	Asp	Val		5 Pro	Arg	Tyr	Thr		10 Leu	Ser	Tyr	Ile	_	15 Glu	Gly	
40	Ala	Tyr	Gly 35	20 Met	Val	Cys	Ser	Ala 40	25 Tyr	Asp	Asn	Leu	Asn 45	30 Lys	Val	Arg	
	Val	Ala 50		Lys	Lys	Ile	Ser 55		Phe	Glu	His	Gln 60		Tyr	Cys	Gln	
45	Arg 65	Thr	Leu	Arg	Glu	Ile 70	Lys	Ile	Leu	Leu	Arg 75	Phe	Arg	His	Glu	Asn 80	
	Ile	Ile	Gly	Ile	Asn 85	Asp	Ile	Ile	Arg	Ala 90	Pro	Thr	Ile	Glu	Gln 95	Met	
	Lys	Asp	Val	Tyr 100	Ile	Val	Gln	Asp	Leu 105	Met	Glu	Thr	Asp	Leu 110	Tyr	Lys	
50	Leu	Leu	Lys 115	Thr	Gln	His	Leu	Ser 120	Asn	Asp	His	Ile	Cys 125	Tyr	Phe	Leu	
	Tyr	Gln 130	Ile	Leu	Arg	Gly	Leu 135	Lys	Tyr	Ile	His	Ser 140	Ala	Asn	Val	Leu	
55	His 145	Arg	Asp	Leu	Lys	Pro 150		Asn	Leu	Leu	Leu 155	Asn	Thr	Thr	Сув	Asp 160	
		Lys	Ile	Cys	Asp			Leu	Ala	Arg		Ala	Asp	Pro	Asp		

•																
	7 ~~		n Orba		165					170	)				175	i
				TRC	,				185	; ·				190		Arg
5			195	)				200					205	;		Asp
		210	)				215	5				220				Pro
	425					230	ı				235					Gly 240
10					245					250					255	Leu
				260					265					270	Val	Pro
15			2/5					280					285	Asp		Leu
		290					295					300		Val		
00	202					310					315		*			Glu 320
20					325					330				Asp	335	Leu
				340					345					Ala 350		
25			355					360					365	Met		
		3/0					375					380		Val		
30	385					390					395			Glu		400
30					405					410				Cys	415	
				420					425					Leu 430		
35			435			•		440					445	Gln		
		450					455					460		Arg		
40	465					470					475			Val		480
					485					490				Ile	495	
				500					505					Asn 510		
45			212					520					525	Gly		
		230					535					540				
50	Ala 545					550					555					560
	Leu				565			•		570					575	
	Pro .			580					585				Phe	Val 590	Thr	Ala
55	Ala	1	595	~ 111	neu.	GTÅ	MET	Asp 600	GIU	ьeп	Tyr	гàг				

127

(2) INFORMATION	FOR	SEQ	ID	NO:6	0
-----------------	-----	-----	----	------	---

5	(	i) SEQU (A) LEI (B) TY: (C) STI (D) TO:	NGTH: PE: no RANDE	251: ucle: DNES	l bas ic as S: s:	se pa cid ingle	airs					
10	-	ii) MOLI ix) FEA		TYPI	E: CI	ANC						
15	(:	(A) N; (B) L; (D) O' xi) SEQ	CATION :	ON: :	RMAT	2508 ION:		NO:	50:			
20	ATG GAG Met Glu 1											48
25	GAA GGG Glu Gly											96
	ATC CTG Ile Leu											144
30 .	ATA GAC Ile Asp 50											192
35	CTG CTT Leu Leu 65											240
40	ATT CAG Ile Gln											288
45	AAA CTG Lys Leu		Lys									336
	AAG TCC Lys Ser											384
50	ACG GAG Thr Glu 130											432
55	TGT GCA Cys Ala 145											480

	TA:	r CT r Le	G GA	C AGO	C ATC	TTI	TTT	GAC Asp	C CGG	TT:	r CTC	CAC	G TGO	AA(	G TG	G TTG p Leu	528
5					165	i		_		170			<b>-</b> -	,.	17		
	GAZ Glu	A AG	G CA	A CCC	GTG Val	ACC	AAA Lys	AAC Asn	ACI	TTC	AGG	CAC	TAT	CGA	GTO	G CTA	576
				180	)		_		185	;	3	, 011	y-	190		L Deu	
10	GG# Gly	A AAi	A GG( 5 Gl) 195	GIA	TTC Phe	GGG Gly	GAG Glu	GTC Val 200	Cys	GCC Ala	TGC Cys	CAC Gln	GTT Val 205	Arg	GCC Ala	ACG Thr	624
15	GGT Gly	Lys 210	s Met	TAT	GCC Ala	TGC Cys	AAG Lys 215	Arg	TTG Leu	GAG Glu	AAG Lys	AAG Lys 220	Arg	ATC	Lys	AAG Lys	672
20	AGG Arg 225	ry	A GGG Gly	GAG Glu	TCC	ATG Met 230	GCC Ala	CTC Leu	AAT Asn	GAG Glu	AAG Lys 235	CAG Gln	ATC Ile	CTC Leu	GAG Glu	AAG Lys 240	720
25	GTC Val	AAC	AGT Ser	CAG Gln	TTT Phe 245	GTG Val	GTC Val	AAC Asn	CTG Leu	GCC Ala 250	TAT Tyr	GCC Ala	TAC Tyr	GAG Glu	ACC Thr 255	AAG Lys	768
	GAT Asp	GCA Ala	CTG Leu	TGC Cys 260	TTG Leu	GTC Val	CTG Leu	ACC Thr	ATC Ile 265	ATG Met	AAT Asn	GGG Gly	GGT Gly	GAC Asp 270	CTG Leu	AAG Lys	816
30	TTC Phe	CAC His	ATC Ile 275	TAC Tyr	AAC Asn	ATG Met	GGC Gly	AAC Asn 280	CCT Pro	GGC Gly	TTC Phe	GAG Glu	GAG Glu 285	GAG Glu	CGG Arg	GCC Ala	864
35	TTG Leu	TTT Phe 290	TAT Tyr	GCG Ala	GCA Ala	GAG Glu	ATC Ile 295	CTC Leu	TGC Cys	GGC Gly	TTA Leu	GAA Glu 300	GAC Asp	CTC Leu	CAC His	CGT Arg	912
40	GAG Glu 305	AAC Asn	ACC Thr	GTC Val	TAC Tyr	CGA Arg 310	GAT Asp	CTG Leu	AAA Lys	CCT Pro	GAA Glu 315	AAC Asn	ATC Ile	CTG Leu	TTA Leu	GAT Asp 320	960
A.E.	GAT Asp	TAT Tyr	GGC Gly	CAC His	ATT Ile 325	AGG Arg	ATC Ile	TCA Ser	GAC Asp	CTG Leu 330	GGC Gly	TTG Leu	GCT Ala	GTG Val	AAG Lys 335	ATC Ile	1008
45	CCC	GAG	GGA	GAC	CTG	ATC	CGC	GGC	CGG		CCC	እ Cm	GTT	cca		» ma	
	Pro	Glu	Gly	Asp 340	Leu	Ile :	Arg	Gly	Arg 345	Val	Gly	Thr	Val	Gly 350	Tyr	Met	1056
50	GCC Ala	CCC Pro	GAA Glu 355	GTC Val	CTG . Leu .	AAC A	Asn	CAG . Gln . 360	AGG Arg	TAC Tyr	GGC Gly	Leu	AGC Ser 365	CCC Pro	GAC Asp	TAC Tyr	1104
55	rrp	GGC Gly 370	CTT Leu	GGC Gly	TGC ( Cys :	Leu :	ATC ( Ile ( 375	TAT (	GAG . Glu	ATG Met	Ile	GAG Glu 380	GGC (	CAG Gln	TCG Ser	CCG Pro	1152

5				CGT Arg													1200
3				ACG Thr													1248
10				TGC Cys 420													1296
15				GAG Glu													1344
20				AAC Asn													1392
25	Phe 465	Val	Pro	GAC Asp	Pro	Arg 470	Ala	Val	Tyr	Cys	Lys 475	Asp	Val	Leu	Asp	Ile 480	1440
				TCC Ser													1488
30				TCC Ser 500											•		1536
35				ATA Ile													1584
40				ACC Thr													1632
45				AAA Lys													1680
				AAG Lys													1728
50				AAC Asn 580													1776
55				GCC Ala													1824

5	GT( Va)	G GT0 L Va:	r PI	TA C	C CTO	G GT(	GAG Glu	ı Leı	G GAC	GGG Gly	C GA( / Asp	GT/ O Val 620	l Ası	C GG(	CAC	C AAG s Lys	1872
	TT( Phe 625	361	C GTC	TCC Ser	GGG Gly	GAG Glu 630	GIY	GAC Glu	GGC Gly	GAT Asp	GCC Ala 635	Thr	TAC	GGC Gly	AA(	G CTG S Leu 640	1920
10	ACC Thr	CTC	AAC Lys	TTC Phe	11e 645	: Cys	ACC	ACC Thr	GGC Gly	AAC Lys 650	Leu	CCC Pro	GTG Val	CCC Pro	TGC Trp 655	G CCC Pro	1968
15	ACC Thr	CTC	GTG Val	Thr	THE	CTG Leu	ACC Thr	TAC	GGC Gly 665	GTG Val	CAG Gln	TGC Cys	TTC Phe	AGC Ser 670	Arg	TAC Tyr	2016
20	CCC Pro	GAC Asp	CAC His	Mec	AAG Lys	CAG Gln	CAC His	GAC Asp 680	Phe	TTC	AAG Lys	TCC Ser	GCC Ala 685	ATG Met	CCC	GAA Glu	2064
25	GGC Gly	TAC Tyr 690	GTC Val	CAG Gln	GAG Glu	CGC Arg	ACC Thr 695	ATC Ile	TTC Phe	TTC Phe	AAG Lys	GAC Asp 700	GAC Asp	GGC Gly	AAC Asn	TAC Tyr	2112
	AAG Lys 705	ACC Thr	CGC Arg	GCC Ala	GAG Glu	GTG Val 710	AAG Lys	TTC Phe	GAG Glu	GGC Gly	GAC Asp 715	ACC Thr	CTG Leu	GTG Val	AAC Asn	CGC Arg 720	2160
30	ATC Ile	GAG Glu	CTG Leu	AAG Lys	GGC Gly 725	ATC Ile	GAC Asp	TTC Phe	AAG Lys	GAG Glu 730	GAC Asp	GGC Gly	AAC Asn	ATC Ile	CTG Leu 735	GGG Gly	2208
35	CAC His	AAG Lys	CTG Leu	GAG Glu 740	TAC Tyr	AAC Asn	TAC Tyr	AAC Asn	AGC Ser 745	CAC His	AAC Asn	GTC Val	TAT Tyr	ATC Ile 750	ATG Met	GCC Ala	2256
40	GAC Asp	AAG Lys	CAG Gln 755	AAG Lys	AAC Asn	GGC Gly	ATC Ile	AAG Lys 760	GTG Val	AAC Asn	TTC Phe	AAG Lys	ATC Ile 765	CGC Arg	CAC His	AAC Asn	2304
45	ATC Ile	GAG Glu 770	GAC Asp	Gly	AGC Ser	GTG Val	CAG Gln 775	CTC Leu	GCC Ala	GAC Asp	CAC His	TAC Tyr 780	CAG Gln	CAG Gln	AAC Asn	ACC Thr	2352
	CCC Pro 785	ATC Ile	GGC Gly	GAC Asp	GGC Gly	CCC Pro 790	GTG Val	CTG Leu	CTG Leu	CCC Pro	GAC Asp 795	AAC Asn	CAC His	TAC Tyr	CTG Leu	AGC Ser 800	2400
50	ACC Thr	CAG Gln	TCC Ser	Ala	CTG Leu 805	AGC . Ser :	AAA ( Lys )	GAC Asp	Pro	AAC Asn 810	GAG Glu	AAG Lys	CGC Arg	Asp	CAC His 815	ATG Met	2448
55	GTC Val	CTG Leu	Leu	GAG Glu 820	TTC Phe	GTG . Val '	ACC (	Ala	GCC ( Ala ( 825	GGG Gly	ATC .	ACT   Thr	Leu	GGC . Gly :	ATG Met	GAC Asp	2496

131

GAG CTG TAC AAG TAA 2511
Glu Leu Tyr Lys 835

5

10

15

## (2) INFORMATION FOR SEQ ID NO:61:

(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 836 amino acids(B) TYPE: amino acid

(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(v) FRAGMENT TYPE: internal

(ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:61:

20 Met Glu Leu Glu Asn Ile Val Ala Asn Thr Val Leu Leu Lys Ala Arg Glu Gly Gly Gly Lys Arg Lys Gly Lys Ser Lys Lys Trp Lys Glu 25 Ile Leu Lys Phe Pro His Ile Ser Gln Cys Glu Asp Leu Arg Arg Thr 25 40 Ile Asp Arg Asp Tyr Cys Ser Leu Cys Asp Lys Gln Pro Ile Gly Arg 55 60 Leu Leu Phe Arg Gln Phe Cys Glu Thr Arg Pro Gly Leu Glu Cys Tyr 70 30 Ile Gln Phe Leu Asp Ser Val Ala Glu Tyr Glu Val Thr Pro Asp Glu 90 Lys Leu Gly Glu Lys Gly Lys Glu Ile Met Thr Lys Tyr Leu Thr Pro 105 Lys Ser Pro Val Phe Ile Ala Gln Val Gly Gln Asp Leu Val Ser Gln 35 120 Thr Glu Glu Lys Leu Gln Lys Pro Cys Lys Glu Leu Phe Ser Ala 135 140 Cys Ala Gln Ser Val His Glu Tyr Leu Arg Gly Glu Pro Phe His Glu 150 155 40 Tyr Leu Asp Ser Met Phe Phe Asp Arg Phe Leu Gln Trp Lys Trp Leu 165 170 Glu Arg Gln Pro Val Thr Lys Asn Thr Phe Arg Gln Tyr Arg Val Leu Gly Lys Gly Gly Phe Gly Glu Val Cys Ala Cys Gln Val Arg Ala Thr 45 200 Gly Lys Met Tyr Ala Cys Lys Arg Leu Glu Lys Lys Arg Ile Lys Lys 215 Arg Lys Gly Glu Ser Met Ala Leu Asn Glu Lys Gln Ile Leu Glu Lys 225 230 50 Val Asn Ser Gln Phe Val Val Asn Leu Ala Tyr Ala Tyr Glu Thr Lys 245 . 250 Asp Ala Leu Cys Leu Val Leu Thr Ile Met Asn Gly Gly Asp Leu Lys 265 Phe His Ile Tyr Asn Met Gly Asn Pro Gly Phe Glu Glu Glu Arg Ala 55 280 Leu Phe Tyr Ala Ala Glu Ile Leu Cys Gly Leu Glu Asp Leu His Arg

											132	2		٠			•
			90					29	95				30	10			
	G]	u A	sn	Th	r Va	1 ту	r Ar 31	g As	p Le	u Lj	s Pr	o G1	u As	n Il	e Le	u Le	u Asp
5	As	рТ	Эr	Gl	/ Hi	s Il 32	e Ar	g Il	e Se	r As	p Le	31 u Gl	y Le	u Al	a Va	1 Гу	320 s Ile
•	Pr	o G	lu	Gly	/ As <sub>j</sub>	p Le	u Il	e Ar	g Gl	y Ar	33 g Va	1 G1	y Th	r Va	l Gl	33 y Ty	5 r Met
				Glu	ı Va	•			n Gl	n Ar	5						p Tyr
10		рG			•			u Il	e Ty	U				2 ~	_		r Pro
		e A					s Gl	u Ly					20	^			g Arg
		_										70	_				
15						Z U .	,				471	n					400 1 Ala 5
					720	,				42	5				420		g Leu
20				エココ					44(	3				4 4 5	•		Phe
								45:	o ·				ACC	`			Pro
	465	e va S	11	Pro	Asp	Pro	Arc 470	, Ala	a Val	Ту	Cys	Lys	Asp	Val	Leu	Asp	lle '
25			ln	Phe	Ser	Thr	Val	. Lys	Gly	v Val	l Asr	475 Leu	i Asp	His	Thr	Asp	480 Asp
•	Asp	Ph	e	Tyr	Ser 500	Lys		Ser	Thr	Gl	490 Ser	Val	Ser	Ile	Pro	495 Trp	Gln
	Asn	Gl	u .	Met 515	-		Thr	Glu	Cys 520	505 Phe	Lys	Glu	Leu			Phe	Gly
30	Pro	As 53	n		Thr	Leu	Pro	Pro	Asp	Leu	Asn	Arg	Asn	525 His	Pro	Pro	Glu
	Pro 545	Pr	o :	Lys	Lys	Gly	Leu 550	Leu	Gln	Arg	Leu	Phe 555	540 Lys	Arg	Gln	His	Gln
35						202	Ser				570	Thr	Ser		Asn		
										- 5 N 5	Ser	Thr			Ser 590		
			-						600	Lys				COE	Phe		
40		~ -	_					012					620	Asn	Gly		
							030					635	Thr		Gly		
45						0-20					650	Leu			Pro	CEE	Pro
					000					665	Val				Ser 670	Arg	
			_						680	Phe				C 0 F	Met		
50			•					בעס	Ile				700	Asp	Gly		
							110	Lys				715	Thr		Val .		
55						, 23					770	Asp			Ile		
	His	Lys	Ļ	eu (	3lu'	Tyr .	Asn	Tyr	Asn	Ser	His	Asn	Val	Tyr	Ile	Met .	Ala

	7 cm	T 1/6	C) n	740	Asn	Glv.	T10	Tura	745	λαπ	Dho	T	T10	750	wic	) en		
			755					760				_	765					
5	Ile	Glu 770	Asp	Gly	Ser	Val	Gln 775	Leu	Ala	Asp	His	Tyr 780	Gln	Gln	Asn	Thr		
		Ile	Gly	Asp	Gly	Pro 790	Val	Leu	Leu	Pro	_	Asn	His	Tyr	Leu	Ser 800		
	785 Thr	Gln	Ser	Ala	Leu		Lys	Asp	Pro		795 Glu	Lys	Arg	Asp				
10	Val	Leu	Leu	•	805 Phe	Val	Thr	Ala		810 Gly	Ile	Thr	Leu		815 Met	Asp		
	Glu	Leu	Tyr 835	820 Lys					825					830				
15			(2)	INE	FORM	MOITA	1 FOR	R SE	Q ID	NO : 6	52:							
20		. (4	(A) (B) (C)	LENC TYPE STRA	NCE C STH: S: nu ANDEI OLOGY	1893 iclei NESS	bas ic ac S: si	se pa cid ingle	airs									
25			ix) I	FEAT	CULE JRE: ME/KE				eauer	nce								
30			(B)	LOC	CATIO HER I	NFOR	RMAT	.890 ION:	-		NO:	52:				-		
	ΔTG	ልርር	ADA	AGC	AAG	ССТ	GAC	אאר	דעע	ተነውጥ	тΔт	ልርጥ	стъ	GAG	ידידע	GGA		48
					Lys 5													
35	СУТ	ጥርጥ	ארא	ттс	ACA	GTC	CTG	מממ	CGA	ידמיד	CAG	אמ מ	מידים	ΔΔΔ	רכיזי	מדמ		96
					Thr													
40	GGC	TCA	GGA	GCT	CAA	GGA	ATA	GTA	TGC	GCA	GCT	TAT	GAT	GCC	ATT	CTT	1	44
	Gly	Ser	Gly 35	Ala	Gln	Gly	Ile	Val 40	Cys	Ala	Ala	Tyr	Asp 45	Ala	Ile	Leu		
	GAA	AGA	AAT	GTT	GCA	ATC	AAG	AAG	CTA	AGC	CGA	CCA	TTT	CAG	AAT	CAG	1	92
45	Glu	Arg 50	Asn	Val	Ala	Ile	Lys 55	Lys	Leu	Ser	Arg	Pro 60	Phe	Gln	Asn	Gln		
					CGG Arg												2	40
50	65			_		70		_			75			-		80		
					ATA Ile 85												2	88
55	יוירי	СТЪ	GAD	G Z D	TTT	CDD	GΔͲ	ىنىلىت	ጥልሮ		ርጥሮ	ΔሞŒ	GAG	רייירי		GAT	3	36
			1	J. 111		<del></del> 1			-77	*****			UNU				_	_ 4

										.04							
	Se	r Le	eu Gl	u Gl 10	u Ph O	e Gli	n Ası	o Va	1 Ty:	r Il	e Va	l Me	t Gl	u Le 11		et Asp	
5	GC Al	A AA a As	T CT n Le 11	u cy.	C CA	A GTO	ATT	CAC Gl:	n Met	G GA	G CT	A GA	T CA: p His	Gl	A AG u Ar	A ATG	384
10	TC Se	C TA r Ty 13		T CT( u Le	TA:	r CAG	ATO Met	Let	G TGT 1 Cys	r GGA	A ATO	2 AA0 2 Ly:	s His	C CT	Г СА ı Ні	T TCT s Ser	432
15	145	5	, 11.	- 116	. nrs	150	Asp	Let	ı Lys	Pro	Ser 155	Ası	ı İle	· Val	l Va	A AAA l Lys 160	480
	50.		p cyr	, 1111	165	rys	TIE	Leu	Asp	Phe 170	Gly	Lev	Ala	Arg	17!		528
20	GG# Gly	ACC Thi	G AGT	TTT Phe 180	Met	ATG Met	ACG Thr	CCT Pro	TAT Tyr 185	GTA Val	GTG Val	ACT Thr	CGC Arg	TAC Tyr 190	Туз	AGA Arg	576
25	GCA Ala	CCC Pro	GAG Glu 195	val	ATC	CTT Leu	GGC Gly	ATG Met 200	GGC Gly	TAC Tyr	AAG Lys	GAA Glu	AAC Asn 205	GTG Val	GAT Asp	TTA Leu	624
30	TGG Trp	TCI Ser 210		GGG Gly	TGC Cys	ATT Ile	ATG Met 215	GGA Gly	GAA Glu	ATG Met	GTT Val	TGC Cys 220	CAC His	AAA Lys	ATC	CTC Leu	672
35	TTT Phe 225	CCA Pro	GGA Gly	AGG Arg	GAC Asp	TAT Tyr 230	ATT Ile	GAT Asp	CAG Gln	TGG Trp	AAT Asn 235	AAA Lys	GTT Val	ATT Ile	GAA Glu	CAG Gln 240	720
			****	110	245	PLO	GIU	Pne	Met	Lys 250	Lys	Leu	CAA Gln	Pro	Thr 255	Val	768
40	****		171	260	Giu	ASI	Arg	Pro	Lys 265	Tyr	Ala	Gly	TAT Tyr	Ser 270	Phe	Glu	816
45	AAA Ĺys	CTC Leu	TTC Phe 275	CCT Pro	GAT Asp	GTC Val	ren	TTC Phe 280	CCA Pro	GCT Ala	GAC Asp	TCA Ser	GAA Glu 285	CAC His	AAC Asn	AAA Lys	864
50	CTT Leu	AAA Lys 290	GCC Ala	AGT Ser	CAG Gln	AIA .	AGG ( Arg )	GAT Asp	TTG Leu	TTA Leu	Ser	AAA Lys 300	ATG Met	CTG Leu	GTA Val	ATA Ile	912
55	GAT Asp 305	GCA Ala	TCT Ser	AAA Lys	nr 9	ATC ' Ile : 310	TCT ( Ser '	GTA Val	GAT ( Asp (	Glu .	GCT Ala : 315	CTC Leu	CAA ( Gln )	CAC His	CCG Pro	TAC Tyr 320	960
	ATC	AAT	GTC	TGG '	TAT (	GAT (	CCT :	FCT (	GAA (	GCA (	GAA (	GCT	CCA (	CCA	CCA	AAG	1008

135

										135							
	Ile	Asn	Val	Trp	Tyr 325	Asp	Pro	Ser	Glu	Ala 330	Glu	Ala	Pro	Pro	Pro 335	Lys	
5					CAG Gln												1056
10					TAT Tyr									٠,			1104
15					CGG Arg												1152
					GTC Val												1200
20					CCC Pro 405												1248
25					GTG Val												1296
30					AAG Lys												1344
35					GTG Val												1392
30					CAC His												1440
40					GTC Val 485												1488
45					CGC Arg												1536
50					CTG Leu												1584
55					CTG Leu												1632
<b>55</b>	ATG	GCC	GAC	AAG	CAG	AAG	AAC	GGC	ATC	AAG	GTG	AAC	TTC	AAG	ATC	CGC	1680

										136	;		•			•	•
	Me 54	t Al 5	a As	р Ly	s Gl	n Lys 550	S Ası	n Gl	y Il	e Ly	s Va 55		n Ph	e Ly	s Il	e Arg 560	
5	n,	s AS.	11 116	5 610	56!	e ery	Sei	c Va.	l Gl	n Lei 57	u Ala O	a As	p Hi	в Ту	r Gl: 57		1728
10	ASI	1 111.	L PIC	580	) s GTZ	y Asp	GTA	' Pro	585	L Lei	ù Lei	ı Pr	o Ası	2 As:	n Hi: O	C TAC	1776
15	net	, sei	595	GIR	ı Sei	. Ala	Leu	600	C Lys	a Asp	p Pro	) Ası	n Glu 605	ı Ly:	s Arg	C GAT G Asp	1824
	CAC His	Met 610	. var	CTG	CTG Leu	GAG Glu	TTC Phe 615	Val	ACC Thr	GCC Ala	GCC A Ala	GG( Gl) 62(	/ Ile	C ACT	r CTC	GGC Gly	1872
20	Met 625	Asp	GAG Glu	CTG Leu	TAC	AAG Lys 630	TAA				٠						1893
25			(2	) IN	FORM	ATIO	N FO	R SE	Q ID	NO:	63:						
30			(A) (B) (C)	LENG TYP: STR	GTH: E: a ANDE	CHARA 630 mino DNESS Y: li	amin acio 3: s:	no a i ingl	cids	-							
35		(·	v) FI	RAGMI	ENT '	TYPE: TYPE:	int	ern	al	Q ID	NO:	63:					-
	Met					Arg		,					Val	Glu	Ile	Glv	
40	_			Phe	5	Val				3.0					1 =		
				20		Gly			25				Asp	3 0			
45	Glu	Arg 50		Val	Ala	Ile	Lys 55		Leu	Ser	Arg	Pro 60	45 Phe	Gln	Asn	Gln	
	05					Ala 70					75	Leu				9.0	
50					85	Ile				90	Val				95	Lys	
50				100		Gln .			105					110	Met		
			112			Val		120					125				
55		130					135					140					
		-	116	44C	1115	Arg	nsp :	Leu	ŗÀŝ	Pro	Ser	Asn	Ile	Val	Val	Lys	420

	145					150					155					160
					Leu 165	-				170	_				175	
5				180	Met				185					190		
			195		Ile			200					205			
		210			Cys		215					220				
10	225	•			Asp	230			•		235	-				240
					Cys 245					250					255	
15				260	Glu				265			_	_	270		
			275		Asp			280					285			
20		290			Gln		295	_				300				
20	305				Arg	310					315					320
					Tyr 325				٠	330					335	
25				340	Gln				345					350		_
			355		Tyr			360					365			
20		370			Arg		375					380				
30	385				Val	390					395	_				400
					Pro 405					410					415	
35				420	Val				425			_		430		
			435		Lys			440			_	-	445			
40		450			Val		455			_	_	460		-		
40	465				His	470					475					480
					Val 485					490			_		495	
45				500	Arg				505			-	_	510		
			515		Leu			520					525			
50		530			Leu		535					540				
50	545				Gln	550					555					560
					Asp 565			•		570				-	575	
55				580	Gly				585					590		, -
	ьeu	ser	Thr	GID	Ser	Ala	Leu	Ser	Lys	Asp	Pro	Asn	Glu	Lys	Arg	Asp

	138
	595 600 605
	Ala Gly Ile Thr Leu Gly
	Met Asp Glu Leu Tyr Lys 620
5	625 630
	(2) INFORMATION FOR SEQ ID NO:64:
10	<ul> <li>(i) SEQUENCE CHARACTERISTICS:</li> <li>(A) LENGTH: 1821 base pairs</li> <li>(B) TYPE: nucleic acid</li> <li>(C) STRANDEDNESS: single</li> <li>(D) TOPOLOGY: linear</li> </ul>
15	(ii) MOLECULE TYPE: cDNA (ix) FEATURE:
. 20	(A) NAME/KEY: Coding Sequence (B) LOCATION: 11818 (D) OTHER INFORMATION:
	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:64:
25	ATG TCT CAG GAG AGG CCC ACG TTC TAC CGG CAG GAG CTG AAC AAG ACA  Met Ser Gln Glu Arg Pro Thr Phe Tyr Arg Gln Glu Leu Asn Lys Thr  1 5 10 15
30	ATC TGG GAG GTG CCC GAG CGT TAC CAG AAC CTG TCT CCA GTG GGC TCT 96  Ile Trp Glu Val Pro Glu Arg Tyr Gln Asn Leu Ser Pro Val Gly Ser  20 25 30
35	GGC GCC TAT GGC TCT GTG TGT GCT GCT TTT GAC ACA AAA ACG GGG TTA 144 Gly Ala Tyr Gly Ser Val Cys Ala Ala Phe Asp Thr Lys Thr Gly Leu 35 40 45
	CGT GTG GCA GTG AAG AAG CTC TCC AGA CCA TTT CAG TCC ATC ATT CAT 192 Arg Val Ala Val Lys Lys Leu Ser Arg Pro Phe Gln Ser Ile Ile His 50 55 60
40	GCG AAA AGA ACC TAC AGA GAA CTG CGG TTA CTT AAA CAT ATG AAA CAT Ala Lys Arg Thr Tyr Arg Glu Leu Arg Leu Leu Lys His Met Lys His 70 75 80
45	GAA AAT GTG ATT GGT CTG TTG GAC GTT TTT ACA CCT GCA AGG TCT CTG  Glu Asn Val Ile Gly Leu Leu Asp Val Phe Thr Pro Ala Arg Ser Leu  85  90  95
50	GAG GAA TTC AAT GAT GTG TAT CTG GTG ACC CAT CTC ATG GGG GCA GAT Glu Glu Phe Asn Asp Val Tyr Leu Val Thr His Leu Met Gly Ala Asp 100 105 110
55	CTG AAC AAC ATT GTG AAA TGT CAG AAG CTT ACA GAT GAC CAT GTT CAG Leu Asn Asn Ile Val Lys Cys Gln Lys Leu Thr Asp Asp His Val Gln 115 120 125
	TTC CTT ATC TAC CAA ATT CTC CGA GGT CTA AAG TAT ATA CAT TCA GCT 432
	138

139

										139								
	Phe	Leu 130	Ile	Tyr	Gln	Ile	Leu 135	Arg	Gly	Leu	Lys	Tyr 140	Ile	His	Ser	Ala		
5					AGG Arg												480	)
10					AAG Lys 165												528	3
15					GGC Gly												576	5
10					TGG Trp												624	ŀ
20					ATG Met												672	2
25					ATT Ile												720	)
30					GAG Glu 245												768	3
35					TCT Ser												816	5
33					GCC Ala												864	l
40					TCA Ser												912	2
45					GCT Ala												960	ס
50					CAG Gln 325												1008	3
55					ACC Thr												105	5
00	CTT	GAC	CAA	GAA	GAG	ATG	GAG	TCC	GAG	GAT	CCA	CCG	GTC	GCC	ACC	ATG	110	4

•										140							
	Leu	Asp	Gln 355	Glu	Glu	Met	Glu	Ser 360		Asp	Pro	Pro	Val 365		Thr	Met	
5	GTG Val	AGC Ser 370	Lys	GGC	GAG Glu	GAG Glu	CTG Leu 375	Phe	ACC Thr	GGG	GTG Val	GTG Val 380	Pro	ATC Ile	CTG Leu	GTC Val	1152
10	GAG Glu 385	Leu	GAC Asp	GGC Gly	GAC Asp	GTA Val 390	AAC Asn	GGC Gly	CAC	AAG Lys	TTC Phe 395	AGC Ser	GTG Val	TCC	GGC	GAG Glu 400	1200
15	GGC Gly	GAG Glu	GGC	GAT Asp	GCC Ala 405	ACC Thr	TAC Tyr	GGC	AAG Lys	CTG Leu 410	ACC Thr	CTG Leu	AAG Lys	TTC Phe	ATC Ile 415	TGC Cys	1248
	ACC Thr	ACC Thr	GGC	AAG Lys 420	CTG Leu	CCC	GTG Val	CCC Pro	TGG Trp 425	CCC	ACC Thr	CTC Leu	GTG Val	ACC Thr 430	ACC Thr	CTG Leu	1296
20	ACC Thr	TAC Tyr	GGC Gly 435	GTG Val	CAG Gln	TGC Cys	TTC Phe	AGC Ser 440	CGC Arg	TAC Tyr	CCC Pro	GAC Asp	CAC His 445	ATG Met	AAG Lys	CAG Gln	1344
25	CAC His	GAC Asp 450	TTC Phe	TTC Phe	AAG Lys	TCC Ser	GCC Ala 455	ATG Met	CCC Pro	GAA Glu	GGC Gly	TAC Tyr 460	GTC Val	CAG Gln	GAG Glu	CGC Arg	1392
30	ACC Thr 465	ATC Ile	TTC Phe	TTC Phe	AAG Lys	GAC Asp 470	GAC Asp	GGC Gly	AAC Asn	TAC Tyr	AAG Lys 475	ACC Thr	CGC Arg	GCC Ala	GAG Glu	GTG Val 480	1440
35	AAG Lys	TTC Phe	GAG Glu	GGC Gly	GAC Asp 485	ACC Thr	CTG Leu	GTG Val	AAC Asn	CGC Arg 490	ATC Ile	GAG Glu	CTG Leu	AAG Lys	GGC Gly 495	ATC Ile	1488
	GAC Asp	TTC Phe	AAG Lys	GAG Glu 500	GAC Asp	GGC Gly	AAC Asn	ATC Ile	CTG Leu 505	GGG Gly	CAC His	AAG Lys	CTG Leu	GAG Glu 510	TAC Tyr	AAC Asn	1536
40	TAC Tyr	AAC Asn	AGC Ser 515	CAC His	AAC Asn	GTC Val	TAT Tyr	ATC Ile 520	ATG Met	GCC Ala	GAC Asp	AAG Lys	CAG Gln 525	AAG Lys	AAC Asn	GGC Gly	1584
45	ATC Ile	AAG Lys 530	GTG Val	AAC Asn	TTC Phe	AAG Lys	ATC Ile 535	CGC Arg	CAC His	AAC Asn	ATC Ile	GAG Glu 540	GAC Asp	GGC Gly	AGC Ser	GTG Val	1632
50	CAG Gln 545	CTC Leu	GCC Ala	GAC Asp	CAC His	TAC Tyr 550	CAG Gln	CAG Gln	AAC Asn	ACC Thr	CCC Pro 555	ATC Ile	GGC Gly	GAC Asp	GGC Gly	CCC Pro 560.	1680
55	GTG Val	CTG Leu	CTG Leu	CCC Pro	GAC Asp 565	AAC Asn	CAC His	TAC Tyr	CTG Leu	AGC Ser 570	ACC Thr	CAG Gln	TCC Ser	GCC Ala	CTG Leu 575	Ser	1728
	AAA	GAC	CCC	AAC	GAG	AAG	CGC	GAT	CAC	ATG	GTC	CTG	CTG	GAG	TTC	GTG	1776 1

Lys Asp Pro Asn Glu Lys Arg Asp His Met Val Leu Leu Glu Phe Val
580 585 590

ACC GCC GCC GGG ATC ACT CTC GGC ATG GAC GAG CTG TAC AAG TAA 1821

Thr Ala Ala Gly Ile Thr Leu Gly Met Asp Glu Leu Tyr Lys
595 600 605

(2) INFORMATION FOR SEQ ID NO:65:

(a) LENGTH: 606 amino acids
(b) TYPE: amino acid
(c) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein
(v) FRAGMENT TYPE: internal

20 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:65:

Met Ser Gln Glu Arg Pro Thr Phe Tyr Arg Gln Glu Leu Asn Lys Thr Ile Trp Glu Val Pro Glu Arg Tyr Gln Asn Leu Ser Pro Val Gly Ser 25 25 Gly Ala Tyr Gly Ser Val Cys Ala Ala Phe Asp Thr Lys Thr Gly Leu 40 Arg Val Ala Val Lys Lys Leu Ser Arg Pro Phe Gln Ser Ile Ile His 30 Ala Lys Arg Thr Tyr Arg Glu Leu Arg Leu Leu Lys His Met Lys His 75 Glu Asn Val Ile Gly Leu Leu Asp Val Phe Thr Pro Ala Arg Ser Leu 90 Glu Glu Phe Asn Asp Val Tyr Leu Val Thr His Leu Met Gly Ala Asp 35 105 Leu Asn Asn Ile Val Lys Cys Gln Lys Leu Thr Asp Asp His Val Gln 120 Phe Leu Ile Tyr Gln Ile Leu Arg Gly Leu Lys Tyr Ile His Ser Ala 40 Asp Ile Ile His Arg Asp Leu Lys Pro Ser Asn Leu Ala Val Asn Glu 150 155 Asp Cys Glu Leu Lys Ile Leu Asp Phe Gly Leu Ala Arg His Thr Asp 170 Asp Glu Met Thr Gly Tyr Val Ala Thr Arg Trp Tyr Arg Ala Pro Glu 45 Ile Met Leu Asn Trp Met His Tyr Asn Gln Thr Val Asp Ile Trp Ser 200 Val Gly Cys Ile Met Ala Glu Leu Leu Thr Gly Arg Thr Leu Phe Pro 215 220 50 Gly Thr Asp His Ile Asp Gln Leu Lys Leu Ile Leu Arg Leu Val Gly 230 235 Thr Pro Gly Ala Glu Leu Leu Lys Lys Ile Ser Ser Glu Ser Ala Arg 250 Asn Tyr Ile Gln Ser Leu Thr Gln Met Pro Lys Met Asn Phe Ala Asn 55 265 Val Phe Ile Gly Ala Asn Pro Leu Ala Val Asp Leu Leu Glu Lys Met

141

```
275
                                   280
       Leu Val Leu Asp Ser Asp Lys Arg Ile Thr Ala Ala Gln Ala Leu Ala
                               295
                                                   300
       His Ala Tyr Phe Ala Gln Tyr His Asp Pro Asp Asp Glu Pro Val Ala
  5
                           310
                                               315
       Asp Pro Tyr Asp Gln Ser Phe Glu Ser Arg Asp Leu Leu Ile Asp Glu
                       325
                                           330
       Trp Lys Ser Leu Thr Tyr Asp Glu Val Ile Ser Phe Val Pro Pro
                                       345
       Leu Asp Gln Glu Glu Met Glu Ser Glu Asp Pro Pro Val Ala Thr Met
 10
                                   360
       Val Ser Lys Gly Glu Glu Leu Phe Thr Gly Val Val Pro Ile Leu Val
                               375
                                                  380
       Glu Leu Asp Gly Asp Val Asn Gly His Lys Phe Ser Val Ser Gly Glu
 15
                           390
                                              395
       Gly Glu Gly Asp Ala Thr Tyr Gly Lys Leu Thr Leu Lys Phe Ile Cys
                       405
                                          410
       Thr Thr Gly Lys Leu Pro Val Pro Trp Pro Thr Leu Val Thr Thr Leu
                  420
                                      425
 20
       Thr Tyr Gly Val Gln Cys Phe Ser Arg Tyr Pro Asp His Met Lys Gln
               435
                                  440
      His Asp Phe Phe Lys Ser Ala Met Pro Glu Gly Tyr Val Gln Glu Arg
                             455
                                                  460
      Thr Ile Phe Phe Lys Asp Asp Gly Asn Tyr Lys Thr Arg Ala Glu Val
25
                         470
                                              475
      Lys Phe Glu Gly Asp Thr Leu Val Asn Arg Ile Glu Leu Lys Gly Ile
                      485
                                         490
      Asp Phe Lys Glu Asp Gly Asn Ile Leu Gly His Lys Leu Glu Tyr Asn
                  500 .
                                      505
30
      Tyr Asn Ser His Asn Val Tyr Ile Met Ala Asp Lys Gln Lys Asn Gly
                                  520
      Ile Lys Val Asn Phe Lys Ile Arg His Asn Ile Glu Asp Gly Ser Val
                             535
                                                  540
      Gln Leu Ala Asp His Tyr Gln Gln Asn Thr Pro Ile Gly Asp Gly Pro
35
                         550
                                              555
      Val Leu Leu Pro Asp Asn His Tyr Leu Ser Thr Gln Ser Ala Leu Ser
                     565
                                          570
      Lys Asp Pro Asn Glu Lys Arg Asp His Met Val Leu Leu Glu Phe Val
                                     585
      Thr Ala Ala Gly Ile Thr Leu Gly Met Asp Glu Leu Tyr Lys
40
                                  600
               (2) INFORMATION FOR SEQ ID NO:66:
45
            (i) SEQUENCE CHARACTERISTICS:
              (A) LENGTH: 2913 base pairs
              (B) TYPE: nucleic acid
              (C) STRANDEDNESS: single
              (D) TOPOLOGY: linear
50
            (ii) MOLECULE TYPE: cDNA
            (ix) FEATURE:
```

142

(A) NAME/KEY: Coding Sequence

(B) LOCATION: 1...2910 (D) OTHER INFORMATION:

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:66:

5			_	GAG Glu	_		_			_					_	_	48
10				GAA Glu 20													96
15				TCC Ser													144
10				GAA Glu													192
20				GAC Asp													240
25				CCT Pro													288
30				GGT Gly 100									_	_	_	_	<b>336</b> 
35				CCG Pro			_								_		384
				CTT Leu													432
40				ACT Thr													480
45				CTT Leu													528
50				CAC His 180													576
55				CCT Pro													624
	TTA	GCT	CCA	GAA	GTA	CAA	AGC	TCC	GAA	GAA	TAT	ATT	CAG	CTA	TTG	AAG	672

•										144							
	Le	u Al 21	.a Pr .0	o Gl	u Va	l <sub>.</sub> Gla	n Se: 21	r Se 5	r Gli	u Gl	u Ty	r Il.		n Le	u Le	u Lys	
5	22!	5	u 11	c Ar	y se.	230	)	r II	e Pro	) Hi	5 Gl: 23	n Tyi	r Trp	) Le	ı Th	G CTT r Leu 240	720
10	011	. <b>.</b> y	ı ne	ם הפו	245	5 H1S	s Pne	Phe	: Гуз	250	ı Sei	c Glr	1 Thr	Sei	25!		768
15	7151	. BC	u nei	260	)	a Arg	yaı	. Let	265	Glu	ı Ile	Phe	: Ser	270	Met	G CTT	816
	1.1.0	. A.	275	5	. Ald	. Ala	ser	280	Asp	Asn	Thr	Glu	Asn 285	Leu	Ile	AAA Lys	864
20	•441	290	) .	1116	: Leu	ııre	295	Thr	Glu	Trp	Asn	Glu 300	Arg	Gln	Pro	GCA Ala	912
25	CCA Pro 305	AIG	CTG Leu	CCT Pro	CCT Pro	AAA Lys 310	CCA Pro	CCA Pro	AAA Lys	CCT Pro	ACT Thr 315	ACT Thr	GTA Val	GCC Ala	AAC Asn	AAC Asn 320	960
30	GGT Gly	ATG Met	AAT Asn	AAC Asn	AAT Asn 325	ATG Met	TCC Ser	TTA Leu	CAA Gln	AAT Asn 330	GCT Ala	GAA Glu	TGG Trp	TAC Tyr	TGG Trp 335	GGA Gly	1008
35	GAT Asp	ATC Ile	TCG Ser	AGG Arg 340	GAA Glu	GAA Glu	GTG Val	AAT Asņ	GAA Glu 345	AAA Lys	CTT Leu	CGA Arg	GAT Asp	ACA Thr 350	GCA Ala	GAC Asp	1056
	GGG Gly	ACC Thr	TTT Phe 355	TTG Leu	GTA Val	CGA Arg	GAT Asp	GCG Ala 360	TCT Ser	ACT Thr	AAA Lys	ATG Met	CAT His 365	GGT Gly	GAT Asp	TAT Tyr	1104
40	ACT Thr	CTT Leu 370	ACA Thr	CTA Leu	AGG Arg	AAA Lys	GGG Gly 375	GGA Gly	AAT Asn	AAC Asn	AAA Lys	TTA Leu 380	ATC Ile	AAA Lys	ATA Ile	TTT Phe	1152
45	CAT His 385	CGA Arg	GAT Asp	GGG Gly	AAA Lys	TAT Tyr 390	GGC Gly	TTC Phe	TCT Ser	GAC Asp	CCA Pro 395	TTA Leu	ACC Thr	TTC Phe	AGT Ser	TCT Ser 400	1200
50	GTG Val	GTT Val	GAA Glu	TTA Leu	ATA Ile 405	AAC Asn	CAC His	TAC Tyr	Arg	AAT Asn 410	GAA Glu	TCT Ser	CTA :	GCT Ala	CAG Gln 415	TAT Tyr	1248
55	AAT Asn	CCC Pro	AAA Lys	TTG Leu 420	GAT Asp	GTG :	AAA Lys	Leu	CTT Leu L	TAT Tyr	CCA Pro	GTA Val	Ser :	AAA Lys 430	TAC Tyr	CAA Gln	12,96
	CAG	GAT	CAA	GTT	GTC	AAA (	GAA (	GAT .	AAT Z	ATT (	GAA	GCT (	GTA (	GGG .	AAA .	AAA	1344 14

										170							
	Gln	Asp	Gln 435	Val	Val	Lys	Glu	Asp 440	Asn	Ile	Glu	Ala	Val 445	Gly	Lys	Lys	
	TTA	CAT	GAA	TAT	AAC	ACT	CAG	TTT	CAA	GAA	AAA	AGT	CGA	GAA	TAT	GAT	1392
5	Leu	His 450	Glu	Tyr	Asn	Thr	Gln 455	Phe	Gln	Glu	Lys	Ser 460	Arg	Glu	Tyr	Asp	
	AGA	TTA	TAT	GAA	GAA	TAT	ACC	CGC	ACA	TCC	CAG	GAA	ATC	CAA	ATG	AAA	1440
	Arg	Leu	Tyr	Glu	Glu	Tyr	Thr	Arg	Thr	Ser	Gln	Glu	Ile	Gln	Met	Lys	
10	465					470					475					480	
			_		GAA	_									_		1488
	Arg	Thr	Ald	TIE	Glu 485	Ala	Pne	ASII	GIU	490	TTE	гÀв	11e	Pne	495	GIU.	
15										150					150		
	CAG	TGC	CAG	ACC	CAA	GAG	CGG	TAC	AGC	AAA	GAA	TAC	ATA	GAA	AAG	TTT	1536
	Gln	Cys	Gln	Thr 500	Gln	Glu	Arg	Tyr	Ser 505	Lys	Glu	Tyr	Ile	Glu 510	Lys	Phe	
20		aam	G 3 3	000	220	<b>G1.</b> G						3 mm		~~ m		m = m	
20					AAT Asn												1584
	2,0	**** 9	515			oru	ביים	520	110	J111	nig	110	525	1110	7.511	* 7 *	
					TCT												1632
<b>25</b>	Asp	Lys 530	Leu	Lys	Ser	Arg	Ile 535	Ser	Glu	Ile	Ile	Asp 540	Ser	Arg	Arg	Arg	
	TTG	GAA	GAA	GAC	TTG	AAG	AAG	CAG	GCA	GCT	GAG	TAT	CGA	GAA	ATT	GAC	1680
					Leu												
30	545					550					555					560	
					AGC												1728
	гуѕ	Arg	Met	Asn	Ser 565	ше	гÀв	Pro	Asp	ьец 570	me	Gin	Leu	Arg	ப்ys 575	Tnr	
35					505					370					373		
	AGA	GAC	CAA	TAC	TTG	ATG	TGG	TTG	ACT	CAA	AAA	GGT	GTT	CGG	CAA	AAG	1776
	Arg	Asp	${\tt Gln}$	Tyr	Leu	Met	Trp	Leu	Thr	Gln	Lys	Gly	Val	Arg	Gln	Lys	
				580					585					590			
40	AAG	TTG	AAC	GAG	TGG	TTG	GGC	AAT	GAA	AAC	ACT	GAA	GAC	CAA	TAT	TCA	1824
	Lys	Leu	Asn	$\operatorname{Glu}$	Trp	Leu	Gly	Asn	Glu	Asn	Thr	Glu	Asp	Gln	Tyr	Ser	
			595					600					605				
	CTG	GTG	GAA	GAT	GAT	GAA	GAT	TTG	CCC	САТ	CAT	GAT	GAG	AAG	ACA	TGG	1872
45					Asp												
		610					615					620		-			
	AAT	GTT	GGA	AGC	AGC	AAC	CGA	AAC	ааа	GCT	GAA	AAC	CTG	TTG	CGA	GGG	1920
					Ser												
50	625		-			630	-		-		635				_	640	
					ACT												1968
	пÀр	wid	чер	GIA	Thr 645	rne	neu	val	Arg	650	ser	ser	nys	GIH	655	cys	
55				٠						230					0,00		
	TAT	GCC	TGC	TCT	GTA	GTG	GTG	GAC	GGC	GAA	GTA	AAG	CAT	TGT	GTC	ATA	2016

										14									
									66				/s Hi	67	70				
5		•	6	75			·y -y	68	IO PE	le Al	.a G1	u Pr	C TA O Ty 68	r As 5	n Le	eu 7	ſyr	20	64
10		69	0	<b>-</b> ,		u nc	u va 69	т <u>ь</u> е	u Hl	s ту	r Gl	n Hi 70		r Se	r Le	u V	/al	21	12
15	70	5			<b>P</b> 50	71	0	n va	ı ın	r Le	u Al 71	а Ту: 5	C CCI	Va.	1 ту	r A 7	la 20	21	60
20				J	725	5 .	, PI	o Pro	o va.	73 (	a Th:	r Met	G GTG	Ser	73!	s G 5	ly	22	08
20				74	0	. G <u>.</u> y	va.	. val	745	) Ile	e Lei	ı Val	GAG Glu	Let 750	ı Ası	O G	ly	225	56
25			75	5	* ****	, пуъ	PHE	760	val	Ser	Gly	Glu	GGC Gly 765	Glu	Gly	/ As	sp.	230	4
30		770	)	,	275	пец	775	ren	гуs	Phe	Ile	Cys 780		Thr	Gly	Lу	's	235	<b>2</b> .
35	785					790	1111	ьец	vai	Thr	Thr 795	Leu	ACC Thr	Tyr	Gly	Va 80	0	240	0
		-, -		501	805	TYL	PIO	Asp	HIS	Met 810	Lys	Gln	CAC His	Asp	Phe 815	Ph	e	244	8
40	AAG Lys	TCC Ser	GCC Ala	ATG Met 820	CCC Pro	GAA Glu	GGC Gly	TAC Tyr	GTC Val 825	CAG Gln	GAG Glu	CGC Arg	ACC Thr	ATC Ile 830	TTC Phe	TT(	C e	2496	5-
45	AAG Lys	GAC Asp	GAC Asp 835	GGC Gly	AAC Asn	TAC Tyr	AAG Lys	ACC Thr 840	CGC Arg	GCC Ala	GAG Glu	GTG Val	AAG ' Lys : 845	TTC Phe	GAG Glu	GG( Gl <sub>3</sub>	C /	2544	•
50	GAC Asp	ACC Thr 850	CTG Leu	GTG Val	AAC Asn	AL 9	ATC Ile 855	GAG Glu	CTG Leu	AAG Lys	GGC Gly	ATC Ile 860	GAC '	TTC Phe	AAG Lys	GA0	<b>3</b> 1	2592	
55	GAC Asp 865	GGC Gly	AAC Asn	ATC Ile	200	GGG Gly : 870	CAC His	AAG Lys	CTG Leu	GIu	TAC Tyr 875	AAC Asn	TAC I	AAC . Asn	Seŗ	CAC His	;	2640	
	AAC	GTC	TAT	ATC	ATG (	GCC (	GAC .	AAG	CAG .	AAG .	AAC (	GGC 2	ATC A	AG (	GTG .	AAC		2688	146

										147							
	Asn	Val	Tyr	Ile	Met 885		Asp	Lys	Gln	Lys 890	Asn	Gly	Ile	Lys	Val 895	Asn	
5												GTG Val					2736
10												CCC Pro					2784
15												AGC Ser 940					2832
10												GTG Val					2880
20				GGC Gly							TAA						2913
25		<b>:</b> )		INI EQUE							57:				•		
30		/ -	(B) (C) (D)	TYPE STRA	E: an ANDEI OLOGY	mino ONESS (: li	ació S: si inear	l ingle	2								
35		- (1	/) FI	MOLEC RAGMI SEQUI	ENT 7	TYPE:	int	erna	al	) ID	NO: 6	57:					
	Met 1	Ser	Ala	Glu	Gly 5	Tyr	Gln	Tyr	Arg	Ala 10	Leu	Tyr	Asp	туr	Lys 15	Lys	
40		Arg	Glu	Glu 20	_	Ile	Asp	Leu	His 25		Gly	Asp	Ile	Leu 30		Val	
		-	35					40	-			Asp	45				
45		50					55					Asn 60					
	65					70			.\/		75	Tyr				80	
50	_				85					90		Val	Ā		95		
				100					105		_	Pro		110			•
			115					120				Glu	125	_			
55	Glu	130 Cys	Ser	Thr	Leu	Tyr	135 Arg	Thr	Gln	Ser	Ser	140 Ser	Asn	Leu	Ala	Glu	

	145					150					155					16Ò
					165					170					175	Met
5				180					185		Lys			190	Leu	Asp
			195					200					205			Ser
		210					215					220				Lys
10	225					230					235					Leu 240
					245					250	Ser				255	
15				260					265		Ile			270		
			275					280			Thr		285			
00		290					295				Asn	300				
20	305					310					Thr 315					320
					325					330	Ala				335	_
25				340					345		Leu			350		
			355				-	360			Lys		365			
30		370					375				Lys	380				
<b>3</b> 0	385					390		,			Pro 395					400
					405					410	Glu				415	
35				420					425		Pro			430		
			435					440			Glu		445			
40		450					455				Lys	460				
40	465					470					Gln 475					480
					485					490	Ile				495	
45				500					505		Glu			510		
			515					520			Arg		525			
50		530					535				Ile	540				
50	545					550					Glu 555					560
					565	•				570	Ile				575	
55				580					585		Lys			590		
	пÄр	nen	ASII	GIU	тгЪ	ьeп	GIY	Asn	Glu	Asn	Thr	Glu	Asp	Gln	Tyr	Ser

149

			595					600					605			
	Leu	Val 610	Glu	Asp	Asp	Glu		Leu	Pro	His	His	Asp	Glu	Lys	Thr	Trp
	N c m		Clv	co-	car	λcn	615	7.00	T + + =	7 J -	<b>a</b> 2	620 Asn		T	7	<b>01.</b> .
5	625	vai	GIY	261	SEL	630	Arg	ASII	гув	Ala		ASII	Leu	Leu	Arg	_
3		720	λen	Glv	Thr		Lou	นาไ	A ~~	<b>a</b> 1	635	Ser	T	<b>~1</b> -	<b>~1</b>	640
	пуъ	Arg	vsb	GIY	645	FIIC	пеп	vai	AIG	650	ser	ser	rys	GIII	655	Cys
	Tur	בומ	Cve	Ser		V=1	Val	) en	G3 v		17-1	Lys	mi -	C		т1.
	TYL	AIG	Cys	660	V		vai	Asp	665	Giu	vai	гув	urs	670	Val	TIE
10	Aen	Lve	Thr		Thr	Glv	ጥህጕ	Gly		- ות	G1	Pro	T-1-		Lou	т
	NO11	цуз	675	AIG	1111	Gry	TYL	680	PIIC	MIG	GIU	PIO	685	ASII	neu	TYL
•	Sar	Sor		Take	Glu	T.011	17 a 1		uic	Ф.	C1 =	His		C.~	T 011	37-7
	361	690	Deu	כעם	Olu	пец	695		птэ	IYL	GIII	700	1111	per	Tea	vai
	Gln		yan	Δen	Ser	T.e.11		Va l	Thr	Len	אן א	Tyr	Dro	17-1	The	חות
15	705	пть	Maii	rsb	DEL	710	ASII	val	TILL	neu	715	TYL	PIO	vai	ıyı	
15		Gl n	720	7 ~~	Gln		Dro	Dro	1701	ח 1 ת		Met	17- 1	Com	T	720
	GIII	GIII	ALG	Arg	725	wab	FIU	PIO	vaı	730	THE	Met	var	Ser	_	GIY
	ci.,	Glu	T.ou	Dhe		G]v	1751	1701	Dro		T 011	Val	α3	7 011	735	<b>a</b> 1
	GIU	Gru	Deu	740	1111	GIY	vai	vai	745	116	neu	vai	GIU	750	Asp	GIY
20	Λcn	Val	λen.		uic	Lvc	Dhe	Co.~		C 0 ==	<b>~1</b>	Glu	<b>01</b>		<b>~1</b>	7
20	Asp	vaı	755	GIY	ura	цуь	FIIC	760	vai	ser	GTÅ	GIU	765	GIU	GIY	Asp
	ת 1 ת	Thr		Glv.	Laze	Ť OU	Th~		Tara	Dho	T] _	Cys		mb	<b>a</b> 3	T
	ALA	770	TAT	Gry	пуз	neu	775	пеп	тÀв	Pne	116	780	IIII	THE	GIY	гув
	Len		Wal	Dro	Trn	Pro		T 011	17-1	Th~	mh	Leu	mb	<i>T</i>	a1	171
25	785	PIO	Val	PIO	тъ	790	IIII	пеп	vai	1111	795	beu	IIII	IAT	GIY	
23		Cve	Dhe	Sar	7~~		Dro	A co	uio	Mot		Gln	174 -	7	Dha	800
	GIII	Cys	FIIC	Ser	805	TYL	PIO	ASP	пта	810	. пув	GIII	UIR	Asp		Pne
	Tare	Ser	בומ	Met		Glu	Glv	The	1727		C311	Arg	Th~	τ10	815	Dho
	шуы	Der	AIG	820	FIU	GIU	Gry	TYT	825	GIII	GIU	Arg	1111	830	Pile	PHE
30	Lare	) en	Acn		λen	Тъгъ	Laze	Thr		- ו ת	C1.,	Val	Tara		C1.,	Cly
00	275	nop.	835	Cly	7,511	- 7 -	_y 5	840	Arg	ALG	GIU	Val	845	FIIC	GIU	Gly
	Asn	Thr		Val	Asn	Ara	Tle		T.e.1	Lve	Glv	Ile		Dhe	Lve	Glu
	,,op	850	<b>HCU</b>	• • • •	ASII	AI 9	855	OIU	пеп	БуS	GIY	860	Asp	FIIC	цуз	Gru
	Asn		Asn	Tle	Len	Glv		Taye	Ĭ.e.11	Glu	ጥኒም	Asn	Tur	λεπ	Ser	uie
35	865	<b>-</b>				870		<i>, -</i>	LCu	014	875	ND11	171	ASII	JCI	880
-		Val	Tvr	Tle	Met		Δsn	Lvg	Gln	Tare		Gly	Tla	Laze	Val	
			-1-		885		1100	<i> y - -</i>	0111	890	ns	Ory	110	פעם	895	A311
	Phe	Lvs	Tle	Ara		Asn	Tle	Glu	Asn		Ser	Val	Gln	ī.en		Asn
		2,0		900		*****	110	014	905	O <sub>1</sub>	JCI	VOL	GIII	910	AIG	vob
40	His	Tvr	Gln		Δsn	Thr	Pro	Tle		Λen	Glv	Pro	Val		T.011	Dro
		-1-	915	·		••••	110	920				FIO	925	пси	пси	110
	Asp	Δsn		Tvr	Leu	Ser	Thr			<b>Δ</b> Ι =		Ser		) en	Dro	λen
		930		-1-			935			****	عابط	940	כעם	nsp	110	ADII
	Glu		Ara	Asp	His	Met		Leu	T.en	Glu	Dhe	Val	Thr	Δla	Δla	Glv
45	945	-1-	5	F		950					955		****	* 1. J. Cl	-1.4 CI	960
		Thr	Leu	Glv	Met		Glu	Leu	Tvr	Lvs						200
. •				2	965	F			-1-	970						
										•						

(2) INFORMATION FOR SEQ ID NO:68:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 1788 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
- 55 (D) TOPOLOGY: linear

150

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

5

(A) NAME/KEY: Coding Sequence

(B) LOCATION: 1...1785

(D) OTHER INFORMATION:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:68:

		(	xi)	SEQU	ENCE	DES	CRIP	TION	: SE	Q ID	NO:	68:					
10	ATG Met 1	GGC	AAC Asn	GCC Ala	GCC Ala 5	GCC Ala	GCC Ala	AAG Lys	AAG Lys	GGC Gly 10	AGC Ser	GAG Glu	CAG Gln	GAG Glu	AGC Ser 15	GTG Val	48
15	Lys	GAG Glu	Phe	Leu 20	Ala	Lys	Ala	Lys	Glu 25	Asp	Phe	Leu	Lys	Lys	Trp	Glu	96
20	Asp	CCC Pro	Ser 35	Gln	Asn	Thr	Ala	Gln 40	Leu	Asp	Gln	Phe	Asp 45	Arg	Ile	Lys	144
25	Thr	CTT Leu 50	Gly	Thr	Gly	Ser	Phe 55	Gly	Arg	Val	Met	Leu 60	Val	Lys	His	Lys	192
	Glu 65	AGT Ser	Gly	Asn	His	Tyr 70	Ala	Met	Lys	Ile	Leu 75	Asp	Lys	Gln	Lys	Val 80	240
30	Val	AAG Lys	Leu	Lys	Gln 85	Ile	Glu	His	Thr	Leu 90	Asn	Glu	Lys	Arg	Ile 95	Leu	288
35	Gln	GCC Ala	Val	Asn 100	Phe	Pro	Phe	Leu	Val 105	Lys	Leu	Glu	Phe	Ser 110	Phe	Lys	336
40	Asp	AAC Asn	Ser 115	Asn	Leu	Tyr	Met	Val 120	Met	Glu	Tyr	Val	Ala 125	Gly	Gly	Glu	384
45	Met	TTC Phe 130	Ser	His	Leu	Arg	Arg 135	Ile	Gly	Arg	Phe	Ser 140	Glu	Pro	His	Ala	432
50	Arg 145	TTC Phe	Tyr	Ala	Ala	Gln 150	Ile	Val	Leu	Thr	Phe 155	Glu	Tyr	Leu	His	Ser 160	480
50	Leu	GAC Asp	Leu	Ile	Tyr 165	Arg	Asp	Leu	Lys	Pro 170	Glu	Asn	Leu	Leu	Ile 175	Asp	528
55	Gln	CAG Gln	GGC	TAT Tyr 180	ATT Ile	Gln	GTG Val	ACA Thr	GAC Asp 185	TTC Phe	GGT Gly	TTT Phe	GCC Ala	AAG Lys 190	CGT Arg	GTG Val	576

5			ACT Thr							624
			CTG Leu							672
10			CTC Leu							720
15		1	CCT Pro							768
20			TCC Ser 260							816
25			GTG Val							864
			ATC Ile							912
30			CAG Gln							960
35			GAC Asp							1008
40			ATC Ile 340							1056
45			AGT Ser							1104
			TTA Leu							1152
50			GAA Glu							1200
55			ACT Thr							1248

5	ACT C		420	)	• • • • • • • • • • • • • • • • • • • •	GII	ı cy:	425	s sei	c Arg	Tyr	Pro	430	P Hi	s Met	1296
	AAA CA Lys Gl	AG CA' In Hi: 43!		TTT Phe	TTC Phe	AAG Lys	AGT Ser 440	Ата	ATO Met	CCC Pro	GAA Glu	GGT Gly 445	ТАТ	r GTZ Val	A CAG l Gln	1344
10	GAA AG Glu Ar 45	A ACT g Thi	T ATA	TTT Phe	TAC Tyr	AAA Lys 455	Asp	GAC Asp	GGG Gly	AAC Asn	TAC Tyr 460	AAG Lys	ACA Thr	CGT	GCT J Ala	1392
15	GAA GT Glu Va 465	_			470	rsp		ren	vaı	475	Arg	Ile	Glu	Leu	Lys 480	1440
20	GGT AT			485	GIU	wsh	GIĀ	Asn	11e 490	Leu	Gly	His	Lys	Met 495	Glu	1488
25	TAC AAT	- 3 -	500	501		WPII	Vai	1yr 505	lle	Met	Ala .	Asp	Lys 510	Pro	Lys	1536
	AAT GGO Asn Gly	I ATC Ile 515	AAA Lys	GTT Val	AAC ' Asn '	Pne	AAA Lys 520	ATT Ile	AGÀ Arg	CAC His	Asn :	ATT . Ile : 525	AAA Lys	GAT Asp	GGA Gly	1584
30	AGC GTT Ser Val 530		Leu	AIG .	i daw	535	Tyr	GIn	Gln	Asn	Thr I 540	Pro :	Ile	Gly	Asp	1632
35	GGC CCT Gly Pro 545	GTC Val	CTT Leu		CCA ( Pro <i>P</i> 550	SAC A	AAC Asn	CAT '	Tyr	CTG : Leu : 555	TCC # Ser I	ACG (	CAA Gln	TCT Ser	GCC Ala 560	1680
40	CTT TCC Leu Ser	AAA Lys	. بر حد	CCC 1 Pro 1 565	AAC G	SAA A Slu I	AAG i	arg A	GAT ( Asp 1	CAC /	ATG A Met I	TC C	eu :	CTT Leu 575	GAG Glu	1728
45 .	TTT GTA Phe Val		GCT ( Ala 1 580	GCT (	GG A	TT F	inr i	CAT ( His (	GC A	ATG C	GAT G Asp G	lu L	TA : eu :	rac . Fyr :	AAA Lys	1776
	CCT CAG Pro Gln	GAG : Glu 595	TAA													1788
50		(2)	INFO	RMAT	ION 1	FOR	SEQ	ID N	0:69	·:						

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 595 amino acids
- 55 (B) TYPE: amino acid
  - (C) STRANDEDNESS: single

153

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(v) FRAGMENT TYPE: internal

5

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:69:

	Met 1	Gly	Asn	Ala	Ala 5	Ala	Ala	Lys	Lys	Gly 10	Ser	Glu	Gln	Glu	Ser 15	Val
10	Lys	Glu	Phe	Leu 20	Ala	Lys	Ala	Lys	Glu 25	Asp	Phe	Leu	Lys	Lys 30	Trp	Glu
			35					40					45	Arg		
15		50					55	_				60		Lys		
	Glu 65	Ser	Gly	Asn	His	Tyr 70	Ala	Met	Lys	Ile	Leu 75	Asp	Lys	Gln	Lys	Val 80
	Val	Lys	Leu	Lys	Gln 85	Ile	Glu	His	Thr	Leu 90	Asn	Glu	Lys	Arg	Ile 95	Leu
20	Gln	Ala	Val	Asn 100	Phe	Pro	Phe	Leu	Val 105	Lys	Leu	Glu	Phe	Ser 110	Phe	Lys
	Asp	Asn	Ser 115	Asn	Leu	Tyr	Met	Val 120	Met	Glu	Tyr	Val	Ala 125	Gly	Gly	Glu
25	Met	Phe 130	Ser	His	Leu	Arg	Arg 135	Ile	Gly	Arg	Phe	Ser 140	Glu	Pro	His	Ala
	Arg 145	Phe	Tyr	Ala	Ala	Gln 150	Ile	Val	Leu	Thr	Phe 155	Glu	Tyr	Leu	His	Ser 160
	Leu	Asp	Leu	Ile	Tyr 165		Asp	Leu	Lys	Pro 170		Asn	Leu	Leu	Ile 175	
30	Gln	Gln	Gly	Tyr 180		Gln	Val	Thr	Asp 185		Gly	Phe	Ala	Lys 190		Val
	Lys	Gly	Arg 195		Trp	Thr	Leu	Cys 200		Thr	Pro	Glu	Tyr 205	Leu	Ala	Pro
35	Glu	Ile 210		Leu	Ser	Lys	Gly 215		Asn	Lys	Ala	Val 220		Trp	Trp	Ala
	Leu 225		Val	Leu	Ile	Tyr 230		Met	Ala	Ala	Gly 235		Pro	Pro	Phe	Phe 240
	Ala	Asp	Gln	Pro	Ile 245	Gln	Ile	Tyr	Glu	Lys 250		Val	Ser	Gly	Lys 255	
40	Arg	Phe	Pro	Ser 260	His	Phe	Ser	Ser	Asp 265	Leu	Lys	Asp	Leu	Leu 270	Arg	Asn
	Leu	Leu	Gln 275	Val	Asp	Leu	Thr	Lys 280	Arg	Phe	Gly	Asn	Leu 285	Lys	Asp	Gly
45	Val	Asn 290	Asp	Ile	Lys	Asn	His 295	Lys	Trp	Phe	Ala	Thr 300	Thr	Asp	Trp	Ile
	Ala 305	Ile	Tyr	Gln	Arg	Lys 310	Val	Glu	Ala	Pro	Phe 315	Ile	Pro	Lys	Phe	Lys 320
	Gly	Pro	Gly	Asp	Thr 325	Ser	Asn	Phe	Asp	Asp 330	Tyr	Glu	Glu	Glu	Glu 335	Ile
50	Arg	Val	Ser	Ile 340	Asn	Glu	Lys	Cys	Gly 345	Lys	Glu	Phe	Thr	Glu 350	Phe	Gly
	Arg	Ala	Met 355	Ser	Lys	Gly	Glu	Glu 360		Phe	Thr	Gly	Val 365	Val	Pro	Ile
55	Leu	Val 370	Glu	Leu	Asp	Gly	Asp 375	Val	Asn	Gly	Gln	Lys 380		Ser	Val	Ser
	Gly		Gly	Glu	Gly	Asp	_	Thr	Tyr	Gly	Lys		Thr	Leu	Lys	Phe

	385					390					395					400	
					Gly 405					410	Trp	Pro			415	Thr	
5				420					425					430	His	Met	
			433		Phe			440					445				
10		420			Phe		455					460					
10	703				Glu	4/0					475					400	
					Lys 485					490					. 405		
15				500	Ser				505					E10			
			212		Val			520					525				
20		530			Ala		535		-			540					
20	243				Leu	220					555					EEA	
					Pro 565					570					E75		
25		Gln		580	Ala	GIY	116	Thr	His 585	Gly	Met	Asp	Glu	Leu 590	Tyr	Lys	
	710	GIII	595														
30			(2)	INF	ORMA	TION	FOF	SEC	) ID	NO:7	0:					•	
		(i	) SE (A)	QUEN LENG	CE C	HARA 2181	CTER	ISTI	CS:								
			(B)	TYPE	: nu	clei	c ac	id								٠	
35					LOGY				•								
			i) M x) F		ULE '	TYPE	: cD	NA		•							
40		-	(A)	NAM	E/KE	Y: C	odin	g Se	quen	ce							
			(B) (D)	LOC	ATIO ER II	N: 1 NFORI	2 MATI	178 ON:									
45		(x:	i) SI	EQUE	NCE I	DESCI	RIPT	ION:	SEQ	ID 1	NO:70	) :					
	ATG A	AGC ( Ser <i>l</i>	GAC (	GTG (	GCT A	ATT (	GTG .	AAG	GAG (	GGT :	rgg (	CTG (	CAC A	AAA	CGA (	GGG	48
	1	-	•		5			275	314 (	10	irp i	nen 1	11S J		Arg ( 15	яТХ	
50	GAG :	FAC A	ATC A	AAG :	ACC 1	GG (	CGG (	CCA (	CGC :	TAC :	TTC (	CTC (	CTC A	AAG	AAT (	SAT	96
			2	20			. ر	-5 :	25	- 1 4 1	C 1	Jeu I		ays .	ASN A	-sp	
55	GGC A	ACC I	TTC A	ATT (	GGC T	AC A	AAG (	GAG (	CGG (	CCG (	CAG C	SAT G	GTG (	GAC (	CAA (	CGT	144
		3	35		-	-	- 4	40	5 4				5	raħ (	arii b	rr G	

									CAG Gln		192
5									TGC Cys	_	240
10						 		_	CCT Pro		288
15									GGC Gly		336
20									CCC Pro 125		384
25									CCC Pro		432
	-						-		GGC Gly		480
30									GGC Gly		528
35									AAG Lys		576
40		_					-		TCC Ser 205	_	624
45									GAC Asp		672
									TTC Phe		720
50									TAT Tyr		768
55									AAC Asn		816

5	CG( Arg	GA(	C CTC P Let 275	ı uya	G CTC	G GAC	AA( Asi	CTC Leu 280	Met	G CTC	G GAC	AAC Lys	GAC Asp 285	Gly	G CA	C ATT	864
	AAC Lys	3 ATC 3 Ile 290	e Thr	GAC Asp	TTC Phe	GGG Gly	CTC Leu 295	Cys	: AAG	GAG Glu	GGG Gly	ATC Ile 300	Lys	GAC Asp	GG:	r GCC / Ala	912
10	ACC Thr 305	met	AAG Lys	ACC Thr	TTT Phe	TGC Cys 310	Gly	ACA Thr	CCT Pro	GAG	TAC Tyr 315	Leu	GCC Ala	CCC	GAC	GTG Val 320	960
15	CTG Leu	GAG Glu	GAC Asp	AAT Asn	GAC Asp 325	Tyr	GGC Gly	CGT Arg	GCA Ala	GTG Val 330	GAC Asp	TGG Trp	TGG Trp	GGG Gly	CTG Leu 335	GGC Gly	1008
20	GTG Val	GTC Val	ATG Met	TAC Tyr 340	GAG Glu	ATG Met	ATG Met	TGC Cys	GGT Gly 345	CGC Arg	CTG Leu	CCC Pro	TTC Phe	TAC Tyr 350	AAC Asn	CAG Gln	1056
25	Asp	nis	GAG Glu 355	rys	Leu	Phe	Glu	Leu 360	Ile	Leu	Met	Glu	Glu 365	Ile	Arg	Phe	1104
	7	370	ACG Thr	Leu	GIÀ	Pro	375	Ala	Lys	Ser	Leu	Leu 380	Ser	Gly	Leu	Leu	1152
30	385	ьуѕ	GAC Asp	Pro	Lys	Gln 390	Arg	Leu	Gly	Gly	Gly 395	Ser	Glu	Asp	Ala	Lys 400	1200
∕35	Giu	116	ATG Met	GIN	H15	Arg	Phe	Phe	Ala	Gly 410	Ile	Val	Trp	Gln	His 415	Val	1248
40	ıyı	GIU	AAG Lys	Lys 420	Leu	Ser	Pro	Pro	Phe 425	Lys	Pro	Gln	Val	Thr 430	Ser	Glu	1296
45		Asp	ACC Thr 435	Arg	Tyr	Phe	Asp	Glu 440	Glu	Phe	Thr	Ala	Gln 445	Met	Ile	Thr	1344
	116	ACA Thr 450	CCA Pro	CCT Pro	GAC Asp	Gin .	GAT Asp 455	GAC Asp	AGC Ser	ATG Met	Glu	TGT Cys 460	GTG (	GAC Asp	AGC Ser	GAG Glu	1392
50	CGC Arg 465	AGG Arg	CCC Pro	CAC His	Phe	CCC ( Pro ( 470	CAG Gln	TTC Phe	TCC Ser	Tyr	TCG ( Ser ) 475	GCC . Ala	AGC :	AGC	Thr	GCC Ala 480	1440
55	TCG Ser	GAT Asp	CCA Pro	Pro	GTC ( Val :	GCC : Ala :	ACC :	ATG (	Val	AGC : Ser :	AAG ( Lys (	GGC (	GAG ( Glu (	3lu	CTG Leu 495	TTC Phe	1488

		GTG Val 500								1536
5		AGC Ser								1584
10		CTG Leu								1632
15	 	CTC Leu								1680
20		GAC Asp						_		1728
25		TAC Tyr 580								1776
		ACC Thr							_	1824
30		GAG Glu								1872
35		AAG Lys								1920
40		AAG Lys	_			_		_		1968
45		GAG Glu 660								2016
40		ATC Ile								2064
50		CAG Gln								2112
55		CTG Leu							•	2160

ATG GAC GAG CTG TAC AAG TAA Met Asp Glu Leu Tyr Lys 725

2181

5

10

## (2) INFORMATION FOR SEQ ID NO:71:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 726 amino acids
  - (B) TYPE: amino acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear
- 15 (ii) MOLECULE TYPE: protein
  - (v) FRAGMENT TYPE: internal

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:71:

			,			DES	CKIF	TION	: 55	Q II	NO:	71:				
20	_				2				•	7.0					3 -	Gly
				20					25					20	Asn	Asp
25			23		Gly			40					15			
		50			Asn		55					60				
20	0.5				Arg	70					75					0.0
30					Glu 85					90					95	
				T00	Thr				105					110		_
35			113		Glu			120					125			•
		130			Glu		135					140				
40	113				Glu	T20					155					160
40					Ile 165					170					175	
				180	Leu				185					190		
45			132		Thr			200					205			
		210			Leu		215					220				
50					Tyr	230					235					242
30					Phe 245					250		•			255	
				200	Leu				265					270		
55			2/5		Leu			280					295			
	Lys	Ile	Thr	Asp	Phe	Gly	Leu	Cys	Lys	Glu	Gly	Ile	Lys	Asp	Gly	Ala

		290					295					300				
	Thr	Met	Lys	Thr	Phe	Cys		Thr	Pro	Glu	Tyr		Ala	Pro	Glu	Val
	305		-			310	•				315					320
5	Leu	Glu	Asp	Asn	Asp 325	Tyr	Gly	Arg	Ala	Val 330	Asp	Trp	Trp	Gly	Leu 335	Gly
	Val	Val	Met	Tyr 340		Met	Met	Сув	Gly 345		Leu	Pro	Phe	Tyr 350		Gln
	Asp	His			Leu	Phe	Glu			Leu	Met	Glu			Arg	Phe
10	Pro	Arg	355 Thr	Leu	Gly	Pro		360 Ala	Lys	Ser	Leu		365 Ser	Gly	Leu	Leu
	Lys	370 Lys	Asp	Pro	Lys		375 Arg	Leu	Gly	Gly	Gly	380 Ser	Glu	Asp	Ala	Lys
	385	_				390					395					400
15		Ile			405				•	410					415	
		Glu		420					425					430		
٠	Thr	Asp	Thr 435	Arg	Tyr	Phe	Asp	Glu 440	Glu	Phe	Thr	Ala	Gln 445	Met	Ile	Thr
20	Ile	Thr 450	Pro	Pro	Asp	Gln	Asp 455	Asp	Ser	Met	Glu	Cys 460	Val	Asp	Ser	Glu
	Arg 465	Arg	Pro	His	Phe	Pro 470	Gln	Phe	Ser	Tyr	Ser 475	Ala	Ser	Ser	Thr	Ala 480
25	Ser	Asp	Pro	Pro	Val 485	Ala	Thr	Met	Val	Ser 490	Lys	Gly	Glu	Glu	Leu 495	Phe
	Thr	Gly	Val	Val 500	Pro	Ile	Leu	Val	Glu 505	Leu	Asp	Gly	Asp	Val 510	Asn	Gly
	His	Lys	Phe 515	Ser	Val	Ser	Gly	Glu 520	Gly	Glu	Gly	Asp	Ala 525	Thr	Tyr	Gly
30	Lys	Leu 530	Thr	Leu	Lys	Phe	Ile 535	Суѕ	Thr	Thr	Gly	Lys 540	Leu	Pro	Val	Pro
	Trp 545	Pro	Thr	Leu	Val	Thr 550	Thr	Leu	Thr	Tyr	Gly 555	Val	Gln	Cys	Phe	Ser 560
35	Arg	Tyr	Pro	Asp	His 565	Met	Lys	Gln	His	Asp 570	Phe	Phe	Lys	Ser	Ala 575	Met
	Pro	Glu	Gly	Tyr 580	Val	Gln	Glu	Arg	Thr 585	Ile	Phe	Phe	Lys	Asp 590	Asp	Gly
	Asn	Tyr	Lys 595	Thr	Arg	Ala	Glu	Val 600	Lys	Phe	Glu	Gly	Asp 605	Thr	Leu	Val
40		Arg 610		Glu								Glu 620		Gly	Asn	Ile
	Leu 625	Gly	His	Lys	Leu	Glu 630	Tyr	Asn	Tyr	Asn	Ser 635	His	Asn	Val	Tyr	Ile 640
45	Met	Ala	Asp	Lys	Gln 645	Lys	Asn	Gly	Ile	Lys 650	Val	Asn	Phe	Lys	Ile 655	Arg
	His	Asn	Ile	Glu 660	Asp	Gly	Ser	Val	Gln 665	Leu	Ala	Asp	His	Tyr 670	Gļn	Gln
	Asn	Thr	Pro 675	Ile	Gly	Asp	Gly	Pro 680	Val	Leu	Leu	Pro	Asp 685	Asn	His	Tyr
50	Leu	Ser 690	Thr	Gln	Ser	Ala	Leu 695		Lys	Asp	Pro	Asn 700	Glu	Lys	Arg	Asp
	His 705	Met	Val	Leu	Leu	Glu 710		Val	Thr	Ala	Ala 715		Ile	Thr	Leu	Gly 720
55	Met	Asp	Glu	Leu	Tyr 725	Lys										

## (2) INFORMATION FOR SEQ ID NO:72:

	(2) INFORMATION FOR SEQ ID NO:72:	
5	<ul> <li>(i) SEQUENCE CHARACTERISTICS:</li> <li>(A) LENGTH: 2751 base pairs</li> <li>(B) TYPE: nucleic acid</li> <li>(C) STRANDEDNESS: single</li> <li>(D) TOPOLOGY: linear</li> </ul>	
10	(ii) MOLECULE TYPE: CDNA (ix) FEATURE:	
15	(A) NAME/KEY: Coding Sequence (B) LOCATION: 12748 (D) OTHER INFORMATION:  (xi) SEQUENCE DESCRIPTION: SEQ ID NO:72:	
20	ATG GCT GAC GTT TAC CCG GCC AAC GAC TCC ACG GCG TCT CAG GAC GTG Met Ala Asp Val Tyr Pro Ala Asn Asp Ser Thr Ala Ser Gln Asp Val 1 5 10	48
25	GCC AAC CGC TTC GCC CGC AAA GGG GCG CTG AGG CAG AAG AAC GTG CAT Ala Asn Arg Phe Ala Arg Lys Gly Ala Leu Arg Gln Lys Asn Val His 20 25 30	96
	GAG GTG AAA GAC CAC AAA TTC ATC GCC CGC TTC TTC AAG CAA CCC ACC Glu Val Lys Asp His Lys Phe Ile Ala Arg Phe Phe Lys Gln Pro Thr 35 40 45	144
30	TTC TGC AGC CAC TGC ACC GAC TTC ATC TGG GGG TTT GGG AAA CAA GGC Phe Cys Ser His Cys Thr Asp Phe Ile Trp Gly Phe Gly Lys Gln Gly 50 55 60	192
35	TTC CAG TGC CAA GTT TGC TGT TTT GTG GTT CAT AAG AGG TGC CAT GAG Phe Gln Cys Gln Val Cys Cys Phe Val Val His Lys Arg Cys His Glu 65 70 75 80	240
40	TTC GTT ACG TTC TCT TGT CCG GGT GCG GAT AAG GGA CCT GAC ACT GAC Phe Val Thr Phe Ser Cys Pro Gly Ala Asp Lys Gly Pro Asp Thr Asp 85 90 95	288
45	GAC CCC AGG AGC AAG CAC AAG TTC AAA ATC CAC ACA TAC GGA AGC CCT Asp Pro Arg Ser Lys His Lys Phe Lys Ile His Thr Tyr Gly Ser Pro 100 105 110	336
	ACC TTC TGT GAT CAC TGT GGG TCC CTG CTC TAT GGA CTT ATC CAC CAA Thr Phe Cys Asp His Cys Gly Ser Leu Leu Tyr Gly Leu Ile His Gln 115 120 125	384
50	GGG ATG AAA TGT GAC ACC TGC GAC ATG AAT GTT CAC AAC CAG TGT GTG Gly Met Lys Cys Asp Thr Cys Asp Met Asn Val His Asn Gln Cys Val 130	432
55	ATC AAT GAC CCT AGC CTC TGC GGA ATG GAT CAC ACA GAG AAG AGG GGG  Ile Asn Asp Pro Ser Leu Cys Gly Met Asp His Thr Glu Lys Arg Gly  150 155 160	480

<u>.</u> .						Glu	CTC Leu				528
5							AAT Asn	_			576
10							AAG Lys 205		_		624
15							CCT Pro	_			672
20							GAC Asp				720
25							AAT Asn				768
							ATG Met				816
30							TAT Tyr 285			_	864
35							CTC Leu		_		912
40							GTC Val	_			960
45							AGA Arg				1008
							AGT Ser				1056
50							TAC Tyr 365				1104
55		Lys					GTG Val				1152

5	100	1200
	ACA CAG CTG CAC TCC TGC TTC CAG ACA GTG GAC CGG CTG TAC TTC GTC Thr Gln Leu His Ser Cys Phe Gln Thr Val Asp Arg Leu Tyr Phe Val 405 410 415	1248
10	ATG GAA TAC GTC AAC GGC GGG GAT CTT ATG TAC CAC ATT CAG CAA GTC  Met Glu Tyr Val Asn Gly Gly Asp Leu Met Tyr His Ile Gln Gln Val  420  425  430	1296
15	GGG AAA TTT AAG GAG CCA CAA GCA GTA TTC TAC GCA GCC GAG ATC TCC Gly Lys Phe Lys Glu Pro Gln Ala Val Phe Tyr Ala Ala Glu Ile Ser 435 440 445	1344
20	ATC GGA CTG TTC TTC CTT CAT AAA AGA GGG ATC ATT TAC AGG GAT CTG  Ile Gly Leu Phe Phe Leu His Lys Arg Gly Ile Ile Tyr Arg Asp Leu  450  450	1392
25	AAG CTG AAC AAT GTC ATG CTG AAC TCA GAA GGG CAC ATC AAA ATC GCC Lys Leu Asn Asn Val Met Leu Asn Ser Glu Gly His Ile Lys Ile Ala 470 475 480	1440
	GAC TTC GGG ATG TGC AAG GAA CAC ATG ATG GAT GGA GTC ACG ACC AGG Asp Phe Gly Met Cys Lys Glu His Met Met Asp Gly Val Thr Thr Arg 485 490 495	1488
30	ACC TTC TGC GGA ACT CCG GAC TAC ATT GCC CCA GAG ATA ATC GCT TAC Thr Phe Cys Gly Thr Pro Asp Tyr Ile Ala Pro Glu Ile Ile Ala Tyr 500 510	1536
35	CAG CCG TAC GGG AAG TCT GTA GAT TGG TGG GCG TAC GGT GTG CTG Gln Pro Tyr Gly Lys Ser Val Asp Trp Trp Ala Tyr Gly Val Leu Leu 515 520 525	1584
40	TAC GAG ATG CTA GCC GGG CAG CCT CCG TTT GAT GGT GAA GAT GAA GAT Tyr Glu Met Leu Ala Gly Gln Pro Pro Phe Asp Gly Glu Asp Glu Asp 530 540	1632
45	545 550 555 560	1680
,	565 Lys Gly Leu Met Thr Lys Gln 570 575	1728
50	CCT GCC AAG CGA CTG GGC TGC GGG CCC GAG GGA GAG AGG GAT GTC AGA Pro Ala Lys Arg Leu Gly Cys Gly Pro Glu Gly Glu Arg Asp Val Arg 580 585 590	1776
55	GAG CAT GCC TTC TTC AGG AGG ATC GAC TGG GAG AAA CTG GAG AAC AGG Glu His Ala Phe Phe Arg Arg Ile Asp Trp Glu Lys Leu Glu Asn Arg 595 600 605	.824

		Ile		CCA Pro			Lys					Gly				GAA Glu	187	2
_		610					615					620						
5																		
	AAC	TTT	GAC	AAG	TTC	TTC	ACG	CGA	GGA	CAG	CCT	GTC	TTA	ACA	CCA	CCA	192	0
	Asn	Phe	Asp	Lys	Phe	Phe	Thr	Arg	Gly	Gln	Pro	Val	Leu	Thr	Pro	Pro		
	625					630					635					640		
10	GAT	CAG	CTG	GTC	ATT	GCT	AAC	ATA	GAC	CAA	TCT	GAT	TTT	GAA	GGG	TTC	196	8
	Asp	Gln	Leu	Val	Ile	Ala	Asn	Ile	Asp	Gln	Ser	asp	Phe	Glu	Glv	Phe		
					645					650					655			
	TCG	тат	GTC.	AAC	CCC	CAG	ידייניים	GTG	CAC	CCA	እ ጥር	ጥጥር	CAA	ΔСΤ	CCA	СТА	201	6
15				Asn													201	٠
13	261	TYL	V 4 1		FLO	GIII	FILE	vai		PIO	116	neu	GIII		AIG	VAI		
				660					665					670				
				ATG													206	4
	GIÀ	Arg		Met	ser	гàв	GIY		GIu	Leu	Phe	Thr		Val	Val	Pro		
20			675					680					685					
	TTA	CTT	GTT	GAA	TTA	GAT	GGC	GAT	GTT	AAT	GGG	CAA	AAA	TTC	TCT	GTT	211	2
	Ile	Leu	Val	Glu	Leu	Asp	Gly	Asp	Val	Asn	Gly	Gln	Lys	Phe	Ser	Val		
		690					695					700						
25																		
	AGT	GGA	GAG	GGT	GAA	GGT	GAT	GCA	ACA	TAC	GGA	AAA	CTT	ACC	CTT	AAA	216	0
				Gly														
	705	1		2		710				-1-	715	-1-				720		
	, 00																	
30	thathati	יוייני ע	TCC	ACT	א טייי	ccc	AAG	CTIA	CCT	Cutur	ככא	TCC	CCN	NCC	CTT	CTC	220	٥
30																	220	٥
	Pne	TTE	Cys	Thr		GIY	ьуѕ	ren	Pro		Pro	Trp	PIO	THE		vai		
					725					730					735			
																		_
				ACT													225	6
35	Thr	Thr	Leu	Thr	Tyr	Gly	Val	Gln	Сув	Phe	Ser	Arg	Tyr	Pro	Asp	His		
				740					745					750				
	ATG	AAA	CAG	CAT	GAC	TTT	TTC	AAG	AGT	GCC	ATG	CCC	GAA	GGT	TAT	.GTA	230	4
	Met	Lys	Gln	His	Asp	Phe	Phe	Lys	Ser	Ala	Met	Pro	Glu	Gly	Tyr	Val		
40			755					760					765					
	CAG	GAA	AGA	ACT	ATA	TTT	TAC	AAA	GAT	GAC	GGG	AAC	TAC	AAG	ACA	CGT	235	2
				Thr														
		770	5				775	_,_	р				-1-	-1-		5		
45							,,,					, 50						
70	CCT	C 7 7	CTC	א א מ	יווייייייי	C 2 2	CCT	CAT	N.C.C	Comm	C TOTO	יוי א א	חרים	አመረግ	CNC	מידים	240	_
				AAG													240	U
		GIU	vai	Lys	Pne		GIA	Asp	Thr	Leu		ASI	Arg	тте	GIU			
	785					790					795					800	•	
50																	_	_
50				GAT													244	8
	Lys	Gly	Ile	Asp	Phe	Lys	Glu	Asp	Gly	Asn	Ile	Leu	Gly	His	Lys	Met		
					805					810					815			
	GAA	TAC	AAT	TAT	AAC	TCA	CAT	AAT	GTA	TAC	ATC	ATG	GCA	GAC	AAA	CCA	249	6
55				Tyr												••		
		-		820					825	_				830	•			

5	AA( Lys	G AAT S Asi	GGC Gly 835	lle	Lys	GTI Val	' AAC Asn	Phe	Lys	ATT	AGA Arg	CAC His	AAC Asn 845	Ile	AAA Lys	GAT Asp	2544
_	GGA Gly	A AGO / Ser 850	val	CAA Gln	TTA Leu	GCA Ala	GAC Asp 855	CAT His	TAT Tyr	CAA	CAA Gln	AAT Asn 860	Thr	CCA Pro	ATT Ile	GGC Gly	2592
10	GAT Asp 865	о Сту	CCT Pro	GTC Val	CTT Leu	TTA Leu 870	Pro	GAC Asp	AAC Asn	CAT	TAC Tyr 875	Leu	TCC	ACG Thr	CAA Gln	TCT Ser 880	2640
15	GCC Ala	CTI Leu	TCC Ser	AAA Lys	GAT Asp 885	CCC Pro	AAC Asn	GAA Glu	AAG Lys	AGA Arg 890	Asp	CAC His	ATG Met	ATC Ile	CTT Leu 895	CTT Leu	2688
20	GAG Glu	TTT Phe	GTA Val	ACA Thr 900	GCT Ala	GCT Ala	GGG Gly	ATT Ile	ACA Thr 905	CAT His	GGC Gly	ATG Met	GAT Asp	GAA Glu 910	CTA Leu	TAC Tyr	2736
25			CAG Gln 915		TAA				8) •								2751
			(2)	INI	FORM	OITA	N FOF	SEC	מד כ	NO:	73.						
		,									,,,						
30		(.	(B) (C)	LENC TYPE STRA	STH: E: an ANDEI	916 nino NESS	ACTER amin acid S: si Inear	o ac l .ngle	cids				٠				
35		: ) ? )	ii) M /) FR	OLEC RAGME	ULE NT 1	TYPE:	: pr	otei erna	n il								
		()	ci) s	EQUE	NCE	DESC	RIPT	'ION:	SEÇ	) ID	NO:7	3:					
40	Met 1	Ala	Asp	Val	Tyr 5	Pro	Ala	Asn	Asp		Thr	Ala	Ser	Gln	Asp	Val	
		Asn	Arg	Phe 20		Arg	Lys			10 Leù	Arg	Gln	Lys		15 Val	His	
45	Glu	Val	Lys 35		His	Lys			25 Ala	Arg	Phe	Phe		30 Gln	Pro	Thr	
	Phe	Cys 50	Ser	His	Cys	Thr			Ile	Trp	Gly	Phe 60	45 Gly	Lys	Gln	Gly	
	Phe 65	Gln	Cys	Gln	Val	Cys 70		Phe	Val	Val	His 75	Lys	Arg	Cys			
50	Phe	Val	Thr	Phe	Ser 85		Pro	Gly		Asp 90	Lys	Gly	Pro	Asp	Thr	80 Asp	
	Asp	Pro	Arg			His	Lys				His	Thr		Gly 110	95 Ser	Pro	
55	Thr	Phe	Cys 115		His	Cys				Leu	Tyr		Leu 125	Ile	His	Gln .	
	Gly	Met	Lys	Cys .	Asp	Thr			Met	Asn	Val	His	Asn	Gln	Cvs '	Val	

												140			•	
	Tla	130	Asp	Dro	sår	T.e.11	135 Cvs	Glv	Met	Aen	Wie	140	Glu	Lve	Δτα	Glv
	145	ASII	rsp	FIU	Der	150	Cys	Gry	1100	nsp	155	1111	Giu	цуз	77.9	160
		Ile	Tyr	Leu	Lvs		Glu	Val	Thr	Asp		Lvs	Leu	His	Val	
5	5		-1-		165					170		4			175	
	Val	Arg	Asp	Ala	Lys	Asn	Leu	Ile	Pro	Met	Asp	Pro	Asn	Gly	Leu	Ser
				180					185					190		
	Asp	Pro	Tyr	Val	Lys	Leu	Lys		Ile	Pro	Asp	Pro	_	Asn	Glu	Ser
4.0	_		195		_			200	_		_	_	205	~~	_	_
10	Lys		ГЛE	Thr	rys	Thr	11e 215	Arg	ser	Asn	Leu	Asn 220	Pro	GIN	Trp	Asn
	Glu	210	Phe	ጥh r	Dhe	Lvs		Lvs	Pro	Ser	Δsn		Asn	Ara	Ara	Leu
	225		1110			230		_,_			235	-,-		5	••••	240
		Val	Glu	Ile	Trp	Asp	Trp	Asp	Arg	Thr	Thr	Arg	Asn	Asp	Phe	Met
15					245					250					255	
	Gly	Ser	Leu	Ser	Phe	Gly	Val	Ser		Leu	Met	Lys	Met		Ala	Ser
	_			260			_		265				_	270	_	÷
	Gly	Trp	Tyr	Lys	Ala	His	Asn		GIu	GIu	GIY	GIu		Tyr	Asn	vaı
20	Dro	Tla	2.75 Pro	Glu	Glv	Acn	Glu	280 Glu	Glv	Aen	Met	Glu	285	Ara	Gln.	Lvs
20	FLO	290	FIG	o i u	Gry	vab	295	Olu	O.L.y	A511		300	200	**** 9	0111	_,_
	Phe		Lys	Ala	Lys	Leu		Pro	Val	Gly	Asn	Lys	Val	Ile	Ser	Pro
	305		_		-	310					315					320
	Ser	Glu	Asp	Arg	Lys	Gln	Pro	Ser	Asn			Asp	Arg	Val		Leu
25		_	_,	_	325				_	330		~7	_	<b>71</b> -	335	T
	Thr	Asp	Phe	Asn 340	Phe	Leu	Met	vai	ьеи 345	GIĀ	гàв	GIY	ser	350	GIY	гуѕ
	Val	Met	Leu		Asp	Ara	Lvs	Glv		Glu	Glu	Leu	Tvr		Ile	Lvs
	Vul	rice	355	Alu	nop	**** 9	275	360	****				365			-1-
30	Ile	Leu	Lys	Lys	Asp	Val	Val	Ile	Gln	Asp	Asp	Asp	Val	Glu	Сув	Thr
		370					375					380				
		Val	Glu	Lys	Arg		Leu	Ala	Leu	Leu		Lys	Pro	Pro	Phe	
	385	<b>03</b>	<b>T</b>	77.1 _	0	390	Dh.	<b>a</b> 1	mb	17 I	395	7	T	m	Dho	400
35	Thr	GIN	Leu	HIS	405	Cys	Pne	GIN	Thr	410	Asp	Arg	Leu	TYL	415	val
55	Met	Glu	Tyr	Val		Glv	Glv	asp	Leu		Tvr	His	Ile	Gln		Val
			-1-	420		1	1		425		-1-			430		
	Gly	Lys	Phe	Lys	Glu	Pro	Gln	Ala	Val	Phe	Tyr	Ala	Ala	Glu	Ile	Ser
			435					440					445			
40	Ile	_	Leu	Phe	Phe	Leu		Lys	Arg	Gly	Ile		Tyr	Arg	Asp	Leu
	T ***	450	7	7 ~ ~	1701	Mot	455	700	Cor	<b>~1</b>	<b>~1</b>	460	730	Tarc	Tlo	λla
	165	ren	Asn	Asn	vai	470	Leu	ASII	ser	GIU	475	nıs	116	пув	116	480
		Phe	Gly	Met	Cvs		Glu	His	Met	Met		Gly	Val	Thr	Thr	
45			- 4	-	485	•				490	•	•			495	_
	Thr	Phe	Cys	Gly	Thr	Pro	Asp	Tyr	Ile	Ala	Pro	Glu	Ile	Ile	Ala	Tyr
				500					505					510		
	Gln	Pro	Tyr	Gly	Lys	Ser	Val		Trp	Trp	Ala	Tyr		Val	Leu	Leu
50	M	<b>~</b> 3	515 Met	7	N 7 -	a1	<b>01</b> -	520	n	Dho	7	<b>a</b> 1	525	N a m	Glu.	N c r
50	ıyı	530		Leu	ATG	GIY	535	PIO	PIO	Pite	АБР	540	GIU	ASP	Giu	Top
	Glu		Phe	Gln	Ser	Ile		Glu	His	Asn	Val		Tyr	Pro	Lys	Ser
	545				_	550					555		•		•	560
	Leu	Ser	Lys	Glu		Val	Ser	Ile	Cys			Leu	Met	Thr		Glr
55		. =			565				_	570					575	
	Pro	Ala	Lvs	Ara	Leu	Glv	Cvs	Glv	Pro	Glu	GIV	Giu	Ara	αsa	val	Arc

```
580
                                       585
       Glu His Ala Phe Phe Arg Arg Ile Asp Trp Glu Lys Leu Glu Asn Arg
                                   600
       Glu Ile Gln Pro Pro Phe Lys Pro Lys Val Cys Gly Lys Gly Ala Glu
  5
                               615
       Asn Phe Asp Lys Phe Phe Thr Arg Gly Gln Pro Val Leu Thr Pro Pro
                           630
                                               635
       Asp Gln Leu Val Ile Ala Asn Ile Asp Gln Ser Asp Phe Glu Gly Phe
                       645
                                           650
       Ser Tyr Val Asn Pro Gln Phe Val His Pro Ile Leu Gln Ser Ala Val
 10
                   660
                                       665
       Gly Arg Ala Met Ser Lys Gly Glu Glu Leu Phe Thr Gly Val Val Pro
                                   680
       Ile Leu Val Glu Leu Asp Gly Asp Val Asn Gly Gln Lys Phe Ser Val
 15
                               695
                                                   700
       Ser Gly Glu Gly Glu Gly Asp Ala Thr Tyr Gly Lys Leu Thr Leu Lys
                           710
                                              715
       Phe Ile Cys Thr Thr Gly Lys Leu Pro Val Pro Trp Pro Thr Leu Val
                       725
                                           730
 20
       Thr Thr Leu Thr Tyr Gly Val Gln Cys Phe Ser Arg Tyr Pro Asp His
                                      745
      Met Lys Gln His Asp Phe Phe Lys Ser Ala Met Pro Glu Gly Tyr Val
                                  760
      Gln Glu Arg Thr Ile Phe Tyr Lys Asp Asp Gly Asn Tyr Lys Thr Arg
25
                              775
      Ala Glu Val Lys Phe Glu Gly Asp Thr Leu Val Asn Arg Ile Glu Leu
                          790
                                              795
      Lys Gly Ile Asp Phe Lys Glu Asp Gly Asn Ile Leu Gly His Lys Met
                      805
                                          810
      Glu Tyr Asn Tyr Asn Ser His Asn Val Tyr Ile Met Ala Asp Lys Pro
30
                  820
                                      825
      Lys Asn Gly Ile Lys Val Asn Phe Lys Ile Arg His Asn Ile Lys Asp
                                  840
                                                      845
      Gly Ser Val Gln Leu Ala Asp His Tyr Gln Gln Asn Thr Pro Ile Gly
35
                              855
      Asp Gly Pro Val Leu Leu Pro Asp Asn His Tyr Leu Ser Thr Gln Ser
                         870
                                             875
      Ala Leu Ser Lys Asp Pro Asn Glu Lys Arg Asp His Met Ile Leu Leu
                     885
                                         890
      Glu Phe Val Thr Ala Ala Gly Ile Thr His Gly Met Asp Glu Leu Tyr
40
                                    905
      Lys Pro Gln Glu
              915
45
               (2) INFORMATION FOR SEQ ID NO:74:
            (i) SEQUENCE CHARACTERISTICS:
              (A) LENGTH: 2157 base pairs
              (B) TYPE: nucleic acid
50
              (C) STRANDEDNESS: single
              (D) TOPOLOGY: linear
           (ii) MOLECULE TYPE: cDNA
```

166

(A) NAME/KEY: Coding Sequence

55

(ix) FEATURE:

(B) LOCATION: 1...2154

		(D)	OTI	HER :	INFOR	RMAT	ION:							•	
5	(၁	ki) S	SEQUI	ENCE	DESC	CRIPT	rion:	: SE(	Q ID	NO:	74:				
J			ATC Ile												48
10			AAG Lys 20												96
15			CAG Gln												144
20			CTA Leu												192
25			CAA Gln								•				240
			ATT Ile												288
30.			GGC Gly 100												336
35			CAG Gln										_		384
40			TGG Trp		-										432
45			AAC Asn											GTA Val 160	480
			CCT Pro												528
50			GTG Val 180												576
55			TAT Tyr										•		624

167

5						AGT Ser											672
Ü	TAT Tyr 225	ATC Ile	AGT Ser	GAA Glu	GAT Asp	GGA Gly 230	GAA Glu	ACA Thr	AGT Ser	GAC Asp	CAA Gln 235	CAG Gln	TTG Leu	AAT Asn	CAA Gln	AGT Ser 240	720
10						CCA Pro											768
15						GAT Asp											816
20	Phe	Trp	Cys 275	Ser	Ile	GCA Ala	Tyr	Tyr 280	Glu	Leu	Asn	Gln	Arg 285	Val	Gly	Glu	864
25	Thr	Phe 290	His	Ala	Ser	Gln	Pro 295	Ser	Leu	Thr	Val	Asp 300	Gly	Phe	Thr		912
					Glu	AGG Arg 310											960
30	CGA Arg	AAT Asn	GCC Ala	ACG Thr	GTA Val 325	GAA Glu	ATG Met	ACA Thr	AGA Arg	AGG Arg 330	CAT His	ATA Ile	GGA Gly	AGA Arg	GGA Gly 335	GTG Val	1008
35						GGT Gly											1056
40	AGT Ser	GCA Ala	ATC Ile 355	TTT Phe	GTG Val	CAG Gln	AGC Ser	CCC Pro 360	AAT Asn	TGT Cys	AAT Asn	CAG Gln	AGA Arg 365	TAT Tyr	GGC Gly	TGG Trp	1104
45						TGT Cys											1152
						TTT Phe 390											1200
50	GGT Gly	TTT Phe	GAA Glu	GCC Ala	GTC Val 405	TAT Tyr	CAG Gln	CTA Leu	ACT Thr	AGA Arg 410	ATG Met	TGC Cys	ACC Thr	ATA Ile	AGA Arg 415	ATG Met	1248
55	AGT Ser	TTT Phe	GTG Val	AAA Lys 420	GGG Gly	TGG Trp	GGA Gly	GCA Ala	GAA Glu 425	TAC Tyr	CGA Arg	AGG Arg	CAG Gln	ACG Thr 430	GTA Val	ACA Thr	1296

															•		
					TGG Trp											TGG . Trp	1344
5																	
	TTG	GAC	AAA	GTA	TTA	ACT	CAG	ATG	GGA	TCC	CCT	TCA	GTG	CGT	TGC	TCA	1392
					Leu												
		450	-				455		•			460			-		
10	AGC	ATG	TCA	TGG	GTA	CCG	CGG	GCC	CGG	GAT	CCA	CCG	GTC	GCC	ACC	ATG	1440
					Val												
	465					470	5		5		475					480	
	-05				•			•			2,5						
	GTG	AGC	AAG	GGC	GAG	GAG	СТС	ጥጥር	A C C	GGG	GTG	ĠТС	ccc	<b>አ</b> ጥሮ	СТС	GTC .	1488
15					Glu												1400
10	Vai	261	цуз	Gry	485	Giu	Deu	FIIC	1111	490	vai	vaı	PIO	116	495	VAI	
					403					490					495		
	CNC	CTC	CAC	ccc	CNC	CTD	አአሮ	ccc	CNC	770	mma	700	OTO:	maa	ccc	CAC	1526
					GAC												1536
20	GIU	Leu	ASD	-	Asp	Val	WBII	Gry		пλг	Pne	ser	var		GIA	GIU	
20				500					505					510			
	000	~~~		~ m	-	200	m 2 C					cma			3 ma	maa	1504
					GCC												1584
	GIY	GIU	-	Asp	Ala	Thr	туг		гÀг	Leu	Thr	Leu	_	Pne	TIE	Cys	
25			515					520					525				
<b>25</b> .	100				c.m.a												
					CTG												1632
	Thr		Gly	гуs	Leu	Pro		Pro	Trp	Pro	Thr		Val	Thr	Thr	Leu	
		530					535					540		•			
20			~~~						~~~							-	
30					CAG												1680
		Tyr	GIY	vai	Gln	_	Phe	Ser	Arg	-		Asp	His	Met	Lys		
	545					550					555	•				560	
0.5					AAG												1728
35	His	Asp	Phe	Phe	Lys	Ser	Ala	Met	Pro	~1	Glv	TVY	Val	Gln	Glu	Ara	
										Gru	2	- 7 -				5	
					565					570	7	-7-			575	3	
										570	-	•			575		
					ÄAG			GGC	AAC	570 TAC	AAG	ACC	CGC		575 GAG	GTG.	1776
								GGC	AAC	570 TAC	AAG	ACC	CGC		575 GAG	GTG.	1776
40					ÄAG			GGC	AAC	570 TAC	AAG	ACC	CGC		575 GAG	GTG.	1776
40	Thr	Ile	Phe	Phe 580	AAG Lys	Asp	Asp	GGC Gly	AAC Asn 585	570 TAC Tyr	AAG Lys	ACC Thr	CGC Arg	Ala 590	575 GAG Glu	GTG Val	1776
40	Thr	Ile	Phe	Phe 580	ÄAG	Asp	Asp	GGC Gly	AAC Asn 585	570 TAC Tyr	AAG Lys	ACC Thr	CGC Arg	Ala 590	575 GAG Glu	GTG Val	1776
40	Thr AAG	Ile	Phe GAG	Phe 580 GGC	AAG Lys	Asp	Asp CTG	GGC Gly GTG	AAC Asn 585 AAC	TAC Tyr	AAG Lys ATC	ACC Thr	CGC Arg	Ala 590 AAG	575 GAG Glu GGC	GTG- Val	
	Thr AAG	Ile	Phe GAG	Phe 580 GGC	AAG Lys GAC	Asp	Asp CTG	GGC Gly GTG	AAC Asn 585 AAC	TAC Tyr	AAG Lys ATC	ACC Thr	CGC Arg	Ala 590 AAG	575 GAG Glu GGC	GTG- Val	
40	Thr AAG	Ile	Phe GAG Glu	Phe 580 GGC	AAG Lys GAC	Asp	Asp CTG	GGC Gly GTG Val	AAC Asn 585 AAC	TAC Tyr	AAG Lys ATC	ACC Thr	CGC Arg CTG Leu	Ala 590 AAG	575 GAG Glu GGC	GTG- Val	
	Thr AAG Lys GAC	Ile TTC Phe	Phe GAG Glu 595 AAG	Phe 580 GGC Gly	AAG Lys GAC Asp	Asp ACC Thr	Asp CTG Leu AAC	GGC Gly GTG Val 600	AAC Asn 585 AAC Asn	TAC Tyr CGC Arg	AAG Lys ATC Ile	ACC Thr GAG Glu	CGC Arg CTG Leu 605	Ala 590 AAG Lys GAG	575 GAG Glu GGC Gly	GTG- Val ATC Ile	
	Thr AAG Lys GAC	Ile TTC Phe	Phe GAG Glu 595 AAG	Phe 580 GGC Gly	AAG Lys GAC Asp	Asp ACC Thr	Asp CTG Leu AAC	GGC Gly GTG Val 600	AAC Asn 585 AAC Asn	TAC Tyr CGC Arg	AAG Lys ATC Ile	ACC Thr GAG Glu	CGC Arg CTG Leu 605	Ala 590 AAG Lys GAG	575 GAG Glu GGC Gly	GTG- Val ATC Ile	1824
	Thr AAG Lys GAC	Ile TTC Phe	Phe GAG Glu 595 AAG	Phe 580 GGC Gly	AAG Lys GAC Asp	Asp ACC Thr	Asp CTG Leu AAC	GGC Gly GTG Val 600	AAC Asn 585 AAC Asn	TAC Tyr CGC Arg	AAG Lys ATC Ile	ACC Thr GAG Glu	CGC Arg CTG Leu 605	Ala 590 AAG Lys GAG	575 GAG Glu GGC Gly	GTG- Val ATC Ile	1824
45	Thr AAG Lys GAC	TTC Phe	Phe GAG Glu 595 AAG	Phe 580 GGC Gly	AAG Lys GAC Asp	Asp ACC Thr	CTG Leu AAC Asn	GGC Gly GTG Val 600	AAC Asn 585 AAC Asn	TAC Tyr CGC Arg	AAG Lys ATC Ile	ACC Thr GAG Glu AAG Lys	CGC Arg CTG Leu 605	Ala 590 AAG Lys GAG	575 GAG Glu GGC Gly	GTG- Val ATC Ile	1824
	Thr  AAG Lys  GAC Asp	TTC Phe	GAG Glu 595 AAG Lys	Phe 580 GGC Gly GAG Glu	AAG Lys GAC Asp	ASP ACC Thr GGC Gly	CTG Leu AAC Asn 615	GGC Gly GTG Val 600 ATC Ile	AAC Asn 585 AAC Asn CTG Leu	TAC Tyr CGC Arg GGG Gly	AAG Lys ATC Ile CAC	ACC Thr GAG Glu AAG Lys 620	CGC Arg CTG Leu 605 CTG Leu	Ala 590 AAG Lys GAG Glu	575 GAG Glu GGC Gly TAC Tyr	GTG- Val ATC Ile AAC Asn	1824
45	Thr  AAG Lys  GAC Asp	TTC Phe 610	GAG Glu 595 AAG Lys	Phe 580 GGC Gly GAG Glu	AAG Lys GAC Asp GAC Asp	ASP ACC Thr GGC Gly GTC	CTG Leu AAC Asn 615	GGC Gly GTG Val 600 ATC Ile	AAC Asn 585 AAC Asn CTG Leu	TAC Tyr CGC Arg GGG Gly	AAG Lys ATC Ile CAC His	ACC Thr GAG Glu AAG Lys 620	CGC Arg CTG Leu 605 CTG Leu	Ala 590 AAG Lys GAG Glu	GAG Glu GGC Gly TAC Tyr	GTG- Val ATC Ile AAC Asn	1824 1872
45	Thr  AAG Lys  GAC Asp	TTC Phe 610	GAG Glu 595 AAG Lys	Phe 580 GGC Gly GAG Glu	AAG Lys GAC Asp GAC Asp	ASP ACC Thr GGC Gly GTC	CTG Leu AAC Asn 615	GGC Gly GTG Val 600 ATC Ile	AAC Asn 585 AAC Asn CTG Leu	TAC Tyr CGC Arg GGG Gly	AAG Lys ATC Ile CAC His	ACC Thr GAG Glu AAG Lys 620	CGC Arg CTG Leu 605 CTG Leu	Ala 590 AAG Lys GAG Glu	GAG Glu GGC Gly TAC Tyr	GTG- Val ATC Ile AAC Asn	182 <b>4</b> 1872
45	Thr  AAG Lys  GAC Asp  TAC Tyr 625	TTC Phe TTC Phe 610 AAC Asn	GAG Glu 595 AAG Lys AGC Ser	Phe 580 GGC Gly GAG Glu CAC His	AAG Lys GAC Asp GAC Asp	ASP ACC Thr GGC Gly GTC Val 630	CTG Leu AAC Asn 615 TAT Tyr	GGC Gly GTG Val 600 ATC Ile	AAC Asn AAC Asn CTG Leu ATG	TAC Tyr CGC Arg GGG Gly GCC	AAG Lys ATC Ile CAC His GAC Asp	ACC Thr GAG Glu AAG Lys 620 AAG Lys	CGC Arg CTG Leu 605 CTG Leu CAG Gln	Ala 590 AAG Lys GAG Glu AAG Lys	GAG Glu GGC Gly TAC Tyr	GTG- Val ATC Ile AAC Asn GGC Gly 640	182 <b>4</b> 1872
45	Thr  AAG Lys  GAC Asp  TAC Tyr 625	TTC Phe TTC Phe 610 AAC Asn	GAG Glu 595 AAG Lys AGC Ser	Phe 580 GGC Gly GAG Glu CAC His	AAG Lys GAC Asp GAC Asp	ASP ACC Thr GGC Gly GTC Val 630	CTG Leu AAC Asn 615 TAT Tyr	GGC Gly GTG Val 600 ATC Ile	AAC Asn 585 AAC Asn CTG Leu	TAC Tyr CGC Arg GGG Gly GCC	AAG Lys ATC Ile CAC His GAC Asp	ACC Thr GAG Glu AAG Lys 620 AAG Lys	CGC Arg CTG Leu 605 CTG Leu CAG Gln	Ala 590 AAG Lys GAG Glu AAG Lys	GAG Glu GGC Gly TAC Tyr	GTG- Val ATC Ile AAC Asn GGC Gly 640	182 <b>4</b> 1872
45	Thr  AAG Lys  GAC Asp  TAC Tyr 625	TTC Phe TTC Phe 610 AAC Asn	GAG Glu 595 AAG Lys AGC Ser	Phe 580 GGC Gly GAG Glu CAC His	AAG Lys GAC Asp GAC Asp	ASP ACC Thr GGC Gly GTC Val 630 AAG	Asp CTG Leu AAC Asn 615 TAT Tyr	GGC Gly GTG Val 600 ATC Ile	AAC Asn 585 AAC Asn CTG Leu ATG Met	TAC Tyr CGC Arg GGG Gly GCC Ala	AAG Lys ATC Ile CAC His GAC Asp 635	ACC Thr GAG Glu AAG Lys 620 AAG Lys	CGC Arg CTG Leu 605 CTG Leu CAG Gln	Ala 590 AAG Lys GAG Glu AAG Lys	GAG Glu GGC Gly TAC Tyr AAC Asn	GTG-Val ATC Ile AAC Asn GGC Gly 640 GTG	1824 1872 1920

	CA Gl	G CT n Le	C GC	C GA a As 66	ρит	C TA	C CA r Gl	G CA n Gl	G AA n As	n Th	CC CC	C AT	C GG e Gl	GC GA y As	p G	GC CCC	2016
5										_				0 /	U		
	GT( Va)	G CT	G CT u Le 67	u PI	C GA o As	C AA	C CA	C TA S Ty 68	r Le	G AG u Se	C AC	C CA r Gl	G TC n Se 68	r Al	C CT a Le	G AGC u Ser	2064
10	7.78.1			~													
	<b>-</b> 27.	690	ָם ס		ı Gı	u гу	695	g As	p Hi	s Me	t Va	1 Le <sup>-</sup> 70	u Le O	u Gl	u Ph	C GTG e Val	2112
	ACC	GCC	GC	GGG	AT(	CACI	CTC	GG	САТ	G GA	ר מאי	2 CT/	י אידוי יי	ת הי	~ ~~		
15	Thr 705	. MIC	a Ala	a Gly	/ Ile	710	Let	ı Gl	y Me	t As	p Gli 71	ı Le	u Ty:	r Ly	G TA	А	2157
20			. (2	) IN	IFORN	/ATIC	N FC	R SI	EQ II	ои с	:75:	•					•
			'i) c	יבטוופ	MOD	CITAD	3 cm=										
			(A) (B)	LEN TYP	GTH:	CHAR 718 mino	ami aci	no a	cids	3		-					
25		-	(D)	STR	OLOG	DNES Y: 1	S: s inea	ing] r	le								
		(	ii) v) F	MOLE RAGM	CULE ENT	TYPE	E: p : in	rote tern	in al					-			
30						DES				•							
	-				Þ					10						Leu	
35				20					25					2 ^	Gly	Glu	
			33					40		-			45			Leu	
	vai	Lys 50	гуs	Leu	Lys	Lys	Thr	Gly	Arg	Leu	Asp		Leu	Glu	Lys	Ala	
40	Ile 65		Thr	Gln	Asn	Cys 70				Сув		60 Thr	Ile	Pro	Ser	Thr	
	Cvs	Ser	Glu	Tle	Tro		T 033		m).	_	75					80	
					03	Gly				٩n					0.5		
45				100		Tyr			105					310			
			TTO			Ser		120					125				
50		130				Trp	135					140	His				
50	Ala	Ile	Glu	Asn	Cys	Glu	Tyr	Ala	Phe	Asn	Leu	Lys	Lvs	Asp	Glu	Val	
					•	TOU					155					7.00	
	Cys	Val	Asn	Pro	Tyr	His	Tyr	Gln	Arg	Val	Glu	Thr	Pro	Val	Leu	Pro	
					T02					170					375		
55	Pro			100					185					100	Pro		
	Leu	Asp	Asp	Tyr	Thr	His	Ser	Ile	Pro	Glu	Asn	Thr	Asn	Phe	Pro	Ala	

			195					200					205			
	Gly	Ile 210	Glu	Pro	Gln'	Ser	Asn 215	Tyr		Pro	Glu	Thr 220	Pro	Pro	Pro	Gly
5	Tyr 225	Ile	Ser	Glu	Asp	Gly 230	Glu	Thr	Ser	Asp	Gln 235	Gln	Leu	Asn	Gln	Ser 240
	Met	Asp	Thr	Gly	Ser 245	Pro	Ala	Glu	Leu	Ser 250	Pro	Thr	Thr	Leu	Ser 255	Pro
	Val	Asn	His	Ser 260	Leu	Asp	Leu	Gln	Pro 265	Val	Thr	Tyr	Ser	Glu 270	Pro	Ala
10		_	275					280			Asn		285		_	
		290					295				Val	300				
15	305					310				_	Leu 315					320
					325				_	330	His		_		335	
00				340					345		Ala		<del>-</del>	350		
20			355					360			Asn		365			
		370					375				Gly	380				
25	385					390					Ala 395					400
	_				405	-				410	Met	-			415	
20				420					425		Arg			430		
30			435					440			Asn		445			
		450	٠.				455				Pro	460				•
35	465					470	•			_	Pro 475					480
				_	485					490	Val				495	
40				500					505	-	Phe			510		
40			515					520			Thr		525			
		530					535		_		Thr	540				
45	545					550				-	Pro 555					560
					565					570	Gly				575	
50				580					585	_	Lys			590		
30			595					600		_	Ile		605	_	_	
		610					615				His	620			•	
55	625					630					Asp 635					640

	CAE																
					64					650	0				65	5	
				66	0				665	5 .				67	p Gly	y Pro	
5			675	•				680	)				689	Ala	a Let	u Ser	•
	-	690	,				695	;				700	ı Let	ı Glı		e Val	
	Thr 705	Ala	Ala	a Gly	/ Ile	Th:	r Leu O	Gly	Met	: Asp	Glu 715		і Туі	Lys	5		
· 10			(2	2) IN	IFORM	MATIC	ON FO	R SE	Q II	NO:	76:						
		(	i) S	EQUE	ENCE	CHAF	RACTE	RIST	ICS:			-	•				
15			(B)	TYF	E: n	ucle	97 ba eic a	cid		•							·
•.							SS: s inea		е	•							
20	(ii) MOLECULE TYPE: cDNA (ix) FEATURE:																
		`					a- 44	.i									
			(B	) Lo	CATI	ON:	Codi 1 RMAT	2394	eque	nce							
25		(:					CRIP		: SE	Q ID	NO:	76:					•
	ATG	GAC	AAT	ATG	TCT	ATT	ACG	AAT	ACA	CCA	ACA	AGT	AAT	GAT	GCC	TGT	48
30	Met 1	Asp	Asn	Met	Ser 5	Ile	Thr	Asn	Thr	Pro 10	Thr	Ser	Asn	Asp	Ala 15	Cys	
•	CTG	AGC	АТТ	GTG	רמידי	ልርጥ	יייים	አጥሮ	maa	C2 m	202		·~~=				
	Leu	Ser	Ile	Val	His	Ser	Leu	Met	Cys 25	His	AGA	Gln	Gly	GGA Gly 30	GAG Glu	AGT Ser	96
35		7 C N	m/mm														
	Glu	Thr	Phe	Ala	AAA Lys	AGA	GCA Ala	ATT Ile	GAA Glu	AGT Ser	TTG	GTA Val	AAG	AAG	CTG	AAG	144
		•	35					40.					45	2,5	Dou	273	•
40	GAG	AAA	AAA	GAT	GAA	TTG	GAT	TCT	TTA	ATA	ACA	GCT	ATA	ACT	ACA	AAT	192
	Giu	50	цуѕ	Asp	GIU	ьeu	Asp 55	Ser	Leu	Ile	Thr	Ala 60	Ile	Thr	Thr	Asn	
4E	GGA	GCT	CAT	CCT	AGT	AAA	TGT	GTT	ACC	ATA	CAG	AGA	ACA	TTG	GAT	GGG ·	240
45	65 65	Ala	His	Pro	Ser	Lys 70	Cys	Val	Thr	Ile	Gln 75	Arg	Thr	Leu	Asp	Gly 80	
	AGG	CTT	CAG	GTG	GCT	GGT	CGG	AAA	GGA	TTT	ССТ	САТ	GTG	ATC	тат	GCC	288
50	Arg	Leu	Gln	Val	Ala 85	Gly	Arg	Lys	Gly	Phe 90	Pro	His	Val	Ile	Tyr 95	Ala	200
	CGT	CTC	TGG	AGG	TGG	CCT	GAT	CTT	CAC	AAA	AAT	GAA	CTA	AAA	CAT	GTT	336
- 55	Arg	ьeu	Trp	Arg 100	Trp	Pro	Asp	Leu	His 105	Lys	Asn	Glu	Leu	Lys 110	His	Val	
	AAA	TAT	TGT	CAG	TAT	GCG	TTT	GAC	TTĄ	AAA	TGT	GAT	AGT	GTC	TGT	GTG	384
														٠.			172

										173								
	Lys	Tyr	Cys 115	Gln	Tyr .	Ala	Phe	Asp 120	Leu	Lys	Cys	Asp	Ser 125	Val	Cys	Val		
5				CAC His													432	
10				CTG Leu			Asn										480	
				CAT													528	
13				CAA Gln 180													576	
20				AGC Ser													624	
25				GCC Ala												_	672	,
30				ATA Ile													720	
25				CCT Pro													768	
35				TAC Tyr 260													816	
40				TAC Tyr													864	
45			His	CCG									Tyr				912	
50				CTT								Asn					960	
				TGT Cys		Ile										Gly	1008	
55	GAG	ACA	TTT	AAG	GTT	CCT	TCA	AGC	·TGC	CCT	ATT	GTT	ACT	GTT	GAT	GGA	1056	173

•										174								
	Glu	Thr	Phe	Lys 340	Val	Pro	Ser	Ser	Cys 345	Pro	Ile	Val	Thr	Val 350	Asp	Gly		
<b>5</b> .						GGA Gly											1104	
10						GAA Glu											1152	
15						GAA Glu 390											1200	
10						GCG Ala											1248	
20						CCT Pro											1296	
25						TTT Phe											1344	
30						GCA Ala											1392	
		Ala				CCT Pro 470											1440	
35						GCT Ala											1488	
40				_		AGG Arg											1536	
45						ATC Ile						Trp					1584	
50						CAG Gln											1632	,
						CCT Pro 550											1680	
55	GTG	AGC	AAG	GGC	GAG	GAG	CTG	TTC	ACC	GGG	GTG	GTG	CCC	ATC	CTG	GTC	1728	4

										1/5								
	Val	Ser	Lys	Gly	Glu 565	Glu	Leu	Phe	Thr	Gly 570	Val	Val	Pro	Ile	Leu 575	Val		
5			GAC Asp														1776	
10			GGC Gly 595														1824	
15			GGC Gly														1872	
10			GGC Gly														1920	•
20			TTC Phe			Ser											1968	
25			TTC Phe					Gly		Tyr							2016	
30			GAG Glu 675														2064	
			ÀAG Lys														2112	
35		Asn	AGC Ser														2160	
40	ATC Ile	AAG Lys	GTG Val	AAC Asn	TTC Phe 725	AAG Lys	ATC Ile	CGC Arg	CAC	AAC Asn 730	ATC Ile	GAG Glu	GAC Asp	GGC Gly	AGC Ser 735	GTG Val	2208	
45			GCC Ala		His					Thr					Gly		2256	
50			CTG Leu 755	Pro					Leu					Ala			2304	
			CCC Pro					Asp					Leu				2352	
55	ACC	GCC	GCC	GGG	ATC	ACT	CTC	GGC	TA:	GAC	GAG	CTG	TAC	AAG	TAA		2397	, 175

176

Thr Ala Ala Gly Ile Thr Leu Gly Met Asp Glu Leu Tyr Lys

- 5 (2) INFORMATION FOR SEQ ID NO:77:
  - (i) SEQUENCE CHARACTERISTICS:
    - (A) LENGTH: 798 amino acids
    - (B) TYPE: amino acid
    - (C) STRANDEDNESS: single
    - (D) TOPOLOGY: linear
  - (ii) MOLECULE TYPE: protein
  - (v) FRAGMENT TYPE: internal
- 15

10

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:77:

Met Asp Asn Met Ser Ile Thr Asn Thr Pro Thr Ser Asn Asp Ala Cys Leu Ser Ile Val His Ser Leu Met Cys His Arg Gln Gly Glu Ser 10 20 .25 Glu Thr Phe Ala Lys Arg Ala Ile Glu Ser Leu Val Lys Lys Leu Lys · 40 Glu Lys Lys Asp Glu Leu Asp Ser Leu Ile Thr Ala Ile Thr Thr Asn 25 Gly Ala His Pro Ser Lys Cys Val Thr Ile Gln Arg Thr Leu Asp Gly Arg Leu Gln Val Ala Gly Arg Lys Gly Phe Pro His Val Ile Tyr Ala 7.5 85 . 30 Arg Leu Trp Arg Trp Pro Asp Leu His Lys Asn Glu Leu Lys His Val 90 105 Lys Tyr Cys Gln Tyr Ala Phe Asp Leu Lys Cys Asp Ser Val Cys Val 115 120 Asn Pro Tyr His Tyr Glu Arg Val Val Ser Pro Gly Ile Asp Leu Ser 35 135 Gly Leu Thr Leu Gln Ser Asn Ala Pro Ser Ser Met Met Val Lys Asp Glu Tyr Val His Asp Phe Glu Gly Gln Pro Ser Leu Ser Thr Glu Gly His Ser Ile Gln Thr Ile Gln His Pro Pro Ser Asn Arg Ala Ser Thr 170 40 Glu Thr Tyr Ser Thr Pro Ala Leu Leu Ala Pro Ser Glu Ser Asn Ala 185 200 Thr Ser Thr Ala Asn Phe Pro Asn Ile Pro Val Ala Ser Thr Ser Gln 45 215 Pro Ala Ser Ile Leu Gly Gly Ser His Ser Glu Gly Leu Leu Gln Ile Ala Ser Gly Pro Gln Pro Gly Gln Gln Asn Gly Phe Thr Gly Gln Pro Ala Thr Tyr His His Asn Ser Thr Thr Thr Trp Thr Gly Ser Arg 250 50 265 Thr Ala Pro Tyr Thr Pro Asn Leu Pro His His Gln Asn Gly His Leu 280 Gln His His Pro Pro Met Pro Pro His Pro Gly His Tyr Trp Pro Val

His Asn Glu Leu Ala Phe Gln Pro Pro Ile Ser Asn His Pro Ala Pro

295

	305					310					315					320
	Glu	Tyr	Trp	Cys	Ser 325	Tle	Ala	Tyr	Phe	Glu 330	Met	Asp	Val	Gln	Val 335	Gly
5	Glu	Thr	Phe	Lys 340	Val	Pro	Ser	Ser	Cys 345	Pro	Ile	Val	Thr	Val 350	Asp	Gly
	Tyr	Val	Asp 355	Pro	Ser	Gly	Gly	Asp 360	Arg	Phe	Сув	Leu	Gly 365	Gln	Leu	Ser
	Asn	Val 370	His	Arg	Thr	Glu	Ala 375	Ile	Glu	Arg	Ala	Arg 380	Leu	His	Ile	Gly
10	385	_				390			_		395	_		Trp		400
	-				405					410		٠.		Leu	415	
15				420					425					Tyr 430		
		_	435					440					445	Gln		
		450					455					460		Ala		
20	465					470	٠				475			Ile		480
	•				485					490				Asp	495	
25			_	500					505	•	_		_	Gly 510		
			515					520			_		525	Glu		
20		530					535				•	540		Thr		
30	545	٠.				550					555			Ala		560
					565	٠	-			570				Ile	575	
35				580				_	585					Ser 590		
			595					600	-				605	Phe		
40		610		_			615		_			620		Met		
40	625					630					635			Gln		640
					645					650				·Ala	655	*
45	•			660	•				665					670 Lys		
			675					680					685	Glu		
50		690					695					700		Lys		
	705	V211	JCI	1113	W911	710	TYL	116	MCC.	AIG	715	БyS	0111	2,5	7,011	720
		Lys	Val	Asn	Phe 725		Ile	Arg	His	Asn 730		Glu	Asp	Gly	Ser 735	Val
55	Gln	Leu	Ala	Asp 740	His	Tyr	Gln	Gln	Asn 745	Thr	Pro	Ile	Gly	Asp 750	Gly	Pro
	77-3	•		B			•	_	_	-	P21	91.0	0	B 7 -	*	0

•										178	3							
			75	5				76	0				76	5				
	Ly	s As	p Pr	o As	n Gl	u Ly	s Ar			s Me	t Va	l Le	u Le	u Gl	ıı Ph	e Val		
		,,	U				77.	5				78	n			o vai		
5	Th	r Al	a Al	a Gl	y Il	e Th	r Le	u Gl	y Me	t As	p Gl	u Le	и Ту	r Ly	s			
5	78	5				. 79	0				79			_				
			,	2 ) T	MEODI	M 70 TT 2	<b>337</b> 776											
			,	2, 1,	NFOR	OITAM	ON F	OR S	EQ II	о ио	:78:							
			(i)	SEOU	ENCE	CHAI	יייי) ע כ	יסדפי	TTOC									
10			(A	) LE	NGTH	: 313	38 ba	356 I	naire	:								
			(B)	<b>TY</b>	PE: 1	nucle	eic a	cid	Juli	•								
			(C	STI	RANDI	EDNES	SS: 8	ing	le								-	
			(D)	TOI	POLO	3Y: ]	linea	ır				•						
15			/::\	WOTT			_											
. 15			(1 <u>~</u> )	FEAT	COLL	TYF	'E: C	:DNA										
			(17,	FEA.	UKE:	1							•					
			(2	A) NA	ME/F	ŒY:	Codi	na s	Semie	mce								
	-		(E	3) LC	CATI	ON:	1	3135	ieque S	ince								
20			(I	נס (כ	HER	INFO	RMAT	'ION:			•							•
		(	(xi)	SEQU	ENCE	DES	CRIP	TION	: SE	Q II	NO:	78:						
	ΔTC	GCG	e cec	י זייכר	י אוייר	C 2 C												
25	Met	Ala	Glv	. 100 Trr	AIC a[T	CAG	Ala	CAG	CAG	CTG	CAG	GGA	GAC	GCG	CTG	CGC	48	
<b>25</b>	1				5	GIII	MIG	GIII	GIN	. ьеч 10	GIn	GIY	Asp	Ala		Arg		
										10					15	-		
	CAG	ATG	CAG	GTG	CTG	TAC	GGC	CAG	CAC	TTC	ccc	ATC	GAG	GTC	CGG	CAC	96	
	Gln	Met	Gln	Val	Leu	Tyr	Gly	Gln	His	Phe	Pro	Ile	Glu	Val	Arg	His	20	
30				20					25		٠.			3.0	3			
	<b>ጥአ</b> ር	mmo		~~~														
	Tvr	Len	Δla	CAG	TGG	ATT	GAG	AGC	CAG	CCA	TGG	GAT	GCC	ATT	GAC	TTG	144	
	-1-		35	0111	11p	Ile	. Gitu	40	GIN	Pro	Trp	Asp			Asp	Leu		
35					•			40					45					
	GAC	AAT	CCC	CAG	GAC	AGA	GCC	CAA	GCC	ACC	CAG	CTC	CTG	GAG	GGC	СТС	192	
:	Asp	ASI	Pro	Gln	Asp	Arg	Ala	Gln	Ala	Thr	Gln	Leu	Leu	Glu	Gly	Leu	192	
		50					55					60		•	•			
40	GTG	CAC	CAC	ama	C													
,0	Val	Gln	GAG	LAU	CAG	AAG	AAG	GCG	GAG	CAC	CAG	GTG	GGG	GAA	GAT	GGG	240	
	65	0111	Q1 u	neu	GIII	Lys 70	гуѕ	AIA	GIU	His		Val	Gly	Glu	Asp			
						. •					75					80		
	TTT	TTA	CTG	AAG	ATC	AAG	CTG	GGG	CAC	TAC	GCC	ACG	CAG	CTC	CNG	***	. 200	
45	Phe	Leu	Leu	Lys	Ile	Lys	Leu	Gly	His	Tyr	Ala	Thr	Gln	Leu	Gln	lvs	288	
					85					90					95	-1-		
	אכא	mam	~~~	000														
	Thr	Tyr	Aen	Ara	TGC	CCC	CTG	GAG	CTG	GTC	CGC	TGC	ATC	CGG	CAC	ATT	336	
50		-7-	ASP	100	Cys	Pro	Leu	GIU	Leu	Val	Arg	Cys	Ile		His	Ile		
					-				105					110				
	CTG	TAC	AAT	GAA	CAG	AGG	CTG	GTC	CGA	GAA	GCC	AAC	ייממ	тсс	AGC	புடும்	. 204	
	Leu	Tyr	Asn	${\tt Glu}$	Gln	Arg	Leu	Val	Arg	Glu	Ala	Asn	Asn	Cvs	Ser	Ser	384	
E.E.			115					120	_				125		•			
55	CCC	CCE	000	N CCC	Ome	<b></b>									•	••		
	CCG	GCI	تاتات	ATC	CIG	GTT	GAC	GCC	ATG	TCC	CAG	AAG	CAC	CTT	CAG	ATC	432	
																	178	8

										179								
	Pro	Ala 130	Gly	Ile	Leu	Val	Asp 135	Ala	Met	Ser	Gln	Lys 140	His	Leu	Gln	Ile		
5					GAG Glu												480	
10					CTG Leu 165												528	
45					AGG Arg											CTG Leu	576	
15					CGT Arg												624	
20					GCC Ala												672	
25					CTG Leu							Thr					720	
30					ACC Thr 245												768	
35					CTG Leu												816	
33					TCC												864	
40					ATC Ile												912	
45		Pro			GTG Val												960	
50					TCA Ser 325												1008	
<b>E E</b>					Val					Thr					Thr	GTA Val	1056	
55	CGC	CTG	CTG	GTG	GGC	GGG	AAG	CTG	AAC	GTG	CAC	ATG	AAT	CCC	ccc	CAG	1104	1
																		•

-	180	•
	Arg Leu Leu Val Gly Gly Lys Leu Asn Val His Met Asn Pro Pro Gln 355 360 365	
5	370 375 380	1152
10	AAT GAG AAC ACC CGC AAC GAG TGC AGT GGT GAG ATC CTG AAC AAC TGC Asn Glu Asn Thr Arg Asn Glu Cys Ser Gly Glu Ile Leu Asn Asn Cys 385 390 395 400	1200
15 <sup>^</sup>	·	1248
	AGG AAC ATG TCA CTG AAG AGG ATC AAG CGT GCT GAC CGG CGG GGT GCA Arg Asn Met Ser Leu Lys Arg Ile Lys Arg Ala Asp Arg Arg Gly Ala 420 425 430	1296
20	GAG TCC GTG ACA GAG GAG AAG TTC ACA GTC CTG TTT GAG TCT CAG TTC Glu Ser Val Thr Glu Glu Lys Phe Thr Val Leu Phe Glu Ser Gln Phe 435 440 445	1344
25	AGT GTT GGC AGC AAT GAG CTT GTG TTC CAG GTG AAG ACT CTG TCC CTA  Ser Val Gly Ser Asn Glu Leu Val Phe Gln Val Lys Thr Leu Ser Leu  450  460	1392
30	470 475 480	1440
35	ACT GTG CTG TGG GAC AAT GCC TTT GCT GAG CCG GGC AGG GTG CCA TTT Thr Val Leu Trp Asp Asn Ala Phe Ala Glu Pro Gly Arg Val Pro Phe 485 490 495	1488
40	GCC GTG CCT GAC AAA GTG CTG TGG CCG CAG CTG TGT GAG GCG CTC AAC Ala Val Pro Asp Lys Val Leu Trp Pro Gln Leu Cys Glu Ala Leu Asn 500 505 510	1536
40	ATG AAA TTC AAG GCC GAA GTG CAG AGC AAC CGG GGC CTG ACC AAG GAG Met Lys Phe Lys Ala Glu Val Gln Ser Asn Arg Gly Leu Thr Lys Glu 515 520 525	1584
45	AAC CTC GTG TTC CTG GCG CAG AAA CTG TTC AAC AAC AGC AGC AGC CAC Asn Leu Val Phe Leu Ala Gln Lys Leu Phe Asn Asn Ser Ser Ser His 530 540	1632
50	CTG GAG GAC TAC AGT GGC CTG TCC GTG TCC TGG TCC CAG TTC AAC AGG Leu Glu Asp Tyr Ser Gly Leu Ser Val Ser Trp Ser Gln Phe Asn Arg 545 550 560	1680
55	565 Trp Ash Tyr Thr Phe Trp Gln Trp Phe Asp Gly	1728
	GTG ATG GAG GTG TTG AAG AAG CAC CAC AAG CCC CAC TGG AAT GAT GGG	1776 180

SUBSTITUTE SHEET (RULE 26)

										101								
	Val	Met	Glu	Val 580	Leu <sub>.</sub>	Lys	Lys	His	His 585	Lys	Pro	His	Trp	Asn 590	Asp	Gly	•	
	GCC	ATC	CTA	GGT	ттт	GTG	AAT	AAG	CAA	CAG	GCC	CAC	GAC	CTG	CTC	ATC	1824	
5			Leu 595															
	AAC	DAG	ccc.	GAC	GGG	ACC	TTC	TTG	TTG	CGC	ттт	AGT	GAC	TCA	GAA	ATC	1872	
			Pro															
10		610					615					620						
			ATC														1920	
	•	GIY	Ile	Thr	IIe	630	Trp	rys	Phe	Asp	Ser	Pro	GIU	Arg	Asn	Leu 640		
15	625					630					635					040		
. •	TGG	AAC	CTG	AAA	CCA	TTC	ACC	ACG	CGG	GAT	TTC	TCC	ATC	AGG	TCC	CTG	1968	
	Trp	Asn	Leu	Lys	Pro	Phe	Thr	Thr	Arg	Asp	Phe	Ser	Ile	Arg	Ser	Leu		
					645					650					655			
20			CGG														2016	
	Ala	Asp	Arg	660 Fea	GIÀ	Asp	Leu	ser	1yr 665	Leu	11e	Tyr	vai	670	PIO	Asp		
	CGC	CCC	AAG	GAT	GAG	GTC	TTC	TCC	AAG	TAC	TAC	ACT	CCT	GTG	CTG	GCT	2064	
25	Arg	Pro	Lys	Asp	Glu	Val	Phe	Ser	Lys	Tyr	Tyr	Thr	Pro	Val	Leu	Ala		
			675					680					685			•		
		a am	GTT	C N M	CCN	m n m	CTC		CCA	CAC	איזיי	חחת	C2 2	cmc	CTC	ССТ	2112	•
			Val												_		2112	
30		690			,	-1-	695	-7-				700						
					•					•				•	•			
			GTG												_		2160	
		Phe	Val	Asn	Ala		Ala	Asp	Ala	Gly	_	Ser	Ser	Ala	Thr	Tyr 720		
35	705					710					715	·				720		
55	ATG	GAC	CAG	GCC	CCC	TCC	CCA	GCT	GTG	TGC	CCC	CAG	GCT	CCC	TAT	AAC	2208	
			Gln															
					725					730					735			
40			CCA														2256	
	Met	Tyr	Pro		Asn	Pro	Asp	His		Leu	Asp	Gln	Asp		Glu	Pne		
		•		740					745					750				
	GAC	CTG	GAT	GAG	ACC	ATG	GAT	GTG	GCC	AGG	CAC	GTG	GAG	GAA	CTC	TTA	2304	
45			Asp															
			755					760					765					
								,							~~~	~~~	2252	
			CCA													_	2352	
50	Arg	770	Pro	Mec	Asp	261	775	Asp	Ser	Arg	пеп	780	PIO	PIO	AIG	Gly		
55												. 55						
	CTT	TTC	ACC	TCT	GCC	AGA	GGC	TCC	CTC	TCA	TGG	GTA	CCG	CGG	GCC	CGG	2400	
		Phe	Thr	Ser	Ala	_	Gly	Ser	Leu	Ser	-	Val	Pro	Arg	Ala			
	785					790					795					800		
55	ርኔጥ	רכז	CCG	GTC	GCC	ארר	ልጥር	ሮጥር	ልርሮ	אמ	GGC	GAG	GAG	СТС	ттс	ACC	2448	
	GMI	CCA	CCG	GIC	555		710	010	AGC	מאה	550		UNU					181

	Asp	Pro	Pro	Val	Ala 805	Thr	Met	: Va]	l Sei	r Ly:	s Gly	y Gli	ı Glı	ı Lei	ı Ph 81	e Thr	
5	GGG Gly	GTG Val	GTG Val	Pro 820	, тте	CTG Leu	GTC Val	GAC Glu	CTC Lev 825	ı Ası	GGC Gly	C GAC	C GTA	AAA LASI 188	Gl	C CAC Y His	2496
40	AAG Lys	TTC Phe	Set	val	TCC Ser	GGC Gly	GAG	GGC	GAG	GGC Gly	C GAT	GCC Ala	C ACC	TAC	GG(	C AAG	2544
10			033					840	•				845	;		TGG	
15	Leu	Thr 850	Leu	Lys	Phe	Ile	Cys 855	Thr	Thr	Gly	Lys	Leu 860	Pro	Val	Pro	Trp	2592
	CCC Pro 865	ACC Thr	CTC Leu	GTG Val	ACC Thr	ACC Thr 870	CTG Leu	ACC Thr	TAC Tyr	GGC	GTG Val 875	Gln	TGC Cys	TTC	AGC Ser	CGC Arg 880	2640
20	TAC Tyr	CCC Pro	GAC Asp	CAC His	ATG Met 885	AAG Lys	CAG Gln	CAC His	GAC Asp	TTC Phe 890	Phe	AAG Lys	TCC Ser	GCC Ala	ATG Met	CCC Pro	2688
25	GAA Glu	GGC Gly	TAC Tyr	GTC Val 900	CAG Gln	GAG Glu	CGC Arg	ACC Thr	ATC Ile 905	TTC Phe	TTC Phe	AAG Lys	GAC Asp	GAC Asp 910	GGC Gly	AAC Asn	2736
30		тув	915	Arg	Ala	GIu	Val	Lys 920	Phe	Glu	Gly	Asp	Thr 925	Leu	Val	AAC Asn	2784
35	Arg	930	GIU	ьeu	Lys	GIA	11e 935	Asp	Phe	Lys	Glu	Asp 940	Gly	Asn	Ile		2832
	GGG Gly 945	CAC His	AAG Lys	CTG Leu	GAG Glu	TÀC Tyr 950	AAC Asn	TAC Tyr	AAC Asn	AGC Ser	CAC His 955	AAC Asn	GTC Val	TAT Tyr	ATC Ile	ATG Met 960	2880
40	GCC Ala	GAC Asp	AAG Lys	GII	AAG Lys 965	AAC Asn	GGC Gly	ATC Ile	AAG Lys	GTG Val 970	AAC Asn	TTC Phe	AAG Lys	ATC Ile	CGC Arg 975	CAC His	2928·
45	AAC . Asn	ATC.	GIU.	GAC Asp 980	GGC Gly	AGC Ser	GTG Val	CAG Gln	CTC Leu 985	GCC Ala	GAC Asp	CAC His	TAC Tyr	CAG Gln 990	CAG Gln	AAC Asn	2976
50	ACC (	PIO .	ATC Ile 995	GGC Gly	GAC Asp	GGC Gly	Pro	GTG Val 000	CTG Leu	CTG Leu	CCC Pro	Asp	AAC Asn 005	CAC His	TAC Tyr	CTG Leu	3024
55	AGC A	ACC ( Thr (	CAG '	TCC Ser	GCC Ala	Leu	AGC . Ser :	AAA Lys	GAC Asp	CCC Pro	Asn	GAG Glu 020	AAG Lys	CGC Arģ	GAT Asp	CAC His	3072
	ATG (	GTC (	CTG (	CTG (	GAG '	TTC (	GTG :	ACC	GCC	GCC	GGG	ATC	ACT	CTC	GGC	ATG	3120 182

Met Val Leu Glu Phe Val Thr Ala Ala Gly Ile Thr Leu Gly Met 1030 1035 GAC GAG CTG TAC AAG TAA 3138 5 Asp Glu Leu Tyr Lys 1045 (2) INFORMATION FOR SEQ ID NO:79: 10 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1045 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single 15 (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (v) FRAGMENT TYPE: internal 20. (xi) SEQUENCE DESCRIPTION: SEQ ID NO:79: Met Ala Gly Trp Ile Gln Ala Gln Gln Leu Gln Gly Asp Ala Leu Arg Gln Met Gln Val Leu Tyr Gly Gln His Phe Pro Ile Glu Val Arg His 25 20 25 Tyr Leu Ala Gln Trp Ile Glu Ser Gln Pro Trp Asp Ala Ile Asp Leu 40 Asp Asn Pro Gln Asp Arg Ala Gln Ala Thr Gln Leu Leu Glu Gly Leu Val Gln Glu Leu Gln Lys Lys Ala Glu His Gln Val Gly Glu Asp Gly 30 Phe Leu Leu Lys Ile Lys Leu Gly His Tyr Ala Thr Gln Leu Gln Lys 90 Thr Tyr Asp Arg Cys Pro Leu Glu Leu Val Arg Cys Ile Arg His Ile 35 105 Leu Tyr Asn Glu Gln Arg Leu Val Arg Glu Ala Asn Asn Cys Ser Ser 120 Pro Ala Gly Ile Leu Val Asp Ala Met Ser Gln Lys His Leu Gln Ile 135 Asn Gln Thr Phe Glu Glu Leu Arg Leu Val Thr Gln Asp Thr Glu Asn 40 150 155 Glu Leu Lys Lys Leu Gln Gln Thr Gln Glu Tyr Phe Ile Ile Gln Tyr 170 Gln Glu Ser Leu Arg Ile Gln Ala Gln Phe Ala Gln Leu Ala Gln Leu 45 185 Ser Pro Gln Glu Arg Leu Ser Arg Glu Thr Ala Leu Gln Gln Lys Gln 200 Val Ser Leu Glu Ala Trp Leu Gln Arg Glu Ala Gln Thr Leu Gln Gln 215 220 Tyr Arg Val Glu Leu Ala Glu Lys His Gln Lys Thr Leu Gln Leu Leu 50 230 235 Arg Lys Gln Gln Thr Ile Ile Leu Asp Asp Glu Leu Ile Gln Trp Lys 250 Arg Arg Gln Gln Leu Ala Gly Asn Gly Gly Pro Pro Glu Gly Ser Leu 55 265 Asp Val Leu Gln Ser Trp Cys Glu Lys Leu Ala Glu Ile Ile Trp Gln

										104						
		_	27					28	0				28	5		
	AS	n Ar	g Gl	n Gl	n Il	e Ar	g Ar	g Al	a Gl	u Hi	s Le	и Су	s G1:	n Gl	n Le	u Pro
		~ ~	•				29.	5				30	^			
5	1.10	e Pr	0 G1	y Pro	o Va	l Gl	u Gl	u Me	t Le	u Ala	a Gl	u Vai	l As	n Al	a Th	r Ile
3		_				211	U				211	5				
	111.	I AS	b тт	e II	e Se	r Ala	a Le	u Va	l Th	r Se	r Th	r Phe	≥ Ile	e Il	e Gl	u Lys
					<b>3</b> ∠:	•				221	3					_
	GII	II PI	O PI	34(	o va.	ı Leı	л Гу	5 Thi	r Gli	1 Th	r Lys	Phe	Ala	a Ala	a Th	r Val
10				241	•				34	š				200	•	
	••••	,	35	i val	r G13	GI	, rà	s ref	l Asr	ı Val	l His	Met	Ası	1 Pro	Pro	o Gln
	Va]	l Lvs			- Tle	. T1e		360	, 01-			_	365	5		
		370	)			10	375	. G1(	ı GII	1 GII	ı Ale	Lys	Sei	: Lei	ı Leı	ı Lys
	Asr	ı Glı	ı Ası	1 Thr	Arc	Asr	Gl:	, 1 Cve				380	_	_	_	n Cys
15	385	5				390	)	· Cys	, 261	. GIŞ	305	r TTE	. Let	ı Asr	ı Ası	
	Cys	. Val	Met	: Glu	Tyr	His	Gln	ı Ala	Thr	· Glu	395 The		0		•	400 Phe
					303					410	l .				4	
	Arg	J Asn	Met	Ser	Leu	Lys	Arc	Ile	Lvs	Ara	בומי	λcn	7~~	, n	415	, Alá
				. 420			•••		425					420		
20	Glu	Ser	Val	Thr	Glu	Glu	Lys	Phe	Thr	Val	Leu	Phe	Glu	Ser	Gl <sub>T</sub>	Phe
			433	•				440					AAE			
	Ser	Val	Gly	Ser	Asn	Glu	Leu	Val	Phe	Gln	Val	Lys	Thr	Leu	Ser	Leu
		450					455					160				
25	Pro	val	Val	Val	Ile	Val	His	Gly	Ser	Gln	Asp	His	Asn	Ala	Thr	Ala
23						4/0					475					
	1111	vai	ren	Trp	Asp	Asn	Ala	Phe	Ala	Glu	Pro	Gly	Arg	Val	Pro	980 Phe
					400					490					405	
		V41	110	500	гλя	vaı	ren	Trp	Pro	Gln	Leu	Cys	Glu	Ala	Leu	Asn
30	Met	Lvs	Phe			Glu	V-3	C1-	505		_			510		
			515	-75	u	GIU	val	520	ser	Asn	Arg	GLY		Thr	Lys	Glu
	Asn	Leu		Phe	Leu	Ala	Gln	LVS	T.e.:	Dhe	7.00	. 7	525			•
		330					535					E 4 0	•			
	Leu	Glu	Asp	Tyr	Ser	Gly	Leu	Ser	Val	Ser	Trn	Ser	Gln	Dho	700	7
35						220					555					F C A
	Glu	Asn	Leu	Pro	Gly	Trp	Asn	Tyr	Thr	Phe	Trp	Gln	Trp	Phe	asp	Glv
					202					570						
	Vai	Met	Glu	Val	Leu	Lys	Lys	His	His	Lys	Pro	His	Trp	Asn	Asp	Glv
40				200					585					FOA		
40	AIG	116	rèn	Gly	Phe	Val	Asn	Lys	Gln	Gln	Ala	His	Asp	Leu	Leu	Ile
			333					600					6 N E			
	11011	610	PIU	Asp	GIY	Thr	Phe	Leu	Leu	Arg	Phe	Ser	Asp	Ser	Glu	Ile
		0 1 0					PTP					620				
45	625	<b>-</b> 1		Thr	116	630	Trp	гÀг	Phe	Asp	Ser	Pro	Glu	Arg	Asn	Leu
		Asn	Leu	Lvs	Pro		Thr	Th ~	7	<b>3</b>	635	2.0		_		640
	•			Lys	645	1110	1111	1111	Arg	ASP	Phe	Ser	Ile	Arg		Leu
	Ala	Asp	Arg	Leu		asA	Len	Ser	Tree	650	T1.	TT	17- 7	<b>D</b> 1	655	_
		_	_	660	•				665	Deu	TIE	TYE	vaı		Pro	Asp
50	Arg	Pro	Lys	Asp	Glu	Val	Phe	Ser	Lvs	ጥህጕ	ጥኒ/ነ-	Thr	Dro	670	T	77.
			9,5					680					C 0 C			
	Lys	Ala	Val .	Asp	Gly	Tyr	Val	Lys	Pro	Gln	Ile	Lvs	Gln	Va 1	Va 1	Dro
		920					פעס					700				
E E	Glu 705	Phe	Val	Asn	Ala	Ser .	Ala	Asp	Ala	Gly	Gly	Ser	Ser	Ala	Thr	Tvr
55	, 00					110					715					700
	Met .	Asp	Gin	Ala	Pro	Ser	Pro .	Ala	Val	Cys	Pro	Gln .	Ala	Pro	Tyr	Asn
															•	

185

					725					730					735		
	Met	Tyr	Pro	Gln 740	Asn	Pro	Asp	His	Val 745		qaA	Gln	Asp	Gly 750	Glu	Phe	
5	Asp	Leu	Asp 755	Glu	Thr	Met	Asp	Val 760	Ala	Arg	His	Val	Glu 765	Glu	Leu	Leu	٠
	Arg	Arg 770	Pro	Met	Asp	Ser	Leu 775	qaA	Ser	Arg	Leu	Ser 780	Pro	Pro	Ala	Gly	
	Leu 785	Phe	Thr	Ser	Ala	Arg 790	Gly	Ser	Leu	Ser	Trp 795	Val	Pro	Arg	Ala	Arg 800	
10	Asp	Pro	Pro	Val	Ala 805	Thr	Met	Val	Ser	Lys 810	Gly	Glu	Glu	Leu	Phe 815	Thr	
	Gly	Val	Val	Pro 820	Ile	Leu	Val	Glu	Leu 825	Asp	Gly	Asp	Val	Asn 830	Gly	His	
15	Lys	Phe	Ser 835	Val	Ser	Gly	Glu	Gly 840	Glu	Gly	Asp	Ala	Thr 845	Tyr	Gly	Lys	
	Leu	Thr 850	Leu	Lys	Phe	Ile	Cys 855	Thr	Thr	Gly	Lys	Leu 860	Pro	Val	Pro	Trp	
	Pro 865	Thr	Leu	Val	Thr	Thr 870	Leu	Thr	Tyr	Gly	Val 875	Gln	Сув	Phe	Ser	Arg 880	
20	Tyr	Pro	Asp	His	Met 885	Lys	Gln	His	Asp	Phe 890	Phe	Lys	Ser	Ala	Met 895	Pro	•
	Glu	Gly	Tyr	Val 900	Gln	Glu	Arg	Thr	Ile 905	Phe	Phe	Lys	Asp	Asp 910	Gly	Asn	
25	Tyr	Lys	Thr 915	Arg	Ala	Glu	Val	Lys 920	Phe	Glu	Gly	Asp	Thr 925	Leu	Val	Asn	
	Arg	Ile 930	Glu	Leu	Lys	Gly	Ile 935	_	Phe	Lys	Glu	Asp 940	Gly	Asn	Ile	Leu	
	Gly 945	His	Lys	Leu	Glu	Tyr 950	Asn	Tyr	Asn	Ser :	His 955	Asn	Val	Tyr	Ile	Met 960	
30	Ala	Asp	Lys	Gln	Lys 965	Asn	Gly	Ile	Lys	Val 970	Asn	Phe	Lys	Ile	Arg 975	His	
	Asn	Ile	Glu	Asp 980	Gly	Ser	Val	Gln	Leu 985	Ala	Asp	His	Tyr	Gln 990	Gln	Asn	
35	Thr	Pro	Ile 995	Gly	Asp	Gly		Val 1000	Leu	Leu	Pro		Asn 1005	His	Tyr	Leu	
		Thr 1010	Gln	Ser	Ala		Ser 1015	Lys	Asp	Pro		Glu 1020	Lys	Arg	Asp	His	
	Met 025		Leu	Leu		Phe 1030	Val	Thr	Ala		Gly 1035	Ile		Leu		Met 1040	
40	Asp	Glu	Leu	-	Lys 1045												
			(2)	) IN	FORM	ATIO	V FO	R SE	Q ID	NO:	80:						
45		(:		_		CHAR											
			(B)	TYP	E: n	28 l ucle	ic a	cid									
50	•					DNES: Y: 1		_	е								
		(:	xi)	SEQU	ENCE	DES	CRIP	TION	: SE	Q ID	NO:	80:					
55	TGG	GATC	CTC :	AGGC	CGTG	CT G	CTGG	CCG									28
50			(2	) IN	FORM	OITA	N FO	R SE	Q ID	NO:	81:						

5	<ul><li>(i) SEQUENCE CHARACTERISTICS:</li><li>(A) LENGTH: 27 base pairs</li><li>(B) TYPE: nucleic acid</li><li>(C) STRANDEDNESS: single</li><li>(D) TOPOLOGY: linear</li></ul>	
10	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:81:	
	GTCTCGAGGG AGCATGGGCA CCTTGCG	27
15	(2) INFORMATION FOR SEQ ID NO:82:	
13	<ul><li>(i) SEQUENCE CHARACTERISTICS:</li><li>(A) LENGTH: 27 base pairs</li><li>(B) TYPE: nucleic acid</li><li>(C) STRANDEDNESS: single</li></ul>	
20	(D) TOPOLOGY: linear	
	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:82:	.*
25	TGGGATCCGA GAAGTCTATA TCCCATC	. 27
	(2) INFORMATION FOR SEQ ID NO:83:	
30	<ul><li>(i) SEQUENCE CHARACTERISTICS:</li><li>(A) LENGTH: 28 base pairs</li><li>(B) TYPE: nucleic acid</li><li>(C) STRANDEDNESS: single</li></ul>	
	(D) TOPOLOGY: linear	
35	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:83:	
	TGGGATCCTT AGAAGTCTAT ATCCCATC	28
40	(2) INFORMATION FOR SEQ ID NO:84:	
	(i) SEQUENCE CHARACTERISTICS:  (A) LENGTH: 28 base pairs  (B) TYPE: nucleic acid	
45	(C) STRANDEDNESS: single (D) TOPOLOGY: linear	
	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:84:	· · · · ·
50	GTCTCGAGCC ATGAACGCCC CCGAGCGG	28
	(2) INFORMATION FOR SEQ ID NO:85:	
55	<ul><li>(i) SEQUENCE CHARACTERISTICS:</li><li>(A) LENGTH: 30 base pairs</li><li>(B) TYPE: nucleic acid</li></ul>	
		186

	(C) STRANDEDNESS: single (D) TOPOLOGY: linear	
5	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:85:	
	GTGAATTCTC GTCTGATTTC TGGCAGGAGG	30
10	(2) INFORMATION FOR SEQ ID NO:86:	
15	<ul><li>(i) SEQUENCE CHARACTERISTICS:</li><li>(A) LENGTH: 30 base pairs</li><li>(B) TYPE: nucleic acid</li><li>(C) STRANDEDNESS: single</li><li>(D) TOPOLOGY: linear</li></ul>	
	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:86:	
20	GTGAATTCTT TACGTCTGAT TTCTGGCAGG	30
	(2) INFORMATION FOR SEQ ID NO:87:	
25	<ul><li>(i) SEQUENCE CHARACTERISTICS:</li><li>(A) LENGTH: 34 base pairs</li><li>(B) TYPE: nucleic acid</li><li>(C) STRANDEDNESS: single</li><li>(D) TOPOLOGY: linear</li></ul>	
30		
	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:87:	- 4
25	GTCTCGAGCC ATGGACGAAC TGTTCCCCCT CATC	34
35	(2) INFORMATION FOR SEQ ID NO:88:  (i) SEQUENCE CHARACTERISTICS:	
40	(A) LENGTH: 31 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
45	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:88:	
45	GTGGATCCAA GGAGCTGATC TGACTCAGCA G	31
	(2) INFORMATION FOR SEQ ID NO:89:	
50	(i) SEQUENCE CHARACTERISTICS:  (A) LENGTH: 32 base pairs  (B) TYPE: nucleic acid  (C) STRANDEDNESS: single	
55	(D) 'TOPOLOGY: linear	

	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:89:	
	GTGGATCCTT AGGAGCTGAT CTGACTCAGC AG	32
5	(2) INFORMATION FOR SEQ ID NO:90:	
10	(i) SEQUENCE CHARACTERISTICS:  (A) LENGTH: 32 base pairs  (B) TYPE: nucleic acid  (C) STRANDEDNESS: single  (D) TOPOLOGY: linear	
15	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:90:	
	CCTCCTAAGC TTATCATGGA CCATTATGAT TC	32
	(2) INFORMATION FOR SEQ ID NO:91:	
20	(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 33 base pairs	
	(B) TYPE: nucleic acid (C) STRANDEDNESS: single	
25	(D) TOPOLOGY: linear	
	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:91:	
30	CCTCCTGGAT CCCTGCGCAG GATGATGGTC CAG	33
	(2) INFORMATION FOR SEQ ID NO:92:	-
35	<ul> <li>(i) SEQUENCE CHARACTERISTICS:</li> <li>(A) LENGTH: 45 base pairs</li> <li>(B) TYPE: nucleic acid</li> <li>(C) STRANDEDNESS: single</li> <li>(D) TOPOLOGY: linear</li> </ul>	
40	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:92:	
	GGATGGAAGC TTCAATGGCT GCCATCCGGA AGAAACTGGT GATTG	45
45	(2) INFORMATION FOR SEQ ID NO:93:	
	<ul><li>(i) SEQUENCE CHARACTERISTICS:</li><li>(A) LENGTH: 45 base pairs</li><li>(B) TYPE: nucleic acid</li></ul>	
50	(C) STRANDEDNESS: single (D) TOPOLOGY: linear	
	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:93:	
55	GGATGGGGAT CCTCACAAGA CAAGGCAACC AGATTTTTC TTCCC	45

	109	
	(2) INFORMATION FOR SEQ ID NO:94:	
5	<ul><li>(i) SEQUENCE CHARACTERISTICS:</li><li>(A) LENGTH: 29 base pairs</li><li>(B) TYPE: nucleic acid</li></ul>	
J	(C) STRANDEDNESS: single (D) TOPOLOGY: linear	
10	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:94:	
	GGGAAGCTTC CATGAGCGAG ACGGTCATC	29
15	(2) INFORMATION FOR SEQ ID NO:95:	
	(i) SEQUENCE CHARACTERISTICS:  (A) LENGTH: 28 base pairs  (B) TYPE: nucleic acid	
20	(C) STRANDEDNESS: single (D) TOPOLOGY: linear	٠
	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:95:	
25	CCCGGATCCT CAGGGAGAAC CCCGCTTC	28
	(2) INFORMATION FOR SEQ ID NO:96:	
30	<ul><li>(i) SEQUENCE CHARACTERISTICS:</li><li>(A) LENGTH: 30 base pairs</li><li>(B) TYPE: nucleic acid</li><li>(C) STRANDEDNESS: single</li><li>(D) TOPOLOGY: linear</li></ul>	
35	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:96:	
	GTGAATTCGA CCATGGAGCG GCCCCCGGGG	30
40	(2) INFORMATION FOR SEQ ID NO:97:	30
	(i) SEQUENCE CHARACTERISTICS:	
	(A) LENGTH: 27 base pairs (B) TYPE: nucleic acid	
45	(C) STRANDEDNESS: single (D) TOPOLOGY: linear	
50	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:97:	
	GTGGTACCCA TTCTGTTAAC CAACTCC	27
	(2) INFORMATION FOR SEQ ID NO:98:	
55	(i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 28 base pairs	

	(B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear	
5		
	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:98:	
	GTGGTACCTC ATTCTGTTAA CCAACTCC	28
10	(2) INFORMATION FOR SEQ ID NO:99:	
15	(i) SEQUENCE CHARACTERISTICS:  (A) LENGTH: 28 base pairs  (B) TYPE: nucleic acid	
	(C) STRANDEDNESS: single (D) TOPOLOGY: linear	
20	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:99:	
	GTCTCGAGAG ATGCTGTCCC GTGGGTGG	28
	(2) INFORMATION FOR SEQ ID NO:100:	
25	(i) SEQUENCE CHARACTERISTICS:  (A) LENGTH: 27 base pairs  (B) TYPE: nucleic acid	
30	(C) STRANDEDNESS: single (D) TOPOLOGY: linear	
	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:100:	
35	GTGAATTCGC TTCCTCTTGA GGGAACC	27
	(2) INFORMATION FOR SEQ ID NO:101:	
40	<ul> <li>(i) SEQUENCE CHARACTERISTICS:</li> <li>(A) LENGTH: 27 base pairs</li> <li>(B) TYPE: nucleic acid</li> <li>(C) STRANDEDNESS: single</li> <li>(D) TOPOLOGY: linear</li> </ul>	
45	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:101:	
	GTGAATTCAC TTCCTCTTGA GGGAACC	27
50	(2) INFORMATION FOR SEQ ID NO:102:	
	<ul><li>(i) SEQUENCE CHARACTERISTICS:</li><li>(A) LENGTH: 29 base pairs</li><li>(B) TYPE: nucleic acid</li></ul>	
55	(C) STRANDEDNESS: single (D) TOPOLOGY: linear	

	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:102:	
_	GTCTCGAGCC ATGGAGAACT TCCAAAAGG	29
5	(2) INFORMATION FOR SEQ ID NO:103:	
10	<ul><li>(i) SEQUENCE CHARACTERISTICS:</li><li>(A) LENGTH: 28 base pairs</li><li>(B) TYPE: nucleic acid</li><li>(C) STRANDEDNESS: single</li><li>(D) TOPOLOGY: linear</li></ul>	
15	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:103:	
	GTGGATCCCA GAGTCGAAGA TGGGGTAC	28
20	(2) INFORMATION FOR SEQ ID NO:104:	
20	<ul><li>(i) SEQUENCE CHARACTERISTICS:</li><li>(A) LENGTH: 29 base pairs</li><li>(B) TYPE: nucleic acid</li></ul>	
25	(C) STRANDEDNESS: single (D) TOPOLOGY: linear	
	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:104:	
30	GTGGATCCTC AGAGTCGAAG ATGGGGTAC	29
	(2) INFORMATION FOR SEQ ID NO:105:	
35	<ul><li>(i) SEQUENCE CHARACTERISTICS:</li><li>(A) LENGTH: 30 base pairs</li><li>(B) TYPE: nucleic acid</li><li>(C) STRANDEDNESS: single</li><li>(D) TOPOLOGY: linear</li></ul>	
40	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:105:	-
	GTGAATTCGG CGATGCCAGA CCCCGCGGCG	30
45	(2) INFORMATION FOR SEQ ID NO:106:	
50	<ul><li>(i) SEQUENCE CHARACTERISTICS:</li><li>(A) LENGTH: 32 base pairs</li><li>(B) TYPE: nucleic acid</li><li>(C) STRANDEDNESS: single</li><li>(D) TOPOLOGY: linear</li></ul>	
	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:106:	
55	GTGGATCCCA GGCACAGGCA GCCTCAGCCT TC	32
		19

. 192

	(2) INFORMATION FOR SEQ ID NO: 107:	
5	<ul> <li>(i) SEQUENCE CHARACTERISTICS:</li> <li>(A) LENGTH: 33 base pairs</li> <li>(B) TYPE: nucleic acid</li> <li>(C) STRANDEDNESS: single</li> <li>(D) TOPOLOGY: linear</li> </ul>	
10	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:107:	
	GTGGATCCTC AGGCACAGGC AGCCTCAGCC TTC	33
15	(2) INFORMATION FOR SEQ ID NO:108:	33
20	<ul> <li>(i) SEQUENCE CHARACTERISTICS:</li> <li>(A) LENGTH: 2616 base pairs</li> <li>(B) TYPE: nucleic acid</li> <li>(C) STRANDEDNESS: single</li> <li>(D) TOPOLOGY: linear</li> </ul>	
25	(ii) MOLECULE TYPE: cDNA (ix) FEATURE:	
	<ul><li>(A) NAME/KEY: Coding Sequence</li><li>(B) LOCATION: 12613</li><li>(D) OTHER INFORMATION:</li></ul>	
30	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:108:	
	ATG GTG AGC AAG GGC GAG GAG CTG TTC ACC GGG GTG GTG CCC ATC CTG  Met Val Ser Lys Gly Glu Glu Leu Phe Thr Gly Val Val Pro Ile Leu  1 5 10 15	48
35	GTC GAG CTG GAC GGC GAC GTA AAC GGC CAC AAG TTC AGC GTG TCC GGC Val Glu Leu Asp Gly Asp Val Asn Gly His Lys Phe Ser Val Ser Gly 20 25 30	96
40	GAG GGC GAG GGC GAT GCC ACC TAC GGC AAG CTG ACC CTG AAG TTC ATC Glu Gly Glu Gly Asp Ala Thr Tyr Gly Lys Leu Thr Leu Lys Phe Ile 35	144
45	TGC ACC ACC GGC AAG CTG CCC GTG CCC TGG CCC ACC CTC GTG ACC ACC Cys Thr Thr Gly Lys Leu Pro Val Pro Trp Pro Thr Leu Val Thr Thr 50 55 60	192
50	CTG ACC TAC GGC GTG CAG TGC TTC AGC CGC TAC CCC GAC CAC ATG AAG Leu Thr Tyr Gly Val Gln Cys Phe Ser Arg Tyr Pro Asp His Met Lys 65 70 75 80	240
55	CAG CAC GAC TTC TTC AAG TCC GCC ATG CCC GAA GGC TAC GTC CAG GAG Gln His Asp Phe Phe Lys Ser Ala Met Pro Glu Gly Tyr Val Gln Glu 85 90 95	288
	CGC ACC ATC TTC TTC AAG GAC GAC GGC AAC TAC AAG ACC CGC GCC GAG	336 192

										193								
·	Arg	Thr	Ile	Phe 100	Phe	Lys	Asp	Asp	Gly 105	Asn	Tyr	Lys	Thr	Arg 110	Ala	Glu		
5				GAG Glu													384	
10		_		AAG Lys													432	
15				AGC Ser													480	
				GTG Val													528	
20				GCC Ala 180													576	
25				CTG Leu													624	
30			Asp	CCC Pro													672	
35				GCC Ala													720	
33				TCT Ser													768	
40				CTG Leu 260												GCC Ala	816	
45				CTG Leu												CTG Leu	864	
50				CTG Leu									Ser				912	
<b></b>		Val		TTC Phe													960	
55	TAC	GCC	ATT	GCC	GGC	GGC	AAA	GCG	CAC	TGT	GGA	CCG	GCA	GAG	CTC	TGC	1008	193

•	194
	Tyr Ala Ile Ala Gly Gly Lys Ala His Cys Gly Pro Ala Glu Leu Cys 325 330 335
5	340 345 350 CGC AAG 1056
10	360 365
15	TGC CTG CGA GAC GCC ATG GTG CGT GAC TAC GTG CGC CAG ACG TGG AAG  Cys Leu Arg Asp Ala Met Val Arg Asp Tyr Val Arg Gln Thr Trp Lys  370  375  380
20	CTG GAG GGC GAG GCC CTG GAG CAG GCC ATC ATC AGC CAG GCC CCG CAG  Leu Glu Gly Glu Ala Leu Glu Gln Ala Ile Ile Ser Gln Ala Pro Gln  395  400
20	GTG GAG AAG CTC ATT GCT ACG ACG GCC CAC GAG CGG ATG CCC TGG TAC  Val Glu Lys Leu Ile Ala Thr Thr Ala His Glu Arg Met Pro Trp Tyr  405  410  415
25	CAC AGC AGC CTG ACG CGT GAG GAG GCC GAG CGC AAA CTT TAC TCT GGG 1296 His Ser Ser Leu Thr Arg Glu Glu Ala Glu Arg Lys Leu Tyr Ser Gly 420 425 430
30	GCG CAG ACC GAC GGC AAG TTC CTG CTG AGG CCG CGG AAG GAG CAG GGC  Ala Gln Thr Asp Gly Lys Phe Leu Leu Arg Pro Arg Lys Glu Gln Gly  435  440  445
35	ACA TAC GCC CTG TCC CTC ATC TAT GGG AAG ACG GTG TAC CAC TAC CTC  Thr Tyr Ala Leu Ser Leu Ile Tyr Gly Lys Thr Val Tyr His Tyr Leu  450  450
	ATC AGC CAA GAC AAG GCG GGC AAG TAC TGC ATT CCC GAG GGC ACC AAG  Ile Ser Gln Asp Lys Ala Gly Lys Tyr Cys Ile Pro Glu Gly Thr Lys  475  480
40	TTT GAC ACG CTC TGG CAG CTG GTG GAG TAT CTG AAG CTG AAG GCG GAC  Phe Asp Thr Leu Trp Gln Leu Val Glu Tyr Leu Lys Leu Lys Ala Asp  485  490  495
45	GGG CTC ATC TAC TGC CTG AAG GAG GCC TGC CCC AAC AGC AGT GCC AGC Gly Leu Ile Tyr Cys Leu Lys Glu Ala Cys Pro Asn Ser Ser Ala Ser 500 505 510
50	AAC GCC TCA GGG GCT GCT CCC ACA CTC CCA GCC CAC CCA TCC ACG Asn Ala Ser Gly Ala Ala Ala Pro Thr Leu Pro Ala His Pro Ser Thr 515 520 525
55	TTG ACT CAT CCT CAG AGA CGA ATC GAC ACC CTC AAC TCA GAT GGA TAC Leu Thr His Pro Gln Arg Arg Ile Asp Thr Leu Asn Ser Asp Gly Tyr 530 535 540
	ACC CCT GAG CCA GCA CGC ATA ACG TCC CCA GAC AAA CCG CGG CCG ATG 1680

			•	•						195							
	Thr 545	Pro	Glu	Pro	Ala	Arg 550	Ile	Thr	Ser	Pro	Asp 555	Lys	Pro	Arg ·	Pro	Met 560	
5					AGC Ser 565												1728
10					AAG Lys												1776
15					GGC Gly				,								1824
15					AAG Lys											AAG Lys	1872
20					AAG Lys												1920
25					CTG Leu 645												1968
30					GCC Ala												2016
25					TTC Phe												2064
35					CTG Leu												2112
40					TTT Phe												2160
45					CAC His 725												2208
50					GAC Asp												2256
					TGG Trp												2304
55	TCC	AGC	CGC	AGC	GAT	GTC	TGG	AGC	TAT	GGG	GTC	ACC	ATG	TGG	GAG	GCC	2352

			•		•					40			-					
•	0-									19	_							-
	se	77	r Arq O	g Se:	r As <sub>l</sub>	o Va	1 Tr	p Se 5	r Ty	r G	ly '	Val	Thr 780		Trj	Gl	u Ala	
_	TT	G TC	C TAC	GGG	CAC	AA E	G CC	C TA	C AA	G A	AG A	ATG	מממ	GGG	· ccc	י מא	G GTC	
5	Le:		r Tyı	Gly	/ Gli	1 Ly:	5 PIC	э Ту	r Ly	s L	ys N	let 195	Lys	Gly	Pro	Gli	G GTC u Val 800	2400
	7. TV	~ ~~	3 mmc															
	Met	: Ala	. IIC a Phe	. Alc	GAC	CAC	GGC	AA	G CG	G A	rg c	AG	TGC	CCA	CCA	GAG	G TGT	2448
10					002	•				8.	LO					815	5	•
	CCZ	CCC	GAA	CTG	TAC	GCA	CTC	AT	G AG	T GA	AC T	GC	TGG	ATC	TAC	AAG	TGG	2496
	Pro	Pro	Glu	Leu 820	TAT	Ala	Leu	Me	: Se	r As	sp C	ys	Trp	Ile	Tyr	Lys	TGG Trp	2470
15				020					82	5					830			
	GAG	GAT	CGC	CCC	GAC	TTC	CTG	AC	GT	G GA	G C	AG (	CGC	ATG	CGA	GCC	TGT	2544
	Glu	Asp	Arg 835	Pro	Asp	Phe	Leu	Th:	· Va.	l G1	u G	ln i	Arg	Met 845	Arg	Ala	Cys	2544
20	TAC	TAC	AGC	CTG	GCC	AGC	AAG	GTG	. Ca	۰		00					CAG	
	Tyr	Tyr	Ser	Leu	Ala	Ser	Lys	Val	. Gli	1 GC 1 G1	v P	ro I	CCA Pro	GGC	AGC	ACA	CAG Gln	2592
		.850					855				4 -		360	O.J.	DCI	1111	GIII	
	AAG	GCT	GAG	GCT	GCC	тст	ccc	TIC N										`
25	Lys	Ala	Glu	Ala	Ala	Cys	Ala	IGA				-						2616
	865					870												
			,	•							-							
			(2)	INE	· ORM	TIOI	V FOI	2 SE	O Tr	N NO	. 101	١.						
30				•							: 103	<i>,</i> :						
		(:	i) SE	QUEN	ICE (	HAR	ACTE	RIST	ICS:									
			(A)	TYPE	TH: !: an	871	amir	10 a	cids									
							3: si		e									
35			(D)	TOPO	LOGY	: li	near	:										
		( i	i) M	OT.FC	ם.זזו	ጥህከር	٠											
		7)	i) M r) FR	AGME	NT I	YPE:	.: pr int	ote.	ln al									,
40																		
40		κ)	i) s	EQUE	NCE	DESC	RIPT	NOI	SE	Q II	) NO	:10	9:					•
	Met	Val	Ser	Lys	Glv	Glu	Glu	ī.en	Dhe	The					_			
	-				Þ					10								
45	Val	Gľu	Leu .	Asp	Gly	Asp	Val	Asn	Gly	His	Ly	s Pl	he S	er v	Val	Ser	Gly	
40			•						25									
	Glu							40										
	Cys	Thr 50	Thr (	Gly 1	Lys :	Leu	Pro '	Val	Pro	Trp	Pro		nr I	eu (	/al '	rhr	Thr	
50	Leu 65		Tyr (	3ly v	/al (	3ln	oo Cvs :	Phe	Ser	Δτα	т.,	6( - D	, )	1				
						, ,					76						~ ~	
	Gln :	His .	Asp I	he 1	he 1	Lys :	Ser 1	Ala	Met	Pro	Glı	ı G]	ly т	yr V	al (	3ln	Glu	
				•	, ,					۵0						-		
55	Arg '								ากร					-	2 0			
	Val 1	Lys :	Phe C	Slu (	ly /	\sp '	Thr I	Leu	Val	Asn	Arg	, Il	e G	lu L	eu I	ys (	Gly	

			115					120			•		125			
	Ile	Asp		Lvs	Glu	Asp	Glv	-	Ile	Leu	Glv	His			Glu	Tyr
		130			His		135					140				
5	145					150					155					160
	Gly	Ile	Lys	Val	Asn 165	Phe	Lys	Ile	Arg	His 170	Asn	Ile	Glu	Asp	Gly 175	Ser
	Val	Gln	Leu	Ala 180	Asp	His	Tyr	Gln	Gln 185	Asn	Thr	Pro	Ile	Gly 190	Asp	Gly
10	Pro	Val	Leu 195	Leu	Pro	Asp	Asn	His 200	Tyr	Leu	Ser	Thr	Gln 205	Ser	Ala	Leu
	Ser	Lys 210	Asp	Pro	Asn	Glu	Lys 215	Arg	Asp	His	Met	Val 220	Leu	Leu	Glu	Phe
15	Val 225	Thr	Ala	Ala	Gly	Ile 230	Thr	Leu	Gly	Met	Asp 235	Glu	Leu	Tyr	Lys	Ser 240
		Leu	Arg	Ser	Arg 245	Ala	Gln	Ala	Ser	Asn 250		Ala	Met	Pro	Asp 255	Pro
	Ala	Ala	His	Leu 260	Pro	Phe	Phe	Tyr	Gly 265		Ile	Ser	Arg	Ala 270		Ala
20	Glu	Glu	His 275		Lys	Leu	Ala	Gly 280		Ala	Asp	Gly	Leu 285		Leu	Leu
	Arg	Gln 290		Leu	Arg	Ser	Leu 295		Gly	Tyr	Val	Leu 300		Leu	Val	His
25	Asp 305		Arg	Phe	His	His 310		Pro	Ile	Glu	Arg 315		Leu	Asn	Gly	Thr
20		Ala	Ile	Ala	Gly 325		Lys	Ala	His	Cys 330		Pro	Ala	Glu	Leu 335	
	Glu	Phe	Tyr	Ser 340	Arg	Asp	Pro	Asp	Gly 345		Pro	Cys	Asn	Leu 350		Lys
30	Pro	Cys	Asn 355		Pro	Ser	Gly	Leu 360		Pro	Gln	Pro	Gly 365	Val		Asp
•	Cys	Leu 370		Asp	Ala	Met	Val 375		Asp	Tyr	Val	Arg 380		Thr		Lys
35	Leu 385		Gly	Glu	Ala	Leu 390		Gln	Ala	Ile	Ile 395		Gln	Ala	Pro	Gln 400
33		Glu	Lys	Leu	Ile		Thr	Thr	Ala	His 410		Arg	Met	Pro	Trp	
	His	Ser	Ser	Leu 420	Thr	Arg	Glu	Glu	Ala 425		Arg	Lys	Leu	Tyr 430		Gly
40	Ala	Gln	Thr		Gly	Lys	Phe	Leu 440		Arg	Pro	Arg	Lys		Gln	Gly
	Thr	Tyr 450		Leu	Ser	Leu	Ile 455		Gly	Lys	Thr	Val		His	Tyr	Leu
45	Ile 465		Gln	Asp	Lys	Ala 470		Lys	Tyr	Cys	Ile 475		Glu	Gly	Thr	Lys
70		Asp	Thr	Leu	Trp		Leu	Val	Glu	Tyr 490		Lys	Leu	Lys	Ala 495	
	Gly	Leu	Ile	Tyr 500	Cys	Leu	Lys	Glu	Ala 505		Pro	Asn	Ser	Ser 510		Ser
50	Asn	Ala	Ser 515		Ala	Ala	Ala	Pro 520		Leu	Pro	Ala	His 525		Ser	Thr
	Leu	Thr 530	His	Pro	Gln	Arg	Arg 535		Asp	Thr	Leu	Asn 540		Asp	Gly	Туг
55	Thr 545			Pro	Ala	Arg 550		Thr	Ser	Pro	Asp 555		Pro	Arg	Pro	Met
<b>J</b> J	243	Mah	7		Cor	-	<b></b>	<b>a</b> 1	0	D		C	7 00	Dro	<i>C</i> 1	

```
565
                                             570
         Leu Lys Asp Lys Lys Leu Phe Leu Lys Arg Asp Asn Leu Leu Ile Ala
         Asp Ile Glu Leu Gly Cys Gly Asn Phe Gly Ser Val Arg Gln Gly Val
                                        585
    5
                                    600
         Tyr Arg Met Arg Lys Lys Gln Ile Asp Val Ala Ile Lys Val Leu Lys
                                615
        Gln Gly Thr Glu Lys Ala Asp Thr Glu Glu Met Met Arg Glu Ala Gln
        Ile Met His Gln Leu Asp Asn Pro Tyr Ile Val Arg Leu Ile Gly Val
  10
        Cys Gln Ala Glu Ala Leu Met Leu Val Met Glu Met Ala Gly Gly
                                            650
                                        665
        Pro Leu His Lys Phe Leu Val Gly Lys Arg Glu Glu Ile Pro Val Ser
  15
                                   680
        Asn Val Ala Glu Leu Leu His Gln Val Ser Met Gly Met Lys Tyr Leu
                                695
        Glu Glu Lys Asn Phe Val His Arg Asp Leu Ala Ala Arg Asn Val Leu
                            710
        Leu Val Asn Arg His Tyr Ala Lys Ile Ser Asp Phe Gly Leu Ser Lys
                                                715
  20
                                            730
       Ala Leu Gly Ala Asp Asp Ser Tyr Tyr Thr Ala Arg Ser Ala Gly Lys
                                        745
       Trp Pro Leu Lys Trp Tyr Ala Pro Glu Cys Ile Asn Phe Arg Lys Phe
 25
                                   760
       Ser Ser Arg Ser Asp Val Trp Ser Tyr Gly Val Thr Met Trp Glu Ala
                               775
       Leu Ser Tyr Gly Gln Lys Pro Tyr Lys Lys Met Lys Gly Pro Glu Val
                                                   780
                           790
       Met Ala Phe Ile Glu Gln Gly Lys Arg Met Glu Cys Pro Pro Glu Cys
                                               795
 30
                                           810
       Pro Pro Glu Leu Tyr Ala Leu Met Ser Asp Cys Trp Ile Tyr Lys Trp
                                       825
       Glu Asp Arg Pro Asp Phe Leu Thr Val Glu Gln Arg Met Arg Ala Cys
 35
                                   840
       Tyr Tyr Ser Leu Ala Ser Lys Val Glu Gly Pro Pro Gly Ser Thr Gln
      Lys Ala Glu Ala Ala Cys Ala
40
               (2) INFORMATION FOR SEQ ID NO:110:
            (i) SEQUENCE CHARACTERISTICS:
              (A) LENGTH: 2598 base pairs
45
              (B) TYPE: nucleic acid
              (C) STRANDEDNESS: single
              (D) TOPOLOGY: linear
          " (ii) MOLECULE TYPE: cDNA
50
            (ix) FEATURE:
               (A) NAME/KEY: Coding Sequence
               (B) LOCATION: 1...2595
               (D) OTHER INFORMATION:
55
            (xi) SEQUENCE DESCRIPTION: SEQ ID NO:110:
```

							CAC His										4	48
5							CAC His										!	96
10							TGC Cys										14	44
15							CGC Arg 55										1:	92
20							ATT Ile										2	40
05							TAC Tyr										. 2	88
25							AAC Asn										3	36
30							CGA Arg										3	84
35							GGC Gly 135										4	32
40							AAG Lys										4	80
45	ATG Met	CCC Pro	TGG Trp	TAC Tyr	CAC His 165	AGC Ser	AGC Ser	CTG Leu	ACG Thr	CGT Arg 170	GAG Glu	GAG Glu	GCC Ala	GAG Glu	CGC Arg 175	AAA Lys		28
45					Ala					Lys						CGG Arg	5	576 <sub>.</sub>
50				Gly					Ser					Lys		GTG Val	€	524
55			Tyr					Asp					Tyr			CCC	6	572

5	22	5	-,	<i></i> ,	5 11	23	0	r re	u Tr	b GT	n Le	eu Va 85	al Gl	и Ту	r Le	G AAG u Lys 240	;
	CT <sup>(</sup>	G AA u L	AG GC 's Al	CG GA .a As	C GG p Gl 24	y re	C ATO	TA Ty:	C TG	C CT s Le	u Ly	AG GA 's Gl	G GC u Al	C TG a Cy	C CC S Pr 25	C AAC o Asn 5	768
10				26	0	n Ale	a Sel	GLY	265 265	a Ala 5	a Al	a Pr	O Th	r Le 27	u Pr 0	A GCC o Ala	
15			27	5	. ne		. nis	280	) O GII	ı Arg	g Ar	g Il	e Asp 285	Th:	r Lei	C AAC 1 Asn	864
20		29	0	, <u>-</u> y-	. 1111	. PIC	295	Pro	) Ala	Arc	j Ile	300	r Ser O	Pro	) Asp	AAA Lys	912
25	305	;	,	, ,,,,,	· FIC	310	Asp	ınr	Ser	· Val	315	r Glı 5	ı Ser	Pro	Туг	AGC Ser 320	960
				. 014	325	пуъ	Asp	ьys	гÀг	1330	Phe	e Leu	l Lys	Arg	Asp 335	AAC Asn	1008
30		200		GCT Ala 340	Asp	116	GIU	Leu	G1y 345	Cys	Gly	Asn	Phe	Gly 350	Ser	Val	1056
35	5		355		ıyı	Arg	Met	360	Lys	Lys	Gln	Ile	Asp 365	Val	Ala	Ile	1104
40	-72	370	Deu	AAG Lys	GIII	GIY	375	GIu	Lys	Ala	Asp	Thr 380	Glu	Glu	Met	Met	1152
45	385		*****	CAG Gln	116	390	HIS	GIN	Leu	Asp	Asn 395	Pro	Tyr	Ile	Val	Arg 400	1200
			OL,	GTC Val	405	GIII	Ala	GIU	Ala	Leu 410	Met	Leu	Val	Met	Glu 415	Met	1248
50		O <sub>1</sub>	Cly	GGG Gly 420	-	ьеи	HIS .	Lys	Phe 425	Leu	Val	Gly	Lys	Arg 430	Glu	Glu	1296
55	ATC Ile	CCT Pro	GTG Val 435	AGC Ser	AAT Asn	GTG ( Val ,	ата (	GAG Glu 140	CTG   Leu	CTG Leu	CAC His	CAG Gln	GTG Val 445	TCC Ser	ATG Met	GGG Gly	1344

5		CTG Leu								1392
		CTG Leu								1440
10		AAA Lys								1488
15		AAG Lys 500			 	 				1536
20		TTC Phe					_	_	_	1584
25		GCC Ala								1632
		GTC Val								1680
30		TGT Cys								1728
35		TGG Trp 580								1776
40		TGT Cys								1824
45		CAG Gln								1872
		GTG Val								1920
50		GAG Glu								1968
55		GGC Gly 660								2016

5					ACC Thr												2064
	ACC Thr	ACC Thr 690	CTG Leu	ACC Thr	TAC Tyr	GGC Gly	GTG Val 695	CAG Gln	TGC Cys	TTC Phe	AGC Ser	CGC Arg 700	TAC Tyr	CCC Pro	GAC Asp	CAC His	2112
10					GAC Asp												2160
15					ATC Ile 725												2208
20					TTC Phe												2256
25					TTC Phe												2304
					AAC Asn												2352
30					AAG Lys												2400
35					CTC Leu 805											GGC Gly	2448
40					CTG Leu												2496
45					GAC Asp				Lys								2544
	GAG Glu	TTC Phe 850	GTG Val	ACC Thr	GCC Ala	GCC Ala	GGG Gly 855	ATC Ile	ACT Thr	CTC Leu	GGC Gly	ATG Met 860	GAC Asp	GAG Glu	CTG Leu	TAC Tyr	2592
50	AAG Lys 865	TAA															2598

55 (2) INFORMATION FOR SEQ ID NO:111:

203

.

(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 865 amino acids

(B) TYPE: amino acid

- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

5

- (ii) MOLECULE TYPE: protein
- (v) FRAGMENT TYPE: internal
- 10 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:111:

Met Pro Asp Pro Ala Ala His Leu Pro Phe Phe Tyr Gly Ser Ile Ser 10 Arg Ala Glu Ala Glu Glu His Leu Lys Leu Ala Gly Met Ala Asp Gly 15 20 25 Leu Phe Leu Leu Arg Gln Cys Leu Arg Ser Leu Gly Gly Tyr Val Leu Ser Leu Val His Asp Val Arg Phe His His Phe Pro Ile Glu Arg Gln 55 20 Leu Asn Gly Thr Tyr Ala Ile Ala Gly Gly Lys Ala His Cys Gly Pro 70 Ala Glu Leu Cys Glu Phe Tyr Ser Arg Asp Pro Asp Gly Leu Pro Cys Asn Leu Arg Lys Pro Cys Asn Arg Pro Ser Gly Leu Glu Pro Gln Pro 25 105 Gly Val Phe Asp Cys Leu Arg Asp Ala Met Val Arg Asp Tyr Val Arg 120 Gln Thr Trp Lys Leu Glu Gly Glu Ala Leu Glu Gln Ala Ile Ile Ser 135 30 Gln Ala Pro Gln Val Glu Lys Leu Ile Ala Thr Thr Ala His Glu Arg 150 155 Met Pro Trp Tyr His Ser Ser Leu Thr Arg Glu Glu Ala Glu Arg Lys 165 170 Leu Tyr Ser Gly Ala Gln Thr Asp Gly Lys Phe Leu Leu Arg Pro Arg 35 180 185 Lys Glu Gln Gly Thr Tyr Ala Leu Ser Leu Ile Tyr Gly Lys Thr Val 200 Tyr His Tyr Leu Ile Ser Gln Asp Lys Ala Gly Lys Tyr Cys Ile Pro 215 220 40 Glu Gly Thr Lys Phe Asp Thr Leu Trp Gln Leu Val Glu Tyr Leu Lys 230 235 Leu Lys Ala Asp Gly Leu Ile Tyr Cys Leu Lys Glu Ala Cys Pro Asn 250 Ser Ser Ala Ser Asn Ala Ser Gly Ala Ala Ala Pro Thr Leu Pro Ala 45 265 His Pro Ser Thr Leu Thr His Pro Gln Arg Arg Ile Asp Thr Leu Asn 280 Ser Asp Gly Tyr Thr Pro Glu Pro Ala Arg Ile Thr Ser Pro Asp Lys 295 . 50 Pro Arg Pro Met Pro Met Asp Thr Ser Val Tyr Glu Ser Pro Tyr Ser 315 Asp Pro Glu Glu Leu Lys Asp Lys Lys Leu Phe Leu Lys Arg Asp Asn 330 Leu Leu Ile Ala Asp Ile Glu Leu Gly Cys Gly Asn Phe Gly Ser Val

203

340 345 350 Arg Gln Gly Val Tyr Arg Met Arg Lys Lys Gln Ile Asp Val Ala Ile

	_		35	-				360	0				365	5		
		3/0	,				375	5				386	)			. Met
5	Arg 38	g Glu 5	ı Ala	a Gli	n Ile	Met 390	His	Glr	ı Let	ı Ası	Ası 395	Pro	туз	: Ile	· Val	l Arg
	Let	ı Ile	Gly	/ Val	l Cys	Gln		a Glu	ı Ala	Let	Met	Let	val	Met		400 Met
	Ala	a Gly	, Gl	/ Gly	/ Pro		His	Lys	Phe	410 Lev	v ı Val	. Gly	Lys			Glu
10	Ile	Pro	Va]	Ser		Val	Ala	Glu	425 Leu	Leu	His	Gln			Met	Gly
	Met	Lys 450	Туг		Glu	Glu	Lys	440 Asn		· Val	His			Leu	Ala	Ala
45	Arg	Asn		Leu	Leu	Val	455 Asn		His	Tyr	Ala	460 Lys	Ile	Ser	Asp	Phe
15	400	)				470					475					480
					400					490					495	Arg
				500					505					E10		Asn
20			212					520					525			Thr
		230					535					540				Lys
25	243					550					555	Lys				Cys 560
	Pro	Pro	Glu	Cys	Pro 565	Pro	Glu	Leu	Tyr	Ala 570	Leu	Met	Ser	Asp	Cys 575	Trp
				580	Glu				585	Phe				590	Gln	
30			595		Tyr			600	Ala	Ser			605	Gly		
	Gly	Ser 610	Thr	Gln	Lys	Ala	Glu 615	Ala	Ala	Сув	Ala	Trp 620	Asp	Pro	Pro	Val
35	Ala 625	Thr	Met	Val	Ser	Lys 630	Gly	Glu	Glu	Leu	Phe 635	Thr	Gly	Val	Val	
	Ile	Leu	Val	Glu	Leu 645	Asp	Gly	Asp	Val	Asn 650	Gly	His	Lys	Phe		640 Val
	Ser	Gly	Glu	Gly 660	Glu	Gly	Asp	Ala	Thr 665	Tyr	Gly	Lys	Leu		655 Leu	Lys
40	Phe	Ile	Cys 675	Thr	Thr	Gly	Lys	Leu 680	Pro			Trp			Leu	Val
	Thr	Thr 690	Leu	Thr	Tyr	Gly	Val 695	Gln	Cys	Phe	Ser	Arg 700	Tyr	Pro	Asp	His
45	Met 705	Lys	Gln	His	Asp	Phe 710		Lys	Ser	Ala		Pro	Glu	Gly	Tyr	
	Gln	Glu	Arg	Thr	Ile 725		Phe	Lys	Asp	Asp	715 Gly	Asn	Tyr	Lys		720 Arg
	Ala	Glu	Val	Lys 740	Phe	Glu	Gly	Asp	Thr	730 Leu	Val	Asn	Arg		735 Glu	Leu
50	Lys	Gly	Ile 755		Phe	Lys	Glu	Asp	745 Gly	Asn	Ile	Leu		750 His	Lys	Leu
	Glu	Tyr 770		Tyr	Asn	Ser	His	760 Asn	Val	Tyr	Ile		765 Ala	Asp	Lys	Gln
55	Lys 785		Gly	Ile	Lys		775 Asn	Phe	Lys	Ile	Arg	780 His	Asn	Ile	Glu	
		Ser	Val	Gln	Leu .		Asp	His	Tyr	Gln	795 Gln	Asn	Thr	Pro	Ile	800 Glv

										200								
					805					810					815			
	Asp	Gly	Pro	Val 820		Leu	Pro	Asp	Asn 825		Tyr	Leu	Ser	Thr 830		Ser		
5	Ala	Leu	Ser 835		Asp	Pro	Asn	Glu 840		Arg	Asp	His	Met 845	Val	Leu	Leu		
	Glu	Phe 850		Thr	Ala	Ala	Gly 855	Ile	Thr	Leu	Gly	Met 860	Asp	Glu	Leu	Tyr		
	Lys 865																	
10			(2)	INE	FORM	TION	ı FOF	R SE(	Q ID	NO:	112:							
		į)	i) SI	EQUEN	ICE C	HAR	ACTER	RIST	ICS:									
15			(B)	TYPE	: nu	ıclei	ic ad	cid										
				TOPO				_	9									
20			•	OLEC FEATU		TYPE	E: cI	ANC					•					
20		(-		IAN (		EY: (	Codin	ng Se	eauei	nce								
			(B)	LOC	CATIO	N: 1	١:	1632	<b>.</b>									
25		()	xi) s	SEQUE	ENCE	DESC	CRIP'	rion	: SE	Q ID	NO:	112:					•	
	_	GAG															48	
30	Met 1	Glu	Asn	Phe	Gln 5	Lys	Val	Glu	Lys	Ile 10	Gly	GIu	GIÀ	Thr	1yr 15	GIÀ		
		GTG Val															96	
35	Vai	Val	111	20	AIG	nrg	AJII	цуб	25	****	Cly	014	• • • •	30				
		AAA Lys															144	
	1	•	35	-		•		40			-		45					
40		CGA Arg															192	
		50			Y-,		55					60						
45	Lys	CTG Leu				Ile					Lys				_	Phe	240	
	65	TTT	CTTC	כאכ	ראא	70 GNT	CTTC	አለር	מממ	ጥጥር	75 2TG	CDT	GCC	ጥርጥ	ርር ፓ	80 CTC	288	
50		Phe															200	
00	ACT	GGC	ATT	CCT	•	CCC	CTC	ATC	AAG		TAT	CTG	TTC	CAG		CTC	336	
		Gly		_						Ser								
55	CAG	GGC	CTA	GCT	TTC	TGC	CAT	TCT	CAT	CGG	GTC	CTC	CAC	CGA	GAC	CTT	384	
																		205

206

•										200								
	Gln	Gly	Leu 115	Ala	Phe	Cys	His	Ser 120	His	Arg	Val	Leu	His 125	Arg	Asp	Leu	٠	
5				AAT Asn													•	432
10				CTA Leu														480
15				GTG Val														528
				TAT Tyr 180														576
20				ATG Met														624
25				CTC Leu														672
30				CCA Pro														720
35		•		GCC Ala														768
				CGG Arg 260														816
40				TCG Ser														864
45				CCA Pro														912
50				AGC Ser														960
EE				CTG Leu													1	800
55	GGC	GAG	GGC	GAG	GGC	GAT	GCC	ACC	TAC	GGC	AAG	CTG	ACC	CTG	AAG	TTC	נ	1056

									•	207								
	Gly	Glu	Gly	Glu 340	Gly	Asp	Ala	Thr	Tyr 345	Gly	Lys	Leu	Thr	Leu 350	Lys	Phe		
5					GGC Gly													1104
10					GGC Gly													1152
15					TTC Phe													1200
15					TTC Phe 405													1248
20					GAG Glu													1296
25					AAG Lys													1344
30			Tyr		AGC Ser													1392
0.5					GTG Val							Asn						1440
35					GCC Ala 485													1488
40					CTG Leu					Tyr					Ser			1536
<sub>.</sub> 45				Asp	CCC Pro				Arg					Leu		GAG Glu		1584
50			Thr		GCC Ala			Thr					Glu			AAG Lys	Т	1633
	AA									•						_		1635
			(2	) IN	IFORM	LATIC	N FC	R SE	Q II	NO:	113:							

(i) SEQUENCE CHARACTERISTICS:

207

(A) LENGTH: 544 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

5

- (ii) MOLECULE TYPE: protein
- (v) FRAGMENT TYPE: internal
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:113:

10 Met Glu Asn Phe Gln Lys Val Glu Lys Ile Gly Glu Gly Thr Tyr Gly Val Val Tyr Lys Ala Arg Asn Lys Leu Thr Gly Glu Val Val Ala Leu 25 Lys Lys Ile Arg Leu Asp Thr Glu Thr Glu Gly Val Pro Ser Thr Ala 15 Ile Arg Glu Ile Ser Leu Leu Lys Glu Leu Asn His Pro Asn Ile Val Lys Leu Leu Asp Val Ile His Thr Glu Asn Lys Leu Tyr Leu Val Phe 20 75 70 Glu Phe Leu His Gln Asp Leu Lys Lys Phe Met Asp Ala Ser Ala Leu Thr Gly Ile Pro Leu Pro Leu Ile Lys Ser Tyr Leu Phe Gln Leu Leu 100 105 Gln Gly Leu Ala Phe Cys His Ser His Arg Val Leu His Arg Asp Leu 25 120 Lys Pro Gln Asn Leu Leu Ile Asn Thr Glu Gly Ala Ile Lys Leu Ala 135 Asp Phe Gly Leu Ala Arg Ala Phe Gly Val Pro Val Arg Thr Tyr Thr 30 150 . 155 His Glu Val Val Thr Leu Trp Tyr Arg Ala Pro Glu Ile Leu Leu Gly 170 165 Ser Lys Tyr Tyr Ser Thr Ala Val Asp Ile Trp Ser Leu Gly Cys Ile 180 185 Phe Ala Glu Met Val Thr Arg Arg Ala Leu Phe Pro Gly Asp Ser Glu 35 200 205 Ile Asp Gln Leu Phe Arg Ile Phe Arg Thr Leu Gly Thr Pro Asp Glu 215 220 Val Val Trp Pro Gly Val Thr Ser Met Pro Asp Tyr Lys Pro Ser Phe 40 230 235 Pro Lys Trp Ala Arg Gln Asp Phe Ser Lys Val Val Pro Pro Leu Asp 245 250 Glu Asp Gly Arg Ser Leu Leu Ser Gln Met Leu His Tyr Asp Pro Asn 260 . 265 45 Lys Arg Ile Ser Ala Lys Ala Ala Leu Ala His Pro Phe Phe Gln Asp 280 Val Thr Lys Pro Val Pro His Leu Arg Leu Trp Asp Pro Pro Val Ala 295 Thr Met Val Ser Lys Gly Glu Glu Leu Phe Thr Gly Val Val Pro Ile 50 315 310 Leu Val Glu Leu Asp Gly Asp Val Asn Gly His Lys Phe Ser Val Ser 330 Gly Glu Gly Glu Gly Asp Ala Thr Tyr Gly Lys Leu Thr Leu Lys Phe 345 Ile Cys Thr Thr Gly Lys Leu Pro Val Pro Trp Pro Thr Leu Val Thr 55

208

209

	Thr	Leu 370	Thr	Tyr	Gly	Val	Gln 375	Сув	Phe	Ser	Arg	Tyr 380	Pro	Asp	His	Met	
	Lys 385	Gln	His	Asp	Phe	Phe 390	Lys	Ser	Ala	Met	Pro 395		Gly	Tyr	Val	Gln 400	
5	Glu	Arg	Thr	Ile	Phe 405	Phe	Lys	Asp	Asp	Gly 410		Tyr	Lys	Thr	Arg	Ala	
	Glu	Val	Lys	Phe 420	Glu	Gly	Asp	Thr	Leu 425	Val	Asn	Arg	Ile	Glu 430	Leu	Lys	
10	Gly	Ile	Asp	Phe	Lys	Glu	Asp	Gly 440		Ile	Leu	Gly	His		Leu	Glu	
	Tyr	Asn 450		Asn	Ser	His	Asn 455	Val	Tyr	Ile	Met	Ala 460		Lys	Gln	Lys	
	Asn 465	Gly	Ile	Lys	Val	Asn 470	Phe	Lys	Ile	Arg	His 475	Asn	Ile	Glu	Asp	Gly 480	
15	Ser	Val	Gln	Leu	Ala 485	Asp	His	Tyr	Gln	Gln 490	Asn	Thr	Pro	Ile	Gly 495	Asp	
	Gly	Pro	Val	Leu 500	Leu	Pro	Asp	Asn	His 505	•	Leu	Ser	Thr	Gln 510	Ser	Ala	
20	Leu	Ser	Lys 515	Asp	Pro	Asn	Glu	Lys 520	Arg	Asp	His	Met	Val 525	Leu	Leu	Glu	
	Phe	Val 530	Thr	Ala	Ala	Gly	Ile 535	Thr	Leu	Gly	Met	Asp 540		Leu	Tyr	Lys	
			(2)	INE	FORM	TION	ı FOF	R SE(	O ID	NO:	114:						
25		(±	i) SI	EQUEN	ICE (	CHARA	CTE	RIST	CS:								
				LENC TYPE				-	airs								
30				STRA				_	2								
		( :	ii) N	OLEC	CULE	TYPE	E: cI	ANC									
		( :		FEATU													
35			(B)	I LOC	CATIO	ON: 3	L]	L632	equer	ıce							
				OTE													
40				SEQUE						-							
	Met			AAG Lys	Gly					Thr					Ile		48
45	1				5					10					15		
45				GAC Asp					Gly					Val			96
				20					25					30			
50			Glu	GGC Gly				Tyr					Leu				144
	mer		35	225			000	40		<b>.</b>		3.55	45.		200	1.00	
E		Thr		GGC Gly			Pro					Thr					192
55		50					55					60					

					GTG Val												240
5	CAG Gln	CAC His	GAC Asp	TTC Phe	TTC Phe 85	AAG Lys	TCC Ser	GCC Ala	ATG Met	CCC Pro 90	GAA Glu	GGC Gly	TAC Tyr	GTC Val	CAG Gln 95	GAG Glu	288
10					TTC Phe												336
15					GGC Gly												384
20					GAG Glu												432
					CAC His												480
25					AAC Asn 165												528
30					GAC Asp												576
35					CCC Pro												624
40					AAC Asn												672
	GTG Val 225	ACC Thr	GCC Ala	GCC Ala	GGG Gly	ATC Ile 230	ACT Thr	CTC Leu	GGC Gly	ATG Met	GAC Asp 235	GAG Glu	CTG Leu	TAC Tyr	AAG Lys	TCC Ser 240	720
45					CGA Arg 245												768
50					TAC Tyr												816
55					GCG Ala												864

			ACT Thr							912
5			ATT Ile			 				960
10			GTT Val 325							1008
15			GCT Ala							1056
20			CTG Leu							1104
			GAC Asp							1152
25	 	 	CTA Leu		 	 	 		 	1200
30			TAC Tyr 405							1248
35			CTG Leu							1296
40			TGC Cys					Arg		1344
			TCT Ser							1392
45			GAT Asp							1440
50			AGT Ser 485							1488
55			CTG Leu							1536

-	212	
	CTG CAC TAC GAC CCT AAC AAG CGG ATT TCG GCC AAG GCA GCC CTG GCT Leu His TVr ASD Pro ASD Live New Till Code CCC AAG GCA GCC CTG GCT	1584
	The Ash bys Arg He Ser Ala Lys Ala Ala Leu Ala	2307
	520 525	
5	CAC CCT TTC TTC CAG GAT GTG ACC AAG CCA GTA CCC CAT CTT CGA CTC	
	His Pro Phe Phe Gln Asp Val Thr Lys Pro Val Pro His Leu Arg Leu	T 1633
	530 535 540	
	GA	
10		1635
	(2) INFORMATION FOR SEQ ID NO:115:	
	(i) SEQUENCE CHARACTERISTICS:	
15	(A) LENGTH: 544 amino acids	
0	(B) TYPE: amino acid	
	(C) STRANDEDNESS: single (D) TOPOLOGY: linear	
	Tancar	
20	(ii) MOLECULE TYPE: protein	
20	(v) FRAGMENT TYPE: internal	
	(Xi) SPONENCE DECORTERED	
	(xi) SEQUENCE DESCRIPTION: SEQ ID NO:115:	
	Met Val Ser Lys Gly Glu Glu Leu Phe Thr Gly Val Val Pro Ile Leu	
25		
	Val Glu Leu Asp Gly Asp Val Asn Gly His Lys Phe Ser Val Ser Gly	
	Glu Gly Glu Gly Asp Ala Thr Tyr Gly Lys Leu Thr Leu Lys Phe Ile	
30	Cys Thr Thr Gly Lys Leu Pro Val Pro Trp Pro Thr Leu Val Thr Thr	
	Led Thr Tyr Gly Val Gln Cys Phe Ser Arg Tyr Pro Asp His Met Lys	
35	Gln His Asp Phe Phe Lys Ser Ala Met Pro Glu Gly Tyr Val Gln Glu	
	Arg Thr Ile Phe Phe Lys Asp Asp Gly Asn Tyr Lys Thr Arg Ala Glu	
	val Lys Phe Giu Gly Asp Thr Leu Val Asn Arg Ile Gly Ley Lyc Cly	
40		
	Ile Asp Phe Lys Glu Asp Gly Asn Ile Leu Gly His Lys Leu Glu Tyr  130  135	
	Asn Tyr Asn Ser His Asn Val Tyr Ile Met Ala Asp Lys Gln Lys Asn	
	145 150 155 160	
45	Gly He Lys Val Asn Phe Lys Ile Arg His Asn Ile Glu Asn Gly Ser	
. •		
-	Val Gln Leu Ala Asp His Tyr Gln Gln Asn Thr Pro Ile Gly Asp Gly	
	Pro Val Leu Leu Pro Asp Asn His Tyr Leu Ser Thr Gln Ser Ala Leu	
50		
50	Ser Lys Asp Pro Asn Glu Lys Arg Asp His Met Val Leu Glu Phe	
	Val Thr Ala Ala Gly Ile Thr Leu Gly Met Asp Glu Leu Tyr Lys Ser  220 221	
	Gly Leu Arg Ser Arg Ala Met Glu Asn Phe Gln Lys Val Glu Lys Ile	
55	245 250 255	
	Gly Glu Gly Thr Tyr Gly Val Val Tyr Lys Ala Arg Asn Lys Leu Thr	
	James Life Bett III	240

213

				260					265					270				
	Gly	Glu	Val 275	Val	Ala	Leu	Lys	Lys 280		Arg	Leu	Asp	Thr 285		Thr	Glu		
5	Gly	Val 290	Pro	Ser	Thr	Ala	Ile 295	Arg	Glu	Ile	Ser	Leu 300	Leu	Lys	Glu	Leu		
	Asn 305	His	Pro	Asn	Ile	Val 310	Lys	Leu	Leu	Asp	Val 315	Ile	His	Thr	Glu	Asn 320		
				Leu	325					330		_		•	335			
10				Ser 340					345					350				
			355	Gln				360					365					
15		370		Arg			375					380						
	385			Lys		390					395					400		
20			•	Thr	405					410					415			
20				Leu 420		_		-	425	_				430	_			
			435	Gly				440					445					
25		450		Asp			455					460						
	465			Pro Pro		470					475					480		
30					485					490					495			
30				Pro 500					505					510				
			515	Asp Phe			-	520				-	525					
35	1115	530	rnc	FIIC	GIII	rsp	535	1111	nys	FIO	Vai	540	ure	Deu	Arg	neu		
			(2)	INI	ORM	OITA	I FOI	R SEÇ	) ID	NO:	116:							
40		(3	(A) (B) (C)	EQUEN LENC TYPI STRA TOPO	GTH: E: n\ ANDEI	2532 aclei ONESS	2 bas ic ac 3: s:	se pa cid ingle	airs									
45			ix) I	MOLE TEAT	JRE:													
50		(3	(B) (D)	NAI LOC OTI	CATIO	ON: I	RMAT	2529 ION:			NO.							
	y mc		٠										ama	000	3 m.c	CITIC		
55				AAG Lys													4	8

5	GT( Va]	C GAO	G CTO	GAC ASP 20	GGG Gly	GAC Asp	GTA Val	AA( Ası	GG( Gl) 25	C CAC	AAC Lys	TT Ph	C AGO	GT( Va.	G TC	C GGC r Gly	96
	GAC Glu	GGC Gly	GAG Glu 35	GGC Gly	GAT Asp	GCC Ala	ACC Thr	TAC Tyr	GGC Gly	AAC Lys	CTC Lev	ACO Th	C CTC r Leu 45	AA(	TTO	C ATC	144
10	Cys	50	1111	GIY	rys	reu	55	Val	Pro	Trp	Pro	Thi 60	: Leu	Va]	l Thr	ACC Thr	192
15	65	1111	lyl	GIÀ	vai	70	Cys	Phe	Ser	Arg	Tyr 75	Pro	Asp	His	Met	AAG Lys 80	240
20	GIII	піз	Asp	Pne	Phe 85	гуs	Ser	Ala	Met	Pro 90	Glu	Gly	Tyr	Val	Gln 95	GAG Glu	288
25	Arg	IIII	116	100	Pne	rys	Asp	Asp	Gly 105	Asn	Tyr	Lys	Thr	Arg 110	Ala	GAG Glu	336
	vai	гуѕ	115	GIU	GIÀ	Asp	Thr	Leu 120	Val	Asn	Arg	Ile	GAG Glu 125	Leu	Lys	Gly	384
30	116	130	Pne	rys	GIU	Asp	135	Asn	Ile	Leu	Gly	His 140	AAG Lys	Leu	Glu	Tyr	432
35	145	TYL	ASII	ser	HIS	150	Val	Tyr	Ile	Met	Ala 155	Asp	AAG Lys	Gln	Lys	Asn 160	480
40	GIY	116	ьуs	val	165	Phe	Lys	Ile	Arg	His 170	Asn	Ile	GAG Glu	Asp	Gly 175	Ser	528
45	vai	GIN	ren	180	Asp	His	Tyr	Gln	Gln 185	Asn	Thr	Pro	ATC Ile	Gly 190	Asp	Gly	576
	CCC Pro	vaı	CTG Leu 195	CTG Leu	CCC Pro	GAC Asp	Asn	CAC His 200	TAC Tyr	CTG Leu	AGC Ser	ACC Thr	CAG Gln 205	TCC Ser	GCC Ala	CTG Leu	624
50	AGC . Ser	AAA Lys 210	GAC Asp	CCC . Pro	AAC Asn	Glu :	AAG Lys 2 215	CGC Arg	GAT Asp	CAC .	Met	GTC Val 220	CTG Leu	CTG Leu	GAG Glu	TTC Phe	672
55	GTG . Val . 225	ACC (	GCC (	GCC (	GIY .	ATC : Ile ' 230	ACT (	CTC ( Leu (	GGC . Gly i	Met .	GAC Asp 235	GAG Glu	CTG Leu	TAC Tyr	Lys	TCC Ser 240	720
																	214

5	_		CGA Arg 245	_						768
3			GAT Asp							816
10			GCT Ala							864
15			GTG Val							912
20			TAT Tyr							960
25			GAG Glu 325							1008
			ATC Ile							1056
30			AGG Arg							1104
35			CAG Gln							1152
40			CAG Gln							1200
45			GGC Gly 405							1248
			GGT Gly							1296
50			GAC Asp							1344
55			GCC Ala							1392

5	AGG Arg 465	Val	AAT Asn	GCG Ala	GCT Ala	GAC Asp 470	ATT Ile	GAG Glu	AAC Asn	CGA Arg	GTG Val 475	TTG Leu	GAA Glu	CTG Leu	AAC Asn	AAG Lys 480	1440
Ū	AAG Lys	CAG Gln	GAG Glu	TCC Ser	GAG Glu 485	GAT Asp	ACA Thr	GCC Ala	AAG Lys	GCT Ala 490	GGC Gly	TTC Phe	TGG Trp	GAG Glu	GAG Glu 495	TTT Phe	1488
10	GAG Glu	AGT Ser	TTG Leu	CAG Gln 500	AAG Lys	CAG Gln	GAG- Glu	GTG Val	AAG Lys 505	AAC Asn	TTG Leu	CAC His	CAG Gln	CGT Arg 510	CTG Leu	GAA Glu	1536
15	Gly	Gln	Arg 515	Pro	GAG Glu	Asn	Lys	Gly 520	Lys	Asn	Arg	Tyr	Lys 525	Asn	Ile	Leu	1584
20	Pro	Phe 530	Asp	His	AGC Ser	Arg	Val 535	Ile	Leu	Gln	Gly	Arg 540	Asp	Ser	Asn	Ile	1632
25	Pro 545	Gly	Ser	Asp	TAC Tyr	Ile 550	Asn	Ala	Asn	Tyr	Ile 555	Lys	Asn	Glņ	Leu	Leu 560	1680
	GGC Gly	CCT Pro	GAT Asp	GAG Glu	AAC Asn 565	GCT Ala	AAG Lys	ACC Thr	TAC Tyr	ATC Ile 570	GCC Ala	AGC Ser	CAG Gln	GGC Gly	TGT Cys 575	CTG Leu	1728
30	GAG Glu	GCC Ala	ACG Thr	GTC Val 580	AAT Asn	GAC Asp	TTC Phe	TGG Trp	CAG Gln 585	ATG Met	GCG Ala	TGG Trp	CAG Gln	GAG Glu 590	AAC Asn	AGC Ser	1776 
35	CGT Arg	GTC Val	ATC Ile 595	GTC Val	ATG Met	ACC Thr	ACC Thr	CGA Arg 600	GAG Glu	GTG Val	GAG Glu	AAA Lys	GGC Gly 605	CGG Arg	AAC Asn	AAA Lys	1824
40	TGC Cys	GTC Val 610	CCA Pro	TAC Tyr	TGG Trp	CCC Pro	GAG Glu 615	GTG Val	GGC Gly	ATG Met	CAG Gln	CGT Arg 620	GCT Ala	TAT Tyr	GGG Gly	CCC Pro	1872
45	TAC Tyr 625	TCT Ser	GTG Val	ACC Thr	AAC Asn	TGC Cys 630	GGG Gly	GAG Glu	CAT His	GAC Asp	ACA Thr 635	ACC Thr	GAA Glu	TAC Tyr	AAA Lys	CTC Leu 640	1920
	CGT Arg	ACC Thr	TTA Leu	CAG Gln	GTC Val 645	TCC Ser	CCG Pro	CTG Leu	GAC Asp	AAT Asn 650	GGA Gly	GAC Asp	CTG Leu	ATT Ile	CGG Arg 655	GAG Glu	1968
50	ATC Ile	TGG Trp	CAT His	TAC Tyr 660	CAG Gln	TAC Tyr	CTG Leu	AGC Ser	TGG Trp 665	CCC Pro	GAC Asp	CAT His	GGG Gly	GTC Val 670	CCC Pro	AGT Ser	2016
55	GAG Glu	CCT Pro	GGG Gly 675	GGT Gly	GTC Val	CTC Leu	AGC Ser	TTC Phe 680	CTG Leu	GAC Asp	CAG Gln	ATC Ile	AAC Asn 685	CAG Gln	CGG Arg	CAG Gln	2064

217

5				CCT Pro												GGC Gly	2112
3	ATC	GGC	CGC	ACA	GGC	ACC	ATC	АТТ	GTC	АТС	GAC	ATG	CTC	ATG	GAG	AAC	2160
				Thr													2200
	705	1				710					715					720	
10	ATC	TCC	ACC	AAG	GGC	CTG	GAC	TGT	GAC	ATT	GAC	ATC	CAG	AAG	ACC	ATC	2208
	Ile	Ser	Thr	Lys	Gly	Leu	Asp	Cys	Asp	Ile	Asp	Ile	Gln	Lys	Thr	Ile	
			•		725					730					735		
4-				CGG													2256
15	Gln	Met	Val	Arg	Ala	Gln	Arg	Ser	-	Met	Val	Gln	Thr		Ala	Gin	
				740					745					750			
	тас	AAG	ጥፐር	ATC	тас	стс	GCC	ΔТС	GCC	CAG	TTTC	ידידע	445	ACC	ACT	DAG	2304
				Ile													2301
20	- ] -	-,-	755		-1-			760		<b></b>			765			-,-	
	AAG	AAG	CTG	GAG	GTC	CTG	CAG	TCG	CAG	AAG	GGC	CAG	GAG	TCG	GAG	TAC	2352
	Lys	Lys	Leu	Glu	Val	Leu	Gln	Ser	Gln	Lys	Gly	${\tt Gln}$	Glu	Ser	${\tt Glu}$	Tyr	
		770					775					780					
25																	
				ACC													2400
	_	Asn	IIe	Thr	Tyr		Pro	Ala	Met	Lys		Ala	His	Ala	Lys		
	785					790					795		•			800	
30	TCC	CGC	ACC	TCG	TCC	AAA	CAC	AAG	GAG	GAT	GTG	тат	GAG	AAC	CTG	CAC	2448
-				Ser													
		5			805	-1 -				810		-2-			815		
		•											•				
	ACT	AAG	AAC	AAG	AGG	GAG	GAG	AAA	GTG	AAG	AAG	CAG	CGG	TCA	GCA	GAC	2496
35	Thr	Lys	Asn	Lys	Arg	Glu	Glu	Lys	Val	Lys	Lys	Gln	Arg	Ser	Ala	Asp	
				820					825					830			
						~~~	=	·									0530
				AGC								TGA				•	2532
40	ъλг	GIU	835	Ser	гЛя	GIY	ser	840	гуз	Arg	гур						
40			633					040									
•																	
			(2)	) IN	FORM	OITA	N FOI	R SE	Q ID	NO:	117:						
45	٠	(:		EQUE													
				LEN					cids								
				TYP													
				STR					e								
50			(11)	TOP	OTOG.	x: 1.	ınea	Ľ									
50				MOT E	מ זזור	πýn	F. 5	+-									
				MOLE: RAGM:			-			•							
		`	- , E				- 111										
		(:	xi)	SEQU:	ENCE	DES	CRIP'	TION	: SE	Q ID	NO:	117:					
55																••	
	Met	Val	Ser	Lys	Gly	Glu	Glu	Leu	Phe	Thr	Gly	Val	Val	Pro	Ile	Leu	

													218	3		-					•
		1					5						10							_	
	V	al	Gli	ı Le	u A	sp (	ly	Asp	o Va	l A	sn	Gly	/ Hi	s Ly	/s P	he	Sea	r Va	al S	o er	Gly
5																					Ile
																ır .	Leu				Thr
	Le 65	eu 5	Thr	Ту	r G	ly V	al (	31n 70	Су	s Pi	ıe	Ser	Arg	д Ту	r Pi	:0	Asp	Hi	s M	et	Lys
10					p Ph	ne P	he 1														
					e Ph 10																
	Va	17	Lve	Dha	10	0	1 *				•	105	•••	y	Luy	<b>'</b> 5 .	ınr	11	g Al 0	la	Glu
15		-	<b>-</b> , 5	115	e Gl 5	u G	ry F	sp	Thi	r Le 12	u ' 0	Val	Asn	Ar	g Il	e (	31u 25	Le	u Ly	/S	Gly
	11	.e :	Asp 130	Phe	e Ly	s G	Lu A	sp	Gly 135	/ As	n :	Ile	Leu	Gl	y Hi 14	s I	ys	Le	u Gl	u	Tyr
	As 14	n : 5	Гуr	Asr	ı Se	r H	is A	sn 50	Va]	Ту	r :	Ile	Met	Ala	a As	p L	ys	Glı	ı Ly	s	Asn
20	Gl	у ]	lle	Lys	va va	l As 16	n P	he	Lys	: 11	e 2	Arg	His	Ası	5 1 Il	e G	lu	Asp	o Gl	y (	160 Ser
	۷a	1 0	Sln	Leu	Al.	a As	р Н	is	Tyr	Gl	n (	Sln	170 Asn	Thr	Pr	о Т	ء ا	Gla	17	5	77
25																					
					Pro											L	eu				
	Va]	l T	hr	Ala	Ala	Gl	y I	le	Thr	Lei	1 G	ly	Met	Asp	220 Glu	) 1 L:	eu	Tvr	Lv	<b>.</b>	er.
30					Ser																
	Len	, 9	er i	cl.,	Τ	24	5						2 <b>5</b> 0	GIY	irr	) PI	1e	His	Arg 255	g A 5	.sp
					Leu 260																
35	Gly	S	er 1	Phe 275	Leu	Ala	a Ar	g	Pro	Ser 280	A	rg ]	Lys	Asn	Gln	. G1	у	Asp	Phe	s	er
	Leu	Se 29	er V	Val	Arg	Va:	l G1	у ;	Asp	Gln	V	al :	Thr	His	Ile	28 Ar	15 :g :	Ile	Gln	A	sn
	Ser	G.	ly 1	qaA	Phe	Туз	As	p I	295 Leu	Tyr	G.	ly (	Gly	Glu	300 Lvs	Ph	e 2	בומ	Thr	т.	
40																					
				_	Val	325	i ly		гĀТ	inr	G.	ln G	31n 330	Gln	Gly	Va	1 1	Leu	Gln	A	sp
	Arg	As	sp G	;ly	Thr 340	Il€	Il	e H	lis	Leu	L)	s T	yr :	Pro	Leu	As	n (	Cys	Ser	As	g
45	Pro	Th	r S	er	Glu	Arg	Tr	r q	yr	His	G1	у Н	lis 1	Met	Ser	Gl	у G	350 31y	Gln	A]	la
	Glu																				
F0	Glu 385																				
50	Gln	Pr	O L	ys .	Ala	Gly 405	Pro	G	ly :	Ser	Pr	o L	eu A	Arg	Val	Thi	г н	is	Ile	40 Ly	s
	Val			ys (	Glu																
	Asp																				
	Glu	AI	a Se	er (	яŢУ	Ala	Phe	V	al.7	ľyr	Le	u A	rg G	ln :	Pro	Туг	T	yr i	Ala	Th	r

219

		450					455					460				
	Arg 465	Val	Asn	Ala	Ala	Asp 470	Ile	Glu	Asn	Arg	Val 475	Leu	Glu	Leu	Asn	Lys 480
5			Glu		485				-	490			_		495	
			Leu	500					5 <b>05</b>					510		
			Arg 515					520					525			
10		530	Asp				535					540				
	545		Ser			550				_	555					560
15	_		Asp		565		_		_	570				_	575	
			Thr	580				_	585			_		590		
			Ile 595					600					605			
20		610	Pro				615					620		-		
	625		Val			630					635					640
25			Leu		645				_	650	•	_			655	
		_	His	660		_			665		_		_	670		
••			Gly 675					680		_			685			
30		690	Leu				695					700	_			_
	705		Arg			710					715					720
35			Thr		725		_			730	_				735	
			Val	740					745					750		
40			Phe 755					760	٠				765			
40		770	Leu				775				_	780				
	785		Ile		_	790				_	795				_	800
45			Thr		805	_		-		810					815	
			Asn	820					825			Gln	Arg	Ser 830	Ala	Asp
	Lys	Glu	Lys 835	Ser	Lys	Gly	Ser	Leu 840	Lys	Arg	Lys					
50																

(2) INFORMATION FOR SEQ ID NO:118:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 2562 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single

			•						220	)						
		(D	) TO	POLO	GY:	line	ar									
5		(ii) (ix)	MOL:	ECUL! FURE	E TY	PE:	cDNA									
ŭ		(.	A) NI B) L(	CAT:	ON:	1	.255	9	ence							
10			SEQU		-				EQ II	ои с	:118	•				
15	ATG CT Met Le 1	G TC	C CGI	GGG	TGG	TT	r ca	C CGI	A GAC	י כיתי	ם אכיר	r cc/	G CTO	G GA u As 15	r GCA p Ala	48
	GAG AC	C CTO	G CTC Leu 20	AAG Lys	GGC Gly	CGA Arg	A GG7 g Gl <sub>y</sub>	GTC Val 25	CAC His	GG7 Gly	C AGO	TTC Phe	C CTC Let 30	G GC	CGG Arg	96
20	CCC AG Pro Se:	T CGC r Arg 35	AAG Lys	AAC Asn	CAG Gln	GGT	GAC Asp 40	TTC Phe	TCG Ser	CTC Leu	TCC Ser	GTC Val	AGC Arc	GTC J Val	GGG Gly	144
25	GAT CAC Asp Gl:	G GTG	ACC Thr	CAT His	ATT Ile	CGG Arg 55	ATC Ile	CAG Gln	AAC Asn	TCA Ser	GGG Gly 60	GAT Asp	TTC Phe	TAT	GAC Asp	192
30	CTG TAT Leu Tyr 65	r GGA Gly	GGG Gly	GAG Glu	AAG Lys 70	TTT Phe	GCG Ala	ACT Thr	CTG Leu	ACA Thr 75	GAG Glu	CTG Leu	GTG Val	GAG Glu	TAC Tyr 80	240
35	TAC ACT	CAG Gln	CAG Gln	CAG Gln 85	GGT Gly	GTC Val	CTG Leu	CAG Gln	GAC Asp 90	CGC Arg	GAC Asp	GGC Gly	ACC Thr	ATC Ile 95	ATC Ile	288
	CAC CTC His Leu	AAG Lys	TAC Tyr 100	CCG Pro	CTG Leu	AAC Asn	TGC Cys	TCC Ser 105	GAT Asp	CCC Pro	ACT Thr	AGT Ser	GAG Glu 110	AGG Arg	TGG Trp	336
40	TAC CAT	GGC Gly 115	CAC His	ATG Met	TCT Ser	GGC Gly	GGG Gly 120	CAG Gln	GCA Ala	GAG Glu	ACG Thr	CTG Leu 125	CTG Leu	CAG Gln	GCC Ala	384
45	AAG GGC Lys Gly 130	GAG Glu	CCC Pro	TGG Trp	inr	TTT Phe 135	CTT Leu	GTG Val	CGT Arg	GAG Glu	AGC Ser 140	CTC Leu	AGC Ser	CAG Gln	CCT Pro	432
50	GGA GAC Gly Asp 145	riic	vaı	neu	ser 150	val	ьеп	Ser	Asp	Gln 155	Pro	Lys	Ala	Gly	Pro 160	480
55	GGC TCC Gly Ser	CCG Pro	neu .	AGG Arg 165	GTC . Val	ACC Thr	CAC His	Ile	AAG Lys 170	GTC Val	ATG Met	TGC Cys	GAG Glu	GGT Gly 175	GGA Gly	528
	CGC TAC	ACA	GTG (	GGT (	GGT '	TTG	GAG	ACC	TTC	GAC	AGC	CTC	ACG	GAC	CTG	576

									•	221								
	Arg	Tyr	Thr	Val 180	Gly	Gly	Leu	Glu	Thr 185	Phe	Asp	Ser	Leu	Thr 190	Asp	Leu		
5												GCC Ala					624	
10												GTG Val 220					672	
15												CAG Gln			_		720	
15												AGT Ser					768	
20												CAG Gln					816	
25												TTT Phe					864	
30												GGG Gly 300					912	
												CCT Pro					960	
35												GCC Ala					1008	
40												GTC Val					1056	
45												GTC Val					1104	
50												TCT Ser 380					1152	
												ACC Thr					1200	
55	CCG	CTG	GAC	AAT	GGA	GAC	CTG	ATT	CGG	GAG	ATC	TGG	CAT	TAC	CAG	TAC	1248	2:

										222							
	Pro	Leu	Asp	Asn	Gly 405		Leu	Ile	Arg	Glu 410		Trp	His	Tyr	Gln 415	_	
5	CTG Leu	AGC Ser	TGG Trp	CCC Pro 420	GAC Asp	CAT	GGG Gly	GTC Val	CCC Pro 425	AGT Ser	GAG Glu	CCT Pro	GGG Gly	GGT Gly 430	Val	CTC Leu	1296
10	AGC Ser	TTC Phe	CTG Leu 435	GAC Asp	CAG Gln	ATC Ile	AAC Asn	CAG Gln 440	CGG Arg	CAG Gln	GAA Glu	AGT Ser	CTG Leu 445	CCT Pro	CAC His	GCA Ala	1344
15	GGG Gly	CCC Pro 450	ATC Ile	ATC Ile	GTG Val	CAC His	TGC Cys 455	AGC Ser	GCC Ala	GGC Gly	ATC Ile	GGC Gly 460	CGC Arg	ACA Thr	GGC Gly	ACC Thr	1392
	ATC Ile 465	ATT Ile	GTC Val	ATC Ile	GAC Asp	ATG Met 470	CTC Leu	ATG Met	GAG Glu	AAC Asn	ATC Ile 475	TCC Ser	ACC Thr	AAG Lys	GGC Gly	CTG Leu 480	1440
20	GAC Asp	TGT Cys	GAC Asp	ATT Ile	GAC Asp 485	ATC Ile	CAG Gln	AAG Lys	ACC Thr	ATC Ile 490	CAG Gln	ATG Met	GTG Val	CGG Arg	GCG Ala 495	CAG Gln	1488
25	CGC Arg	TCG Ser	GGC Gly	ATG Met 500	GTG Val	CAG Gln	ACG Thr	GAG Glu	GCG Ala 505	CAG Gln	TAC Tyr	AAG Lys	TTC Phe	ATC Ile 510	TAC Tyr	GTG Val	1536
<b>30</b> -	GCC Ala	ATC Ile	GCC Ala 515	CAG Gln	TTC Phe	ATT Ile	GAA Glu	ACC Thr 520	ACT Thr	AAG Lys	AAG Lys	AAG Lys	CTG Leu 525	GAG Glu	GTC Val	CTG Leu	1584
35	CAG Gln	TCG Ser 530	CAG Gln	AAG Lys	GGC Gly	CAG Gln	GAG Glu 535	TCG Ser	GAG Glu	TAC Tyr	GGG Gly	AAC Asn 540	ATC Ile	ACC Thr	TAT Tyr	CCC Pro	1632
-8	CCA Pro 545	GCC Ala	ATG Met	AAG Lys	AAT Asn	GCC Ala 550	CAT His	GCC Ala	AAG Lys	GCC Ala	TCC Ser 555	CGC Arg	ACC Thr	TCG Ser	TCC Ser	AAA Lys 560	1680
40	CAC His	AAG Lys	GAG Glu	GAT Asp	GTG Val 565	TAT Tyr	GAG Glu	AAC Asn	CTG Leu	CAC His 570	ACT Thr	AAG Lys	AAC Asn	AAG Lys	AGG Arg 575	GAG Glu	1728
45	GAG Glu	AAA Lys	GTG Val	AAG Lys 580	AAG Lys	CAG Gln	CGG Arg	TCA Ser	GCA Ala 585	GAC Asp	AAG Lys	GAG Glu	AAG Lys	AGC Ser 590	AAG Lys	GGT Gly	1776
50	TCC Ser	CTC Leu	AAG Lys 595	AGG Arg	AAG Lys	CGA Arg	ATT Ile	CTG Leu 600	CAG Gln	TCG Ser	ACG Thr	GTA Val	CCG Pro 605	CGG Arg	GCC Ala	CGG Arg	1824
55	GAT Asp	CCA Pro 610	CCG Pro	GTC Val	GCC Ala	ACC Thr	ATG Met 615	GTG Val	AGC Ser	AAG Lys	GGC Gly	GAG Glu 620	GAG Glu	CTG Leu	TTC Phe	ACC Thr	1872
	GGG	GTG	GTG	ccc	ATC	CTG	GTC	GAG	CTG	GAC	GGC	GAC	GTA	AAC	GGC	CAC Î	1920

										223							
	Gly 625	Val	Val	Pro		Leu 630	Val	Glu	Leu	Asp	Gly 635	Asp	Val	Asn	Gly	His 640	
5				GTG Val											_		1968
10				AAG Lys 660													2016
15				GŤG Val													2064
15				CAC His													2112
20				GTC Val													2160
25				CGC Arg													2208
30				CTG Leu 740													2256
25				CTG Leu													2304
35				CAG Gln													2352
40				GAC Asp													2400
45				GGC Gly		Gly										CTG Leu	2448
50				TCC Ser 820	Ala					Pro						CAC	2496
				Leu					Ala					Leu		ATG Met	2544
55	GAC	GAG	CTG	TAC	AAG	TAA											2562 223

Asp Glu Leu Tyr Lys 850

```
5
                (2) INFORMATION FOR SEQ ID NO:119:
             (i) SEQUENCE CHARACTERISTICS:
               (A) LENGTH: 853 amino acids
               (B) TYPE: amino acid
 10
               (C) STRANDEDNESS: single
               (D) TOPOLOGY: linear
             (ii) MOLECULE TYPE: protein
             (v) FRAGMENT TYPE: internal
 15
             (xi) SEQUENCE DESCRIPTION: SEQ ID NO:119:
      Met Leu Ser Arg Gly Trp Phe His Arg Asp Leu Ser Gly Leu Asp Ala
      Glu Thr Leu Leu Lys Gly Arg Gly Val His Gly Ser Phe Leu Ala Arg
20
      Pro Ser Arg Lys Asn Gln Gly Asp Phe Ser Leu Ser Val Arg Val Gly
                                 40
      Asp Gln Val Thr His Ile Arg Ile Gln Asn Ser Gly Asp Phe Tyr Asp
25
                              55
      Leu Tyr Gly Gly Glu Lys Phe Ala Thr Leu Thr Glu Leu Val Glu Tyr
      Tyr Thr Gln Gln Gln Gly Val Leu Gln Asp Arg Asp Gly Thr Ile Ile
                                          90
30
      His Leu Lys Tyr Pro Leu Asn Cys Ser Asp Pro Thr Ser Glu Arg Trp
                                      105
      Tyr His Gly His Met Ser Gly Gly Gln Ala Glu Thr Leu Leu Gln Ala
                                  120
      Lys Gly Glu Pro Trp Thr Phe Leu Val Arg Glu Ser Leu Ser Gln Pro
35
                              135
                                                  140
      Gly Asp Phe Val Leu Ser Val Leu Ser Asp Gln Pro Lys Ala Gly Pro
                         150
                                              155
      Gly Ser Pro Leu Arg Val Thr His Ile Lys Val Met Cys Glu Gly Gly
                                         170
     Arg Tyr Thr Val Gly Gly Leu Glu Thr Phe Asp Ser Leu Thr Asp Leu
40
                                     185
     Val Glu His Phe Lys Lys Thr Gly Ile Glu Glu Ala Ser Gly Ala Phe
                                 200
     Val Tyr Leu Arg Gln Pro Tyr Tyr Ala Thr Arg Val Asn Ala Ala Asp
45
                             215
                                                 220
     Ile Glu Asn Arg Val Leu Glu Leu Asn Lys Lys Gln Glu Ser Glu Asp
                         230
                                             235
     Thr Ala Lys Ala Gly Phe Trp Glu Glu Phe Glu Ser Leu Gln Lys Gln
                     245
                                         250
     Glu Val Lys Asn Leu His Gln Arg Leu Glu Gly Gln Arg Pro Glu Asn
50
                                     265
     Lys Gly Lys Asn Arg Tyr Lys Asn Ile Leu Pro Phe Asp His Ser Arg
                                 280
     Val Ile Leu Gln Gly Arg Asp Ser Asn Ile Pro Gly Ser Asp Tyr Ile
```

Asn Ala Asn Tyr Ile Lys Asn Gln Leu Leu Gly Pro Asp Glu Asn Ala

300

295

										223						
	305					310					315					320
	Lys	Thr	Tyr	Ile	Ala 325	Ser	Gln	Gly	Cys	Leu 330	Glu	Ala	Thr	Val	Asn 335	Asp
5	Phe	Trp	Gln	Met 340	Ala	Trp	Gln	Glu	Asn 345	Ser	Arg	Val	Ile	Val 350		Thr
	Thr	Arg	Glu 355	Val	Glu	Lys	Gly	Arg 360	Asn	Lys	Cys	Val	Pro 365		Trp	Pro
	Glu	Val 370	Gly	Met	Gln	Arg	Ala 375	Tyr	Gly	Pro	Tyr	Ser 380	Val	Thr	Asn	Cys
10	Gly 385	Glu	His	Asp	Thr	Thr 390	Glu	Tyr	Lys	Leu	Arg 395	Thr	Leu	Gln	Val	Ser 400
	Pro	Leu	Asp	Asn	Gly 405	Asp	Leu	Ile	Arg	Glu 410	Ile	Trp	His	Tyr	Gln 415	Tyr
15			Trp	420					425				_	430		
			Leu 435					440					445			
		450	Ile				455					460				
20	465		Val			470					475					480
			Asp		485			_		490					495	
25			Gly	500					505					510		
			Ala 515					520					525			
30		530	Gln				535					540				
30	545		Met Glu			550					555					560
			Val		565					570					575	
35			Lys	580					585					590		
			595 Pro					600					605	-		_
40		610	Val				615					620				
	625		Ser			630				_	635	_			_	640
			Leu		645					650					655	
45			Leu	660					665					670		
			675 Asp			•	•	680					685			
50		690	Tyr				695					700				
	705		Thr			710					715					720
	Arg	Ile	Glu		725 Lys	Gly	Ile	Asp	Phe	730 Lys	Glu	Asp	Gly	Asn	735 Ile	Leu
55	Gly	His	Lys	740 Leu	Glu	Tyr	Asn	Tyr	745 Asn	Ser	His	Asn	Val	750 Tyr	Ile	Met

		_	75					76	0				76	5			
•		, ,	U				- 77	5				7.9	20			g His	
5	, ,	_				/9	U				79	5				n Asn 800	
					80	>				81	0				01	r Leu	
				021	,		-		821	5				0.2	g Asj	p His	
10	Me	t Va	l Let 839	ս Lei 5	ı Glı	ı Phe	⊇ Val	1 Th:	r Ala	a Al	a Gl	y Il	e Th	r Le	u Gl	y Met	
	As	9 Gl	u Lei 0	ту:	Ly:	3							U T	•			
15			(2	2) II	IFORN	OITAN	ON FO	OR SI	EQ II	ои с	:120	:					
20		1	(B) (C)	EEQUE LEN TYI STR TOI	IGTH: E: r ANDE	299 ucle DNES	4 ba ic a S: s	se p cid ing]	pairs	: 3							
25		(	(ii) (ix)	FEAT	URE:			•		•							
			(B	) NA ) LO ) OT	CATI	ON:	1	2991	eque	nce							
30		(	xi)	SEQU	ENCE	DES	CRIP	TION	: SE	Q ID	NO:	120:					
35	ATG Met 1	GTG Val	AGC Ser	AAG Lys	GGC Gly 5	GAG Glu	GAG Glu	CTG Leu	TTC Phe	ACC Thr 10	GGG Gly	GTG Val	GTG Val	CCC Pro	ATC Ile 15	CTG Leu	48
	GTC Val	GAG Glu	CTG Leu	GAC Asp 20	GGC Gly	GAC Asp	GTA Val	AAC Asn	GGC Gly 25	CAC His	AAG Lys	TTC Phe	AGC Ser	GTG Val 30	TCC Ser	GGC Gly	96
40 .	GAG Glu	GGC Gly	GAG Glu 35	GGC Gly	GAT Asp	GCC Ala	ACC Thr	TAC Tyr 40	GGC Gly	AAG Lys	CTG Leu	ACC Thr	CTG Leu 45	AAG Lys	TTC Phe	ATC Ile	144
45	TGC Cys	ACC Thr 50	ACC Thr	GGC Gly	AAG Lys	CTG Leu	CCC Pro 55	GTG Val	CCC Pro	TGG Trp	CCC Pro	ACC Thr 60	CTC Leu	GTG Val	ACC Thr	ACC Thr	192
50	CTG Leu 65	ACC Thr	TAC Tyr	GGC Gly	GTG Val	CAG Gln 70	TGC Cys	TTC Phe	AGC Ser	CGC Arg	TAC Tyr 75	CCC Pro	GAC Asp	CAC His	ATG Met	AAG Lys 80	240
55	CAG Gln	CAC His	GAC Asp	TTC Phe	TTC Phe 85	AAG Lys	TCC Ser	GCC Ala	ATG Met	CCC Pro 90	GAA Glu	GGC Gly	TAC Tyr	GTC Val	CAG Gln 95	GAG Glu	288
	CGC	ACC	ATC	TTC	TTC	AAG	GAC	GAC	GGC	AAC	TAC	AAG	ACC	CGC	GCC	GAG	336 226

227

										227							
	Arg	Thr	Ile	Phe 100	Phe	Lys ·	Asp	Asp	Gly 105	Asn	Tyr	ГÀЗ	Thr	Arg 110	Ala	Glu	
5		AAG Lys															384
10		GAC Asp 130															432
15		TAC Tyr															480
		ATC Ile															528
20		CAG Gln															576
25		GTG Val															624
30		AAA Lys 210													_		672
35		ACC Thr															720
		CTC Leu														CCC. Pro	768
40		GGG Gly															816
45		GGC														_	864
50		GAT Asp 290															912
55		AAC Asn															960
JJ	AAC	CAT	GCC	AAT	GTT	GTA	AAG	GCC	TGT	GAT	GTT	CCT	GAA	GAA	TTG	TAA	1008

					•						228									
	As	n H	is A	Ala	Asn	. Va.	l Va	l Ly	s Al	a Cy	s As	p Va 0	l Pr	:0 G]	u Gl	lu Le 33		Asn		
5					340	vař	y va	1 PI	о те	T CT u Le 34	u Al 5	a Me	t Gl	и Ту	r Cy 35	s Se 0	er	Gly	10	56
10		,	3	55	9	ny a	, DC	т пе	36		s Pr	o Gl	u As	n Cy 36	s Cy 5	s Gl	у :	Leu	110	04
15	1	37	0			110	. Det	375	2 re	A CTI u Lei	ı Sei	r As <sub>l</sub>	9 Il 38	e Gl <sub>i</sub> O	y Se	r Gl	у:	Ile	115	52
	389	5				Olu	390	п	2 116	r AT? e Ile	His	395	j Ası	) Lei	ı Ly:	s Pr	0 0	31u 100	120	0 .
20	AA( Asr	TAT 11	A G	rr c		CAG Gln 405	GAT Asp	' GTI Val	GG1	r GGA / Gly	AAG Lys 410	Ile	A ATA	A CAT	AA# Lys	A ATA 5 Ile 415	e I	ATT le	124	8
25	GAT Asp	CT Le	G G( u G)	., .	AT yr 20	GCC Ala	AAA Lys	GAT Asp	GTT Val	GAT Asp 425	GIn	GGA Gly	AGI Ser	CTG	TGT Cys 430	Thr	A T	CT	129	6.
30	TTT Phe	' GT	G GC l G1 43		CA hr :	CTG Leu	CAG Gln	TAT Tyr	CTG Leu 440	GCC Ala	CCA Pro	GAG Glu	CTC	TTT Phe	GAG Glu	AA1 Asn	r A	AG ys	1344	4
35	CCT Pro	TA( Ty) 45(		A GO	CC 1	ACT Thr	GTT Val	GAT Asp 455	TAT Tyr	TGG Trp	AGC Ser	TTT Phe	GGG Gly 460	ACC Thr	ATG Met	GTA Val	. T'	TT he	1392	2
	GAA Glu 465	TG1 Cys	T AT	T GO	CT (	GGA Gly	TAT Tyr 470	AGG Arg	CCT Pro	TTT Phe	TTG Leu	CAT His 475	CAT His	CTG Leu	CAG Gln	CCA Pro	Pl	TT he	1440	)
40	ACC Thr	TGG	CA'	T GA s Gl		AAG .ys .85	ATT Ile	AAG Lys	AAG Lys	AAG Lys	GAT Asp 490	CCA Pro	AAG Lys	TGT Cys	ATA Ile	TTT Phe 495	G(	CA la	1488	
45	TGT Cys	GAA Glu	GA(	3 AT 1 Me 50		CA er	GGA Gly	GAA Glu	GTT Val	CGG Arg 505	TTT Phe	AGT Ser	AGC Ser	CAT His	TTA Leu 510	CCT Pro	CA G1	AA .n	1536	
50	CCA Pro	AAT Asn	AGO Ser 515	. це	T T u C	GT :	AGT Ser	геп	ATA Ile 520	GTA Val	GAA Glu	CCC Pro	ATG Met	GAA Glu 525	AAC Asn	TGG Trp	CT Le	'A ·u	1584	
55		TTG Leu 530	ATO Met	TT(	G A u A	AT :	rrb.	GAC Asp 535	CCT Pro	CAG Gln	CAG .	Arg	GGA Gly 540	GGA Gly	CCT Pro	GTT Val	GA As	.c p	1632	
	CTT	ACT	TTG	AA	G C	AG C	CA :	AGA '	TGT	TTT	GTA '	TTA	ATG	GAT	CAC	ATT	TT	G	1680	228

										LLJ							
	Leu 545	Thr	Leu	Lys	Gln	Pro 550	Arg	Cys	Phe	Val	Leu 555	Met	Asp	His	Ile	Leu 560	
5														AAG Lys			1728
10														CAG Gln 590			1776
15														CTT Leu			1824
13														CAA Gln			1872
20														TTG Leu			1920
25							_							AGT Ser			1968
30														CTT Leu 670			2016
25														GTG Val			2064
35														GCA Ala			2112
40														AAG Lys			2160
45														TTT Phe			2208
50														ATG Met 750			2256
														ATG Met			2304
55	AAG	GCC	ATC	CAC	TAT	GCT	GAG	GTT	GGT	GTC	ATT	GGA	TAC	CTG	GAG	GAT	2352

										230							
	Lys	Ala 770	Ile	His	Tyr	Ala	Glu 775	Val	Gly	Val	Ile	Gly 780	Tyr	Leu	Glu	Asp	
5					TTG Leu												2400
10					CAG Gln 805												2448
15					AAG Lys												2496
13					GAG Glu		Val										2544
20					CTC Leu												2592
25					AAG Lys												2640
30					AAA Lys 885												2688
25					GAA Glu												2736
35					TCT Ser												2784
40					GCA Ala												2832
45					GTG Val												2880
50					AAT Asn 965												2928
er					GAG Glu												2976
55	AGT	TGG	TTA	ACA	GAA	TGA										-	2994 23

231

Ser Trp Leu Thr Glu 995

```
5
               (2) INFORMATION FOR SEQ ID NO:121:
            (i) SEQUENCE CHARACTERISTICS:
              (A) LENGTH: 997 amino acids
              (B) TYPE: amino acid
10
              (C) STRANDEDNESS: single
              (D) TOPOLOGY: linear
            (ii) MOLECULE TYPE: protein
            (v) FRAGMENT TYPE: internal
15
            (xi) SEQUENCE DESCRIPTION: SEO ID NO:121:
     Met Val Ser Lys Gly Glu Glu Leu Phe Thr Gly Val Val Pro Ile Leu
20
     Val Glu Leu Asp Gly Asp Val Asn Gly His Lys Phe Ser Val Ser Gly
     Glu Gly Glu Gly Asp Ala Thr Tyr Gly Lys Leu Thr Leu Lys Phe Ile
                                 40
     Cys Thr Thr Gly Lys Leu Pro Val Pro Trp Pro Thr Leu Val Thr Thr
25
     Leu Thr Tyr Gly Val Gln Cys Phe Ser Arg Tyr Pro Asp His Met Lys
                         70
                                             75
     Gln His Asp Phe Phe Lys Ser Ala Met Pro Glu Gly Tyr Val Gln Glu
30
     Arg Thr Ile Phe Phe Lys Asp Asp Gly Asn Tyr Lys Thr Arg Ala Glu
                                     105
     Val Lys Phe Glu Gly Asp Thr Leu Val Asn Arg Ile Glu Leu Lys Gly
                                 120
     Ile Asp Phe Lys Glu Asp Gly Asn Ile Leu Gly His Lys Leu Glu Tyr
35
                             135
     Asn Tyr Asn Ser His Asn Val Tyr Ile Met Ala Asp Lys Gln Lys Asn
                         150
                                             155
     Gly Ile Lys Val Asn Phe Lys Ile Arg His Asn Ile Glu Asp Gly Ser
                     165
                             · 170
40
     Val Gln Leu Ala Asp His Tyr Gln Gln Asn Thr Pro Ile Gly Asp Gly
                                     185
                                          ••
     Pro Val Leu Leu Pro Asp Asn His Tyr Leu Ser Thr Gln Ser Ala Leu
                                 200
     Ser Lys Asp Pro Asn Glu Lys Arg Asp His Met Val Leu Leu Glu Phe
45
                             215
     Val Thr Ala Ala Gly Ile Thr Leu Gly Met Asp Glu Leu Tyr Lys Ser
                         230
                                             235
     Gly Leu Arg Ser Arg Ala Gln Ala Ser Asn Ser Thr Met Glu Arg Pro
50
     Pro Gly Leu Arg Pro Gly Ala Gly Gly Pro Trp Glu Met Arg Glu Arg
                                  . 265
     Leu Gly Thr Gly Gly Phe Gly Asn Val Cys Leu Tyr Gln His Arg Glu
                                 280
     Leu Asp Leu Lys Ile Ala Ile Lys Ser Cys Arg Leu Glu Leu Ser Thr
55
                             295
     Lys Asn Arg Glu Arg Trp Cys His Glu Ile Gln Ile Met Lys Lys Leu
```

										232						
	305	5				310	)				315					320
	Asn	) His	s Ala	Asn	Val 325	. Val	Lys	Ala	Сув	Asp	Val	Pro	Glu	Glu		Asn
5	Ile	Lev	ı Ile	His	Asp		Pro	Leu	Leu 345	Ala	Met	·Glu	Tyr	Cys 350		Gly
	Gly	' Asp	Leu 355	Arg	Lys	Leu	Leu	Asn 360	Lys		Glu	Asn	Cys 365	Cys	Gly	Leu
	Lys	Glu 370	Ser	Gln	Ile	Leu	Ser	Leu		Ser	Asp	Ile 380	Gly	Ser	Gly	Ile
10	Arg 385	Tyr	Leu	His	Glu	Asn 390	Lys		Ile	His	Arg 395	Asp	Leu	Lys	Pro	Glu 400
	Asn	Ile	Val	Leu	Gln 405	Asp	Val	Gly	Gly	Lys 410	Ile	Ile	His	Lys	Ile 415	Ile
15	Asp	Leu	Gly	Tyr 420	Ala	Lys	Asp	Val	Asp 425	Gln	Gly	Ser	Leu	Cys 430	Thr	Ser
			435					440					445	Glu		
		450					455					460		Met		
20	465					470					475			Gln		480
					485					490				Ile	495	
25				500					505					Leu 510		
			515					520					525	Asn		
30		530					535					540		Pro		
30	545					550					555			His		560
					565					570				Lys	575	
35		÷		580					585					Gln 590		
			595					600					605	Leu		
40		610					615					620		Gln		
	025					630					635			Leu Ser		640
					645					650				Leu	655	
45				660					665					670 Val		
			675					680					685	Ala		
50		690					695					700		Lys		
	705					710					715			Lys Phe		720
					725					730					735	
55				740					745					750 Met		
									-		-			<del>-</del>		

```
755
                                 760
                                                    765
     Lys Ala Ile His Tyr Ala Glu Val Gly Val Ile Gly Tyr Leu Glu Asp
                            775
                                               780
     Gln Ile Met Ser Leu His Ala Glu Ile Met Gly Leu Gln Lys Ser Pro
 5
                        790
                                            795
     Tyr Gly Arg Arg Gln Gly Asp Leu Met Glu Ser Leu Glu Gln Arg Ala
                                        810
    . Ile Asp Leu Tyr Lys Gln Leu Lys His Arg Pro Ser Asp His Ser Tyr
                                    825
                 820
10
     Ser Asp Ser Thr Glu Met Val Lys Ile Ile Val His Thr Val Gln Ser
                                840
                                                   845
     Gln Asp Arg Val Leu Lys Glu Leu Phe Gly His Leu Ser Lys Leu Leu
                            855
                                               860
     Gly Cys Lys Gln Lys Ile Ile Asp Leu Leu Pro Lys Val Glu Val Ala
15
                     870
                                            875
     Leu Ser Asn Ile Lys Glu Ala Asp Asn Thr Val Met Phe Met Gln Gly
                     885
                                        890
     Lys Arg Gln Lys Glu Ile Trp His Leu Leu Lys Ile Ala Cys Thr Gln
                                    905
.20
     Ser Ser Ala Arg Ser Leu Val Gly Ser Ser Leu Glu Gly Ala Val Thr
                                 920
                                                    925
     Pro Gln Thr Ser Ala Trp Leu Pro Pro Thr Ser Ala Glu His Asp His
                             935
                                               940
     Ser Leu Ser Cys Val Val Thr Pro Gln Asp Gly Glu Thr Ser Ala Gln
25
                        950
                                           955
     Met Ile Glu Glu Asn Leu Asn Cys Leu Gly His Leu Ser Thr Ile Ile
                                       970
     His Glu Ala Asn Glu Glu Gln Gly Asn Ser Met Met Asn Leu Asp Trp
                 980
                                    985
30
     Ser Trp Leu Thr Glu
             995
              (2) INFORMATION FOR SEQ ID NO:122:
35
          (i) SEQUENCE CHARACTERISTICS:
             (A) LENGTH: 2991 base pairs
              (B) TYPE: nucleic acid
             (C) STRANDEDNESS: single
             (D) TOPOLOGY: linear
40
            (ii) MOLECULE TYPE: cDNA
            (ix) FEATURE:
               (A) NAME/KEY: Coding Sequence
45
               (B) LOCATION: 1...2988
               (D) OTHER INFORMATION:
            (xi) SEQUENCE DESCRIPTION: SEQ ID NO:122:
50
     Met Glu Arg Pro Pro Gly Leu Arg Pro Gly Ala Gly Gly Pro Trp Glu
                                        10
     ATG CGG GAG CGG CTG GGC ACC GGC GGC TTC GGG AAC GTC TGT CTG TAC
     Met Arg Glu Arg Leu Gly Thr Gly Gly Phe Gly Asn Val Cys Leu Tyr
55
                 20
```

5	CAG Gln	CAT His	CGG Arg 35	GAA Glu	CTT Leu	GAT Asp	CTC Leu	AAA Lys 40	ATA Ile	GCA Ala	ATT Ile	AAG Lys	TCT Ser 45	TGT Cys	CGC Arg	CTA Leu	·144
ŭ	GAG Glu	CTA Leu 50	AGT Ser	ACC Thr	AAA Lys	AAC Asn	AGA Arg 55	GAA Glu	CGA Arg	TGG Trp	TGC Cys	CAT His 60	GAA Glu	ATC Ile	CAG Gln	ATT Ile	192
10	ATG Met 65	AAG Lys	AAG Lys	TTG Leu	AAC Asn	CAT His 70	GCC Ala	AAT Asn	GTT Val	GTA Val	AAG Lys 75	GCC Ala	TGT Cys	GAT Asp	GTT Val	CCT Pro 80	240
15	GAA Glu	GAA Glu	TTG Leu	AAT Asn	ATT Ile 85	TTG Leu	ATT Ile	CAT His	GAT Asp	GTG Val 90	CCT Pro	CTT Leu	CTA Leu	GCA Ala	ATG Met 95	GAA Glu	288
20	TAC Tyr	TGT Cys	TCT	GGA Gly 100	GGA Gly	GAT Asp	CTC Leu	CGA Arg	AAG Lys 105	CTG Leu	CTC Leu	AAC Asn	AAA Lys	CCA Pro 110	GAA Glu	AAT Asn	336
25	TGT Cys	TGT Cys	GGA Gly 115	CTT Leu	AAA Lys	GAA Glu	AGC Ser	CAG Gln 120	ATA Ile	CTT Leu	TCT Ser	TTA Leu	CTA Leu 125	AGT Ser	GAT Asp	ATA Ile	384
	GGG Gly	TCT Ser 130	GGG Gly	ATT Ile	CGA Arg	TAT Tyr	TTG Leu 135	CAT His	GAA Glu	AAC Asn	AAA Lys	ATT Ile 140	ATA Ile	CAT His	CGA Arg	GAT Asp	432
30	CTA Leu 145	AAA Lys	CCT Pro	GAA Glu	AAC Asn	ATA Ile 150	GTT Val	CTT Leu	CAG Gln	GAT Asp	GTT Val 155	GGT Gly	GGA Gly	AAG Lys	ATA Ile	ATA Ile 160	480
35	CAT His	AAA Lys	ATA Ile	ATT Ile	GAT Asp 165	CTG Leu	GGA Gly	TAT Tyr	GCC Ala	AAA Lys 170	GAT Asp	GTT Val	GAT Asp	CAA Gln	GGA Gly 175	AGT Ser	528
40	CTG Leu	TGT Cys	ACA Thr	TCT Ser 180	TTT Phe	GTG Val	GGA Gly	ACA Thr	CTG Leu 185	CAG Gln	TAT Tyr	CTG Leu	GCC Ala	CCA Pro 190	GAG Glu	CTC Leu	576
45	TTT Phe	GAG Glu	AAT Asn 195	AAG Lys	CCT Pro	TAC Tyr	ACA Thr	GCC Ala 200	ACT Thr	GTT Val	GAT Asp	TAT Tyr	TGG Trp 205	AGC Ser	TTT Phe	GGG . Gly	624
	ACC Thr	ATG Met 210	GTA Val	TTT Phe	GAA Glu	TGT Cys	ATT Ile 215	GCT Ala	GGA Gly	TAT Tyr	AGG Arg	CCT Pro 220	TTT Phe	TTG Leu	CAT His	CAT His	672
50	CTG Leu 225	CAG Gln	CCA Pro	TTT Phe	ACC Thr	TGG Trp 230	CAT His	GAG Glu	AAG Lys	ATT Ile	AAG Lys 235	AAG Lys	AAG Lys	GAT Asp	CCA Pro	AAG Lys 240	720
55	TGT Cys	ATA Ile	TTT Phe	GCA Ala	TGT Cys 245	GAA Glu	GAG Glu	ATG Met	TCA Ser	GGA Gly 250	GAA Glu	GTT Val	CGG Arg	TTT Phe	AGT Ser 255	AGC Ser	768

															•
					CCA Pro										816
5	C2 2	220	TOO	CTA	CAC	mmc	N MC	mma	2200	maa	a. a	 a. a	a. a	 	
					CAG Gln										864
10					CTT Leu										912
15					AAT Asn										960
20					TCT Ser 325										1008
25					ATT Ile										1056
					GAG Glu										1104
30					CTA Leu										1152
35					AAA Lys										1200
40					GAT Asp 405										1248
					ATA Ile										1296
45					CTA Leu										1344
50					TTA Leu										1392
55					TTG Leu										1440

	GAG	ттт	ттт	CAC	AAA	AGC	ТТА	CAG	رست	GAC	ביתים	GAG	AGA	ፐልሮ	A G C	GAG	1488
					Lys 485												1400
5									•								
					GGG												1536
				500	Gly				505					510			
10					AAG												1584
	Glu	Met	G1u 515	Glu	Lys	Ala	Ile	His 520	Tyr	Ala	Glu	Val	Gly 525	Val	Ile	Gly	
					CAG												1632
15	Tyr	Leu 530	Glu	Asp	Gln	Ile	Met 535	Ser	Leu	His	Ala	Glu 540	Ile	Met	Gly	Leu	
					TAT												1680
20		Lys	Ser	Pro	Tyr		Arg	Arg	Gln	Gly		Leu	Met	Glu	Ser		
20	545					550					555				•	560	
÷					ATT												1728
	Glu	Gln.	Arg	Ala	Ile	Asp	Leu	Tyr	ГЛS		Leu	Lys	His	Arg		Ser	
25					565					570					575		
	GAT	CAC	TCC	TAC	AGT	GAC	AGC	ACA	GAG	ATG	GTG	AAA	ATC	ATT	GTG	CAC	1776
	Asp	His	Ser	_	Ser	Asp	Ser	Thr		Met	Val	Lys	Ile		Val	His	
				580					585					590			
30	ACT	GTG	CAG	AGT	CAG	GAC	CGT	GTG	CTC	AAG	GAG	CTG	TTT	GGT	CAT	TTG	1824
	Thr	Val		Ser	Gln	Asp	Arg		Leu	Lys	Glu	Leu		Gly	His	Leu	
			595					600					605				
	AGC	AAG	TTG	TTG	GGC	TGT	AAG	CAG	AAG	ATT	ATT	GAT	CTA	CTC	CCT	AAG	1872
35	Ser		Leu	Leu	Gly	Суѕ		Gln	Lys	Ile	Ile	Asp	Leu	Leu	Pro	Lys	
		610					615					620					
	GTG	GAA	GTG	GCC	CTC	AGT	AAT	ATC	AAA	GAA	GCT	GAC	TAA	ACT	GTC	ATG	1920
40		Glu	Val	Ala	Leu		Asn	Ile	Lys	Glu		Asp	Asn	Thr	Val		
40	625					630					635					640	
	TTC	ATG	CAG	GGA	AAA	AGG	CAG	AAA	GAA	ATA	TGG	CAT	CTC	CTT	AAA	ATT	1968
	Phe	Met	Gln	Gly	Lys	Arg	Gln	Lys	Glu		Trp	His	Leu	Leu		Ile	
45					645					650					655		
	GCC	TGT	ACA	CAG	AGT	TCT	GCC	CGC	тст	CTT	GTA	GGA	TCC	AGT	CTA	GAA	2016
					Ser												
				660					665				-	670			
50	GGT	GCA	GTA	ACC	CCT	CAG	ACA	TCA	GCA	TGG	CTG	CCC	CCG	ACT	TCA	GCA	2064
					Pro												
			675					680					685				
	GAA	CAT	GAT	CAT	TCT	CTG	TCA	TGT	GTG	GTA	ACT	CCT	CAA	GAT	GGG	GAG	2112
55					Ser												
÷		690					695					700					_

237

5			ATG Met						2160
J			CAT His 725						2208
10			AGT Ser						2256
15			ACC Thr						2304
20			CTG Leu						2352
25			GGC Gly						2400
			ATC Ile 805						2448
30			ACC Thr						2496
35			AAG Lys						2544
40			GAG Glu						2592
45			GAG Glu						2640
			GGC Gly 885						2688
50			TAC Tyr						2736
55			AAC Asn						2784

5	Ile	930	Asp	Gly	Ser	Val	Gln 935	Leu	Ala	Asp	His	Tyr 940	Gln	Gln	Asn	ACC Thr	2832
	Pro 945	Ile	GGC Gly	GAC Asp	GGC	Pro 950	GTG Val	CTG Leu	CTG Leu	CCC	GAC Asp 955	AAC Asn	CAC His	TAC Tyr	CTG Leu	AGC Ser 960	2880
10	ACC Thr	CAG Gln	TCC	GCC Ala	CTG Leu 965	AGC Ser	AAA Lys	GAC Asp	CCC Pro	AAC Asn 970	GAG Glu	AAG Lys	CGC Arg	GAT Asp	CAC His 975	ATG Met	2928
15	GTC Val	CTG Leu	CTG Leu	GAG Glu 980	TTC Phe	GTG Val	ACC Thr	GCC Ala	GCC Ala 985	GGG Gly	ATC Ile	ACT Thr	CTC Leu	GGC Gly 990	ATG Met	GAC Asp	2976
20			TAC Tyr 995		TAA												2991
			(2)	) INI	FORM	ATIO	N FOI	R SE	Q ID	NO:	123:						
25		(.	(B) (C)	TYPE STRA	STH: E: ar ANDEI	996 mino ONES	amin acio 3: si	no ad i ingle	cids								
30		(1	ii) N /) FF	OLEC RAGME	CULE ENT	TYPI YPE:	int	otei	al							·	
35	Met										NO:1		Gly	Pro	Trp	Glu	
	1			-	5					10	Gly			Cys	15		
40	Gln	His	Arg 35		Leu	Asp	Leu	Lys 40		Ala	Ile	Lys	Ser 45	30 Cys	Arg	Leu	
		50					55				Cys	60					
45	65	гÀг	rys	ren	Asn	H1S	Ala	Asn	Val	Val	Lys	Ala	Cys	Asp	Val		
		Glu	Leu	Asn	Ile 85		Ile	His	Asp	Val 90	75 Pro	Leu	Leu	Ala	Met 95	80 Glu	
				100					105	Leu	Leu			110	Glu		
50			115.					120			Ser		125				
		130					135				Lys	140				_	
55	145	-ys	F10	GIU	WPII	150	vai	ьeu	GIN	Asp	Val 155	GIÀ	GTA	Lys	Ile	Ile 160	
	His	Lys	Ile	Ile	Asp		Gly	Tyr	Ala	Lys	Asp	Val	Asp	Gln	Gly	Ser	

					165					170					175	
	Leu	Cys	Thr	Ser 180		Val	Gly	Thr	Leu 185		Tyr	Leu	Ala	Pro 190		Leu
5	Phe	Glu	Asn 195	Lys	Pro	Tyr	Thr	Ala 200	Thr	Val	Asp	Tyr	Trp 205	Ser	Phe	Gly
		210	Val				215		_	=	_	220				
	225		Pro			230					235					240
10	•		Phe		245					250					255	
			Pro	260					265					270		
15			Trp 275					280		_			285			
	_	290					295				_	300				
20	305		Ile Ile			310					315					320
20		•	Ser		325					330	_			•	335	
			Leu	340					345					350		
25			355 Cys				_	360			_		3 <b>65</b>	_		
		370	Phe			_	375		_	_	-	380		_		
30	385		Leu			390				_	395	_				400
			Pro		405					410					415	
	Tyr	Val	Ser	420 Gly	Leu	Lys	Glu	Asp	425 Tyr	Ser	Arg	Leu	Phe	430 Gln	Gly	Gln
<b>35</b> .	Arg	Ala	435 Ala	Met	Leu	Ser	Leu	440 Leu	Arg	Tyr	Asn	Ala	445 Asn	Leu	Thr	Lys
		450 Lys	Asn	Thr	Leu		455 Ser	Ala	Ser	Gln	Gln	460 Leu	Lys	Ala	Lys	
40	465 Glu	Phe	Phe	His		470 Ser	Ile	Gln	Leu	_	475 Leu	Glu	Arg	Tyr		480 Glu
	Gln	Met	Thr	_	485 Gly	Ile	Ser	Ser		490 Lys	Met	Leu	Lys		495 Trp	Lys
45	Glu	Met	Glu 515	500 Glu	Lys	Ala	Ile	His 520	505 Tyr	Ala	Glu	Val	Gly 525	510 Val	Ile	Gly
40	Tyr	Leu 530	Glu	Asp	Gln	Ile	Met 535		Leu	His	Ala	Glu 540		Met	Gly	Leu
	Gln 545		Ser	Pro	Tyr	Gly 550		Arg	Gln	Gly	Asp 555		Met	Glu	Ser	Leu 560
50		Gln	Arg	Ala	Ile 565		Leu	Tyr	Lys	Gln 570		Lys	His	Arg	Pro 575	
	Asp	His	Ser	Tyr 580		Asp	Ser	Thr	Glu 585		Val	Lys	Ile	Ile 590		His
55	Thr	Val	Gln 595	Ser	Gln	Asp	Arg	Val 600		Lys	Glu	Leu	Phe 605	Gly	His	Leu
	Co	T	T 011	T 011	Clar	Care	T	01-	T	T10	T10	7	Ton	Tou	Dro	Lare

```
615
        Val Glu Val Ala Leu Ser Asn Ile Lys Glu Ala Asp Asn Thr Val Met
                                                    620
                           630
                                               635
        Phe Met Gln Gly Lys Arg Gln Lys Glu Ile Trp His Leu Leu Lys Ile
   5
                       645
                                           650
        Ala Cys Thr Gln Ser Ser Ala Arg Ser Leu Val Gly Ser Ser Leu Glu
                                       665
       Gly Ala Val Thr Pro Gln Thr Ser Ala Trp Leu Pro Pro Thr Ser Ala
                                   680
       Glu His Asp His Ser Leu Ser Cys Val Val Thr Pro Gln Asp Gly Glu
  10
                       695
       Thr Ser Ala Gln Met Ile Glu Glu Asn Leu Asn Cys Leu Gly His Leu
                          710
                                               715
       Ser Thr Ile Ile His Glu Ala Asn Glu Glu Gln Gly Asn Ser Met Met
 15
                                           730
       Asn Leu Asp Trp Ser Trp Leu Thr Glu Trp Val Pro Arg Ala Arg Asp
                                       745
       Pro Pro Val Ala Thr Met Val Ser Lys Gly Glu Glu Leu Phe Thr Gly
                                   760
       Val Val Pro Ile Leu Val Glu Leu Asp Gly Asp Val Asn Gly His Lys
 20
                               775
       Phe Ser Val Ser Gly Glu Gly Glu Gly Asp Ala Thr Tyr Gly Lys Leu
                          790
                                              795
       Thr Leu Lys Phe Ile Cys Thr Thr Gly Lys Leu Pro Val Pro Trp Pro
 25
                      805
                                          810
      Thr Leu Val Thr Thr Leu Thr Tyr Gly Val Gln Cys Phe Ser Arg Tyr
                  820
                                      825
      Pro Asp His Met Lys Gln His Asp Phe Phe Lys Ser Ala Met Pro Glu
                                 840
      Gly Tyr Val Gln Glu Arg Thr Ile Phe Phe Lys Asp Asp Gly Asn Tyr
30
                              855
                                                  860
      Lys Thr Arg Ala Glu Val Lys Phe Glu Gly Asp Thr Leu Val Asn Arg
                          870
                                              875
      Ile Glu Leu Lys Gly Ile Asp Phe Lys Glu Asp Gly Asn Ile Leu Gly
35
                      885
                                          890
      His Lys Leu Glu Tyr Asn Tyr Asn Ser His Asn Val Tyr Ile Met Ala
                  900
                                      905
      Asp Lys Gln Lys Asn Gly Ile Lys Val Asn Phe Lys Ile Arg His Asn
                                  920
40
      Ile Glu Asp Gly Ser Val Gln Leu Ala Asp His Tyr Gln Gln Asn Thr
                                                     925
                              935
      Pro Ile Gly Asp Gly Pro Val Leu Leu Pro Asp Asn His Tyr Leu Ser
                         950
                                             955
      Thr Gln Ser Ala Leu Ser Lys Asp Pro Asn Glu Lys Arg Asp His Met
45
                     965
                                         970
     -Val Leu Leu Glu Phe Val Thr Ala Ala Gly Ile Thr Leu Gly Met Asp
     Glu Leu Tyr Lys
             995
50
              (2) INFORMATION FOR SEQ ID NO:124:
```

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1908 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single

241 (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (ix) FEATURE: 5 (A) NAME/KEY: Coding Sequence (B) LOCATION: 1...1905 (D) OTHER INFORMATION: 10 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:124: ATG GTG AGC AAG GGC GAG GAG CTG TTC ACC GGG GTG GTG CCC ATC CTG Met Val Ser Lys Gly Glu Glu Leu Phe Thr Gly Val Val Pro Ile Leu 15 GTC GAG CTG GAC GGC GAC GTA AAC GGC CAC AAG TTC AGC GTG TCC GGC 96 Val Glu Leu Asp Gly Asp Val Asn Gly His Lys Phe Ser Val Ser Gly GAG GGC GAG GGC GAT GCC ACC TAC GGC AAG CTG ACC CTG AAG TTC ATC 20 144 Glu Gly Glu Gly Asp Ala Thr Tyr Gly Lys Leu Thr Leu Lys Phe Ile TGC ACC ACC GGC AAG CTG CCC GTG CCC TGG CCC ACC CTC GTG ACC ACC 192 25 Cys Thr Thr Gly Lys Leu Pro Val Pro Trp Pro Thr Leu Val Thr Thr CTG ACC TAC GGC GTG CAG TGC TTC AGC CGC TAC CCC GAC CAC ATG AAG Leu Thr Tyr Gly Val Gln Cys Phe Ser Arg Tyr Pro Asp His Met Lys 30 75 CAG CAC GAC TTC TTC AAG TCC GCC ATG CCC GAA GGC TAC GTC CAG GAG 288 Gln His Asp Phe Phe Lys Ser Ala Met Pro Glu Gly Tyr Val Gln Glu 35 CGC ACC ATC TTC TTC AAG GAC GAC GGC AAC TAC AAG ACC CGC GCC GAG 336 Arg Thr Ile Phe Phe Lys Asp Asp Gly Asn Tyr Lys Thr Arg Ala Glu 40 GTG AAG TTC GAG GGC GAC ACC CTG GTG AAC CGC ATC GAG CTG AAG GGC 384 Val Lys Phe Glu Gly Asp Thr Leu Val Asn Arg Ile Glu Leu Lys Gly ATC GAC TTC AAG GAG GAC GGC AAC ATC CTG GGG CAC AAG CTG GAG TAC 432

Ile Asp Phe Lys Glu Asp Gly Asn Ile Leu Gly His Lys Leu Glu Tyr 130 135

GGC ATC AAG GTG AAC TTC AAG ATC CGC CAC AAC ATC GAG GAC GGC AGC Gly Ile Lys Val Asn Phe Lys Ile Arg His Asn Ile Glu Asp Gly Ser 165 170 GTG CAG CTC GCC GAC CAC TAC CAG CAG AAC ACC CCC ATC GGC GAC GGC

AAC TAC AAC AGC CAC AAC GTC TAT ATC ATG GCC GAC AAG CAG AAG AAC Asn Tyr Asn Ser His Asn Val Tyr Ile Met Ala Asp Lys Gln Lys Asn

241

50

55

	Val	Glņ	Leu	Ala 180	Asp	His	Tyr	Gln	Gln 185	Asn	Thr	Pro	Ile	Gly 190	Asp	Gly	
5	CCC Pro	GTG Val	CTG Leu 195	CTG Leu	CCC Pro	GAC Asp	AAC Asn	CAC His 200	TAC Tyr	CTG Leu	AGC Ser	ACC Thr	CAG Gln 205	TCC Ser	GCC Ala	CTG Leu	624
10	AGC Ser	AAA Lys 210	GAC Asp	CCC Pro	AAC Asn	GAG Glu	AAG Lys 215	CGC Arg	GAT Asp	CAC His	ATG Met	GTC Val 220	CTG Leu	CTG Leu	GAG Glu	TTC Phe	672
45	GTG Val 225	ACC Thr	GCC Ala	GCC Ala	GGG Gly	ATC Ile 230	ACT Thr	CTC Leu	GGC Gly	ATG Met	GAC Asp 235	GAG Glu	CTG Leu	TAC Tyr	AAG Lys	TCC Ser 240	720
15					CGA Arg 245												768
20					ATC Ile												816
25					CGA Arg												864
30	AGC Ser	CGC Arg 290	GTC Val	CAG Gln	ATC Ile	TAC Tyr	CAC His 295	AAC Asn	CCC Pro	ACG Thr	GCC Ala	AAT Asn 300	TCC Ser	TTT Phe	CGC Arg	GTC Val	912
35					ATG Met												960
					GTC Val 325												1008
40					CGC Arg												1056
45	GAT Asp	GCG Ala	GCC Ala 355	CAG Gln	TTT Phe	GCC Ala	GCC Ala	GGC Gly 360	ATG Met	GCC Ala	AGT Ser	GCC Ala	CTA Leu 365	GAG Glu	GCG Ala	TTG Leu	1104
50					CCC Pro												1152
55					TCC Ser												1200
55	ccc	GGC	CCG	TCG	GAG	CAC	ATA	GAG	ĊGC	CGG	GTC	TCC	AAT	GCA	GGA	GGC	1248

•																	
	Pro	Gly	Pro	Ser	Glu 405		Ile	Glu	Arg	Arg 410	Val	Ser	Asn	Ala	Gly 415	Gly	٠
5		CCT Pro															1296
10		CCT Pro															1344
15		GCT Ala 450															1392
10		CCG Pro															1440
20		GCC Ala															1488
25		GAG Glu															1536
30		GGA Gly															1584
35		AGG Arg 530	Lys														1632
35		AAT Asn															1680
40		CGG Arg															1728
45		TCT Ser															1776
50		AGT Ser															1824
		GTG Val 610															1872
55	TTC	GTC	CAG	GAG	CTG	AGG	AAG	CGG	GGT	TCT	CCC	TGA				•	1908

244

Phe Val Gln Glu Leu Arg Lys Arg Gly Ser Pro

- 5 (2) INFORMATION FOR SEQ ID NO:125:
  - (i) SEQUENCE CHARACTERISTICS:
    - (A) LENGTH: 635 amino acids
    - (B) TYPE: amino acid
- 10 (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear
  - (ii) MOLECULE TYPE: protein
  - (v) FRAGMENT TYPE: internal
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:125:

Met Val Ser Lys Gly Glu Glu Leu Phe Thr Gly Val Val Pro Ile Leu 10 Val Glu Leu Asp Gly Asp Val Asn Gly His Lys Phe Ser Val Ser Gly 20 25 Glu Gly Glu Gly Asp Ala Thr Tyr Gly Lys Leu Thr Leu Lys Phe Ile 40 Cys Thr Thr Gly Lys Leu Pro Val Pro Trp Pro Thr Leu Val Thr Thr 25 55 60 Leu Thr Tyr Gly Val Gln Cys Phe Ser Arg Tyr Pro Asp His Met Lys 70 75 Gln His Asp Phe Phe Lys Ser Ala Met Pro Glu Gly Tyr Val Gln Glu 85 Arg Thr Ile Phe Phe Lys Asp Asp Gly Asn Tyr Lys Thr Arg Ala Glu 30 105 Val Lys Phe Glu Gly Asp Thr Leu Val Asn Arg Ile Glu Leu Lys Gly 120 Ile Asp Phe Lys Glu Asp Gly Asn Ile Leu Gly His Lys Leu Glu Tyr 35 135 140 Asn Tyr Asn Ser His Asn Val Tyr Ile Met Ala Asp Lys Gln Lys Asn 150 155 Gly Ile Lys Val Asn Phe Lys Ile Arg His Asn Ile Glu Asp Gly Ser 170 40 Val Gln Leu Ala Asp His Tyr Gln Gln Asn Thr Pro Ile Gly Asp Gly 185 Pro Val Leu Leu Pro Asp Asn His Tyr Leu Ser Thr Gln Ser Ala Leu Ser Lys Asp Pro Asn Glu Lys Arg Asp His Met Val Leu Leu Glu Phe 45 215 220 Val Thr Ala Ala Gly Ile Thr Leu Gly Met Asp Glu Leu Tyr Lys Ser 235 Gly Leu Arg Ser Arg Ala Gln Ala Ser Met Ser Glu Thr Val Ile Met

244

250

Ser Glu Thr Val Ile Cys Ser Ser Arg Ala Thr Val Met Leu Tyr Asp

Val Gly Arg Lys Met Gln Pro Asp Gln Gln Val Val Ile Asn Cys Ala

295

265 Asp Gly Asn Lys Arg Trp Leu Pro Ala Gly Thr Gly Pro Gln Ala Phe 280 Ser Arg Val Gln Ile Tyr His Asn Pro Thr Ala Asn Ser Phe Arg Val

50

55

245

```
305
                       310
                                           315
     Ile Val Arg Gly Val Lys Tyr Asn Gln Ala Thr Pro Asn Phe His Gln
     Trp Arg Asp Ala Arg Gln Val Trp Gly Leu Asn Phe Gly Ser Lys Glu
5
                                  345
     Asp Ala Ala Gln Phe Ala Ala Gly Met Ala Ser Ala Leu Glu Ala Leu
                               360
     Glu Gly Gly Pro Pro Pro Pro Pro Ala Leu Pro Thr Trp Ser Val
                375
                                              380
10
     Pro Asn Gly Pro Ser Pro Glu Glu Val Glu Gln Gln Lys Arg Gln Gln
                       390
                                          395
     Pro Gly Pro Ser Glu His Ile Glu Arg Arg Val Ser Asn Ala Gly Gly
                    405
                                      410
     Pro Pro Ala Pro Pro Ala Gly Gly Pro Pro Pro Pro Pro Gly Pro Pro
15
                420 . 425
     Pro Pro Pro Gly Pro Pro Pro Pro Gly Leu Pro Pro Ser Gly Val
                                440
     Pro Ala Ala Ala His Gly Ala Gly Gly Pro Pro Pro Ala Pro Pro
                            455
20
     Leu Pro Ala Ala Gln Gly Pro Gly Gly Gly Ala Gly Ala Pro Gly
                        470
     Leu Ala Ala Ala Ile Ala Gly Ala Lys Leu Arg Lys Val Ser Lys Gln
                                       490
     Glu Glu Ala Ser Gly Gly Pro Thr Ala Pro Lys Ala Glu Ser Gly Arg
25
                                   505
     Ser Gly Gly Gly Leu Met Glu Glu Met Asn Ala Met Leu Ala Arg
                               520
     Arg Arg Lys Ala Thr Gln Val Gly Glu Lys Thr Pro Lys Asp Glu Ser
                           535
30
     Ala Asn Gln Glu Glu Pro Glu Ala Arg Val Pro Ala Gln Ser Glu Ser
                       550
                                          555
     Val Arg Arg Pro Trp Glu Lys Asn Ser Thr Thr Leu Pro Arg Met Lys
                   565
                             - 570
     Ser Ser Ser Ser Val Thr Thr Ser Glu Thr Gln Pro Cys Thr Pro Ser
35
                580
                                585
     Ser Ser Asp Tyr Ser Asp Leu Gln Arg Val Lys Gln Glu Leu Leu Glu
                        600
     Glu Val Lys Lys Glu Leu Gln Lys Val Lys Glu Glu Ile Ile Glu Ala
                           615
40
     Phe Val Gln Glu Leu Arg Lys Arg Gly Ser Pro
                        630
              (2) INFORMATION FOR SEQ ID NO:126:
45
           (i) SEQUENCE CHARACTERISTICS:
             (A) LENGTH: 1329 base pairs
             (B) TYPE: nucleic acid
             (C) STRANDEDNESS: single
             (D) TOPOLOGY: linear
50
           (ii) MOLECULE TYPE: cDNA
           (ix) FEATURE:
```

(A) NAME/KEY: Coding Sequence

(B) LOCATION: 1...1326 (D) OTHER INFORMATION:

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:126:

5	ATO Met	GT(	G AGO	AAC Lys	G GGC Gly 5	GAG Glu	GAG Glu	CTG Leu	TTO Phe	C ACC Thr	GGG Gly	GTO Val	GT(	G CCC	C ATO	C CTG	48
10	vai	GIU	. red	20	, GIÀ	Asp	Val	Asn	Gly 25	' His	. Lys	Phe	Ser	Val	Ser	GGC Gly	96
15	Giù	Gly	35	GIY	Asp	Ala	Thr	Tyr 40	Gly	' Lys	Leu	Thr	Leu 45	Lys	Phe	ATC	144
	TGC Cys	ACC Thr 50	ACC Thr	GGC	AAG Lys	CTG Leu	CCC Pro 55	GTG Val	CCC Pro	TGG Trp	CCC	ACC Thr 60	CTC	GTG Val	ACC Thr	ACC	192
20	CTG Leu 65	ACC Thr	TAC Tyr	GGC Gly	GTG Val	CAG Gln 70	TGC Cys	TTC Phe	AGC Ser	CGC Arg	TAC Tyr 75	CCC Pro	GAC Asp	CAC His	ATG Met	AAG Lys 80	240
25	CAG Gln	CAC His	GAC Asp	TTC	TTC Phe 85	AAG Lys	TCC Ser	GCC Ala	ATG Met	CCC Pro 90	GAA Glu	GGC Gly	TAC Tyr	GTC Val	CAG Gln 95	GAG Glu	288
30	CGC Arg	ACC Thr	ATC Ile	TTC Phe 100	TTC Phe	AAG Lys	GAC Asp	GAC Asp	GGC Gly 105	AAC Asn	TAC Tyr	AAG Lys	ACC Thr	CGC Arg 110	GCC Ala	GAG Glu	336
35	GTG Val	AAG Lys	TTC Phe 115	GAĠ Glu	GGC Gly	GAC Asp	ACC Thr	CTG Leu 120	GTG Val	AAC Asn	CGC Arg	ATC Ile	GAG Glu 125	CTG Leu	AAG Lys	GGC Gly	384
	ATC Ile	GAC Asp 130	TTC Phe	AAG Lys	GAG Glu	GAC Asp	GGC Gly 135	AAC Asn	ATC Ile	CTG Leu	GGG Gly	CAC His 140	AAG Lys	CTG Leu	GAG Glu	TAC Tyr	432
40	AAC Asn 145	TAC Tyr	AAC Asn	AGC Ser	CAC His	AAC Asn 150	GTC Val	TAT Tyr	ATC Ile	ATG Met	GCC Ala 155	GAC Asp	AAG Lys	CAG Gln	AAG Lys	AAC Asn 160	480
45	GGC Gly	ATC Ile	AAG Lys	vaı	AAC Asn 165	TTC Phe	AAG . Lys	ATC Ile	Arg	CAC His 170	AAC Asn	ATC Ile	GAG Glu	GAC Asp	GGC Gly 175	AGC Ser	528
50	GTG Val	CAG Gln	neu	GCC Ala 180	GAC Asp	CAC His	TAC (	Gln	CAG Gln 185	AAC Asn	ACC Thr	CCC Pro	ATC Ile	GGC Gly 190	GAC Asp	GGC Gly	576
55	CCC Pro	vaı	CTG Leu 195	CTG	CCC (	GAC :	Asn 1	CAC ' His '	TAC Tyr	CTG . Leu	AGC Ser	Thr	CAG Gln 205	TCC Ser	GCC Ala	CTG Leu	624
	AGC 2	AAA	GAC ·	ccc :	AAC (	GAG 1	AAG (	CGC (	GAT	CAC /	ATG (	GTC	CTG	CTG	GAG	TTC	672 246

	Ser Lys Asp Pro Asn Glu Lys Arg Asp His Met Val Leu Leu Glu Phe																	
	Ser	Lys 210	Asp	Pro	Asn	Glu ·	Lys 215	Arg	Asp	His	Met	Val 220	Leu	Leu	Glu	Phe		
	GTG	ACC	GCC	GCC	GGG	ATC	ACT	CTC	GGC	ATG	GAC	GAG	CTG	TAC	AAG	TCC	720	
5	Val	Thr	Ala	Ala	Gly	Ile	Thr	Leu	Gly	Met	Asp	Glu	Leu	Tyr	Lys	Ser		
	225					230					235					240		
	GGA	СТС	AGA	тст	CGA	GCT	CAA	GCT	тса	ATG	GCT	GCC	ATC	CGG	AAG	AAA	768	
•							Gln										, 55	
10	-		_		245					250					255			
															ama			
							GGA Gly										816	
	Deu	Vai	110	260	Cly	nop	Cry	AIU	265	Ory	цуз	1111	Cys	270	200			
15																		
							TTC										864	
	Val	Phe	275	гÀг	Asp	GIN	Phe	280	GIU	Val	Tyr	vaı	285	Thr	vaı	Pne		
			212					200					203					
20							ATC										912	
	Glu		Tyr	Val	Ala	Asp	Ile	Glu	Val	Asp	Gly	-	Gln	Val	Glu	Leu		
		290					295					300						
	GCT	TTG	TGG	GAC	ACA	GCT	GGG	CAG	GAA	GAT	TAT	GAT	CGC	CTG	AGG	CCC	960	
25	Ala	Leu	Trp	Asp	Thr	Ala	Gly	Gln	Glu	Asp	Tyr	Asp	Arg	Leu	Arg			
	305					310					315					320		
	СТС	TCC	TAC	CCA	GAT	ACC	GAT	GTT	АТА	CTG	ATG	TGT	TTT	TCC	ATC	GAC	1008	
							Asp								_			
30					325					330					335			
	N.C.C	CCT	ርእጥ	አርጥ	מידית	GNN	AAC	איזירי	CCA	GNN	מממ	тсс	ACC	CCA	CAA	GTC	1056	
							Asn								_	_	1000	
				340					345		-	_		350				
35		~~~		mam			ame					c.mm	000	220	220	220	1104	
							GTG Val										1104	
	_,,		355	-,-				360					365		-,-	2		
								_										
40							CAC His										1152	
	мър	370	Arg	ASII	Аэр	Giu	375	1111	Arg	ALG	Giu	380	AIG	пуз	1100	ДуБ		
							GAA									_	1200	
45	Gln 385	Glu	Pro	Val	Lys	Pro 390	Glu	Glu	Gly	Arg	Asp 395	Met	Ala	Asn	Arg	11e 400		
	365					390					393					400		
	GGC	GCT	TTT	GGG	TAC	ATG	GAG	TGT	TCA	GCA	AAG	ACC	AAA	GAT	GGA	GTG	1248	
	Gly	Ala	Phe	Gly	-	Met	Glu	Cys	Ser		Lys	Thr	Lys	Asp	_	Val		
50					405					410					415			
	AGA	GAG	GTT	TTT	GAA	ATG	GCT	ACG	AGA	GCT	GCT	CTG	CAA	GCT	AGA	CGT	1296	
	Arg	Glu	Val	Phe	Glu	Met	Ala	Thr	Arg	Ala	Ala	Leu	Gln	Ala	Arg	Arg	•	
<i></i>				420					425					430				
55	GGG	ልክሮ	תממ	ααα	ጥርጥ	GGT	TGC	بنساب	GTC	ጥጥር፤	TCA						1329	
		~~0	arun.				-00	-11	010		LUA						24	47
																	_	•

248

Gly Lys Lys Ser Gly Cys Leu Val Leu

```
5
              (2) INFORMATION FOR SEQ ID NO:127:
```

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 442 amino acids
  - (B) TYPE: amino acid
- 10 (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear
  - (ii) MOLECULE TYPE: protein
  - (v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:127:

Met Val Ser Lys Gly Glu Glu Leu Phe Thr Gly Val Val Pro Ile Leu 10 Val Glu Leu Asp Gly Asp Val Asn Gly His Lys Phe Ser Val Ser Gly 20 25 Glu Gly Glu Gly Asp Ala Thr Tyr Gly Lys Leu Thr Leu Lys Phe Ile Cys Thr Thr Gly Lys Leu Pro Val Pro Trp Pro Thr Leu Val Thr Thr 25 55 Leu Thr Tyr Gly Val Gln Cys Phe Ser Arg Tyr Pro Asp His Met Lys 70 Gln His Asp Phe Phe Lys Ser Ala Met Pro Glu Gly Tyr Val Gln Glu 85 Arg Thr Ile Phe Phe Lys Asp Asp Gly Asn Tyr Lys Thr Arg Ala Glu 30 100 105 Val Lys Phe Glu Gly Asp Thr Leu Val Asn Arg Ile Glu Leu Lys Gly 120 Ile Asp Phe Lys Glu Asp Gly Asn Ile Leu Gly His Lys Leu Glu Tyr 35 135 140 Asn Tyr Asn Ser His Asn Val Tyr Ile Met Ala Asp Lys Gln Lys Asn 150 155 Gly Ile Lys Val Asn Phe Lys Ile Arg His Asn Ile Glu Asp Gly Ser 170 Val Gln Leu Ala Asp His Tyr Gln Gln Asn Thr Pro Ile Gly Asp Gly 40 185 Pro Val Leu Pro Asp Asn His Tyr Leu Ser Thr Gln Ser Ala Leu Ser Lys Asp Pro Asn Glu Lys Arg Asp His Met Val Leu Leu Glu Phe 45 215 220 Val Thr Ala Ala Gly Ile Thr Leu Gly Met Asp Glu Leu Tyr Lys Ser 230 Gly Leu Arg Ser Arg Ala Gln Ala Ser Met Ala Ala Ile Arg Lys Lys 250 Leu Val Ile Val Gly Asp Gly Ala Cys Gly Lys Thr Cys Leu Leu Ile 50 . 265 Val Phe Ser Lys Asp Gln Phe Pro Glu Val Tyr Val Pro Thr Val Phe 280 Glu Asn Tyr Val Ala Asp Ile Glu Val Asp Gly Lys Gln Val Glu Leu

Ala Leu Trp Asp Thr Ala Gly Gln Glu Asp Tyr Asp Arg Leu Arg Pro

295

249

,

	305					310					315					320		
	Leu	Ser	Tyr	Pro	Asp 325	Thr	Asp	Val	Ile	Leu 330	Met	Cys	Phe	Ser	11e 335	Asp		
5	Ser	Pro	Asp	Ser 340	Leu	Glu	Asn	Ile	Pro 345	Glu	Lys	Trp	Thr	Pro 350	Glu	Val		
	Lys	His	Phe 355	Cys	Pro	Asn	Val	Pro 360	Ile	Ile	Leu	Val	Gly 365	Asn	Lys	Lys		
		Leu 370					375					380		-		-		
10	385	Glu				390					395					400		
		Ala			405					410					415			
15		Glu		420					425		Ala	Leu	Gln	Ala 430	Arg	Arg		
	Gly	Lys	Lys 435	Lys	Ser	Gly	Cys	Leu 440	Val	Leu								
20			(2)	INF	ORM	ATION	1 FOI	R SE	Q ID	NO:	128:							
20		( <u>;</u>	(A) (B)	LENC TYPE	TH: E: nu	1140 iclei	basic ac	se pa	airs									
25				TOPO				_	-									
				OLEC		TYPI	E: cI	AMC										
30			(B) (D)	NAN LOC	CATIO	ON: 3	TAMS	1137 ION:	-									
35				EQUE												<i>a</i>	4.0	
		GAC Asp															48	
40		GAC Asp														CAG Gln	96	
45		AGA Arg															144	
50		ACA Thr 50															192	
r.F		ATĠ Met															240	
55	GAG	CGA	GGC	AAG	ATG	AGA	GTG	CAC	AAG	ATC	TCC	AAC	GTC	AAC	AAG	GCC	. 288	249

				•						250							
	G1	u Ar	g Gl	у Гу	s Met 85	t Arg	g Vai	l His	s Ly:	90	e Se	r As:	n Va	l As	n Ly 95	s Ala	
5	CT Le	G GA u As	T TTO	C AT/ = Ile 100	: AT	C AGO	AAA Lys	A GGO S Gly	GT( Va)	Ly	A CTO	G GTG	G TC	C ATO	e Gl	A GCC y Ala	336
10	GA: Gl:	A GA u Gl	A ATO u Ile 115	: vaj	GAT L Asp	GGG Gly	AAT Asr	GTC Val 120	. Lys	ATO	G ACC	C CTC	G GGG 1 Gly 125	/ Met	E Ile	C TGG E Trp	384
15	ACC Thi	2 ATC	- 116	CTC Leu	G CGC	AGG Arg	GAT Asp 135	Pro	CCG Pro	GTO Val	GCC Ala	C ACC Thr	Met	GTC Val	G AGO	AAG Lys	432
	GG( Gl <sub>3</sub> 145	610	G GAG	CTG Leu	TTC Phe	ACC Thr 150	GIY	GTG Val	GTG Val	Pro	ATC Ile	Leu	GTC Val	GAG Glu	CTC Lev	GAC Asp 160	480
20	GG( Gly	GAC Asp	C GTA Val	AAC Asn	GGC Gly 165	CAC His	AAG Lys	TTC Phe	AGC Ser	GTG Val 170	Ser	Gly	GAG Glu	GGC	GAG Glu 175	GGC Gly	528
25	GAT Asp	GCC Ala	ACC Thr	TAC Tyr 180	GGC Gly	AAG Lys	CTG Leu	ACC Thr	CTG Leu 185	AAG Lys	TTC Phe	ATC	TGC Cys	ACC Thr 190	ACC Thr	GGC Gly	576
30	AAG Lys	CTG Leu	CCC Pro 195	GTG Val	CCC Pro	TGG Trp	CCC Pro	ACC Thr 200	CTC Leu	GTG Val	ACC Thr	ACC Thr	CTG Leu 205	ACC Thr	TAC Tyr	GGC Gly	624
35	GTG Val	CAG Gln 210	TGC Cys	TTC Phe	AGC Ser	CGC Arg	TAC Tyr 215	CCC Pro	GAC Asp	CAC	ATG Met	AAG Lys 220	CAG Gln	CAC His	GAC Asp	TTC Phe	672
	TTC Phe 225	AAG Lys	TCC Ser	GCC Ala	ATG Met	CCC Pro 230	GAA Glu	GGC Gly	TAC Tyr	GTC Val	CAG Gln 235	GAG Glu	CGC Arg	ACC Thr	ATC Ile	TTC Phe 240	720
.40	TTC Phe	AAG Lys	GAC Asp	GAC Asp	GGC Gly 245	AAC Asn	TAC Tyr	AAG Lys	ACC Thr	CGC Arg 250	GCC Ala	GAG Glu	GTG Val	AAG Lys	TTC Phe 255	GAG Glu	768
45	GGC Gly	GAC Asp	ACC Thr	CTG Leu 260	GTG Val	AAC Asn	CGC Arg	ATC Ile	GAG Glu 265	CTG Leu	AAG Lys	GGC Gly	ATC Ile	GAC Asp 270	TTC Phe	AAG Lys	816
50	GAG Glu	GAC Asp	GGC Gly 275	AAC Asn	ATC Ile	CTG Leu	GIY	CAC His 280	AAG Lys	CTG Leu	GAG Glu	TAC Tyr	AAC Asn 285	TAC Tyr	AAC Asn	AGC Ser	864
55	CAC His	AAC Asn 290	GTC Val	TAT Tyr	ATC . Ile :	met.	GCC Ala 295	GAC Asp	AAG Lys	CAG Gln	AAG Lys	AAC Asn 300	GGC Gly	ATC Ile	AAG Lys	GTG Val	912
	AAC	TTC	AAG	ATC	CGC (	CAC .	AAC .	ATC	GAG	GAC	GGC	AGC	GTG	CAG	стс	GCC	960 250

	325  CCC GAC AAC CAC TAC CTG AGC ACC CAG TCC GCC CTG AGC AAA GAC CCC Pro Asp Asn His Tyr Leu Ser Thr Gln Ser Ala Leu Ser Lys Asp Pro 340  AAC GAG AAG CGC GAT CAC ATG GTC CTG GAG TTC GTG ACC GCC GCC ASn Glu Lys Arg Asp His Met Val Leu Leu Glu Phe Val Thr Ala Ala 355  360  335  336																
		Phe	Lys	Ile	Arg		Asn	Ile	Glu	Asp		Ser	Val	Gln	Leu		
5					Gln					Gly					Leu		1008
10				His					Gln					Lys			1056
			Lys					Val					Val				_1104
15						ATG Met						TAA					1140
20			(2)	INI	FORM	ATION	N FOR	R SE(	Q ID	NO::	L29:						
25		(:	(A) (B) (C)	LENC TYPI STRA	ETH: E: ar ANDEI	CHARA 379 mino ONESS	amin acio S: si	no ad i ingle	cids								
30		(1	/) FF	RAGMI	ENT T	TYPE:	int	erna	al	) ID	NO:	129:					
35	Met 1												Met	Gln	Pro 15	Glu	
	_	Asp	Trp	Asp 20	Arg	Asp	Leu	Leu	Leu 25		Pro	Ala	Trp	Glu 30		Gln	
40			35					40					Leu 45 Asp	_	_		
40		50					55					60	Leu	_			
45	65				Met	70				Ile	75		Val	•		80	
45	Leu	Asp	Phe	Ile 100	85 Ala	Ser	Lys	Gly		90 Lys	Leu	Val	Ser		95 Gly	Ala	
	Glu	Glu	Ile 115		Asp	Gly	Asn	Val	105 Lys	Met	Thr	Leu	Gly 125	110 Met	Ile	Trp	
50		130					135					.140	Met				
	145					150					155		Val			160	
55					165					170		_	Glu		175	•-	
	Asp	Ala	Thr	Tyr	Gly	rys	Leu	Thr	Leu	Lys	Phe	Ile	Cys	Thr	Thr	Gly	

				180					185					190				
	Lys	Leu	Pro 195	Val	Pro	Trp	Pro	Thr 200	Leu	Val	Thr	Thr	Leu 205	Thr	Tyr	Gly		
5	Val	Gln 210	Cys	Phe	Ser	Arg	Tyr 215	Pro	Asp	His	Met	Lys 220		His	Asp	Phe		
	Phe 225	Lys	Ser	Ala	Met	Pro 230	Glu	Gly	Tyr	Val			Arg	Thr	Ile			
		Lys	Asp	Asp			Tyr	Lys	Thr		235 Ala	Glu	Val	Lys	Phe	240 Glu		
10	Gly	Asp	Thr		245 Val	Asn	Arg	Ile		250 Leu	Lys	Gly	Ile	Asp	255 Phe	Lys		
	Glu	Asp		260 Asn	Ile	Leu	Gly	His	265 Lys	Leu	Glu	Tyr	Asn	270 Tyr	Asn	Ser		
	His	Asn	275 Val	Tyr	Ile	Met	Ala	280 Asp	Lys	Gln	Lys	Asn	285 Gly	Ile	Lys	Val		
15		290 Phe					295					300						
	305					310					315					320		
		His			325					330					335			
20	Pro	Asp	Asn	His 340	Tyr	Leu	Ser	Thr	Gln 345	Ser	Ala	Leu	Ser	Lys 350	Asp	Pro		
	Asn	Glu	Lys 355	Arg	Asp	His	Met	Val 360	Leu	Leu	Glu	Phe	Val 365	Thr	Ala	Ala		
25	.Gly	Ile 370	Thr	Leu	Gly	Met	Asp 375		Leu	Tyr	Lys		303					
			(2)	TNI	CODM?	\ TT () \		CEC	. TD	170 . 7								
				INE						NO: J	130:							
30		(i		LENC														
				TYPE STRA					<u>.</u>									
			(D)	TOPO	LOGY	/: li	inear											
35				OLEC		TYPE	E: cD	ANG										
				MAN					quer	ice								
40				OTH														
		(э	ai) S	EQUE	NCE	DESC	CRIPT	CION:	SEC	) ID	NO: 3	130:						
		GTG															48	
45	Met 1	Val	Ser	Lys	Gly 5	Glu	Glu	Leu	Phe	Thr 10	Gly	Val	Val	Pro	Ile 15	Leu		
	GTC	GAG	CTG	GAC	GGC	GAC	GTA	AAC	GGC	CAC	AAG	TTC	AGC	GTG	TCC	GGC .	96	
50	Val	Glu	Leu	Asp 20	Gly	Asp	Val	Asn	Gly 25	His	Lys	Phe	Ser	Val	Ser	Gly	50	
	a.a	~~~	<b></b>		~~									30				
		GGC Gly	Glu														144	
55			35					40					45					
	TGC	ACC	ACC	GGC	AAG	CTG	CCC	GTG	CCC	TGG	CCC	ACC	CTC	GTG	ACC	ACC	192	
																•		252

	Cys	Thr 50	Thr	Gly	Lys	Leu	Pro 55	Val	Pro	Trp	Pro	Thr 60	Leu	Val	Thr	Thr		
5					GTG Val												240	
10					TTC Phe 85												288	
15					TTC Phe												336	
10					GGC Gly												384	
20					GAG Glu												432	
25					CAC His												480	
30					AAC Asn 165												528	
35					GAC Asp												576	
33					CCC Pro												624	
40					AAC Asn	_											672	
45					GGG Gly												720	
50					CGA Arg 245												768	
56					GCC Ala												816	
55	GAG	CTT	GAC	TTC	TCC	ATC	CTC	TTC	GAĊ	TAT	GAG	TAT	TTG	AAT	CCG	AAC	864 253	

	Gli	ı Le	u As <sub>l</sub> 27!	p Pho	e Se:	r Ile	e Lei	280	e Asj	р Ту	r Gl	и Ту	r Le		n Pr	o Asn		
5	GA <i>l</i> Gli	A GA 1 Gl 290	1 010	G CCC	AA: Asi	r GCA n Ala	CAT His 295	Lys	GT(	C GC	C AGG	C CC r Pro	o Pro	C TC	C GG, r Gl;	A CCC y Pro	91	L <b>2</b>
10	GCA Ala 305		C CCC	GAT Asp	TAD T	GTA Val 310	met	GAC Asp	TAT	GG(	C CTC / Let 315	ı Lys	G CCA	TAC Ty:	C AGO	C CCC Pro 320	96	0
15	Dea	ALC	. Sel	Den	325	GIY	GIu	Pro	Pro	330	Arg	Phe	Gly	Glı	335		100	8
	AT 9	Val	GIY	340	GIN	гÀг	Pne	Leu	Ser 345	Ala	Ala	Lys	Pro	Ala 350	Gly	GCC Ala	105	6
20	TCG Ser	GGC	CTG Leu 355	ser	CCT Pro	CGG Arg	ATC	GAG Glu 360	ATC Ile	ACT	CCG Pro	TCC	CAC His 365	GAA Glu	. CTG Leu	ATC	1104	4
25	CAG Gln	GCA Ala 370	GTG Val	GGG Gly	CCC Pro	Leu	CGC Arg 375	ATG Met	AGA Arg	GAC Asp	GCG Ala	GGC Gly 380	CTC Leu	CTG Leu	GTG Val	GAG Glu	1152	2
30	CAG Gln 385	CCT Pro	CCC Pro	CTG Leu	GCC Ala	GGG Gly 390	GTG Val	GCC Ala	GCC Ala	AGC Ser	CCG Pro 395	AGG Arg	TTC Phe	ACC Thr	CTG Leu	CCC Pro 400	1200	)
35	GTG Val	CCC Pro	GGC Gly	TTC Phe	GAG Glu 405	GGC Gly	TAC Tyr	CGC Arg	GAG Glu	CCG Pro 410	CTT Leu	TGC Cys	TTG Leu	AGC Ser	CCC Pro 415	GCT Ala	1248	3
	AGC Ser	AGC Ser	GGC Gly	TCC Ser 420	TCT Ser	GCC Ala	AGC Ser	TTC Phe	ATT Ile 425	TCT Ser	GAC Asp	ACC Thr	TTC Phe	TCC Ser 430	CCC Pro	TAC Tyr	1296	
40	ACC Thr	TCG Ser	CCC Pro 435	TGC Cys	GTC Val	TCG Ser	Pro	AAT Asn 440	AAC Asn	GGC Gly	GGG Gly	CCC Pro	GAC Asp 445	GAC Asp	CTG Leu	TGT Cys	1344	
45	CCG Pro	CAG Gln 450	TTT Phe	CAA Gln	AAC Asn	He	CCT Pro . 455	GCT Ala	CAT His	TAT Tyr	TCC Ser	CCC Pro 460	AGA Arg	ACC Thr	TCG Ser	CCA Pro	1392	
50	ATA Ile 465	ATG Met	TCA Ser	CCT Pro	Arg	ACC Thr 470	AGC (	CTC Leu	GCC Ala	Glu	GAC Asp 475	AGC Ser	TGC Cys	CTG Leu	GGC Gly	CGC Arg 480	1440	
55	CAC His	TCG Ser	CCC   Pro	Val	CCC Pro 485	CGT (	CCG (Pro 1	GCC '	Ser	CGC Arg 490	TCC Ser	TCA Ser	TCG Ser	CCT Pro	GGT Gly 495	Ala	1488	
	AAG	CGG	AGG (	CAT	TCG '	TGC (	GCC (	GAG (	GCC	TTG	GTT	GCC	CTG	CCG	ccc	GGA	1536	254

										255							
	Lys	Arg	Arg	His 500	Ser	Cys ·	Ala	Glu	Ala 505	Leu	Val	Ala	Leu	Pro 510	Pro	Gly	
5						TCC Ser											1584
10	GTG Val	GCA Ala 530	CCC Pro	CAG Gln	GAC Asp	CAC His	GGC Gly 535	TCC Ser	CCG Pro	GCT Ala	GGG Gly	TAC Tyr 540	CCC Pro	CCT Pro	GTG Val	GCT Ala	1632
15	GGC Gly 545	TCT Ser	GCC Ala	GTG Val	ATC Ile	ATG Met 550	GAT Asp	GCC Ala	CTG Leu	AAC Asn	AGC Ser 555	CTC Leu	GCC Ala	ACG Thr	GAC Asp	TCG Ser 560	1680
.0						CCC Pro											1728
20	CCG Pro	GTG Val	TCT Ser	GCC Ala 580	GCC Ala	CCA Pro	TCC Ser	AAG Lys	GCC Ala 585	GGC Gly	CTG Leu	CCT Pro	CGC Arg	CAC His 590	ATC Ile	TAC Tyr	1776
25						CTG Leu											1824
30						ATC Ile											1872
35						CCC Pro 630											1920
30						CCG Pro											1968
40	CGG Arg	ATC Ile	GAG Glu	GTG Val 660	CAG Gln	CCC Pro	AAG Lys	CCA Pro	CAT His 665	CAC His	CGG Arg	GCC Ala	CAC His	TAT Tyr 670	GAG Glu	ACA Thr	2016
45	GAA Glu	GGC Gly	AGC Ser 675	CGA Arg	GGG Gly	GCT Ala	GTC Val	AAA Lys 680	GCT Ala	CCA Pro	ACT Thr	GGA Gly	GGC Gly 685	CAC His	CCT Pro	GTG Val	2064
50	GTT Val	CAG Gln 690	CTC Leu	CAT His	GGC Gly	TAC Tyr	ATG Met 695	GAA Glu	AAC Asn	AAG Lys	CCT Pro	CTG Leu 700	GGA Gly	CTT Leu	CAG Gln	ATC Ile	2112
55						GAT Asp 710									Phe		2160
55	CAG	GTG	CAC	CGA	ATC	ACG	GGG	AAA	ACT	GTC	ACC	ACC	ACC	AGC	TAT	GAG	2208

				•						236							
	Gln	val	l His	Arg	725	Thr	: Gly	/ Lys	s Thr	730		Thr	Thr	Ser	735	Glu 5	
5	AAG Lys	ATA Ile	GTG Val	GGC Gly 740	Asn	ACC Thr	Lys	GT(	CTG Leu 745	Glu	ATC	CCC Pro	TTG Leu	GAG Glu 750	Pro	AAA Lys	2256
10	AAC Asn	AAC Asn	ATG Met 755	Arg	GCA Ala	ACC Thr	ATC Ile	GAC Asp 760	Cys	GCG Ala	GGG	ATC Ile	TTG Leu 765	Lys	CTI Leu	AGA Arg	2304
	AAC Asn	GCC Ala 770	Asp	ATT	GAG Glu	CTG Leu	CGG Arg 775	Lys	GGC	GAG Glu	ACG Thr	GAC Asp 780	ATT Ile	GGA Gly	AGA Arg	AAG Lys	2352
	AAC Asn 785	ACG Thr	CGG Arg	GTG Val	AGA Arg	CTG Leu 790	GTT Val	TTC Phe	CGA Arg	GTT Val	CAC His 795	ATC Ile	CCA Pro	GAG Glu	TCC Ser	AGT Ser 800	2400
20	GGC Gly	AGA Arg	ATC Ile	GTC Val	TCT Ser 805	TTA Leu	CAG Gln	ACT Thr	GCA Ala	TCT Ser 810	AAC Asn	CCC Pro	ATC Ile	GAG Glu	TGC Cys 815	TCC Ser	2448
25	CAG Gln	CGA Arg	TCT Ser	GCT Ala 820	CAC His	GAG Glu	CTG Leu	CCC Pro	ATG Met 825	GTT Val	GAA Glu	AGA Arg	CAA Gln	GAC Asp 830	ACA Thr	GAC Asp	2496
30	AGC Ser	TGC Cys	CTG Leu 835	GTC Val	TAT Tyr	GGC Gly	GGC Gly	CAG Gln 840	CAA Gln	ATG Met	ATC Ile	CTC Leu	ACG Thr 845	GGG Gly	CAG Gln	AAC Asn	2544
35	TTT Phe	ACA Thr 850	TCC Ser	GAG Glu	TCC Ser	AAA Lys	GTT Val 855	GTG Val	TTT Phe	ACT Thr	GAG Glu	AAG Lys 860	ACC Thr	ACA Thr	GAT Asp	GGA Gly	2592
	CAG Gln 865	CAA Gln	ATT Ile	TGG Trp	GAG Glu	ATG Met 870	GAA Glu	GCC Ala	ACG Thr	GTG Val	GAT Asp 875	AAG Lys	GAC Asp	AAG Lys	AGC Ser	CAG Gln 880	2640
40	CCC Pro	AAC Asn	ATG Met	CTT Leu	TTT Phe 885	GTT Val	GAG Glu	ATC Ile	CCT Pro	GAA Glu 890	TAT Tyr	CGG Arg	AAC Asn	AAG Lys	CAT His 895	ATC Ile	2688
45	CGC Arg	ACA Thr	CCT Pro	GTA Val 900	AAA Lys	GTG Val	AAC Asn	TTC Phe	TAC Tyr 905	GTC Val	ATC Ile	AAT Asn	GGG Gly	AAG Lys 910	AGA Arg	AAA Lys	2736
50	CGA Arg	AGT Ser	CAG Gln 915	CCT Pro	CAG Gln	CAC His	TTT Phe	ACC Thr 920	TAC Tyr	CAC His	CCA Pro	GTC Val	CCA Pro 925	GCC Ala	ATC Ile	AAG Lys	2784
55	ACG Thr	GAG Glu 930	CCC Pro	ACG Thr	GAT Asp	Glu	TAT Tyr 935	GAC Asp	CCC Pro	ACT Thr	Leu	ATC Ile 940	TGC Cys	AGC Ser	CCC Pro	ACC Thr	2832
55	CAT	GGA	GGC	CTG (	GGG	AGC	CAG	CCT	TAC	TAC	ccc.	CAG	CAC	CCG	ATG	GTG	2880 256

257

	His Gl 945	y Gly	Leu	_	Ser 950	Gln	Pro	Tyr	Tyr	Pro 955	Gln	His	Pro	Met	Val 960	
5	GCC GA Ala Gl		Pro													2928
10	TTC CG Phe Ar															2976
15	CCA GC Pro Al					Gln					Leu					3024
15	CTG GG Leu Gl 101	y Tyr			Pro					Ala						3072
20	GAC GC Asp Al 1025			Ser					Ala					Gln		3120
25	TCA GC Ser Al		Leu					Thr					Ser			3168
30	ATC CA Ile Hi	s Tyr					Gln					Gly		_		3216
25	GAG TT Glu Ph					Tyr					Ala					3264
35	AGA CC Arg Pr 109	o Gly			Pro					Gln					_	3312
40	TCC TA Ser Ty 1105			Val					Asn			_		Arg		3360
45	GCC AA Ala Ly	_	Gly					Asp					Leu			3408
50	GGG GT Gly Va	l Thr					Gln					Thr				3456
	GAT GI Asp Va		Glu			Arg					Gly					3504
55	AAT C	AG ACG	TAA													3516 257

SUBSTITUTE SHEET (RULE 26)

Asn Gln Thr 1170

```
5
                (2) INFORMATION FOR SEQ ID NO:131:
             (i) SEQUENCE CHARACTERISTICS:
               (A) LENGTH: 1171 amino acids
               (B) TYPE: amino acid
 10
               (C) STRANDEDNESS: single
               (D) TOPOLOGY: linear
             (ii) MOLECULE TYPE: protein
             (v) FRAGMENT TYPE: internal
 15
             (xi) SEQUENCE DESCRIPTION: SEQ ID NO:131:
      Met Val Ser Lys Gly Glu Glu Leu Phe Thr Gly Val Val Pro Ile Leu
                                          10
      Val Glu Leu Asp Gly Asp Val Asn Gly His Lys Phe Ser Val Ser Gly
20
                  20
                                       25
      Glu Gly Glu Gly Asp Ala Thr Tyr Gly Lys Leu Thr Leu Lys Phe Ile
      Cys Thr Thr Gly Lys Leu Pro Val Pro Trp Pro Thr Leu Val Thr Thr
25
      Leu Thr Tyr Gly Val Gln Cys Phe Ser Arg Tyr Pro Asp His Met Lys
                                              75
      Gln His Asp Phe Phe Lys Ser Ala Met Pro Glu Gly Tyr Val Gln Glu
                                          90
      Arg Thr Ile Phe Phe Lys Asp Asp Gly Asn Tyr Lys Thr Arg Ala Glu
30
                                      105
      Val Lys Phe Glu Gly Asp Thr Leu Val Asn Arg Ile Glu Leu Lys Gly
                                  120
      Ile Asp Phe Lys Glu Asp Gly Asn Ile Leu Gly His Lys Leu Glu Tyr
35
                              135
                                                  140
      Asn Tyr Asn Ser His Asn Val Tyr Ile Met Ala Asp Lys Gln Lys Asn
                          150
                                              155
      Gly Ile Lys Val Asn Phe Lys Ile Arg His Asn Ile Glu Asp Gly Ser
                                         170
40
      Val Gln Leu Ala Asp His Tyr Gln Gln Asn Thr Pro Ile Gly Asp Gly
                                     185
      Pro Val Leu Leu Pro Asp Asn His Tyr Leu Ser Thr Gln Ser Ala Leu
                                 200
      Ser Lys Asp Pro Asn Glu Lys Arg Asp His Met Val Leu Leu Glu Phe
45
                              215
                                                 220
     Val Thr Ala Ala Gly Ile Thr Leu Gly Met Asp Glu Leu Tyr Lys Ser
                         230
                                             235
     Gly Leu Arg Ser Arg Ala Met Asn Ala Pro Glu Arg Gln Pro Gln Pro
                     245
                                          250
50
     Asp Gly Gly Asp Ala Pro Gly His Glu Pro Gly Gly Ser Pro Gln Asp
                                     265
     Glu Leu Asp Phe Ser Ile Leu Phe Asp Tyr Glu Tyr Leu Asn Pro Asn
                                 280
     Glu Glu Glu Pro Asn Ala His Lys Val Ala Ser Pro Pro Ser Gly Pro
55
                             295
     Ala Tyr Pro Asp Asp Val Met Asp Tyr Gly Leu Lys Pro Tyr Ser Pro
```

	305					310					315					320
	Leu	Ala	Ser	Leu	Ser 325	Gly	Glu	Pro	Pro	Gly 330	Arg	Phe	Gly	Glu	Pro 335	Asp
5	Arg	Val	Gly	Pro 340	Gln	Lys	Phe	Leu	Ser 345	Ala	Ala	Lys	Pro	Ala 350	Gly	Ala
	Ser	Gly	Leu 355	Ser	Pro	Arg	Ile	Glu 360	Ile	Thr	Pro	Ser	His 365	Glu	Leu	Ile
	Gln	Ala 370	Val	Gly	Pro	Leu	Arg 375	Met	Arg	Asp	Ala	Gly 380	Leu	Leu	Val	Glu
10	Gln 385	Pro	Pro	Leu	Ala	Gly 390	Val	Ala	Ala	Ser	Pro 395	Arg	Phe	Thr	Leu	Pro 400
					405	Gly		_		410					415	
15				420		Ala			425					430		
			435			Ser		440					445			
00		450				Ile	455					460	_	•		
20	465					Thr 470					475		_			480
					485	Arg				490					495	
25				500		Cys			505					510		_
			515			His		520					525			
30		530				Met	535					540				
00	545					550 Pro					555					560
			_		565	Pro			_	570					575	
35				580		Leu			585	-				590		-
			595			Ile		600					605			
40	Leu	610					615					620			_	
	625					630 Pro					635					640
					645	Pro				650					655	
45	Glu	Gly	Ser	660 Arg	Gly	Ala	Val	Lys	665 Ala	Pro	Thr	Gly	Gly	670 His	Pro	Val
	Val	Gln	675 Leu	His	Gly	Tyr	Met	680 Glu	Asn	Lys	Pro	Leu	685 Gly	Leu	Gln	Ile
50	Phe	690 Ile	Gly	Thr	Ala	Asp	695 Glu	Arg	Ile	Leu	Lys	700 Pro	His	Ala	Phe	Tyr
	705 Gln	Val	His	Arg		710 Thr	Gly	Lys	Thr	Val	715 Thr	Thr	Thr	Ser	Tyr	720 Glu
55	Lys	Ile	Val		725 Asn	Thr	Lys	Val		730 Glu	Ile	Pro	Leu		735 Pro	Lys
55	Asn	Δen	Met	740	Δla	Thr	Tle	λen	745	בומ	ดาง	Tle	Len	750	T.em	Arc

260

			755					B.C.O.								
	Asn	Δla			Gl 11	1 011	A	760			_,	_	765			
		770					775					780			•	Lys
5	Asn 785	Thr	Arg	Val	Arg	Leu 790	Val	Phe	Arg	Val			Pro	Glu	Ser	
			Tle	Val	Ser			The	27-		795	_				800
					805					810				Glu	815	
				820					825					Asp 830		
10	Ser	Cys	Leu 835	Val	Tyr	Gly	Gly	Gln 840	Gln	Met	Ile	Leu		Gly	Gln	Asn
	Phe	Thr 850	Ser	Glu	Ser	Lys	Val	Val	Phe	Thr	Glu		845 Thr	Thr	Asp	Gly
	Gln		Tle	Trn	Glu	Mot	855	77-	m1		_	860	_			
15	865					870					875			Lys		990
	Pro	Asn	Met	Leu	Phe 885	Val	Glu	Ile	Pro	Glu 890	Tyr	Arg	Asn	Lys	His 895	Ile
	Arg	Thr	Pro	Val 900	Lys	Val	Asn	Phe	Tyr 905	Val	Ile	Asn	Gly	Lys 910	Arg	Lys
20	Arg	Ser	Gl'n 915	Pro	Gln	His	Phe	Thr 920		His	Pro	Val		Ala	Ile	Lys
	Thr	Glu		Thr	Asp	Glu	Tyr	Asp	Pro	Thr	Leu	Ile	925 Cys	Ser	Pro	Thr
	77.5 -	930	<b>a</b> 3	<b>.</b>	~3	_	935					940				
25	945	GIY	GIÀ	ьеu	GIĀ	5er 950	Gln	Pro	Tyr	Tyr		Gln	His	Pro	Met	
20		Glu	Ser	Pro	Ser		T.ou	Va I	71-	mb	955			Cys		960
		•			965					970					975	
				980					985					Gln 990		
30	Pro	Ala	Ala 995	Val	Leu	Tyr	Gln	Arg	Ser	Lys	Ser		Ser .005	Pro	Ser	Leu
	Leu 1	Gly .010	Tyr	Gln	Gln	Pro	Ala .015	Leu	Met	Ala		Pro .020	Leu	Ser	Leu	Ala
	Asp	Ala	His	Arg	Ser			Val	His	Δla	Glv	Ser	Gln	Gly	Gln	ea-
35	025				1	.030			•	1	035				1	040
	Ser	Ala	Leu	Leu	His	Pro	Ser	Pro	Thr	Asn	Gln	Gln	Ala	Ser	Pro	Val
				1	.045				1	.050				1	055	
			1	060				1	065				1	Ser .070		
40	Glu	Phe 1	Gln .075	His	Ile	Met		Cys .080				Ala 1	Pro	Gly	Thr	Thr
	Arg	Pro	Gly	Pro	Pro	Pro			Gln	Glv	Gln	Ara	Leu	Ser	Pro	Glv
	7	090				1	095				1	100				
4.5	Ser	Tyr	Pro	Thr	Val	Ile	Gln	Gln	Gln	Asn	Ala	Thr	Ser	Gln	Arg	Ala
45	102				1	110				1	115				1	120
	Ala			1	125				1	130				1	135	
	Gly	Val	Thr 1	Ile 140	Lys	Gln	Glu	Gln	Asn 145	Leu	Asp	Gln		Tyr	Leu	Asp
50	Asp	Val	Asn	Glu	Ile	Ile	Arq	Lys	Glu	Phe	Ser	Glv	Pro	150 Pro	- Γ Δ	Δrσ
		1	155				1	160					165			J
	Asn		Thr									_	-			
	1	170														

260

(2) INFORMATION FOR SEQ ID NO:132:

261

5		<b>(</b> )	(A) (B) (C)	EQUENTYPE STRA	ETH: E: nu ANDEI	3546 acle: ONES	bas c ac	se pa cid ingle	airs								
				OLEC FEATU		TYPI	E: cI	ANC									
10			(B)	NAM LOC	CATIC	N:	13	3543	equer	ıce							
15		()	(i) 5	EQUI	ENCE	DESC	RIPT	CION:	: SEÇ	סו ס	ио: 1	132:					
				CCC Pro													48
20				CCT Pro 20													96
25				TAT Tyr													144
30				GCC Ala													192
35				GGC Gly													240
33				GGC Gly													288
40				GCG Ala 100													336
45				ACT Thr													384
50				GAC Asp													432
<b>5</b> 5				AGC Ser													480
55	TAC	CGC	GAG	CCG	CTT	TGC	TTG	AGC	ccc	GCT	AGC	AGC	GGC	TCC	TCT	GCC .	528

•										202							
	Tyr	Arg	Glu	Pro	165	Cys	Let	ı Ser	Pro	170		Ser	Gly	/ Sei	Ser 175	r Ala	
5	AGC Ser	TTC Phe	ATT Ile	ser	Asp	ACC Thr	TTC Phe	TCC Ser	CCC	TAC	C ACC	TCG Ser	CCC Pro	TGC Cys	GTC Val	C TCG	576
	ccc	AAT	AAC	GGC	GGG	ccc	GAC	GAC	185 CTG	TGT	CCG	CAG	لمالىك	190	) ממ	י איזיכי	. 624
10	Pro	Asn	Asn 195	Gly	Gly	Pro	Asp	Asp 200	Leu	Cys	Pro	Gln	Phe 205	Gln	Asn	Ile	. 024
	CCT Pro	GCT Ala 210	CAT His	TAT Tyr	TCC Ser	CCC Pro	AGA Arg 215	Thr	TCG Ser	CCA Pro	ATA Ile	Met	TCA Ser	CCT Pro	CGA	ACC Thr	672
15							215					220					
	AGC Ser 225	CTC Leu	GCC Ala	GAG Glu	GAC Asp	AGC Ser 230	TGC Cys	CTG Leu	GGC Gly	CGC Arg	CAC His	TCG Ser	CCC Pro	GTG Val	CCC	CGT Arg 240	720
20	CCG Pro	GCC Ala	TCC Ser	CGC Arg	TCC Ser	TCA Ser	TCG Ser	CCT Pro	GGT Gly	GCC Ala	AAG Lvs	CGG Arg	AGG Ara	CAT	TCG	TGC Cys	768
					245					250					255		
25	Ala	Glu	Ala	Leu 260	Val	Ala	Leu	Pro	Pro 265	Gly	Ala	Ser	Pro	Gln 270	CGC	TCC Ser	816
30	CGG Arg	AGC Ser	CCC Pro 275	TCG Ser	CCG Pro	CAG Gln	CCC Pro	TCA Ser 280	TCT Ser	CAC His	GTG Val	GCA Ala	Pro	CAG Gln	GAC Asp	CAC His	864
								200					285				
	GGC Gly	TCC Ser 290	CCG Pro	GCT Ala	GGG Gly	TAC Tyr	CCC Pro 295	CCT Pro	GTG Val	GCT Ala	GGC Gly	TCT Ser 300	GCC Ala	GTG Val	ATC Ile	ATG Met	912
35																	
	GAT Asp 305	GCC Ala	CTG Leu	AAC Asn	AGC Ser	CTC Leu 310	GCC Ala	ACG Thr	GAC Asp	TCG Ser	CCT Pro 315	TGT Cys	GGG Gly	ATC Ile	CCC Pro	CCC Pro 320	960
40	AAG Lys	ATG Met	TGG Trp	AAG Lys	ACC Thr 325	AGC Ser	CCT Pro	GAC Asp	CCC Pro	TCG Ser 330	CCG Pro	GTG Val	TCT Ser	GCC Ala	GCC Ala 335	CCA Pro	1008
45	TCC Ser	AAG Lys	Ala	GGC Gly 340	CTG Leu	CCT Pro	CGC Arg	CAC His	ATC Ile 345	TAC Tyr	CCG Pro	GCC Ala	GTG Val	GAG Glu 350	TTC Phe	CTG Leu	1056
	GGG	CCC	TGC	GAG	CAG	GGC	GAG	AGG	AGA	AAC	TCG	ርርጥ	CCA	CVV	TOO	እጥሮ	1104
50	Gly	Pro	Cys 355	Glu	Gln	Gly	Glu	Arg 360	Arg	Asn	Ser	Ala	Pro 365	Glu	Ser	Ile	1104
	CTG	CTG	GTT	CCG	CCC	ACT	TGG	CCC	AAG	CCG	CTG	GTG	CCT	GCC	AΤΤ	CCC	1152
55	ьей.	Leu 370	Val :	Pro	Pro	Thr	Trp 375	Pro	Lys	Pro	Leu	Val 380	Pro	Ala	Ile	Pro	
	ATC '	TGC .	AGC :	ATC	CCA	GTG .	ACT	GCA	TCC	CTC	CCT	CCA	CTT	GAG	TGG	CCG	1200 262

263

										203							
	Ile 385	Cys	Ser	Ile	Pro	Val 390	Thr	Ala	Ser	Leu	Pro 395	Pro	Leu	Glu	Trp	Pro 400	
5					TCA Ser 405												1248
10					CGG Arg												1296
15					ACT Thr												1344
					CCT Pro												1392
20					AAG Lys												1440
25					ACC Thr 485												1488
30					ATC Ile												1536
35					GGG Gly												1584
33					ACG Thr												1632
40					CAC His												1680
45					AAC Asn 565												1728
50	CTG Leu	CCC Pro	ATG Met	GTT Val 580	GAA Glu	AGA Arg	CAA Gln	GAC Asp	ACA Thr 585	GAC Asp	AGC Ser	TGC Cys	CTG Leu	GTC Val 590	TAT Tyr	GGC Gly	1776
55					ATC Ile												1824
55	GTT	GTG	TTT	ACT	GAG	AAG	ACC	ACA	GAT	GGA	CAG	CAA	ATT	TGG	GAG	ATG	1872

. .

	204
	Val Val Phe Thr Glu Lys Thr Thr Asp Gly Gln Gln Ile Trp Glu Met 610 . 615 620
5	GAA GCC ACG GTG GAT AAG GAC AAG AGC CAG CCC AAC ATG CTT TTT GTT 1920 Glu Ala Thr Val Asp Lys Asp Lys Ser Gln Pro Asn Met Leu Phe Val 625 630 635 640
10	GAG ATC CCT GAA TAT CGG AAC AAG CAT ATC CGC ACA CCT GTA AAA GTG 1968 Glu Ile Pro Glu Tyr Arg Asn Lys His Ile Arg Thr Pro Val Lys Val 645 650 655
15	AAC TTC TAC GTC ATC AAT GGG AAG AGA AAA CGA AGT CAG CCT CAG CAC 2016 Asn Phe Tyr Val Ile Asn Gly Lys Arg Lys Arg Ser Gln Pro Gln His 660 665 670
	TTT ACC TAC CAC CCA GTC CCA GCC ATC AAG ACG GAG CCC ACG GAT GAA 2064  Phe Thr Tyr His Pro Val Pro Ala Ile Lys Thr Glu Pro Thr Asp Glu 675 680 685
20	TAT GAC CCC ACT CTG ATC TGC AGC CCC ACC CAT GGA GGC CTG GGG AGC  Tyr Asp Pro Thr Leu Ile Cys Ser Pro Thr His Gly Gly Leu Gly Ser  690  695  700
25	CAG CCT TAC TAC CCC CAG CAC CCG ATG GTG GCC GAG TCC CCC TCC TGC 2160 Gln Pro Tyr Tyr Pro Gln His Pro Met Val Ala Glu Ser Pro Ser Cys 715 720
30	CTC GTG GCC ACC ATG GCT CCC TGC CAG CAG TTC CGC ACG GGG CTC TCA 2208  Leu Val Ala Thr Met Ala Pro Cys Gln Gln Phe Arg Thr Gly Leu Ser 725 730 735
35	TCC CCT GAC GCC CGC TAC CAG CAA CAG AAC CCA GCG GCC GTA CTC TAC 2256  Ser Pro Asp Ala Arg Tyr Gln Gln Asn Pro Ala Ala Val Leu Tyr  740 745 750
	CAG CGG AGC AAG AGC CTG AGC CCC AGC CTG CTG GGC TAT CAG CAG CCG 2304 Gln Arg Ser Lys Ser Leu Ser Pro Ser Leu Leu Gly Tyr Gln Gln Pro 755 760 765
40	GCC CTC ATG GCC GCC CCG CTG TCC CTT GCG GAC GCT CAC CGC TCT GTG 2352  Ala Leu Met Ala Ala Pro Leu Ser Leu Ala Asp Ala His Arg Ser Val  770 780
45	CTG GTG CAC GCC GGC TCC CAG GGC CAG AGC TCA GCC CTG CTC CAC CCC Leu Val His Ala Gly Ser Gln Gly Gln Ser Ser Ala Leu Leu His Pro 785 790 795 800
50	TCT CCG ACC AAC CAG CAG GCC TCG CCT GTG ATC CAG TAC TCA CCC ACC Ser Pro Thr Asn Gln Gln Ala Ser Pro Val Ile His Tyr Ser Pro Thr 805 810 815
55	AAC CAG CAG CTG CGC TGC GGA AGC CAC CAG GAG TTC CAG CAC ATC ATG Asn Gln Gln Leu Arg Cys Gly Ser His Gln Glu Phe Gln His Ile Met 820 825 830
	TAC TGC GAG AAT TTC GCA CCA GGC ACC ACC AGA CCT GGC CCG CCC CCG 2544

	Tyr	Cys	Glu 835	Asn	Phe	Ala	Pro	Gly 840	Thr	Thr	Arġ	Pro	Gly 845	Pro	Pro	Pro	
	GTC	AGT	CAA	GGT	CAG	AGG	CTG	AGC	CCG	GGT	TCC	TAC	CCC	ACA	GTC	ATT	2592
5	Val	Ser	Gln	Gly	Gln	Arg	Leu	Ser	Pro	Gly	Ser	Tyr	Pro	Thr	Val	Ile	
		850					855					860					
	CAG	CAG	CAG	TAA	GCC	ACG	AGC	CAA	AGA	GCC	GCC	AAA	AAC	GGA	ccc	CCG	2640
				Asn													
10	865					870	•				875					880	
	GTC	AGT	GAC	CAA	AAG	GAA	GTA	TTA	CCT	GCG	GGG	GTG	ACC	ATT	AAA	CAG	2688
	Val	Ser	Asp	Gln	Lys	Glu	Val	Leu	Pro	Ala	Gly	Val	Thr	Ile	Lys	Gln	
15					885					890	•				895		
15	GAG	CAG	AAC	TTG	GAC	CAG	ACC	TAC	TTG	GAT	GAT	GTT	TAA	GAA	ATT	ATC	2736
				Leu													
				900					905					910			
20	AGG	AAG	GÄG	TTT	TCA	GGA	CCT	ССТ	GCC	AGA	AAT	CAG	ACG	AGA	ATT	CTG	2784
				Phe													
			915					920					925				
	CAG	TCG	ACG	GTA	CCG	CGG	GCC	CGG	GAT	CCA	CCG	GTC	GCC	ACC	ATG	GTG	2832
25				Val													
		930					935					940					
	AGC	AAG	GGC	GAG	GAG	CTG	TTC	ACC	GGG	GTG	GTG	CCC	ATC	CTG	GTC	GAG	2880
	Ser	Lys	Gly	Glu	Glu		Phe	Thr	Gly	Val	Val	Pro	Ile	Leu	Val	Glu	
30	945					950					9 <b>55</b>					960	
	CTG	GAC	GGC	GAC	GTA	AAC	GGC	CAC	AAG	TTC	AGC	GTG	TCC	GGC	GAG	GGC	2928
	Leu	Asp	Gly	Asp		Asn	Gly	His	Lys		Ser	Val	Ser	Gly		Gly	
35					965					970					975		
•	GAG	GGC	GAT	GCC	ACC	TAC	GGC	AAG	CTG	ACC	CTG	AAG	TTC	ATC	TGC	ACC	2976
	Glu	Gly	Asp	Ala	Thr	Tyr	Gly	Lys		Thr	Leu	Lys	Phe		Cys	Thr	
				980					985					990			
40				CTG													3024
	Thr	Gly	_	Leu	Pro	Val		_	Pro	Thr	Leu			Thr	Leu	Thr	
			995				-	1000				-	1005				
	TAC	GGC	GTG	CAG	TGC	TTC	AGC	CGC	TAC	CCC	GAC	CAC	ATG	AAG	CAG	CAC	3072
45	_	-	Val	Gln	Cys			Arg	Tyr	Pro	-		Met	Lys	Gln	His	
	•	1010				-	1015				•	1020					
				AAG													3120
50	Asp 1025	Phe	Phe	Lys		Ala 1030	Met	Pro	Glu			Val	Gln	Glu			
-	1023				•	1030				•	1035				•	1040	
				AAG													3168
	Ile	Phe	Phe	Lys	Asp 1045	Asp	Gly	Asn	_	Lys 1050	Thr	Arg	Ala		Val 1055	-	
55				•					1	-050							
	TTC	GAG	GGC	GAC	ACC	CTG	GTG	AAC	CGC	ATC	GAG	CTG	AAG	GGC	ATC	GAC	3216
																	21

. 266

	Phe	Glu	Gly	Asp 1060	Thr	Leu	Val		Arg 1065		Glu	Leu		Gly 1070	Ile	Asp	
5	TTC Phe	Lys	GAG Glu 1075	GAC Asp	GGC Gly	AAC Asn	Ile	CTG Leu 1080	GGG Gly	CAC His	AAG Lys	Leu	GAG Glu 1085	TAC Tyr	AAC Asn	TAC Tyr	3264
10	Asn	AGC Ser 1090	CAC His	AAC Asn	GTC Val	Tyr	ATC Ile 1095	ATG Met	GCC Ala	GAC Asp	Lys	CAG Gln 1100	AAG Lys	AAC Asn	GGC Gly	ATC Ile	3312
15	AAG Lys 1105	GTG Val	AAC Asn	TTC Phe	Lys	ATC Ile 1110	CGC Arg	CAC His	AAC Asn	Ile	GAG Glu 1115	GAC Asp	GGC Gly	AGC Ser	Val	CAG Gln 1120	3360
	CTC Leu	GCC Ala	GAC Asp	His	TAC Tyr 125	CAG Gln	CAG Gln	AAC Asn	Thr	CCC Pro 1130	ATC Ile	GGC Gly	GAC Asp	Gly	CCC Pro	GTG Val	3408
20	CTG Leu	CTG Leu	Pro	GAC Asp 1140	AAC Asn	CAC His	TAC Tyr	Leu	AGC Ser	ACC Thr	CAG Gln	TCC Ser	Ala	CTG Leu 150	AGC Ser	AAA Lys	3456
25	GAC Asp	Pro	AAC Asn 155	GAG Glu	AAG Lys	CGC Arg	Asp	CAC His	ATG Met	GTC Val	CTG Leu	CTG Leu	GAG Glu 165	TTC Phe	GTG Val	ACC Thr	3504
30	Ala	GCC Ala 170	GGG Gly	ATC Ile	ACT Thr	Leu	GGC Gly .175	ATG Met	GAC Asp	GAG Glu	Leu	TAC Tyr 1180	AAG Lys	TAA			3546
35		(:		INF						NO:1	133:						
50		(1	(A) (B) (C)	QUEN LENG TYPE STRA	TH: : an NDED	1181 ino NESS	ami acid : si	.no a l .ngle	cids	3							
40			i) M	TOPO OLEC AGME	ULE	TYPE	: pr	otei									
45				EQUE													
	Met 1 Gly				5					10					15		
50	Leu	Phe .		20			Leu		25			Glu		30			
		50					Pro 55	Ser	-			Tyr 60	Pro				
55	Met . 65 Glu :					70					75					80	

	Dh.	•	0		85	_	_			90		_			95	
				100					105					110		
5			115		Pro			120					125			
	Arg	Met 130		Asp	Ala	Gly	Leu 135		Val	Glu	Gln	Pro 140	Pro	Leu	Ala	Gl
	Val 145	Ala	Ala	Ser	Pro	Arg 150	Phe	Thr	Leu	Pro	Val 155		Gly	Phe	Glu	Gl <sub>3</sub>
10	Tyr	Arg	Glu	Pro	Leu 165	Cys	Leu	Ser	Pro	Ala 170		Ser	Gly	Ser	Ser 175	
	Ser	Phe	Ile	Ser 180	Asp	Thr	Phe	Ser	Pro 185		Thr	Ser	Pro	Cys 190		Ser
15	Pro	Asn	Asn 195		Gly	Pro	Asp	Asp 200		Cys	Pro	Gln	Phe 205		Asn	Ile
	Pro	Ala 210		Tyr	Ser	Pro	Arg 215	Thr	Ser	Pro	Ile	Met 220		Pro	Arg	Thr
	Ser 225	Leu	Ala	Glu	Asp	Ser 230	Cys	Leu	Gly	Arg	His 235		Pro	Val	Pro	Arg
20	Pro	Ala	Sér	Arg	Ser 245	Ser	Ser	Pro	Gly	Ala 250	Lys	Arg	Arg	His	Ser 255	Суз
				260	Val				265					270		
25	Arg	Ser	Pro 275	Ser	Pro	Gln	Pro	Ser 280	Ser	His	Val	Ala	Pro 285	Gln	Asp	His
		290			Gly		295					300				
	305				Ser	310					315					320
30					Thr 325					330					335	
				340	Leu				345	•				350		
35			35 <b>5</b>		Gln			360					365			
		370			Pro		375					380				
	385				Pro	390					395					400
40					Ser 405					410					415	
				420	Arg				425					430		
45			435		Thr			440					445			
		450			Pro		455					460				
	Glu 465	Arg	Ile	Leu	Lys	Pro 470	His	Ala	Phe	Tyr		Val	His	Arg	Ile	
50		Lys	Thr	Val	Thr 485	Thr	Thr	Ser		Glu 490	475 Lys	Ile	Val	Gly		480 Thr
	Lys	Val	Leu	Glu 500	Ile		Leu	Glu			Asn	Asn	Met	Arg 510	495 Ala	Thr
55	Ile	Asp	Cys 515		Gly	Ile	Leu	Lys 520		Arg	Asn	Ala	Asp 525		Glu	Leu
	Arq	Lvs		Glu	Thr	Asp	T1_		λνα	Tara	λen	Thr		V-1	7 ~~	T 011

										268						
		53					535	5				540	)			
	Va]	l Ph	e Arg	g Val	l His	: Ile	Pro	Glı	ı Sei	s Sei	r Gly	Arc	, I lle	≥ Val	Ser	Leu
	747	,				550	,				555					ECO
_	Glr	1 Th	r Ala	a Sea	: Asr	Pro	) Ile	: Glu	ı Cys	Ser	Gln	Arg	Ser	Ala	His	Glu
5					565	)				570	)				E75	
	nec	Pro	o Met	val	GIU	ı Arc	g Glr	ı Ası	Thr	Asp	Ser	Cys	Lev	va]	Туг	Gly
	Glv	, Glr	n Glr	580 1 Met		T O	. Th.		585	5				590	)	
	<b>01</b>	01.	595	1 1460 5	. 116	. пец	1111	600	GII	ı Asr	. Phe	Thr			Ser	Lys
10	Val	. Val			Glu	Lvs	Thr	Thr	, y	C33		C1 -	605			. Met
		610	)				615			, Gry	Gin	620		irp	GIU	Met
	Glu	Ala	Thr	. Val	Asp	Lys	Asp	Lys	Ser	Gln	Pro	Asn	Met	Leu	Phe	Val
	025					630					635					640
15	Glu	Ile	Pro	Glu	Tyr	Arg	Asn	Lys	His	Ile	Arg	Thr	Pro	Val	Lys	Val
13					645					650					655	
	ASII	FIIC	. Iyı	Val 660	116	ASI	GIY	гуs	Arg	Lys	Arg	Ser	Gln			His
	Phe	Thr	Tyr			Va]	Pro	Δla	665	Lve	mh	C1	D	670		Glu
			675				0	680	110	пуs	1111	GIU	685	Thr	Asp	Glu
20	Tyr	Asp	Pro	Thr	Leu	Ile	Cys	Ser	Pro	Thr	His	Glv	Glv	Leu	Glv	Ser
		690	•				695					700				
	Gin	Pro	Tyr	Tyr	Pro	Gln	His	Pro	Met	Val	Ala	Glu	Ser	Pro	Ser	Cys
	,05					170					715					720
25	пец	vai	Ala	Thr	мес 725	Ala	Pro	Cys	Gln	Gln	Phe	Arg	Thr	Gly	Leu	Ser
	Ser	Pro	Asp	Ala		Tvr	Gln	Gln	Gln	730	Dwo	77-	77-	17- 1	735	_
			-	740					745					750		
	Gln	Arg	Ser	Lys	Ser	Leu	Ser	Pro	Ser	Leu	Leu	Gly	Tyr	Gln	Gln	Pro
30			/25					760					765			
30	Ala	770	met	Ala	Ala	Pro	Leu	Ser	Leu	Ala	Asp		His	Arg	Ser	Val
	Leu		His	Δla	Glv	Ser	775	C1	<b>01</b> -	0		780	_	_		
	785			Ala	017	790	, J	GIY	GIII	ser	795	Ата	ьeu	Leu	His	
	Ser	Pro	Thr	Asn	Gln		Ala	Ser	Pro	Val	Ile	His	Tvr	Ser	Dro	800 Thr
35					805					810					815	
	Asn	Gln	Gln	Leu	Arg	Cys	Gly	Ser	His	Gln	Glu	Phe	Gln	His	Ile	Met
				820					825					830		
	IYL	сув	835	Asn	Pne	Ala	Pro	Gly	Thr.	Thr	Arg	Pro		Pro	Pro	Pro
40	Val	Ser		Glv	Gln	Δra	T.611	840	Dwo	07	0		845			
		850		Gly	0111	m g	855	Set	PIG	Gry	ser	1yr 860	Pro	Thr	Val	Ile
	Gln	Gln	Gln	Asn	Ala	Thr		Gln	Arg	Ala	Ala	Lvs	Asn	Glv	Pro	Pro
	863					870					875					880
45	Val	Ser	Asp	Gln	Lys	Glu	Val	Leu	Pro	Ala	Gly	Val	Thr	Ile	Lys	Gln
40					885					890					895	
	Olu	GIII	ASII	Leu 900	Asp	GIN	Thr	Tyr	Leu	Asp	Asp	Val	Asn		Ile	Ile
	Arg	Lys	Glu		Ser	Glv	Pro	Pro	905 21a	λ~~	7.00	~1 <u>~</u>	771b	910	<b>-</b> 7 -	-
	_	•	915			<b>-</b> -7		920	AIa	Arg	ASII		925	Arg	тте	Leu
50	Gln	Ser	Thr	Val	Pro	Arg	Aļa		Asp	Pro	Pro	Val	Ala	Thr	Met	Va]
		230					935					940				
	Ser	Lys	Gly	Glu	Glu	Leu	Phe	Thr	Gly	Val	Val	Pro	Ile	Leu	Val	Glu
	243					950					955					960
55	Leu	vaħ	ату	мър	965	ASD	GIA	His			Ser	Val	Ser	Gly		Gly
	Glu	Gly	Asp			Tyr	Glv	ī.ve	Len	970 Thr	יים.ז	Lve	Dho	T1-	975	(Tile ex
		-	•				1	- <sub>1</sub> 0	_cu	- 11 L	ueu.	-y s	rne	тте	cys	inr

				980					985					990				
	Thr	Gly	Lys 995	Leu	Pro	Val		Trp 1000			Leu		Thr 1005	Thr	Leu	Thr		
5		Gly	Val	Gln	Cys		Ser 1015	Arg	Tyr	Pro	_	His 1020	Met	Lys	Gln	His		
	Asp		Phe	Lys		Ala		Pro	Glu		Tyr		Gln	Glu	-			
	025	Dl	Db	•		1030	<b>01</b>	•	<b></b>		1035	_				1040		
	TIE	Pne	Pne		Asp 1045	Asp	GIY	Asn ·		ьуs 1050	Thr	Arg	Ala	Glu	Val 1055	Lys		
10	Phe	Glu		Asp		Leu	Val		Arg		Glu	Leu	Lys	Gly		Asp		
	Dhe	Lve		060	Gly	λen	Tle		065	uic	T 1/0	Ton		1070 Tyr	7.00	П- г		
	FIIC		1075	Asp	Gly	Vali		1080		птэ	гуъ		L085	TAT	ASII	ıyı		
			His	Asn	Val			Met	Ala	Asp			Lys	Asn	Gly	Ile		
15		1090 V=1	) en	Dhe	Lve		1095	пie	λεν	Tla		100	C114	Ser	1701	C1 n		
	105	vai	ASII	FIIC		110	Arg	пть	ASII		1115	АБР	GIY	SEI		1120		
	Leu	Ala	Asp			Gln	Gln	Asn			Ile	Gly	Asp	Gly		Val		
20	Leu	Leu	Pro		L125 Asn	His	Tvr	Len		Thr	Gln	Ser	Δla	Leu	Ser	Lve		
				1140			- 7 -		1145	1111	0111	DCL		1150	DCI	Dy 3		
	Asp			Glu	Lys	Arg			Met	Val	Leu			Phe	Val	Thr		
	Ala		Glv	Ile	Thr	Len		Met	Asn	Glu	I.eu		1.vg					
25		170					175		р	O_L		1180	<i></i> 7.5					
			(2)	****	ODM	.mrox		0.00										•
			(2)	INF	·ORM	ATTOR	101	( SE(	מד נ	NO:	134:							
		( :		QUEN														
30				LENG				_	airs									
				STRA					2									
			(D)	TOPO	DLOGY	(: li	near	•										
35		( :	ii) N	OLEC	TULE	TYPE	: cī	AMC										
				EATU														
			(2)	377.1	ATO / 74T	732												
				NAN LOC	•			_	equer	ıce								
40				OTH														
		(3	ci) c	EQUE	NCE	DESC	ים ד מי	rton.	. cec	חד ר	NO - 1	134.						
		(,,	, .	<i>,</i>				LION	. 554	ע גיי	140.1							
45														CCC			48	
45	Met 1	Val	Ser	ràs	GIY 5	GIu	Glu	Leu	Phe	Thr 10	Gly	Val	Val	Pro	Ile 15	Leu		
										10					13			
														GTG			96	
50	vaı	GIU	ren	Asp 20	GIA	Asp	vaı	Asn	G1y 25	His	rys	Phe	Ser	Val	Ser	GIA		
														AAG			144	
	GIU	GIÀ	35	ату	нар	мта	ınr	Tyr 40	σтλ	пÀг	ьeu	ınr	Leu 45	Lys	<b>гле</b>	TTE		
55																•		
	TGC	ACC	ACC	GGC	AAG	CTG	CCC	GTG	CCC	TGG	CCC	ACC	CTC	GTG	ACC	ACC	192	
																		269

	Су	50	r Th:	r Gly	y Lys	s Lev	Pro 55	o Vai	l Pro	Tr	Pro	Thi 60	r Let	ı Vai	l Th	r Thr	
5	CTO Let 65	ACC Thi	TAC Tyi	C GGG C Gly	C GTO Val	G CAG Gln 70	TGC Cys	TTC Phe	C AGC	CGC Arg	TAC TY1 75	C CCC	GAC Asp	CAC His	C ATO	AAG Lys 80	240
10	CAC Glr	G CAC	GAC Asp	TTC Phe	TTC Phe	AAG Lys	TCC	GCC Ala	: ATG	Pro 90	GAA Glu	GGC Gly	TAC Tyr	GTC Val	CAC Glr 95	G GAG	288
15	Arg	ACC Thr	: ATC	Phe	Phe	AAG Lys	GAC Asp	GAC Asp	GGC Gly 105	Asn	TAC	: AAG : Lys	ACC Thr	CGC Arg	Ala	GAG Glu	336
	GTG Val	AAG Lys	TTC Phe 115	GIU	GGC Gly	GAC Asp	ACC Thr	CTG Leu 120	Val	AAC Asn	CGC Arg	ATC Ile	GAG Glu 125	CTG Leu	AAG Lys	GGC Gly	384
20	ATC Ile	GAC Asp 130	TŤC Phe	AAG Lys	GAG Glu	GAC Asp	GGC Gly 135	AAC Asn	ATC Ile	CTG Leu	GGG Gly	CAC His 140	AAG Lys	CTG Leu	GAG Glu	TAC Tyr	432
25	AAC Asn 145	TAC Tyr	AAC Asn	AGC Ser	CAC His	AAC Asn 150	GTC Val	TAT Tyr	ATC Ile	ATG Met	GCC Ala 155	GAC Asp	AAG Lys	CAG Gln	AAG Lys	AAC Asn 160	480
30	GGC Gly	ATC Ile	AAG Lys	GTG Val	AAC Asn 165	TTC Phe	AAG Lys	ATC Ile	CGC Arg	CAC His 170	AAC Asn	ATC Ile	GAG Glu	GAC Asp	GGC Gly 175	AGC Ser	528
35	GTG Val	CAG Gln	CTC Leu	GCC Ala 180	GAC Asp	CAC His	TAC Tyr	CAG Gln	CAG Gln 185	AAC Asn	ACC Thr	CCC Pro	ATC Ile	GGC Gly 190	GAC Asp	GGC Gly	576
	CCC Pro	GTG Val	CTG Leu 195	CTG Leu	CCC Pro	GAC Asp	AAC Asn	CAC His 200	TAC Tyr	CTG Leu	AGC Ser	ACC Thr	CAG Gln 205	TCC Ser	GCC Ala	CTG Leu	624
40	AGC Ser	AAA Lys 210	GAC Asp	CCC Pro	AAC Asn	GAG Glu	AAG Lys 215	CGC Arg	GAT Asp	CAC His	ATG Met	GTC Val 220	CTG Leu	CTG Leu	GAG Glu	TTC Phe	672
45	GTG Val 225	ACC Thr	GCC Ala	GCC Ala	GGG Gly	ATC Ile 230	ACT Thr	CTC Leu	GGC Gly	ATG Met	GAC Asp 235	GAG Glu	CTG Leu	TAC Tyr	AAG Lys	TCC Ser 240	720
50	GGA Gly	CTC Leu	AGA Arg	TCT Ser	CGA Arg 245	GGG Gly	AGC Ser	ATG Met	Gly	ACC Thr 250	TTG Leu	CGG Arg	GAT Asp	Leu	CAG Gln 255	TAC Tyr	768
55	GCG Ala	CTC Leu	GIN	GAG Glu 260	AAG Lys	ATC Ile	GAG Glu	GAG Glu	CTG . Leu . 265	AGG Arg	CAG Gln	CGG Arg	Asp	GCT Ala 270	CTC Leu	ATC Ile	816
	GAC	GAG	CTG	GAG	CTG	GAG '	TTG (	GAT	CAG :	AAG	GAC	GAA	CTG .	ATC	CAG	AAG	864

										211								
	Asp	Glu	Leu 275	Glu	Leu	Glu	Leu	Asp 280	Gln	Lys	Asp	Glu	Leu 285	Ile	Gln	Lys		
5					CTG Leu												912	
10					AAG Lys												960	
45				_	GCG Ala 325	_		_									1008	
15					GTG Val												1056	
20				_	AAG Lys	_	_										1104	
25					CAG Gln												1152	
30					GAC Asp												1200	
0.5					ATG Met 405												1248	
35					ACC Thr												1296	
40					TGT Cys												1344	
45					GCC Ala												1392	
50					ATC Ile												1440	
<b></b>					CAG Gln 485												1488	
55	GAT	GTC	CTT	GAA	GAG	ACC	CAC	TAT	GAA	TAA	GGA	GAA	TAT	ATT	ATC	AGG	1536	27

										272							
	Asp	Va.	l Le	u Gl: 50	u Gl	u Thi	r Hi:	з Ту	50!		n Gly	y Gl	и Ту	r Ile 510		e Arg	
5	CAA Gln	GG Gl	T GC y Ala 515	a Ar	A GGG	G GAO	Thi	TTC Phe 520	Phe	T ATO	C ATO	C AGO	C AAA C Lys 525	Gl)	A ACC	G GTA r Val	1584
10	AAT Asn	' GT( Va]	Ini	CG:	r GAA g Glu	A GAC 1 Asp	Ser 535	Pro	G AGT	GAA Glu	A GAC 1 Asp	C CCA Pro 540	Val	TTT Phe	CT:	r AGA 1 Arg	1632
15	ACT Thr 545	ьet	A GGA 1 Gly	A AAA / Lys	A GGA Gly	A GAC Asp 550	Trp	TTT Phe	GGA Gly	GAG Glu	AAA Lys 555	Ala	TTG Leu	CAG Gln	GGG Gly	GAA Glu 560	1680
	GAT Asp	GTC Val	AGA Arg	ACA Thr	GCA Ala 565	Asn	GTA Val	ATT Ile	GCT Ala	GCA Ala 570	Glu	GCT Ala	'GTA Val	ACC Thr	TGC Cys 575	CTT Leu	1728
20	GTG Val	ATT	GAC Asp	AGA Arg 580	Asp	Ser	TTT Phe	AAA Lys	CAT His 585	TTG Leu	ATT	GGA Gly	GGG Gly	CTG Leu 590	GAT Asp	GAT Asp	1776
25	GTT Val	TCT Ser	AAT Asn 5 <b>95</b>	AAA Lys	GCA Ala	TAT Tyr	GAA Glu	GAT Asp 600	GCA Ala	GAA Glu	GCT Ala	AAA Lys	GCA Ala 605	AAA Lys	TAT Tyr	GAA Glu	1824
30	GCT Ala	GAA Glu 610	GCG Ala	GCT Ala	TTC Phe	TTC Phe	GCC Ala 615	AAC Asn	CTG Leu	AAG Lys	CTG Leu	TCT Ser 620	GAT Asp	TTC Phe	AAC Asn	ATC Ile	1872
35	ATT Ile 625	GAT Asp	ACC Thr	CTT Leu	GGA Gly	GTT Val 630	GGA Gly	GGT Gly	TTC Phe	GGA Gly	CGA Arg 635	GTA Val	GAA Glu	CTG Leu	GTC Val	CAG Gln 640	1920
	neu	гу	ser	GIU	645	TCC Ser	Lys	Thr	Phe	Ala 650	Met	Lys	Ile	Leu	Lys 655	Lys	1968
40	ALG	пі	116	660	Asp		Arg	Gln	Gln 665	Glu	His	Ile	Arg	Ser 670	Glu	Lys	2016
45	CAG Gln	116	675	GIN	GIY	Ala	His	Ser 680	Asp	Phe	Ile	Val	Arg 685	Leu	Tyr	Arg	2064
50	ACA Thr	TTT Phe 690	AAG Lys	GAC Asp	AGC Ser	AAA Lys	TAT Tyr 695	TTG Leu	TAT Tyr	ATG Met	TTG Leu	ATG Met 700	GAA Glu	GCT Ala	TGT Cys	CTA Leu	2112
55	GGT ( Gly ( 705	эту	GIU	ren	Trp	710	Ile	Leu	Arg	Asp	Arg 715	Gly	Ser	Phe	Glu	Asp 720	2160
	TCT I	ACA	ACC	AGA	TTT	TAC	ACA	GCA	TGT	GTG	GTA	GAA	GCT	TTT	GCC	<b>TAT</b> .	2208 272

			•							2/3							
	Ser	Thr	Thr	Arg	Phe 725	Tyr	Thr	Ala	Cys	Val 730	Val	Glu	Ala	Phe	Ala 735	Tyr	
5				AAA Lys 740													2256
10				CAC His													2304
15				GGA Gly		_											2352
				GCC Ala													2400
20				TGG Trp													2448
25				TTC Phe 820													2496
30				ATT Ile													2544
35				TTA Leu		•											2592
		_		TTG Leu													2640
40				TTT Phe													2688
45				CCA Pro 900													2736
50		Phe		GAG Glu													2784
55				GAC Asp		TAA					٠					,	2802

274

## (2) INFORMATION FOR SEQ ID NO:135:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 933 amino acids
- (B) TYPE: amino acid

5

- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- 10 (v) FRAGMENT TYPE: internal

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:135:

45		Val	Ser	Lys	Gly	Glu	Glu	Leu	Phe		Gly	Val	Val	Pro		Leu
15	1	-1	_	_	5	_		_		10					15	
				20	Gly				25					30		_
	Glu	Gly	Glu 35	Gly	Asp	Ala	Thr	Tyr 40	Gly	Lys	Leu	Thr	Leu 45	Lys	Phe	Ile
20	Суѕ	Thr 50	Thr	Gly	Lys	Leu	Pro 55	Val	Pro	Trp	Pro	Thr 60	Leu	Val	Thr	Thr
	Leu 65	Thr	Tyr	Gly	Val	Gln 70	Сув	Phe	Ser	Arg	Tyr 75	Pro	Asp	His	Met	Lys 80
25	Gln	His	Asp	Phe	Phe 85	Lys	Ser	Ala	Met	Pro 90		Gly	Tyr	Val	Gln 95	
	Arg	Thr	Ile	Phe 100	Phe	Lys	Asp	Asp	Gly 105		Tyr	Lys	Thr	Arg		Glu
	Val	Lys	Phe 115	Glu	Gly	Asp	Thr	Leu 120		Asn	Arg	Ile	Glu 125		Lys	Gly
30	Ile	Asp 130	Phe	Lys	Glu	Asp	Gly 135		Ile	Leu	Gly	His		Leu	Glu	Tyr
	Asn 145		Asn	Ser	His	Asn 150		Tyr	Ile	Met	Ala 155		Lys	Gln	Lys	Asn 160
		Ile	Lvs	Val	Asn		Lvs	Tle	Ara	His		Tle	Glu	Asn	Glv	
35	•		•		165					170					175	
	Val	Gln	Leu	Ala 180	Asp	His	Tyr	Gln	Gln 185	Asn	Thr	Pro	Ile	Gly 190	Asp	Gly
	Pro	Val	Leu 195		Pro	Asp	Asn	His 200		Leu	Ser	Thr			Ala	Leu
40	Ser	Lys 210		Pro	Asn	Glu	Lys 215		Asp	His	Met			Leu	Glu	Phe
	Val		בומ	בות	Gly	Tla		Lou	C111	Mot	7	220		The earn	T	Co~
	225	****	AIG	YIG	Gry	230	1111	neu	СТУ	met	235	GIU	реп	ıyı	гуя	240
45	Gly	Leu	Arg	Ser	Arg 245	Gly	Ser	Met	Gly	Thr 250	Leu	Arg	Asp	Leu	Gln 255	Tyr
	Ala	Leu	Gln	Glu 260	Lys	Ile	Glu	Glu	Leu 265	Arg	Gln	Arg	Asp	Ala 270	Leu	Ile
	Asp	Glu	Leu 275	Glu	Leu	Glu	Leu	Asp 280	Gln	Lys	Asp	Glu	Leu 285	Ile	Gln	Lys
50	Leu	Gln 290	Asn	Glu	Leu	Asp	Lys 295	Tyr	Arg	Ser	Val	Ile 300		Pro	Alà	Thr
	Gln 305	Gln	Ala	Gln	Lys	Gln 310		Ala	Ser	Thr	Leu 315		Gly	Glu	Pro	Arg 320
55		Lys	Arg	Gln	Ala 325		Ser	Ala	Glu	Pro		Ala	Phe	Asp	Ile 335	
35	Asp	Leu	Ser	His	Val	Thr	Leu	Pro	Phe		Pro	Lys	Ser	Pro		Ser

				340					345					350		
	Lys	Asp	Leu 355	Ile	Lys	Glu	Ala	Ile 360		Asp	Asn	Asp	Phe	Met	Lys	Asn
5	Leu	Glu 370	Leu	Ser	Gln	Ile	Gln 375	Glu	Ile	Val	Asp	Cys 380		Tyr	Pro	Val
	Glu 385	Tyr	Gly	Lys	Asp	Ser 390	Cys	Ile	Ile	Lys	Glu 395	Gly	Asp	Val	Gly	Ser 400
	Leu	Val	Tyr	Val	Met 405	Glu	Asp	Gly	Lys	Val 410	Glu	Val	Thr	Lys	Glu 415	
10	Val	Lys	Leu	Cys 420		Met	Gly	Pro	Gly		Val	Phe	Gly			Ala
	Ile	Leu	Tyr 435		Cys	Thr	Arg				Val	Lys		430 Leu	Val	Asn
		•		_				440		•			445			
15		450					455				Phe	460				
	465					470					Met 475					480
	Val	Pro	Thr	Phe	Gln 485	Ser	Leu	Pro	Glu	Glu 490	Ile	Leu	Ser	Lys	Leu 495	Ala
20	Asp	Va1		Glu 500	Glu	Thr	His	Tyr	Glu 5 <b>05</b>	Asn	Gly	Glu	Tyr	Ile 510	Ile	Arg
	Gln	Gly	Ala 515	Arg	Gly	Asp	Thr	Phe 520	Phe	Ile	Ile	Ser	Lys 525	Gly	Thr	Val
25	Asn	Val 530	Thr	Arg	Glu	Asp	Ser 535	Pro	Ser	Glu	Asp	Pro 540	Val	Phe	Leu	Arg
	Thr 545	Leu	Gly	Lys	Gly	Asp 550	Trp	Phe	Gly	Glu	Lys 555		Leu	Gln	Gly	Glu 560
	Asp	Val	Arg		Ala 565		Val	Ile	Ala	Ala 570	Glu	Ala	Val	Thr	Cys 575	
30	Val	Ile	Asp	Arg 580	Asp	Ser	Phe	Lys	His 585		Ile	Gly	Gly	Leu 590		Asp
	Val	Ser	Asn 595	Lys	Ala	Tyr	Glu	Asp 600		Glu	Ala	Lys	Ala 605		Tyr	Glu
35	Ala	Glu 610		Ala	Phe	Phe	Ala 615	-	Leu	Lys	Leu	Ser 620		Phe	Asn	Ile
	Ile 625		Thr	Leu	Gly	Val 630		Gly	Phe	Gly	Arg 635		Glu	Leu	Val	
		Lys	Ser	Glu	Glu 645		Lys	Thr	Phe		Met	Lys	Ile	Leu		640 Lys
40	Arg	His	Ile			Thr	Arg	Gln		650 Glu	His	Ile	Arg		655 Glu	Lys
	Gln	Ile	Met 675	660 Gln	Gly	Ala	His		665 Asp	Phe	Ile	Val		670 Leu	Tyr	Arg
45	Thr	Phe 690		Asp	Ser	Lys		680 Leu	Tyr	Met	Leu		685 Glu	Ala	Cys	Leu
75			Glu	Leu	Trp		695 Ile	Leu	Arg	Asp	Arg	700 Gly	Ser	Phe	Glu	
	705 Ser	Thr	Thr	Arg		710 Tyr	Thr	Ala	Cys		715 Val	Glu	Ala	Phe		720 Tyr
50	Leu	His	Ser		725 Gly	Ile	Ile	Tyr		730 Asp	Leu	Lys	Pro	Glu	735 Asn	Leu
	Ile	Leu	Asp 755	740 His	Arg	Gly	Tyr	Ala 760	745 Lys	Leu	Val	Asp	Phe 765	750 Gly	Phe	Ala
55	Lys	Lys 770		Gly	Phe	Gly	Lys 775		Thr	Trp	Thr	Phe 780		Gly	Thr	Pro
	Glu		Val	Ala	Pro	Glu	_	Ile	Leu	Asn	Lys		His	Asp	Ile	Ser

	785	;				790	)				795	;				800	
	Ala	Asp	туз	Tr	Ser	Leu	Gly	/ Ile	. Lei	ı Mei	t Tyr	Glu	Leu	Lev	Thi	Gly	
					805					810	)				819		
5				820	)				825	5				830	1	lle	
			835	1				840	)				845			Asn	
	Ala	Ala 850	Asn	Leu	Ile	Lys	Lys 855	Leu	Cys	Arg	g Asp	Asn 860	Pro	Ser	Glu	Arg	
10	Leu 865	Gly	Asn	Leu	Lys	Asn 870	Gly		Lys	Asp		Gln	Lys	His	Lys	Trp	
			Gly	Phe	Asn 885	Trp		Gly	Lev			Gly	Thr	Leu	Thr	880 Pro	
15	Pro	Ile	Ile	Pro	Ser		Ala	Ser			Asp	Thr	Ser			Asp	
	Ser	Phe	Pro	Glu		Asn	Asp	Glu	905 Pro	Pro	Pro	Asp		910 Asn	Ser	Gly	
	Trp	Asp 930	Ile		Phe			920					925				
20														•			
			(2	) IN	FORM	ATIO	N FO	R SE	Q ID	NO:	136:						
		(	i) S	EQUE:	NCE	CHAR	ACTE	RIST	ICS:								
25			(B)	TYP:	E: n	279: ucle:	ic a	cid									
			(C)	STR	ANDE	DNES: Y: 1:	S: s:	ingl	e								
30				MOLE FEAT		TYP	E: cl	ANC									
			(۵)	ו אמו	4Ε/KI	ΞΥ: (	2044	· ·									
			(B)	LO	CATIO	ON: 1	l2	2795	eque	nce							
35			(D)	OTI	HER I	INFOR	TAM	ON:									
		()	ci) s	EQUI	ENCE	DESC	RIPT	CION	: SE	Q ID	NO:1	36:					
	ATG	GGC	ACC	TTG	CGG	GAT	TTA	CAG	TAC	GCG	CTC	CAG	GAG	AAG	ATC	GAG`	48
40	Met 1	GIY	Thr	Leu	Arg 5	Asp	Leu	Gln	Tyr	Ala 10	Leu	Gln	Glu	Lys	Ile 15	Glu	
•	GAG	CTG	NGG	CAG	ccc	C D TT	00m	~m=									
	Glu	Leu	Arg	Gln	Arg	Asp	Ala	Leu	Ile	GAC Asp	GAG Glu	CTG Leu	GAG Glu	CTG Leu	GAG Glu	TTG Leu	96
45				20					25					30			
	GAT	CAG	AAG	GAC	GAA	CTG	ATC	CAG	AAG	CTG	CAG	AAC	GAG	CTG	GAC	AAG	144
	Asp	Gln	Lys 35	Asp	Glu	Leu	Ile	Gln 40	Lys	Leu	Gln	Asn	Glu 45	Leu	Asp	Lys	
50	<b>ጥ</b> አር	ccc	TCC	C.T.C	3 mc				•								
30	Tyr	Arg	Ser	Val	Ile	CGA Arg	CCA Pro	GCC Ala	ACC Thr	CAG Gln	CAG Gln	GCG Ala	CAG Gln	AAG Lvs	CAG	AGC	192
		50					55					60		<b>.</b> -			
55	GCG	AGC	ACC	TTG	CAG	GGC	GAG	CCG	CGC	ACC	AAG	CGG	CAG	GCG	ATC	TCC	240
50	Ala 65	net	1111	nen	GIU	70 70	GIU	Pro	Arg	Thr	Lys 75	Arg	Gln	Ala	Ile	Ser 80	

5	GCC Ala	GAG Glu	CCC Pro	ACC Thr	GCC Ala 85	TTC Phe	GAC Asp	ATC Ile	CAĢ Gln	GAT Asp 90	CTC Leu	AGC Ser	CAT His	GTG Val	ACC Thr 95	CTG Leu	288
				CCC Pro 100													336
10				AAT Asn													384
15				GAT Asp													432
20	Ile 145	Ile	Lys	GAA Glu	Gly	Asp 150	Val	Gly	Ser	Leu	Val 155	Tyr	Val	Met	Glu	Asp 160	480
25				GAA Glu													528
				GTG Val 180													576
30				GTC Val													624
35				TTT Phe													672
40				ATG Met													720
45				ATC Ile													768
				GGA Gly 260													816
50				ATC Ile													864
55	CCG Pro	AGT Ser 290	GAA Glu	GAC Asp	CCA Pro	GTC Val	TTT Phe 295	CTT Leu	AGA Arg	ACT Thr	TTA Leu	GGA Gly 300	AAA Lys	GGA Gly	GAC Asp	TGG Trp	912

5	30	5	-1			o Al	31	0	и ст	y GI	u As	p Va 31	1 Ar 5	g Th	r Al	a As	AC GTA on Val 320	
	AT Il	T G e A	CT (	GCA Ala	GAI Glu	A GC: 1 Ala 32!	ı va	A AC l Th	C TG r Cy	C CT s Le	T GT u Va 33	1 11	T GA e As	C AG p Ar	A GA g As	C TC p Se 33	T TTT r Phe 5	1008
10	AA: Ly:	A C	AT 1	rrg Leu	ATT Ile	נים:	A GGG	G CT	G GA' u Asj	T GA' p Asj 34	o Va	T TC	T AA r As	T AA n Ly	A GC s Al 35	а Ту	T GAA r Glu	1056
15			3	55	7124	. шуг	, MI	ту:	360	) c GII	ı Ala	a Glu	ı Ala	a Ala 36	a Ph	e Ph	C GCC e Ala	1104
20		37	70		Deu	261	ASŢ	375	Asr	ı Ile	: Ile	e Asp	380	Let	ı Gly	/ Vai	r gga l gly	1152
25	385			-,	Arg	VQI	390	. теп	va1	. Gin	Leu	1 Lys 395	Ser ;	Glu	ı Glı	ser	AAA Lys 400	1200
					ne c	405	116	ьeu	Lys	гуs	Arg 410	His	Ile	· Val	Asp	Thr 415		1248
30		-		·u	420	116	Arg	ser	GIu	Lys 425	Gln	Ile	Met	Gln	Gly 430	Ala	CAT His	1296
35			43	5	116	val	Arg	rea	1yr 440	Arg	Thr	Phe	Lys	Asp 445	Ser	Lys	TAT Tyr	1344
40		450	)		ueu	Met	GIU	455	Cys	CTA Leu	Gly	Gly	Glu 460	Leu	Trp	Thr	Ile	1392
45	465	:	,	ρ,	. <u>.</u> .	GIY	470	рле	GIU	GAT Asp	Ser	Thr 475	Thr	Arg	Phe	Tyr	Thr 480	1440
		-,-	, vu	<b>.</b> '		485	AIG	Pne	Ala		Leu 490	His	Ser	Lys	Gly	Ile 495	Ile	1488
50	TAC Tyr	3	, AS	5	00	Lys .	PIO	GIU	Asn	Leu 505	Ile	Leu	Asp	His	Arg 510	Gly	Tyr	1536
55	GCC Ala	AAA Lys	Le: 51!	<b>u</b> v	TT (	SAT :	rrr Phe	GIY	TTT Phe 520	GCA . Ala	AAG Lys	AAA Lys	Ile	GGA Gly 525	TTT Phe	GGA Gly	AAG Lys	1584

5									CÇA Pro								1632
J									TCA Ser								1680
10									GGC Gly								1728
15									ATA Ile 585								1776
20	Glu	Phe	Pro 595	Lys	Lys	Ile	Ala	Lys 600	AAT Asn	Ala	Ala	Asn	Leu 605	Ile	Lys	Lys	1824
25	Leu								AGA Arg							GGA Gly	1872
									TGG Trp								1920
30									CCT Pro								1968
35			_						GAC Asp 665								2016
40									GGA Gly								2064
45									AAG Lys								2112
,,,									GAC Asp								2160
50									GGC Gly								2208
55									GGC Gly 745								2256

280

5	AC Th:	C CTC	GT( Va) 755	1111	ACC Thr	CTC Lev	ACC Thr	TAC Tyr 760	Gly	GTC Val	CAC Glr	TGC	TTC Phe 765	Sei	CG(	TAC Tyr	2304
	CC(	GAC Asp 770	nis	ATG Met	AAG Lys	CAG Gln	CAC His 775	GAC Asp	TTC Phe	TTC Phe	AAG Lys	TCC Ser 780	Ala	ATC	CCC Pro	GAA Glu	2352
10	GG( Gl <sub>y</sub> 785	TYL	GTC Val	CAG Gln	GAG Glu	CGC Arg 790	ACC Thr	ATC Ile	TTC Phe	TTC Phe	AAG Lys 795	Asp	GAC Asp	GGC	AAC Asn	TAC Tyr 800	2400
15	AAG Lys	ACC Thr	CGC Arg	GCC Ala	GAG Glu 805	GTG Val	AAG Lys	TTC Phe	GAG Glu	GGC Gly 810	GAC Asp	ACC Thr	CTG Leu	GTG Val	AAC Asn 815	CGC	2448
20	ATC Ile	GAG Glu	CTG Leu	AAG Lys 820	GGC Gly	ATC Ile	GAC Asp	TTC Phe	AAG Lys 825	GAG Glu	GAC Asp	GGC Gly	AAC Asn	ATC Ile 830	CTG Leu	GGG · Gly	2496
25	CAC His	AAG Lys	CTG Leu 835	GAG Glu	TAC Tyr	AAC Asn	TAC Tyr	AAC Asn 840	AGC Ser	CAC His	AAC Asn	GTC Val	TAT Tyr 845	ATC Ile	ATG Met	GCC Ala	2544
	GAC Asp	AAG Lys 850	CAG Gln	AAG Lys	AAC Asn	GGC Gly	ATC Ile 855	AAG Lys	GTG Val	AAC Asn	TTC Phe	AAG Lys 860	ATC Ile	CGC Arg	CAC His	AAC Asn	2592
30	ATC Ile 865	GAG Glu	GAC Asp	GGC Gly	AGC Ser	GTG Val 870	CAG Gln	CTC Leu	GCC Ala	GAC Asp	CAC His 875	TAC Tyr	CAG Gln	CAG Gln	AAC Asn	ACC Thr 880	2640
35	CCC Pro	ATC Ile	GGC Gly	GAC Asp	GGC Gly 885	CCC Pro	GTG Val	CTG Leu	CTG Leu	CCC Pro 890	GAC Asp	AAC Asn	CAC His	TAC Tyr	CTG Leu 895	AGC Ser	2688
40	ACC Thr	CAG Gln	ser	GCC Ala 900	CTG Leu	AGC Ser	AAA Lys	GAC Asp	CCC Pro 905	AAC Asn	GAG Glu	AAG Lys	Arg	GAT Asp 910	CAC His	ATG Met	2736
45	GTC Val	CTG Leu	CTG Leu 915	GAG Glu	TTC Phe	GTG Val	Thr	GCC Ala 920	GCC Ala	GGG Gly	ATC Ile	Thr :	CTC Leu 925	GGC Gly	ATG Met	GAC Asp	2784
	Glu	CTG ' Leu ' 930			TAA												2799
50			(2)	INF	ORMA!	rion	FOR	SEQ	ID I	NO:1	37:						
		(i)	SE	QUEN	CE CI	HARA	CTER	STI	cs.						•		

50

55

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 932 amino acids
- (B) TYPE: amino acid
  - (C) STRANDEDNESS: single

281

(D) TOPOLOGY: linear

5

(ii) MOLECULE TYPE: protein

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:137:

Met Gly Thr Leu Arg Asp Leu Gln Tyr Ala Leu Gln Glu Lys Ile Glu 10 Glu Leu Arg Gln Arg Asp Ala Leu Ile Asp Glu Leu Glu Leu Glu Leu Asp Gln Lys Asp Glu Leu Ile Gln Lys Leu Gln Asn Glu Leu Asp Lys 40 Tyr Arg Ser Val Ile Arg Pro Ala Thr Gln Gln Ala Gln Lys Gln Ser 15 55 Ala Ser Thr Leu Gln Gly Glu Pro Arg Thr Lys Arg Gln Ala Ile Ser 70 Ala Glu Pro Thr Ala Phe Asp Ile Gln Asp Leu Ser His Val Thr Leu 20 Pro Phe Tyr Pro Lys Ser Pro Gln Ser Lys Asp Leu Ile Lys Glu Ala 105 Ile Leu Asp Asn Asp Phe Met Lys Asn Leu Glu Leu Ser Gln Ile Gln 120 Glu Ile Val Asp Cys Met Tyr Pro Val Glu Tyr Gly Lys Asp Ser Cys 25 135 140 Ile Ile Lys Glu Gly Asp Val Gly Ser Leu Val Tyr Val Met Glu Asp 150 155 Gly Lys Val Glu Val Thr Lys Glu Gly Val Lys Leu Cys Thr Met Gly 165 170 30 Pro Gly Lys Val Phe Gly Glu Leu Ala Ile Leu Tyr Asn Cys Thr Arg 185 Thr Ala Thr Val Lys Thr Leu Val Asn Val Lys Leu Trp Ala Ile Asp 200 Arg Gln Cys Phe Gln Thr Ile Met Met Arg Thr Gly Leu Ile Lys His 35 215 220 Thr Glu Tyr Met Glu Phe Leu Lys Ser Val Pro Thr Phe Gln Ser Leu 230 235 Pro Glu Glu Ile Leu Ser Lys Leu Ala Asp Val Leu Glu Glu Thr His 245 250 40 Tyr Glu Asn Gly Glu Tyr Ile Ile Arg Gln Gly Ala Arg Gly Asp Thr 265 Phe Phe Ile Ile Ser Lys Gly Thr Val Asn Val Thr Arg Glu Asp Ser 280 Pro Ser Glu Asp Pro Val Phe Leu Arg Thr Leu Gly Lys Gly Asp Trp 45 295 300 Phe Gly Glu Lys Ala Leu Gln Gly Glu Asp Val Arg Thr Ala Asn Val 310 315 Ile Ala Ala Glu Ala Val Thr Cys Leu Val Ile Asp Arg Asp Ser Phe 330 50 Lys His Leu Ile Gly Gly Leu Asp Asp Val Ser Asn Lys Ala Tyr Glu 345 Asp Ala Glu Ala Lys Ala Lys Tyr Glu Ala Glu Ala Ala Phe Phe Ala Asn Leu Lys Leu Ser Asp Phe Asn Ile Ile Asp Thr Leu Gly Val Gly 55 375 Gly Phe Gly Arg Val Glu Leu Val Gln Leu Lys Ser Glu Glu Ser Lys

										202						
	385	;				390					395					400
	Thr	Phe	Ala	Met	Lys 405	` Ile	Leu	Lys	Lys	Arg	His		Val	Asp		Arg
5	Glr	Glr	Glu	His 420	Ile		Ser	Glu	Lys	Gln	Ile	Met	Gln	Gly		His
			435		· Val			440					445	Ser	Lys	
		450			Met		455					460				
10	465				Gly	470					475					480
					Glu 485					490					495	
15				500					505					510		
			515		Asp			520					525			
20		530			Phe		535					540				
20	545				Gly	550					555					560
					Glu 565					570					575	
25				580	Thr				585					590		
			595		Lys			600					605			
30		610			Asn		615					620				
	625				Gln Gly	630					635					640
					645 Thr					650					655	
35				660	Asp				665					670		
			675		Thr			680					685			
40		690			Leu		695					700				
	705				Gly	710					715					720
					725 Ile					730					735	
45				740	Thr				745					750		
			755		Lys			760					765			
50		770			Glu		775					780				
	/85				Glu	790				Gly	795					800
55	Ile	Glu	Leu	Lys 82 <b>0</b>	805 Gly	Ile	Asp	Phe		810 Glu	Asp	Gly	Asn		815 Leu	Gly
	His	Lys			Tyr	Asn	Tyr	Asn	825 Ser	His	Asn	Val	Tyr	830 Ile	Met	Ala

			835			•		840					845					
	Asp	Lys 850	Gln	Lys	Asn	Gly	Ile 855	Lys	Vaļ	Asn	Phe	Lys 860	Ile	Arg	His	Asn		
_		Glu	Asp	Gly	Ser		Gln	Leu	Ala	Asp		Tyr	Gln	Gln	Asn			
5	865 Pro	Ile	Gly	Asp		870 Pro	Val	Leu	Leu		875 Asp	Asn	His	туr		880 Ser		
	Thr	Gln	Ser	Ala	885 Leu	Ser	Lys	Asp		890 Asn	Glu	Lys	Arg	-	895 His	Met		
10	Val	Leu	Leu	900 Glu	Phe	Val	Thr	Ala	905 Ala	Glv	Ile	Thr	Leu	910 Glv	Met	Asp		
		Leu	915					920		2			925	2		•		
		930												٠				
15			(2)	INE	FORM	MOITA	I. FOF	R SEÇ	) ID	NO:1	138:							
		· (i		EQUEN														
20				TYPE														
20				TOPO					•									
				OLEC		TYPE	E: cI	ANO										
25		•					a - 22 -											
			(B)	NAN LOC OTH	CATIO	ON: 1	2	2181	equer	ıce	,							
30		()	ci) S	EQUE	ENCE	DESC	CRIPT	rion:	: SE(	QID	NO:	138:					•	
				AAG													48	
	Met 1	Val	Ser	Lys	Gly 5	Glu	Glu	Leu	Phe	Thr 10	Gly	Val	Val	Pro	Ile 15	Leu		
35	cma	CAC	cmc	- C 2 C	ccc	CNC	CTN	220	ccc	C N C	220	mme.	200	CTT.CT	TOO	CCC	96	
				GAC Asp													36	
٠				20					25					30				
40				GGC													144	
	GIU	GIÀ	35	Gly	Asp	АТА	Thr	1yr 40	GIY	гÀг	ьеи	Thr	45	гуѕ	Pne	116		
	TGC	ACC	ACC	GGC	AAG	CTG	CCC	GTG	ccc	TGG	CCC	ACC	CTC	GTG	ACC	ACC	192	
45	Cys		Thr	Gly	Lys	Leu		Val	Pro	Trp	Pro		Leu	Val	Thr	Thr		
		50					55					60						
				GGC Gly													240	
50 .	65		•	•		70	•			,	75		•			80		
				TTC													288	
	GIN	HIS	ASP	Phe	Phe 85	гÀг	ser	Ala	met	Pro 90	GIU	GIŻ	ıyr	vaı	95	GIU		
55	CGC	ACC	ATC	TTC	ጥጥር	באמ	GAC	GAC	GGC	AAC	тас	DAG	ACC	רפר	GCC.	GAG	336	
					-10	טתי	JAC	JAC	550		, AC	. Fig					550	283

	Arg	Thr	Ile	Phe 100	Phe	Lys	Asp	Asp	Gly 105	Asn	Tyr	Lys	Thr	Arg 110	Ala	Glu	
5		AAG Lys					Thr										384
10		GAC Asp 130															432
15		TAC Tyr															480
		ATC Ile															528
20		CAG Gln															576
25		GTG Val															624
30		AAA Lys 210															672
25		ACC Thr															720
35		CTC Leu															768
40		TGG Trp															`816
45		TTC Phe															86 <b>4</b>
50		CAG Gln 290															912
		CAG Gln															960
55	ATC	ATC	CGC	TGC	CTG	CAG	TGG	ACC	ACT	GTC	ATC	GAA	CGC	ACC	TTC	CAT	1008

										200							
	Ile	Ile	Arg	Cys	Leu 325	Gln	Trp	Thr	Thr	Val 330	Ile	Glu	Arg	Thr	Phe 335	His	
5						GAG Glu											1056
10						AAG Lys											1104
						GAC Asp			•								1152
15						CAC His											1200
20						GGC Gly											1248
25						TAC Tyr											1296
30						GAG Glu						Thr					1344
35						CAC His											1392
30	_					CTC Leu 470											1440
40						CTG Leu											1488
45	•					GCT Ala											1536
50						GTG Val											1584
55						CAC His					-						1632
55	GAG	GGG	ATC	AAG	GAC	GGT	GCC	ACC	ATG	AAG	ACC	TTT	TGC	GGC	ACA	CCT	1680

										200							
	Glu 545	Gly	Ile	Lys	Asp	Gly 550	Ala	Thr	Met	Lys	Thr 555	Phe	Cys	Gly	Thr	Pro 560	
5	GAG Glu	TAC	CTG Leu	GCC Ala	Pro 565	Glu	GTG Val	CTG Leu	GAG Glu	GAC Asp 570	Asn	GAC Asp	TAC Tyr	GGC Gly	CGT Arg 575	GCA Ala	1728
10	GTG Val	GAC Asp	TGG Trp	TGG Trp 580	Gly	CTG Leu	GGC Gly	GTG Val	GTC Val 585	ATG Met	TAC Tyr	GAG Glu	ATG Met	ATG Met 590	TGC Cys	GGT Gly	1776
15	CGC Arg	CTG Leu	CCC Pro 595	TTC Phe	TAC Tyr	AAC Asn	CAG Gln	GAC Asp 600	CAT His	GAG Glu	AAG Lys	CTT Leu	TTT Phe 605	GAG Glu	CTC Leu	ATC Ile	1824
	CTC Leu	ATG Met 610	GAG Glu	GAG Glu	ATC Ile	CGC Arg	TTC Phe 615	CCG Pro	CGC Arg	ACG Thr	CTT Leu	GGT Gly 620	CCC Pro	GAG Glu	GCC Ala	AAG Lys ,	1872
20	TCC Ser 625	TTG Leu	CTT	TCA Ser	GGG Gly	CTG Leu 630	CTC Leu	AAG Lys	AAG Lys	GAC Asp	CCC Pro 635	AAG Lys	CAG Gln	AGG Arg	CTT Leu	GGC Gly 640	1920
25	GGG Gly	GGC Gly	TCC Ser	GAG Glu	GAC Asp 645	GCC Ala	AAG Lys	GAG Glu	ATC Ile	ATG Met 650	CAG Gln	CAT His	CGC Arg	TTC Phe	TTT Phe 655	GCC Ala	1968
30	GGT Gly	ATC Ile	GTG Val	TGG Trp 660	CAG Gln	CAC His	GTG Val	TAC Tyr	GAG Glu 665	AAG Lys	AAG Lys	CTC Leu	AGC Ser	CCA Pro 670	CCC Pro	TTC Phe	2016
35	AAG Lys	CCC Pro	CAG Gln 675	GTC Val	ACG Thr	TCG Ser	GAG Glu	ACT Thr 680	GAC Asp	ACC Thr	AGG Arg	TAT Tyr	TTT Phe 685	GAT Asp	GAG Glu	GAG Glu	2064
	TTC Phe	ACG Thr 690	GCC Ala	CAG Gln	ATG Met	ATC Ile	ACC Thr 695	ATC Ile	ACA Thr	CCA Pro	CCT Pro	GAC Asp 700	CAA Gln	GAT Asp	GAC Asp	AGC Ser	2112 .
40	ATG Met 705	GAG Glu	TGT Cys	GTG Val	GAC Asp	AGC Ser 710	GAG Glu	CGC Arg	AGG. Arg	CCC Pro	CAC His 715	TTC Phe	CCC Pro	CAG Gln	TTC Phe	TCC Ser 720	2160
45	TAC Tyr							TGÀ									2184
50		(i				TION				NO:1	39:						
55		,	(A) (B) (C)	LENG TYPE STRA	TH: : am NDED	727 ino NESS	amin acid : si	o ac	ids								

- (ii) MOLECULE TYPE: protein
  (v) FRAGMENT TYPE: internal
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:139:

_		()	ki) S	SEQUI	ENCE	DESC	CRIP	rion:	SEC	QI Q	№:	139:				
5																
	Met 1	Val	Ser	Lys	Gly 5	Glu	Glu	Leu	Phe	Thr	Gly	Val	Val	Pro	Ile 15	Leu
	Val	Glu	Leu	Asp 20	Gly	Asp	Val	Asn	Gly 25	His	Lys	Phe	Ser	Val 30	Ser	Gly
10	Glu	Gly	Glu 35	Gly	Asp	Ala	Thr	Tyr 40	Gly	Lys	Leu	Thr	Leu 45	Lys	Phe	Ile
	Cys	Thr 50	Thr	Gly	Lys	Leu	Pro 55	Val	Pro	Trp	Pro	Thr 60	Leu	Val	Thr	Thr
15	Leu 65	Thr	Tyr	Gly	Val	Gln 70	Cys	Phe	Ser	Arg	Tyr 75	Pro	Asp	His	Met	Lys 80
	Gln	His	Asp	Phe	Phe 85	Lys	Ser	Ala	Met	Pro 90	Glu	Gly	Tyr	Val	Gln 95	Glu
	Arg	Thr	Ile	Phe 100	Phe	Lys	Asp	Asp	Gly 105	Asn	Tyr	Lys	Thr	Arg 110	Ala	Glu
20	Val	Lys	Phe 115	Glu	Gly	Asp	Thr	Leu 120	Val	Asn	Arg	Ile	Glu 125	Leu	Lys	Gly
	Ile	Asp 130	Phe	Lys	Glu	Asp	Gly 135	Asn	Ile	Leu	Gly	His 140	Lys	Leu	Glu	Tyr
25	145				His	150					155					160
					Asn 165					170					175	
	Val	Gln	Leu	Ala 180	Asp	His	Tyr	Gln	Gln 185	Asn	Thr	Pro	Ile	Gly 190	Asp	Gly
30			195		Pro	_		200	_				205			
		210			Asn		215			•		220				
35	225				Gly	230			_	•	235			_	_	240
					Arg 245					250					255	
40				260	Lys				265					270		
40			275		Lys			280					285			_
		290			Asp		295					300				
45	305				Leu	310					315	_				320
					Leu 325					330					335	
50				340	Glu				345	_				350		
50			355		Leu			360					365			
		370			Ser		375					380				
55	385				Lys	390					395					400
	nys	теп	ьeu	GIÀ	Lys	GIÀ	Thr	hue	GIÀ	гÀг	vaı	тте	Leu	val	гÀг	GIU

```
405
                                          410
       Lys Ala Thr Gly Arg Tyr Tyr Ala Met Lys Ile Leu Lys Lys Glu Val
                                     425
       Ile Val Ala Lys Asp Glu Val Ala His Thr Leu Thr Glu Asn Arg Val
  5
                                  440
       Leu Gln Asn Ser Arg His Pro Phe Leu Thr Ala Leu Lys Tyr Ser Phe
                              455
      Gln Thr His Asp Arg Leu Cys Phe Val Met Glu Tyr Ala Asn Gly Gly
                         470
                                              475
      Glu Leu Phe Phe His Leu Ser Arg Glu Arg Val Phe Ser Glu Asp Arg
 10
                                          490
      Ala Arg Phe Tyr Gly Ala Glu Ile Val Ser Ala Leu Asp Tyr Leu His
                                      505
                                                         510
      Ser Glu Lys Asn Val Val Tyr Arg Asp Leu Lys Leu Glu Asn Leu Met
 15
                                  520
                                                     525
      Leu Asp Lys Asp Gly His Ile Lys Ile Thr Asp Phe Gly Leu Cys Lys
                              535
                                                  540
      Glu Gly Ile Lys Asp Gly Ala Thr Met Lys Thr Phe Cys Gly Thr Pro
                         550
                                             555
      Glu Tyr Leu Ala Pro Glu Val Leu Glu Asp Asn Asp Tyr Gly Arg Ala
20
                                         570
      Val Asp Trp Trp Gly Leu Gly Val Val Met Tyr Glu Met Met Cys Gly
                                     585
                                                         590
      Arg Leu Pro Phe Tyr Asn Gln Asp His Glu Lys Leu Phe Glu Leu Ile
25
                                 600
      Leu Met Glu Glu Ile Arg Phe Pro Arg Thr Leu Gly Pro Glu Ala Lys
                             615
                                                 620
      Ser Leu Leu Ser Gly Leu Leu Lys Lys Asp Pro Lys Gln Arg Leu Gly
                         630
                                             635
      Gly Gly Ser Glu Asp Ala Lys Glu Ile Met Gln His Arg Phe Phe Ala
. 30
                     645
                                         650
      Gly Ile Val Trp Gln His Val Tyr Glu Lys Lys Leu Ser Pro Pro Phe
                 660
                                     665
      Lys Pro Gln Val Thr Ser Glu Thr Asp Thr Arg Tyr Phe Asp Glu Glu
35
                                 680
      Phe Thr Ala Gln Met Ile Thr Ile Thr Pro Pro Asp Gln Asp Asp Ser
                             695
                                                 700
      Met Glu Cys Val Asp Ser Glu Arg Arg Pro His Phe Pro Gln Phe Ser
                       710
                                             715
40
      Tyr Ser Ala Ser Ser Thr Ala
                      725
```

## (2) INFORMATION FOR SEQ ID NO:140:

45 (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 2394 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

50

- (ii) MOLECULE TYPE: cDNA
  (ix) FEATURE:
  - (A) NAME/KEY: Coding Sequence
- (B) LOCATION: 1...2391
  - (D) OTHER INFORMATION:

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO:140:

		•															
5				CTG Leu													48
10				TAT Tyr 20													96
15				TAC Tyr													144
				ACA Thr													192
20				GGA Gly													240
25				CGG Arg													288
30				TAT Tyr 100													336
35				CTG Leu													384
				CAG Gln													432
40				CAG Gln													480
45	TTC	CAG Gln	GTG Val	ACA Thr	GTG Val 165	CGG Arg	GAC Asp	CCA Pro	TCA Ser	GGC Gly 170	AGG Arg	CCC Pro	CTC Leu	CGC Arg	CTG Leu 175	CCG Pro	528
50 .				CCT Pro 180													576 <sup>°</sup>
55				ATC Ile													624
	GGG	GAT	GAG	ATC	TTC	CTA	CTG	TGT	GAC	AAG	GTG	CAG	AAA	GAG	GAC	ATT	672

	Gl	y As 21	p Gl	u Ile	e Phe	e Leu	Leu 215	Cys	Asp	ь Гу	s Val	l G1 22		s Gl	u As	p Ile		
5	GA0 Gl: 225	va.	G TA	r TTO	C ACC	G GGA Gly 230	Pro	GGC Gly	TGG Trp	GAC Glu	G GC0 1 Ala 235	a Ar	A GG	C TC Y Se	C TT	T TCG e Ser 240	72	0
10	CA <i>I</i> Glr	A GC'	r GA: a Asp	r GTO	G CAC His 245	Arg	CAA Gln	GTG Val	GCC	ATT Ile	· Val	TT(	C CGG	G AC	C CC r Pro 255	r ccc Pro	76	8
15	Tyr	. Ale	a Asp	260	Ser	Leu	Gln	Ala	Pro 265	Val	. Arg	Va]	l Sei	270	Glr O	G CTG	81	6
	CGG Arg	Arg	CCI Pro 275	ser	GAC Asp	CGG Arg	GAG Glu	CTC Leu 280	AGT Ser	GAG Glu	CCC Pro	Met	GAA Glu 285	ı Phe	C CAC	TAC Tyr	864	1
20	CTG Leu	Pro 290	Asp	ACA Thr	GAC Asp	GAT Asp	CGT Arg 295	CAC His	CGG Arg	ATT	GAG Glu	GAG Glu 300	Lys	CGI Arg	AAA Lys	AGG	912	2
25	ACA Thr 305	TAT	GAG Glu	ACC Thr	TTC Phe	AAG Lys 310	AGC Ser	ATC Ile	ATG Met	AAG Lys	AAG Lys 315	AGT Ser	CCT Pro	TTC Phe	AGC Ser	GGA Gly 320	960	)
30	CCC Pro	ACC Thr	GAC Asp	CCC Pro	CGG Arg 325	CCT Pro	CCA Pro	CCT Pro	CGA Arg	CGC Arg 330	ATT Ile	GCT Ala	GTG Val	CCT Pro	TCC Ser 335	CGC	1008	l
35	AGC Ser	TCA Ser	GCT Ala	TCT Ser 340	GTC Val	CCC Pro	AAG Lys	CCA Pro	GCA Ala 345	CCC Pro	CAG Gln	CCC Pro	TAT Tyr	CCC Pro 350	TTT Phe	ACG Thr	1056	
	TCA Ser	TCC Ser	CTG Leu 355	AGC Ser	ACC Thr	ATC Ile	Asn	TAT Tyr 360	GAT Asp	GAG Glu	TTT Phe	CCC Pro	ACC Thr 365	ATG Met	GTG Val	TTT Phe	1104	
40	CCT Pro	TCT Ser 370	GGG Gly	CAG Gln	ATC Ile	Ser	CAG Gln 375	GCC Ala	TCG Ser	GCC Ala	TTG Leu	GCC Ala 380	CCG Pro	GCC Ala	CCT Pro	CCC Pro	1152	
15	CAA Gln 385	GTC Val	CTG Leu	CCC Pro	GIn	GCT Ala 390	CCA (	GCC (	CCT Pro	Ala	CCT Pro 395	GCT Ala	CCA Pro	GCC Ala	ATG Met	GTA Val 400	1200	
50	TCA Ser	GCT Ala	CTG Leu	Ala	CAG Gln 405	GCC (	CCA ( Pro )	GCC (	Pro '	GTC Val 410	CCA Pro	GTC Val	CTA Leu	GCC Ala	CCA Pro 415	GGC Gly	1248	
i5	CCT Pro	CCT Pro	GIN	GCT Ala 420	GTG (	GCC ( Ala 1	CCA ( Pro I	Pro A	GCC (Ala :	CCC . Pro	AAG Lys	CCC Pro	ACC Thr	CAG Gln 430	GCT Ala	GGG Gly	1296	
	GAA	GGA	ACG	CTG	TCA (	GAG (	GCC (	CTG (	CTG (	CAG	CTG	CAG	TTT	GAT	GAT	GAA	1344	290

	Glu	Gly	Thr 435	Leu	Ser	Glu	Ala	Leu 440	Leu	Gln	Leu	Gln	Phe 445	Asp	Asp	Glu	
												CCA					1392
5	Asp	Leu 450	Gly	Ala	Leu	Leu	Gly 455	Asn	Ser	Thr	Asp	Pro 460	Ala	Val	Phe	Thr	
												CAG					1440
10	Asp 465	Leu	Ala	Ser	Val	Asp 470	Asn	Ser	Glu	Phe	Gln 475	Gln	Leu	Leu	Asn	Gln 480	
												ATG Met					1488
	GIY	116	PIO	vai	485	FIO	UIP	1111	1111	490	PIO	Met	ьeu	Met	495	Tyr	
15	CCT	CAC	CCT	ת ייי ת	እ ርጥ	ccc	CTA	CTC.	7 C P	600	000	63.6	200	000	000	<b>63.6</b>	
												CAG Gln					1536
				500					505	•				510		-	
20	CCA	GCT	CCT	GCT	CCA	CTG	GGG	GCC	CCG	GGG	CTC	CCC	AAT	GGC	CTC	CTT	1584
	Pro	Ala	Pro 515	Ala	Pro	Leu	Gly		Pro	Gly	Leu	Pro		Gly	Leu	Leu	
								520					525				
25												ATG					1632
25	ser	530	Asp	GIU	Asp	PHE	535	ser	11e	Ala	Asp	Met 540	Asp	Pne	ser	Ala	
												GTC					1680
30	ьец 545	Leu	ser	GIN	11e	550	ser	Leu .	Asp	Pro	Pro 555	Val	Ala	Thr	Met	Val 560	
	700	220	000	G 7 G	03.0	C.T.O.											
												CCC Pro					1728
35					565				_	570			•		575		
33	CTG	GAC	GGC	GAC	GTA	AAC	GGC	CAC	AAG	TTC	AGC	GTG	TCC	GGC	GAG	GGC	1776
				Asp					Lys			Val		Gly			•
				580					585					590			
40												AAG					1824
	GIU	GIY	595	Ala	inr	Tyr	GIY	600	Leu	Tnr	Leu	Lys	Phe 605	ile	Cys	Thr	
	7.00	000		cm <b>c</b>													
45												GTG Val					1872
		610					615	-				620					
	TAC	GGC	GTG	CAG	TGC	TTC	AGC	CGC	TAC	CCC	GAC	CAC	ATG	AAG	CAG	CAC	1920
50	Tyr					Phe					Asp	His				His	
50	625					630					635					640	
												GTC					1968
	Asp	rne	rne	rÀa	Ser 645	Ala	met	Pro	Glu	Gly 650	Tyr	Val	Gln	Glu	Arg 655	Thr	
55		mm.~	mma	225	<b>~</b> ~												
	ATC	TTC	TTC	AAG	GAC	GAC	GGC	AAC	TAC	AAG	ACC	CGC	GCC	GAG	GTG	AAG	2016

	Ile	Phe	Phe	Lys 660	Asp	Asp	Gly	Asn	Tyr 665	Lys	Thr	Arg	Ala	Glu 670	Val	Lys	
5		GAG Glu															2064
10		AAG Lys 690															2112
15		AGC Ser															2160
		GTG Val															2208
20		GCC Ala															2256
25		CTG Leu															2304
30		CCC Pro 770															2352
35		GCC Ala												TAA			2394
			(2)	INF	FORMA	ATION	FOF	R SEÇ	) ID	NO:1	41:						
40		<b>i)</b>	(A) (B) (C)	LENC TYPE STRA	ICE ( STH: E: an ANDEL OLOGY	797 nino NESS	amir ació S: si	no ac i ingle	ids								
45					CULE ENT 1												
		()	i) S	EQUE	ENCE	DESC	RIPT	CION:	: SEÇ	O ID	NO:	41:					
50	Met 1	Asp	Glu	Leu	Phe 5	Pro	Leu	Ile	Phe	Pro 10	Ala	Glu	Pro	Ala	Gln 15	Ala	
		Gly		20					25					30	-		
55		Phe	35					40			•		45				
	Glu	Arg	Ser	Thr	Asp	Thr	Thr	Lys	Thr	His	Pro	Thr	Ile	Lys	Ile	Asn	

		50					55					60				
	65	_		_	Pro	70					75					80
5	Pro	Þŗo	His	Arg	Pro 85	His	Pro	His	Glu	Leu 90	Val	Gly	Lys	Asp	Cys 95	Arg
	Asp	Gly	Phe	Tyr 100	Glu	Ala	Glu	Leu	Cys 105	Pro	Asp	Arg	Cys	Ile 110	His	Ser
	Phe	Gln	Asn 115	Leu	Gly	Ile	Gln	Cys 120	Val	Lys	Lys	Arg	Asp 125	Leu	Glu	Gln
10	Ala	1le 130	Ser	Gln	Arg	Ile	Gln 135	Thr	Asn	Asn	Asn	Pro 140	Phe	Gln	Val	Pro
	Ile 145	Glu	Glu	Gln	Arg	Gly 150	Asp	Tyr	qaA	Leu	Asn 155	Ala	Val	Arg	Leu	Сув 160
15	Phe	Gln	Val	Thr	Val 165	Arg	Asp	Pro	Ser	Gly 170	Arg	Pro	Leu	Arg	Leu 175	Pro
	Pro	Val	Leu	Pro 180	His	Pro	Ile	Phe	Asp 185	Asn	Arg	Ala	Pro	Asn 190	Thr	Ala
			195		Cys			200				_	205			
20		210			Phe		215					220	_			
	225				Thr	230					235					240
25			_		His 245	_				250					255	
	Tyr	Ala	Asp	Pro 260	Ser	Leu	Gln	Ala	Pro 265	Val	Arg	Val	Ser	Met 270	Gln	Leu
	Arg	Arg	Pro 275	Ser	Asp	Arg	Glu	Leu 280	Ser	Glu	Pro	Met	Glu 285	Phe	Gln	Tyr
30		290	•		Asp		295					300	_			
	305				Phe	310					315					320
35			_		Arg 325					330					335	
				340	Val				345					350		
			355		Thr			360					365			
40		370	-		Ile		375					380				
	385				Gln	390					395					400
45	•				Gln 405					410					415	
	Pro	Pro	Gln	Ala 420	Val	Ala	Pro	Pro	Ala 425	Pro	Lys	Pro	Thr	Gln 430	Ala	Gly
	Glu	Gly	Thr 435	Leu	Ser	Glu	Ala	Leu 440	Leu	Gln	Leu	Gln	Phe 445	Asp	Asp	Glu
50	Asp	Leu 450	Gly	Ala	Leu	Leu	Gly 455	Asn	Ser	Thr	Asp	Pro 460		Val	Phe	Thr
	465				Val	470					475					480
55	_				Ala 485					490					495	•
	Pro	Glu	Ala	Ile	Thr	Ara	Leu	Val	Thr	Glv	Δla	Gln	Ara	Pro	Pro	Ast

```
500
                                       505
       Pro Ala Pro Ala Pro Leu Gly Ala Pro Gly Leu Pro Asn Gly Leu Leu
                                 520
       Ser Gly Asp Glu Asp Phe Ser Ser Ile Ala Asp Met Asp Phe Ser Ala
  5
                               535
       Leu Leu Ser Gln Ile Ser Ser Leu Asp Pro Pro Val Ala Thr Met Val
                          550
                                               555
       Ser Lys Gly Glu Glu Leu Phe Thr Gly Val Val Pro Ile Leu Val Glu
                       565
                                           570
       Leu Asp Gly Asp Val Asn Gly His Lys Phe Ser Val Ser Gly Glu Gly
 10
                   580
                                      585
       Glu Gly Asp Ala Thr Tyr Gly Lys Leu Thr Leu Lys Phe Ile Cys Thr
                                  600
       Thr Gly Lys Leu Pro Val Pro Trp Pro Thr Leu Val Thr Thr Leu Thr
 15
                              615
                                                   620
       Tyr Gly Val Gln Cys Phe Ser Arg Tyr Pro Asp His Met Lys Gln His
                          630
                                               635
       Asp Phe Phe Lys Ser Ala Met Pro Glu Gly Tyr Val Gln Glu Arg Thr
                      645
                                          650
      Ile Phe Phe Lys Asp Asp Gly Asn Tyr Lys Thr Arg Ala Glu Val Lys
 20
                   660
                                       665
      Phe Glu Gly Asp Thr Leu Val Asn Arg Ile Glu Leu Lys Gly Ile Asp
                                   680
      Phe Lys Glu Asp Gly Asn Ile Leu Gly His Lys Leu Glu Tyr Asn Tyr
25
                              695
                                                  700
      Asn Ser His Asn Val Tyr Ile Met Ala Asp Lys Gln Lys Asn Gly Ile
                          710
                                              715
      Lys Val Asn Phe Lys Ile Arg His Asn Ile Glu Asp Gly Ser Val Gln
                      725
                                          730
      Leu Ala Asp His Tyr Gln Gln Asn Thr Pro Ile Gly Asp Gly Pro Val
30
                                      745
      Leu Leu Pro Asp Asn His Tyr Leu Ser Thr Gln Ser Ala Leu Ser Lys
                                  760
                                                      765
      Asp Pro Asn Glu Lys Arg Asp His Met Val Leu Leu Glu Phe Val Thr
35
                             775
      Ala Ala Gly Ile Thr Leu Gly Met Asp Glu Leu Tyr Lys
      785
                          790
               (2) INFORMATION FOR SEQ ID NO:142:
40
            (i) SEQUENCE CHARACTERISTICS:
              (A) LENGTH: 2394 base pairs
              (B) TYPE: nucleic acid
              (C) STRANDEDNESS: single
45
              (D) TOPOLOGY: linear
            (ii) MOLECULE TYPE: cDNA
            (ix) FEATURE:
50
               (A) NAME/KEY: Coding Sequence
               (B) LOCATION: 1...2391
               (D) OTHER INFORMATION:
            (xi) SEQUENCE DESCRIPTION: SEQ ID NO:142:
55
     ATG GTG AGC AAG GGC GAG GAG CTG TTC ACC GGG GTG GTG CCC ATC CTG
                                                                           48
                                                                              294
```

295

										295							
	Met 1	Val	Ser	Lys	Gly 5	Glu	Glu	Leu	Phe	Thr 10	Gly	Val	Val	Pro	Ile 15	Leu	
5					GGC Gly												96
10					GAT Asp												144
45					AAG Lys												192
15					GTG Val												240
20					TTC Phe 85												288
25					TTC Phe												336
30					GGC Gly												384
25					GAG Glu												432
35					CAC His												480
40					AAC Asn 165												528
45					GAC Asp												576
50					CCC Pro												624
					AAC Asn												672
55	GTG	ACC	GCC	GCC	GGG	ATC	ACT	CTC	GGC	ATG	GAC	GAG	CTG	TAC	AAG	TCC	720

										230							
	Val 225		Ala	Ala	Gly	Ile 230	Thr	Leu	Gly	Met	Asp 235	Glu	Leu	Tyr	Lys	Ser 240	
5	GGA Gly	CTC Leu	AGA Arg	TCT Ser	CGA Arg 245	GCC Ala	ATG Met	GAC Asp	GAA Glu	CTG Leu 250	TTC Phe	CCC Pro	CTC Leu	ATC Ile	TTC Phe 255	CCG Pro	768
10	GCA Ala	GAG Glu	CCA Pro	GCC Ala 260	CAG Gln	GCC Ala	TCT Ser	GGC Gly	CCC Pro 265	TAT Tyr	GTG Val	GAG Glu	ATC Ile	ATT Ile 270	GAG Glu	CAG Gln	816
15	CCC Pro	AAG Lys	CAG Gln 275	CGG Arg	GGC Gly	ATG Met	CGC Arg	TTC Phe 280	CGC Arg	TAC Tyr	AAG Lys	TGC Cys	GAG Glu 285	GGG Gly	CGC Arg	TCC Ser	864
10	GCG Ala	GGC Gly 290	AGC Ser	ATC Ile	CCA Pro	GGC Gly	GAG Glu 295	AGG Arg	AGC Ser	ACA Thr	GAT Asp	ACC Thr 300	ACC Thr	AAG Lys	ACC Thr	CAC His	912
20	CCC Pro 305	ACC Thr	ATC Ile	AAG Lys	ATC Ile	AAT Asn 310	GGC Gly	TAC Tyr	ACA Thr	GGA Gly	CCA Pro 315	GGG Gly	ACA Thr	GTG Val	CGC Arg	ATC Ile 320	960
25	TCC Ser	CTG Leu	GTC Val	ACC Thr	AAG Lys 325	GAC Asp	CCT Pro	CCT Pro	CAC His	CGG Arg 330	CCT Pro	CAC His	CCC Pro	CAC His	GAG Glu 335	CTT Leu	1008
30									TTC Phe 345								1056
35	GAC Asp	CGC Arg	TGC Cys 355	ATC Ile	CAC His	AGT Ser	TTC Phe	CAG Gln 360	AAC Asn	CTG Leu	GGA Gly	ATC Ile	CAG Gln 365	TGT Cys	GTG Val	AAG Lys	1104
	AAG Lys	CGG Arg 370	GAC Asp	CTG Leu	GAG Glu	CAG Gln	GCT Ala 375	ATC Ile	AGT Ser	CAG Gln	CGC Arg	ATC Ile 380	CAG Gln	ACC Thr	AAC Asn	AAC Asn	1152
40	AAC Asn 385	CCC Pro	TTC Phe	CAA Gln	GTT Val	CCT Pro 390	ATA Ile	GAA Glu	GAG Glu	CAG Gln	CGT Arg 395	GGG Gly	GAC Asp	TAC Tyr	GAC Asp	CTG Leu 400	1200
45									GTG Val								1248
50									CTT Leu 425								1296
55									AAG Lys								1344
55	TCT	GGC	AGC	TGC	CTC	GGT	GGG	GAT	GAG	ATC	TTC	CTA	CTG	TGT	GAC	AAG	1392

										201							
	Ser	Gly 450	Ser	Cys	Leu	Gly	Gly 455	Asp	Glu	Ile	Phe	Leu 460	Leu	Cys	Asp	Lys	
5	GTG Val 465	CAG Gln	AAA Lys	GAG Glu	GAC Asp	ATT Ile 470	GAG Glu	GTG Val	TAT Tyr	TTC Phe	ACG Thr 475	GGA Gly	CCA Pro	GGC Gly	TGG Trp	GAG Glu 480	1440
10	GCC Ala	CGA Arg	GGC Gly	TCC Ser	Phe	TCG Ser	CAA Gln	GCT Ala	GAT Asp	GTG Val 490	CAC His	CGA Arg	CAA Gln	GTG Val	GCC Ala 495	ATT Ile	. 1488
15		TTC Phe															1536
		GTC Val															1584
20	CCC Pro	ATG Met 530	GAA Glu	TTC Phe	CAG Gln	TAC Tyr	CTG Leu 535	CCA Pro	GAT Asp	ACA Thr	GAC Asp	GAT Asp 540	CGT Arg	CAC His	CGG Arg	ATT Ile	1632
25	GAG Glu 545	GAG Glu	AAA Lys	CGT Arg	AAA Lys	AGG Arg 550	ACA Thr	TAT Tyr	GAG Glu	ACC Thr	TTC Phe 555	AAG Lys	AGC Ser	ATC Ile	ATG Met	AAG Lys 560	1680
30	AAG Lys	AGT Ser	CCT Pro	TTC Phe	AGC Ser 565	GGA Gly	CCC Pro	ACC Thr	GAC Asp	CCC Pro 570	CGG Arg	CCT Pro	CCA Pro	CCT Pro	CGA Arg 575	CGC Arg	1728
35	ATT Ile	GCT Ala	GTG Val	CCT Pro 580	TCC Ser	CGC Arg	AGC Ser	TCA Ser	GCT Ala 585	TCT Ser	GTC Val	CCC Pro	AAG Lys	CCA Pro 590	GCA Ala	CCC Pro	1776
	CAG Gln	CCC Pro	TAT Tyr 595	CCC Pro	TTT Phe	ACG Thr	TCA Ser	TCC Ser 600	CTG Leu	AGC Ser	ACC Thr	ATC Ile	AAC Asn 605	TAT Tyr	GAT Asp	GAG Glu	1824
40		CCC Pro 610															1872
45	TTG Leu 625	GCC Ala	CCG Pro	GCC Ala	CCT Pro	CCC Pro 630	CAA Gln	GTC Val	CTG Leu	CCC Pro	CAG Gln 635	GCT Ala	CCA Pro	GCC Ala	CCT Pro	GCC Ala 640	1920
50	ČCT Pro	GCT Ala	CCA Pro	GCC Ala	ATG Met 645	GTA Val	TCA Ser	GCT Ala	CTG Leu	GCC Ala 650	CAG Gln	GCC Ala	CCA Pro	GCC Ala	CCT Pro 655	GTC Val	1968
<b></b>	CCA Pro	GTC Val	CTA Leu	GCC Ala 660	CCA Pro	GGC Gly	CCT Pro	CCT Pro	CAG Gln 665	GCT Ala	GTG Val	GCC Ala	CCA Pro	CCT Pro 670	GCC Ala	CCC Pro	2016
55	AAG	ccc	ACC	CAG	GCT	GGG	GAA	GGA	ACG	CTG	TCA	GAG	GCC	CTG	CTG	CAG	2064

	Lys	Pro	Thr 675	Gln	Ala	Gly	Glu	Gly 680	Thr	Leu	Ser	Glu	Ala 685	Leu	Leu	Gln	
5 .		CAG Gln 690															2112
	GAC Asp 705	CCA Pro															2160
	CAG	CAG Gln	CTG Leu	CTG Leu	Asn	CAG	GGC Gly	ATA Ile	CCT Pro	Val	GCC	CCC Pro	CAC His	ACA Thr	Thr	GAG	2208
15	CCC	ATG	CTG	ATG	725 GAG	TAC	CCT	GAG	GCT	730 ATA	ACT	CGC	СТА	GTG	735 ACA	GGG	2256
20		Met		740					745					750			
20		CAG Gln															2304
25		CCC Pro 770															2352
30		ATG Met												TAA			2394
			(2)	INI	FORM	ATION	I FOR	R SEÇ	Q ID	NO:	143:						
35		<b>i</b> )	(A) (B)	LENC TYPE	NCE C STH: E: an	797 mino	amir acid	no ac	ids	•							
40			(D)	TOPO	OLOGY CULE	(: li TYPE	near : pr	rotei	.n								
45					ENCE					Q ID	NO:1	143:					
10	1	Val			5					10					15		
50		Glu Gly	Glu	20				Tyr	25				Leu	30			
		Thr 50					55					60					
55	65	Thr				70				Arg	Tyr 75	Pro	Asp	His	Met	Lys 80	

		_			85					90					95	
			Ile	100					105					110		
5	Val	Lys	Phe 115	Glu	Gly	Asp	Thr	Leu 120	Val	Asn	Arg	Ile	Glu 125	Leu	Lys	Gly
	Ile	Asp 130	Phe	Lys	Glu	Asp	Gly 135	Asn	Ile	Leu	Gly	His 140	Lys	Leu	Glu	Tyr
	Asn 145	Tyr	Asn	Ser	His	Asn 150	Val	Tyr	Ile	Met	Ala 155	Asp	Lys	Gln	Lys	Asn 160
10	Gly	Ile	Lys	Val	Asn 165	Phe	Lys	Ile	Arg	His 170	Asn	Ile	Glu	Asp	Gly 175	Ser
	Val	Gln	Leu	Ala 180	Asp	His	Tyr	Gln	Gln 185	Asn	Thr	Pro	Ile	Gly 190	Asp	Gly
15	Pro	Val	Leu 195	Leu	Pro	Asp	Asn	His 200	Tyr	Leu	Ser	Thr	Gln 205	Ser	Ala	Leu
	Ser	Lys 210	Asp	Pro	Asn	Glu	Lys 215	Arg	Asp	His	Met	Val 220	Leu	Leu	Glu	Phe
	Val 225	Thr	Ala	Ala	Gly	11e 230	Thr	Leu	Gly	Met	Asp 235	Glu	Leu	Tyr	Lys	Ser 240
20	Gly	Leu	Arg	Ser	Arg 245	Ala	Met	Asp	Glu	Leu 250	Phe	Pro	Leu	Ile	Phe 255	Pro
	Ala	Glu	Pro	Ala 260	Gln	Ala	Ser	Gly	Pro 265	Туг	Val	Glu	Ile	Ile 270	Glu	Gln
25	Pro	Lys	Gln 275	Arg	Gly	Met	Arg	Phe 280	Arg	Tyr	Lys	Cys	Glu 285	Gly	Arg	Ser
	Ala	Gly 290	Ser	Ile	Pro	Gly	Glu 295	Arg	Ser	Thr	Asp	Thr 300	Thr	Lys	Thr	His
	Pro 305	Thr	Ile	Lys	Ile	Asn 310	Gly	Tyr	Thr	Gly	Pro 315	Gly	Thr	Val	Arg	Ile 320
30	Ser	Leu	Val	Thr	Lys 325	Asp	Pro	Pro	His	Arg 330	Pro		Pro	His	Glu 335	Leu
	Val	Gly	Lys	Asp 340	Cys	Arg	Asp	Gly	Phe 345	Tyr	Glu	Ala	Glu	Leu 350	Cys	Pro
35			Cys 355					360					365			
		370	Asp				375					380				
	385		Phe			390					395					400
40			Val		405					410					415	
			Leu	420					425					430	•	
45			Pro 435					440					445			
		450	Ser				455					460				
	Val 465	Gln	Lys	Glu	Asp	Ile	Glu	Val	Tyr	Phe		Gly	Pro	Gly	Trp	
50		Arg	Gjy	Ser	Phe		Gln	Ala	Asp	Val 490	475 His	Arg	Gln	Val		480 Ile
	Val	Phe	Arg	Thr 500		Pro	Tyr	Ala	Asp 505		Ser	Leu	Gln	Ala 510	495 Pro	Val
55	Arg	Val	Ser 515		Gln	Leu	Arg	Arg 520		Ser	Asp	Arg	Glu 525		Ser	Glu
	Pro	Met	Glu	Phe	Gln	ጥ <sub>ህ</sub> አ	T.em		λοπ	Thr	) en	λen		ui.	7~0	Tle

		530					535					540				
	Glu	Glu	Lys	Arg	Lys	Arg	Thr	Tyr	Glu	Thr	Phe	Lys	Ser	Ile	Met	Lvs
	545					550					555					560
	Lys	Ser	Pro	Phe	Ser	Gly	Pro	Thr	Asp	Pro	Arq	Pro	Pro	Pro	Ara	Ara
5					565				-	570	_				575	5
	Ile	Ala	Val	Pro	Ser	Arg	Ser	Ser	Ala	Ser	Val	Pro	Lvs	Pro	Ala	Pro
				580					585				•	590		
	Gln	Pro	Tyr	Pro	Phe	Thr	Ser	Ser	Leu	Ser	Thr	Ile	Asn		asa	Glu
			595					600					605	-1-		
10	Phe	Pro	Thr	Met	Val	Phe	Pro	Ser	Gly	Gln	Ile	Ser	Gln	Ala	Ser	Ala
		610					615					620				
	Leu	Ala	Pro	Ala	Pro	Pro	Gln	Val	Leu	Pro	Gln	Ala	Pro	Ala	Pro	Ala
	625					630					635					640
	Pro	Ala	Pro	Ala	Met	Val	Ser	Ala	Leu	Ala	Gln	Ala	Pro	Ala	Pro	Val
15					645					650					655	
	Pro	Val	Leu	Ala	Pro	Gly	Pro	Pro	Gln	Ala	Val	Ala	Pro	Pro	Ala	Pro
				660					665					670		
	Lys	Pro	Thr	Gln	Ala	Gly	Glu	Gly	Thr	Leu	Ser	Glu	Ala	Leu	Leu	Gln
			6,75					680					685			
20	Leu	Gln	Phe	Asp	Asp	Glu	Asp	Leu	Gly	Ala	Leu	Leu	Gly	Asn	Ser	Thr
		690					695					700				
	Asp	Pro	Ala	Val	Phe	Thr	Asp	Leu	Ala	Ser	Val	Asp	Asn	Ser	Glu	Phe
	705					710					715					720
	Gln	Gln	Leu	Leu	Asn	Gln	Gly	Ile	Pro	Val	Ala	Pro	His	Thr	Thr	Glu
25					725					730					735	
	Pro	Met	Leu	Met	Glu	Tyr	Pro	Glu	Ala	Ile	Thr	Arg	Leu	Val	Thr	Gly
, ,				740					745					750		
	Ala	Gln	Arg	Pro	Pro	Asp	Pro	Ala	Pro	Ala	Pro	Leu	Gly	Ala	Pro	Gly
20	_		755	_				760					765			
30	Leu	Pro	Asn	Gly	Leu	Leu	Ser	Gly	Asp	Glu	Asp	Phe	Ser	Ser	Ile	Ala
		.770					775					780				
	Asp	Met	Asp	Phe	Ser		Leu	Leu	Ser	Gln	Ile	Ser	Ser			
	785					790					795		•			

## **CLAIMS**

5

10

15

20

- 1. A method for extracting quantitative information relating to an influence on a cellular response, the method comprising recording variation, caused by the influence on a mechanically intact living cell or mechanically intact living cells, in spatially distributed light emitted from a luminophore, the luminophore being present in the cell or cells and being capable of being redistributed in a manner which is related with the degree of the influence, and/or of being modulated by a component which is capable of being redistributed in a manner which is related to the degree of the influence, the association resulting in a modulation of the luminescence characteristics of the luminophore, and processing the recorded variation in the spatially distributed light to provide quantitative information correlating the spatial distribution to the degree of the influence on the cellular response.
- 2. A method according to claim 1, as used for extracting quantitative information relating to an influence on an intracellular pathway involving redistribution of at least one component associated with the pathway, or part thereof, the method comprising recording the result of the influence on mechanically intact living cell or cells, as manifested in spatially distributed light emitted from a luminophore which is present in the cell or cells and which is capable of being redistributed, by modulation of the pathway, in a manner which is related to the redistribution of the at least one component of the intracellular pathway, processing the recorded result to provide quantitative information about the spatially distributed light and correlating the quantitative information to the degree of the influence on the intracellular pathway.
  - 3. A method according to claim 1 or 2, wherein the quantitative information which is indicative of the degree of the cellular response to the influence or the result of the influence on the intracellular pathway is extracted from the recording or recordings according to a predetermined calibration based on responses or results, recorded in the same manner, to known degrees of a relevant specific influence.
- 4. A method according to any of the preceding claims, wherein the influence is contact between the mechanically intact living cell or the group of mechanically intact living cells with a

chemical substance and/or incubation of the mechanically intact living cell or the group of mechanically intact living cells with a chemical substance.

- 5. A method according to claim 4 wherein the substance is a substance whose effect on an intracellular pathway is to be determined.
  - 6. A method according to any of the preceding claims, wherein the recording is made at a single point in time after the application of the influence.
- 7. A method according to any of claims 1-5, wherein the recording is made at two points in time, one point being before, and the other point being after the application of the influence.
  - 8. A method according to any of claims 1-5, wherein the recording is performed at a series of points in time, in which the application of the influence occurs at some time after the first time point in the series of recordings, the recording being performed, e.g., with a predetermined time spacing of from 0.1 seconds to 1 hour, preferably from 1 to 60 seconds, more preferably from 1 to 30 seconds, in particular from 1 to 10 seconds, over a time span of from 1 second to 12 hours, such as from 10 seconds to 12 hours, e.g., from 10 seconds to one hour, such as from 60 seconds to 30 minutes or 20 minutes.

20

- 9. A method according to any of claims 1-7, wherein the cell or cells is/are fixed at a point in time after the application of the influence at which the response has been predetermined to be significant, and the recording is made at an arbitrary later time.
- 25 10. A method according to any of the preceding claims, wherein the luminophore is a luminophore which is capable of being redistributed in a manner which is physiologically relevant to the degree of the influence.

- 11. A method according to any of the preceding claims, wherein the luminophore is a luminophore which is capable of associating with a component which is capable of being redistributed in manner which is physiologically relevant to the degree of the influence.
- 12. A method according to any of the preceding claims, wherein the luminophore is a luminophore which is capable of being redistributed in a manner which is experimentally determined to be correlated to the degree of the influence.
- 13. A method according to any of the preceding claims, wherein the luminophore is a luminophore which is capable of being redistributed, by modulation of the intracellular pathway, in substantially the same manner as the at least one component of the intracellular pathway.
- 14. A method according to any of claims 1-13, wherein the luminophore is a luminophore
   which is capable of being quenched upon spatial association with a component which is redistributed by modulation of the pathway, the quenching being measured as a decrease in the intensity of the luminescence.
- 15. A method according to any of claims 1-13, wherein the variation or result with respect to the spatially distributed light emitted by the luminophore is detected by a change in the resonance energy transfer between the luminophore and another luminescent entity capable of delivering energy to the luminophore, each of which has been selected or engineered to become part of, bound to or associated with particular components of the intracellular pathway, and one of which undergoes redistribution in response to the influence, thereby changing the amount of resonance energy transfer, the change in the resonance energy transfer being measured as a change in the intensity of emission from the luminophore.
  - 16. A method according to claim 15, wherein the change in the intensity of the emission from the luminophore is sensed by a single channel photodetector which responds only to the average intensity of the luminophore in a non-spatially resolved fashion

17. A method according to any of claims 1-16, wherein the property of the light being recorded is intensity, fluorescence lifetime, polarization, wavelength shift, or other property which is modulated as a result of the underlying cellular response.

5

- 18. A method according to any of claims 1-15 or 17, wherein the recording of the spatially distributed light is performed using a recording system which records the spatial distribution of a recordable property of the light in the form of an ordered array of values.
- 19. A method according to claim 18, wherein the recording of the spatial distribution of the recordable property of the light is performed using a charge transfer device such as a CCD array or a vacuum tube device such as a vidicon tube.
- 20. A method according to any of the preceding claims, wherein the light to be measured
   passes through a filter which selects the desired component of the light to be measured and rejects other components.
  - 21. A method according to any of the preceding claims, wherein the recording of the spatial distribution of the recordable property of light is performed by fluorescence microscopy.

20

- 22. A method according to any of the preceding claims, wherein the recording of the variation or result with respect to light emitted from the luminophore is performed by recording the spatially distributed light as one or more digital images, and the processing of the recorded variation to reduce it to one or more numbers representative of the degree of redistribution comprises a digital image processing procedure or combination of digital image processing procedures.
- 23. A method according to any of claims 2-22, wherein the intracellular pathway is an intracellular signalling pathway.

- 24. A method according to any of the preceding claims, wherein the luminophore is a fluorophore.
- 25. A method according to any of the preceding claims wherein the luminophore is a polypeptide encoded by and expressed from a nucleotide sequence harboured in the cell or cells.
- 26. A method according to any of the preceding claims, wherein the luminophore is a hybrid polypeptide comprising a fusion of at least a portion of each of two polypeptides one of which comprises a luminescent polypeptide and the other one of which comprises a biologically active polypeptide, as defined herein.
- 27. A method according to claim 26, wherein the luminescent polypeptide is a GFP as defined herein.
  - 28. A method according to claim 27 wherein the GFP is selected from the group consisting of green fluorescent proteins having the F64L mutation as defined herein.
- 29. A method according to claim 28 wherein the GFP is a GFP variant selected from the group consisting of F64L-GFP, F64L-Y66H-GFP, F64L-S65T-GFP, and EGFP.
  - 30. A method according to any of the previous claims for detecting intracellular translocation of a biologically active polypeptide affecting intracellular processes upon activation, the method comprising
    - a) culturing one or more cells containing a nucleotide sequence coding for a hybrid polypeptide comprising a GFP which is N- or C-terminally tagged, optionally through a linker, to a biologically active polypeptide under conditions permitting expression of the nucleotide sequence,

- b) modulating the activity of the biologically active polypeptide by incubating the cell or cells with a substance having biological activity and
- c) measuring the fluorescence produced by the incubated cell or cells and determining the result or variation with respect to the fluorescence, such result or variation being indicative of the translocation of a biologically active polypeptide in said cell.
- 31. A method according to claim 30, wherein the nucleotide sequence is a DNA sequence.
- 32. A method according to claim 30 or 31, wherein the modulation is an activation.

15

5

- 33. A method according to claim 30 or 31, wherein the modulation is a deactivation.
- 34. A method according to any of claims 30-33 wherein the fluorescence of the cell or cells is measured prior to the modulation, and the result or variation determined in step (c) is a change in fluorescence compared to the fluorescence measured prior to the modulation.
- 35. A method according to any of claims 30-34, wherein the intracellular processes are intracellular signalling pathways.
- 36. A method according to claim 34, wherein the change in fluorescence measured in step(c) comprises determining a change in the spatial distribution of the fluorescence.
  - 37. A method according to any of the preceding claims wherein the mechanically intact living cell or cells is/are a mammalian cell/mammalian cells which, during the time peroid over which the influence is observed, is/are incubated at a temperature of 30°C or above, preferably at a temperature of from 32°C to 39°C, more preferably at a temperature of from 35°C to 38°C, and most preferably at a temperature of about 37°C.

307

- 38. A method according to any of the preceding claims, wherein the at least one mechanically intact living cell is part of a matrix of identical or non-identical cells.
- 39. A method according to any of claims 1-36 and 38, wherein the cell or cells is/are selected from the group consisting of fungal cells, such as a yeast cell; invertebrate cells including insect cells; and vertebrate cells, such as mammalian cells.
  - 40. A nucleic acid construct coding for a fusion polypeptide comprising a biologically active polypeptide that is a component of an intracellular signalling pathway, or a part thereof, and a GFP, with the proviso that the construct is not a construct coding for a fusion polypeptide in which the biologically active polypeptide is selected from the group consisting of PKC-alpha, PKC-gamma, and PKC-epsilon.
- 41. A nucleic acid construct coding for a fusion polypeptide comprising a biologically active polypeptide that is a component of an intracellular signalling pathway, or a part thereof, and an F64L mutant of GFP.
  - 42. A nucleic acid construct according to claim 40 or 41, wherein the biologically active polypeptide is a protein kinase or a phosphatase.

20

- 43. A nucleic acid construct according to any of claims 40-42 wherein the GFP is N- or C-terminally tagged, optionally via a peptide linker, to the biologically active polypeptide or part thereof.
- 44. A nucleic acid construct according to any of claims 40, 41 and 43, wherein the biologically active polypeptide is a transcription factor or a part thereof which changes cellular localisation upon activation.

- 45. A nucleic acid construct according to any of claims 40, 41 and 43, wherein the biologically active polypeptide is a protein, or a part thereof, which is associated with the cytoskeletal network and which changes cellular localisation upon activation.
- 46. A nucleic acid construct according to any of claims 40-43, wherein the biologically active polypeptide is a protein kinase or a part thereof which changes cellular localisation upon activation.
- 47. A nucleic acid construct according to claim 46, wherein the protein kinase is a serine/threonine protein kinase or a part thereof capable of changing intracellular localisation
  upon activation.
  - 48. A nucleic acid construct according to claim 46, wherein the protein kinase is a tyrosine protein kinase or a part thereof capable of changing intracellular localisation upon activation.
  - 49. A nucleic acid construct according to claim 46, wherein the protein kinase is a phospholipid-dependent serine/threonine protein kinase or a part thereof capable of changing intracellular localisation upon activation.
- 50. A nucleic acid construct according to claim 46, wherein the protein kinase is a cAMP-dependent protein kinase or a part thereof capable of changing cellular localisation upon activation.
- 51. A nucleic acid construct according to claim 50 which codes for a PKAc-F64L-S65T-GFP fusion.
  - 52. A nucleic acid construct according to claim 46, wherein the protein kinase is a cGMP-dependent protein kinase or a part thereof capable of changing cellular localisation upon activation.

53. A nucleic acid construct according to claim 46, wherein the protein kinase is a calmodulin-dependent serine/threonine protein kinase or a part thereof capable of changing cellular localisation upon activation.

- 54. A nucleic acid construct according to claim 46, wherein the protein kinase is a mitogenactivated serine/threonine protein kinase or a part thereof capable of changing cellular localisation upon activation.
- 55. A nucleic acid construct according to claim 54, which codes for an ERK1-F64L-S65T-GFP fusion.
  - 56. A nucleic acid construct according to claim 54, which codes for an EGFP-ERK1 fusion.
- 57. A nucleic acid construct according to claim 46, wherein the protein kinase is a cyclindependent serine/threonine protein kinase or a part thereof capable of changing cellular localisation upon activation.
- 58. A nucleic acid construct according to claim 42 or 43, wherein the biologically active
   polypeptide is a protein phosphatase or a part thereof capable of changing cellular localisation upon activation.
  - 59. A nucleic acid construct according to any of claims 40-58 which is a DNA construct.
- 60. A nucleic acid construct according to any of claims 40-59 wherein the gene encoding GFP is derived from Aequorea victoria.
  - 61. A nucleic acid construct according to claim 60 in which the gene encoding GFP is the gene encoding EGFP as defined herein.

62. A nucleic acid construct according to claim 60 in which the gene encoding a GFP is a gene encoding a GFP variant selected from F64L-GFP, F64L-Y66H-GFP and F64L-S65T-GFP.

5

10

- 63. A DNA construct according to claim 59 and 61 or, where applicable, 62, which is a construct as identified by any of the DNA sequences shown in SEQ ID NO: 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 136, 138, 140, and 142, or is a variant thereof capable of encoding the same fusion polypeptide or a fusion polypeptide which is biologically equivalent thereto, as defined herein.
- 64. A cell containing a nucleic acid construct according to any of claims 40-63 and capable of expressing the sequence encoded by the construct.

15

- 65. A cell according to claim 64, which is a eukaryotic cell.
- 66. A cell according to claim 64, which is selected from the group consisting of fungal cells, such as yeast cells; invertebrate cells, including insect cells, and vertebrate cells, such as mammalian cells.
- 67. A cell according to claim 66, which is a mammalian cell.
- 68. An organism carrying in at least one of its component cells a nucleic acid sequence as contained in the constructs according to any of claims 40-59, said cell being capable of expressing said nucleic acid sequence.
  - 69. An organism according to claim 68 which is selected from the group consisting of unicellular and multicellular organisms, such as a mammal.

PCT/DK98/00145 WO 98/45704

311

- 70. A fluorescent probe comprising a GFP which is N- or C-terminally tagged, optionally via a peptide linker, to a biologically active polypeptide or a part or a subunit thereof which is a component of a intracellular signalling pathway as defined herein, the probe being a probe which is encoded by the nucleic acid construct according to any of claims 40-59.
- 71. A method according to any of claims 1-39, wherein the luminophore is a fusion polypeptide as encoded by the nucleic acid construct according to any of claims 40-63.
- 72. A method according to any of claims 1-39 or 71 in which the method of the invention is 10 used in a screening program as defined herein.
- 73. An apparatus for measuring the distribution of fluorescence in at least one cell, and thereby any change in the distribution of fluorescence in at least one cell, which includes the following component parts: (a) a light source, (b) a means for selecting the wavelength(s) of light from the source which will excite the fluorescence of the protein, (c) a means for rapidly blocking or pass ing the excitation light into the rest of the system, (d) a series of optical elements for conveying the excitation light to the specimen, collecting the emitted fluorescence in a spatially resolved fashion, and forming an image from this fluorescence, (e) a 20 bench or stand which holds the container of the cells being measured in a predetermined geometry with respect to the series of optical elements, (f) a detector to record the spatially resolved fluorescence in the form of an image, (g) a computer or electronic system and associated software to acquire and store the recorded images, and to compute the degree of redistribution from the recorded images.

25

15

5

- 74. An apparatus according to claim 73 in which some or all of the system is automated.
- 75. An apparatus according to claim 73 in which components d and e comprise a fluorescence microscope.

- 76. An apparatus according to claim 73 in which component f is a CCD camera.
- 77. An apparatus according to claim 73 in which the image is formed and recorded by an optical scanning system.

- 78. An apparatus according to claim 73 in which a liquid addition system is used to add a known or unknown compound to any or all of the cells in the cell holder at a time determined in advance.
- 79. An apparatus according to claim 78 in which the liquid addition system is under the control of the computer or electronic system.
  - 80. A method according to any of claims 1-79 wherein the method is a screening program for the identification of a biologically active substance as defined herein that directly or indirectly affects an intracellular signalling pathway and is potentially useful as a medicament, wherein the result of the individual measurement of each substance being screened which indicates its potential biological activity is based on measurement of the redistribution of spatially resolved luminescence in living cells and which undergoes a change in distribution upon activation of an intracellular signalling pathway.

20

25

- 81 A method according to any of claims 1-79 wherein the method is a screening program for the identification of a biologically toxic substance as defined herein that exerts its toxic effect by interfering with an intracellular signalling pathway, wherein the result of the individual measurement of each substance being screened which indicates its potential biologically toxic activity is based on measurement of the redistribution of said fluorescent probe in living cells and which undergoes a change in distribution upon activation of an intracellular signal-ling pathway.
- 82. A method according to any of claims 1-80 wherein a fluorescent probe is used in back tracking of signal transduction pathways as defined herein.

- 83. A method of treating a condition or disease related to the intracellular function of a protein kinase comprising administering to a patient suffering from said condition or disease an effective amount of a compound which has been discovered by any method according to the invention.
- 84. A compound that modulates a component of an intracellular pathway as defined herein, as determined by a method according to the method of the invention.
- 85. A medical composition comprising a therapeutic amount of a compound identified according the method of the invention.
  - 86. A method of selectively treating a patient suffering from an ailment which responds to medical treatment comprising obtaining a primary cell or cells from said patient, transfecting the cell or cells with at least one DNA sequence encoding a fluorescent probe according to the invention, culturing the cell or cells under conditions permitting the expression of said probes and exposing it to an array of medicaments suspected of being capable of alleviating said ailment, then comparing changes in fluorescence patterns or redistribution patterns of the fluorescent probes in the intact living cell or cells to detect the cellular response to the specific medicaments (obtaining a cellular action profile), then selecting a medicament(s) based on desired activity and acceptable level of side effects and administering an effective amount of said medicament(s) to said patient.
- 87. A method according to any of claims 1-80 of identifying a drug target among the group of biologically active polypeptides which are components of intracellular signalling pathways.

Fig 1




Fig 2









Fig 3




















4/12

Fig 4




Fig 5

[forskolin]µM	t <sub>1/2max</sub> / s	t <sub>max</sub> /s				
1	115±21	310±31				
10	69±14	224±47				
50	47±10	125±28				

Fig 6




Fig 7

c)








Fig 8














d)

WO 98/45704 PCT/DK98/00145










11/12

Fig 11




WO 98/45704 PCT/DK98/00145


12 / 12

Fig. 12













		(.)			•
				•	
		*			
	*				
					•
÷.					
					3.
				•	
					,
	· · .	. 🌣			
	,				
	<u> </u>		•		
	•				•
	,, · · ·				1
¥ (*)					
		2 to 1			•
		2 to 1			
	4. č.				
	-				
	-				

### **PCT**

## WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



### INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6:

G01N 33/50, C12Q 1/48, 1/25

A3

(11) International Publication Number: WO 98/45704

(43) International Publication Date: 15 October 1998 (15.10.98)

(21) International Application Number: PCT/DK98/00145

(22) International Filing Date: 7 April 1998 (07.04.98)

(30) Priority Data: 0392/97 7 April 1997 (07.04.97) DK

(71) Applicant (for all designated States except US): NOVO NORDISK A/S [DK/DK]; Novo Allé, DK-2880 Bagsvaerd

(72) Inventors; and

(75) Inventors/Applicants (for US only): THASTRUP, Ole [DK/DK]; Birkevej 37, DK-3460 Birkerød (DK). PETERSEN BJØRN, Sara [DK/DK]; Klampenborgvej 102, DK-2800 Lyngby (DK). TULLIN, Søren [DK/DK]; Karl Gjellerups Alle 18, DK-2860 Søborg (DK). KASPER, Almholt [DK/DK]; Eigilsgade 32, 4, tv, DK-2300 København S (DK). SCUDDER, Kurt [US/DK]; Lavendelhaven 70, DK-2830 Virum (DK).

(74) Common Representative: NOVO NORDISK A/S; attn. Lars Kellberg, Novo Allé, DK-2880 Bagsværd (DK). (81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published

With international search report.

Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(88) Date of publication of the international search report:
22 April 1999 (22.04.99)

(54) Title: A METHOD FOR EXTRACTING QUANTITATIVE INFORMATION RELATING TO AN INFLUENCE ON A CELLULAR RESPONSE

#### (57) Abstract

Cells are genetically modified to expresss a luminophore, e.g., a modified (F64L, S65T, Y66H) Green Fluorescent Protein (GFP, EGFP) coupled to a component of an intracellular signalling pathway such as a transcription factor, a cGMP- or cAMP-dependent protein kinase, a cyclin-, calmodulin- or phospholipid-dependent or mitogen-activated serine/threonin protein kinase, a tyrosine protein kinase, or a protein phosphatase (e.g. PKA, PKC, Erk, Smad, VASP, actin, p38, Jnk1, PKG, IkappaB, CDK2, Grk5, Zap70, p85, protein-tyrosine phosphatase 1C, Stat5, NFAT, NFkappaB, RhoA, PKB). An influence modulates the intracellular signalling pathway in such a way that the luminophore is being redistributed or translocated with the component in living cells in a manner experimentally determined to be correlated to the degree of the influence. Measurement of redistribution is performed by recording of light intensity, fluorescence lifetime, polarization, wavelength shift, resonance energy transfer, or other properties by an apparatus consisting of e.g. a fluorescence microscope and a CCD camera. Data stored as digital images are processed to numbers representing the degree of redistribution. The method can be used as a screening program for identifying a compound that modulates a component and is capable of treating a disease related to the function of the component.

## FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

L	Albania	. ES	Spain	LS	Lesotho	SI	Slovenia
M	Armenia	FI	Finland	LT	Lithuania	SK ·	Slovakia
\T	Austria	FR	France	LU	Luxembourg	SN	Senegal
ΑŲ	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
ΑZ	Azerbaijan	GB	United Kingdom	· MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin .	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	zw	Zimbabwe
CI	Côte d'Ivoire	KP.	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	. Sudan		
ЭK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

PCT/DK 98/00145

A. CLASSIFICATION OF SUBJECT MATTER IPC 6 G01N33/50 C120 C12Q1/48 C12Q1/25According to International Patent Classification (IPC) or to both national classification and IPC **B. FIELDS SEARCHED** Minimum documentation searched (classification system followed by classification symbols) IPC 6 GOIN C120 C12N C07K Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practical, search terms used) C. DOCUMENTS CONSIDERED TO BE RELEVANT Category <sup>a</sup> Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. X WO 97 11094 A (NOVONORDISK AS ;THASTRUP 1-27. OLE (DK); TULLIN SOEREN (DK); POULSEN LAR) 30 - 40. 27 March 1997 44-60, 64-82.88 see the whole document see claims 28,29, 41,61-63 X WO 91 01305 A (UNIV WALES MEDICINE) 1-27, 7 February 1991 30 - 40. 42-60, 64-84, 87,88 see page 4, line 15 - line 20 Y see claims 28,29, 41,61-63 see examples 1-10 Further documents are listed in the continuation of box C. Patent family members are listed in annex. \* Special categories of cited documents : T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the "A" document defining the general state of the art which is not considered to be of particular relevance invention "E" earlier document but published on or after the international X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents such combination being obvious to a person skilled on the art. "O" document referring to an oral disclosure, use, exhibition or other means document published prior to the international filing date but later than the priority date claimed 3 15 siment member of the same patent family Date of the actual completion of the international search Cute of mailing of the international search report 25, 02, 1999 19 January 1999 Name and mailing address of the ISA Authorized officer European Patent Office, P.B. 5818 Patentiaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016 Hoekstra, S

9

Int ational Application No PCT/DK 98/00145

C.(Continu	ation) (ACCUMENTS CONCIDENTS TO SE	PCT/DK 98/00145
Category '	ation) DOCUMENTS CONSIDERED TO BE RELEVANT  Citation of document, with indication where appropriate, of the relevant passages	
	appropriate, of the relevant passages	Relevant to claim No.
X	WO 95 07463 A (UNIV COLUMBIA ;WOODS HOLE OCEANOGRAPHIC INST (US); CHALFIE MARTIN) 16 March 1995 cited in the application	1-27, 30-40, 42-60, 64-84,
Y	see claim 26 see the whole document	87,88 28,29, 41,61-63
Y	WO 96 23898 A (NOVONORDISK AS ;THASTRUP OLE (DK); TULLIN SOEREN (DK); POULSEN LAR) 8 August 1996	28,29, 41,61-63
x	see the whole document see page 8-17	42,43, 46,47
x	WO 96 03649 A (UNIV NORTH CAROLINA) 8 February 1996 see page 49; example 6.10	45
P,X	WO 97 20931 A (US HEALTH ;HTUN HAN (US); HAGER GORDON L (US)) 12 June 1997 see claims 41-58	40,44
P, X	WO 97 30074 A (CYTOGEN CORP ;UNIV NORTH CAROLINA (US)) 21 August 1997 see page 57	44
, X .	WO 98 02571 A (TSIEN ROGER Y ;CUBITT ANDREW B (US); UNIV CALIFORNIA (US)) 22 January 1998	1-27, 30-40, 42-50, 52-54, 57-60, 64-82,88
	wo 98 30715 A (ISACOFF EHUD Y ;SIEGAL MICAH S (US); UNIV CALIFORNIA (US); CALIFOR) 16 July 1998 see the whole document	1-84,87, 88
	-/	
	÷-	-

9

Form PCT/ISA/210 (continuation of second sheet) (July 1992)

Int ational Application No
PCT/DK 98/00145

		PC1/DK 98/00145
	ation) DOCUMENTS CONSIDERED TO BE RELEVANT	
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	SAKAI, N. ET AL.: "Direct visualization of the translocation of the gamma subspecies of protein kinase c in living cells using fusion proteins with green fluorescent protein."  THE JOURNAL OF CELL BIOLOGY, vol. 139, no. 6, 15 December 1997, pages 1465-1476, XP002078902 see the whole document & Direct visualization of the translocation of the gamma subspecies of protein kinase c in living cells using fusion proteins with green fluorescent protein. Meeting held at 22-23.03.97 cited in the application see abstract	1-43,46, 47,49, 53-57, 59-82,88
<b>X</b>	SCHMIDT, D.J. ET AL.: "Dynamic analysis of alpha-PKC-GFP chimera translocation events in smooth muscle with ultra-high speed 3D fluorescence microscopy" FASEB JOURNAL, vol. 11, no. 3, 28 February 1997, page A505 XP002077257 cited in the application see abstract	1-43,46, 47,49, 53-57, 59-82,88
X	GERISCH, GUENTHER ET AL:  "Chemoattractant-controlled accumulation of coronin at the leading edge of Dictyostelium cells monitored using a green fluorescent protein-coronin fusion protein"  CURR. BIOL. (1995), 5(11), 1280-5 CODEN:  CUBLE2:ISSN: 0960-9822, XP002089510 see abstract p 1281, right col, second full , last sentence	1,40,43, 45
X	SIDOROVA, JULIA M. ET AL: "Cell cycle-regulated phosphorylation of Swi6 controls its nuclear localization" MOL. BIOL. CELL (1995), 6(12), 1641-58 CODEN: MBCEEV; ISSN: 1059-1524, XP002089512 see the whole document	40,43,44
X	HAN HTUN ET AL: "VISUALIZATION OF GLUCOCORTICOID RECEPTOR TRANSLOCATION AND INTRANUCLEAR ORGANIZATION IN LIVING CELLS WITH A GREEN FLUORESCENT PROTEIN CHIMERA" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 93, no. 10, May 1996, pages 4845-4850, XP002029560 see the whole document	1-40,44, 64-72
	-/	

9

In. ational Application No PCT/DK 98/00145

CICconic	elia) DOCUMENTO COMPANION DE LA COMPANION DE L	PCT/DK 98/00145		
Category :	ation) DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document, with indication where appropriate, of the relevant passages	Relevant to claim No.		
X	CAREY K L ET AL: "EVIDENCE USING A GREEN FLUORESCENT PROTEIN-GLUCOCORTICOID RECEPTOR CHIMERA THAT THE RAN/TC4 GTPASE MEDIATES AN ESSENTIAL FUNCTION INDEPENDENT OF NUCLEAR PROTEIN IMPORT" THE JOURNAL OF CELL BIOLOGY, vol. 133, no. 5, June 1996, pages 985-996, XP000670316 cited in the application see the whole document	1-40,44, 64-72		
-	OGAWA H ET AL: "LOCALIZATION, TRAFFICKING, AND TEMPERATURE-DEPENDENCE OF THE AEQUOREA GREEN FLUORESCENT PROTEIN IN CULTURES VERTEBRATE CELLS" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 92, no. 25, 5 December 1995, pages 11899-11903, XP002029556 see the whole document	1-40,44, 64-72		
(	WESTPHAL, MONIKA ET AL: "Microfilament dynamics during cell movement and chemotaxis monitored using a GFP - actin fusion protein" CURR. BIOL. (1997), 7(3), 176-183 CODEN: CUBLE2;ISSN: 0960-9822, XP002090291 see page 181, left-hand column, line 1	1,40,43, 45		
	TODA, TAKASHI ET AL: "The fission yeast sts5+ gene is required for maintenance of growth polarity and functionally interacts with protein kinase C and an osmosensing MAP kinase pathway"  J. CELL SCI. (1996), 109(9), 2331-2342  CODEN: JNCSAI;ISSN: 0021-9533, XP002090292 see abstract	40,42		
	WEBB, CHRIS D. ET AL: "Use of green fluorescent protein for visualization of cell-specific gene expression and subcellular protein localization during sporulation in Bacillus subtilis"  J. BACTERIOL. (1995), 177(20), 5906-11 CODEN: JOBAAY; ISSN: 0021-9193, XP002089513 see the whole document	44		
	WO 94 23039 A (CANCER RES INST ROYAL; MARSHALL CHRISTOPHER JOHN (GB); ASHWORTH AL) 13 October 1994 see the whole document	1-84,87, 88		

Ir. ational application No. PCT/DK 98/00145

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)
This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1. X Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 83-84 and claim 87 relate to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition (Rule 39.1(iv) PCT - Method for treatment of the human or animal body by therapy).  2. X Claims Nos.: 85,86 because they relate to parts of the International Application that do not comply with the prescribed requirements to such
an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
Claims Nos.:     because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
·
Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)
This International Searching Authority found multiple inventions in this international application, as follows:
see additional sheet
As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Remark on Protest  X The additional search fees were accompanied by the applicant's protest.
No protest accompanied the payment of additional search fees.

Form PCT/ISA/210 (continuation of first sheet (1)) (July 1992)

# FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Claims Nos.: 85,86

The subject-matter (compounds per se) is solely characterised in claims 85 and 86 by the result to be achieved, no support of a technical character is derivable from the description for the technical formulation of the subject of the search, accordingly no scope of a search could be defined and a meaningfull search is hence not possible.

#### FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: Partially: 1-43, 46, 59-82 and 88; Entirely: 47, 49. 53-57

Methods for extracting information from influences on a living cell involving observing spatial redistribution or modulation of a luminophore linked to a biologically active molecule, in particular to a molecule involved in intracellular signalling pathways, nucleic acids encoding fusion proteins comprising bothe the luminophore and the biological active molecule, cells containing and expressing these nucleic acids, as well as methods and apparatuses involving above products, inso far as related to the biologically active protein being serine/threonine protein kinases

2. Claims: Partially: 1-41, 43, 59-82 and 88; Entirely: 48

Methods for extracting information from influences on a living cell involving observing spatial redistribution or modulation of a luminophore linked to a biologically active molecule, in particular to a molecule involved in intracellular signalling pathways, nucleic acids encoding fusion proteins comprising bothe the luminophore and the biological active molecule, cells containing and expressing these nucleic acids, as well as methods and apparatuses involving above products, inso far as related to the biologically active protein being to tyrosine kinases

3. Claims: Partially: 1-43, 46, 59-82 and 88; Entirely: 50, 51

MMethods for extracting information from influences on a living cell involving observing spatial redistribution or modulation of a luminophore linked to a biologically active molecule, in particular to a molecule involved in intracellular signalling pathways, nucleic acids encoding fusion proteins comprising bothe the luminophore and the biological active molecule, cells containing and expressing these nucleic acids, as well as methods and apparatuses involving above products, inso far as related to the biologically active protein being to cAMP dependent protein kinases.

4. Claims: Partially: 1-43, 46, 59-82 and 88; Entirely: 52

MMethods for extracting information from influences on a living cell involving observing spatial redistribution or modulation of a luminophore linked to a biologically active

# FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

molecule, in particular to a molecule involved in intracellular signalling pathways, nucleic acids encoding fusion proteins comprising bothe the luminophore and the biological active molecule, cells containing and expressing these nucleic acids, as well as methods and apparatuses involving above products, inso far as related to the biologically active protein being cGMP dependent protein kinases

5. Claims: Partially: 1-43, 59-82 and 88; Entirely: 58

Methods for extracting information from influences on a living cell involving observing spatial redistribution or modulation of a luminophore linked to a biologically active molecule, in particular to a molecule involved in intracellular signalling pathways, nucleic acids encoding fusion proteins comprising bothe the luminophore and the biological active molecule, cells containing and expressing these nucleic acids, as well as methods and apparatuses involving above products, inso far as related to the biologically active protein being protein phosphatases

6. Claims: Partially: 1-41, 43, 59-82 and 88; Entirely: 44

Methods for extracting information from influences on a living cell involving observing spatial redistribution or modulation of a luminophore linked to a biologically active molecule, in particular to a molecule involved in intracellular signalling pathways, nucleic acids encoding fusion proteins comprising bothe the luminophore and the biological active molecule, cells containing and expressing these nucleic acids, as well as methods and apparatuses involving above products, inso far as related to the biologically active protein being to transcription factors

7. Claims: Partially: 1-41, 43, 59-82 and 88; Entirely: 45

Methods for extracting information from influences on a living cell involving observing spatial redistribution or modulation of a luminophore linked to a biologically active molecule, in particular to a molecule involved in intracellular signalling pathways, nucleic acids encoding fusion proteins comprising bothe the luminophore and the biological active molecule, cells containing and expressing these nucleic acids, as well as methods and apparatuses involving above products, inso far as related to the biologically active protein being to proteins associated with the cytoskeletal network

Information on patent family members

In. .national Application No PCT/DK 98/00145

			1 ,	,
Patent document cited in search report	Publication date	Patent memb		Publication date
WO 9711094 A	27-03-1997	AU 44	482996 A	09-04-1997
			232727 A	27-03-1997
			351874 A	08-07-1998
WO 9101305 A	07-02-1991	AU 60	 054590 A	22-02-1991
			064766 A	23-01-1991
			184369 A	13-05-1992
			501862 T	08-04-1993
	·		583888 A	04-11-1997
WO 9507463 A	16-03-1995	. US 54	191084 A	13-02-1996
	·		594745 B	30-07-1998
,		AU 77	795794 A	27-03-1995
			169298 A	16-03-1995
	•		759170 A	26-02-1997
			505981 T	17-06-1997
WO 9623898 A	08-08-1996	AU 44	183096 A	21-08-1996
			217700 A	08-08-1996
		EP 08	315257 A •	07-01-1998
WO 9603649 A	08-02-1996	AU 31	146095 A	22-02-1996
		CA 21	195629 A	08-02-1996
		EP 07	772773 A	14-05-1997
· · · · · · · · · · · · · · · · · · ·		JP 105	503369 T	31-03-1998
WO 9720931 A	12-06-1997	AU 12	283497 A	27-06-1997
		CA 22	239951 A	12-06-1997
WO 9730074 A	21-08-1997	AU 22	272397 A	02-09-1997
WO 9802571 . A	22-01-1998	AU 38	301997 A	09-02-1998
WO 9830715 A	16-07-1998	AU 50	90498 A	03-08-1998
WO 9423039 A	13-10-1994	AU 6	77834 B	08-05-1997
	r		882394 A	24-10-1994
			'03984 A	03-04-1996
			01302 T	10-02-1997
•			96939 B	24-09-1998
			86195 A	29-08-1995
			.82967 A	17-08-1995
			'42827 A	20-11-1996
			521923 A	17-08-1995
		JP 95	08795 T	09-09-1997

Form PCT/ISA/210 (patent family annex) (July 1992)

"HIS PAGE BLANK (USPTO)